Ligand source activities (1 row/activity)





Ligands (move mouse cursor over ligand name to see structure) Receptor Assay information Chemical information
Sel. page Common
name
GPCRdb
ID
#Vendors

Reference
ligand
Fold
selectivity
# Tested
GPCRs
Species

p-value
(-log)
Activity
Type
Activity
Relation
Activity
Value
AssayType

Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

1222 3419 44 None -23 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
3396 3419 44 None -23 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
85 3419 44 None -23 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL46516 3419 44 None -23 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
DB04842 3419 44 None -23 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
2337 6622 53 None -38 21 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
50 6622 53 None -38 21 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
5002 6622 53 None -38 21 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL716 6622 53 None -38 21 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
DB01224 6622 53 None -38 21 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1038/s41467-023-40064-9
5328940 200386 70 None -1 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 529 9 1 8 5.2 COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl 10.1038/s41467-023-40064-9
CHEMBL288441 200386 70 None -1 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 529 9 1 8 5.2 COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl 10.1038/s41467-023-40064-9
DB06616 200386 70 None -1 23 Human 6.0 pAC50 = 6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 529 9 1 8 5.2 COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl 10.1038/s41467-023-40064-9
42890 23729 35 None -1 13 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 497 3 5 10 1.0 CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O 10.1038/s41467-023-40064-9
CHEMBL1117 23729 35 None -1 13 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 497 3 5 10 1.0 CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O 10.1038/s41467-023-40064-9
DB01177 23729 35 None -1 13 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 497 3 5 10 1.0 CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O 10.1038/s41467-023-40064-9
183 84935 67 None -8 22 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
2162 84935 67 None -8 22 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
CHEMBL1491 84935 67 None -8 22 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
DB00381 84935 67 None -8 22 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl 10.1038/s41467-023-40064-9
47979 159788 49 None -3311 9 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 8 2 6 0.7 C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL2105581 159788 49 None -3311 9 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 8 2 6 0.7 C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC 10.1038/s41467-023-40064-9
DB13523 159788 49 None -3311 9 Human 5.0 pAC50 = 5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 8 2 6 0.7 C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC 10.1038/s41467-023-40064-9
2105 6217 26 None -102 15 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
47811 6217 26 None -102 15 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
48 6217 26 None -102 15 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
CHEMBL531 6217 26 None -102 15 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
DB01186 6217 26 None -102 15 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 10.1038/s41467-023-40064-9
4209 8026 58 None -15 11 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
4893 8026 58 None -15 11 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
5385 8026 58 None -15 11 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
CHEMBL2 8026 58 None -15 11 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1038/s41467-023-40064-9
2657 470626 56 None -1 14 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
5472 470626 56 None -1 14 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
CHEMBL833 470626 56 None -1 14 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
DB00208 470626 56 None -1 14 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 10.1038/s41467-023-40064-9
1028 599 43 None -1122 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
479 599 43 None -1122 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816 599 43 None -1122 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL679 599 43 None -1122 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00668 599 43 None -1122 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5360696 2892 19 None -4 8 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
6953 2892 19 None -4 8 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
842 2892 19 None -4 8 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
CHEMBL52440 2892 19 None -4 8 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
DB00514 2892 19 None -4 8 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 271 1 0 2 3.4 COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C 10.1038/s41467-023-40064-9
2200 44053 46 None -6 10 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
224 44053 46 None -6 10 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL1305 44053 46 None -6 10 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
DB08799 44053 46 None -6 10 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 5 1 3 2.7 c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1 10.1038/s41467-023-40064-9
6436173 117955 32 None -3 22 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 785 2 5 13 6.2 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
CHEMBL1617 117955 32 None -3 22 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 785 2 5 13 6.2 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
DB01220 117955 32 None -3 22 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 785 2 5 13 6.2 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
108000 119651 28 None -32 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
135418340 119651 28 None -32 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1643895 119651 28 None -32 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
DB09290 119651 28 None -32 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 2 1 3 2.9 Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21 10.1038/s41467-023-40064-9
55645 175337 2 None -3890 11 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 7 2 4 2.1 CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21 10.1038/s41467-023-40064-9
CHEMBL2218861 175337 2 None -3890 11 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 7 2 4 2.1 CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21 10.1038/s41467-023-40064-9
135398735 270475 30 None -4 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
136262914 270475 30 None -4 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
5381226 270475 30 None -4 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
CHEMBL374478 270475 30 None -4 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
DB01045 270475 30 None -4 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 822 4 6 15 4.3 CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C 10.1038/s41467-023-40064-9
2320 468583 19 None -218 13 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
4976 468583 19 None -218 13 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL668 468583 19 None -218 13 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
DB00344 468583 19 None -218 13 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 4 1 1 4.3 CNCCCC1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
242 971 74 None -9 29 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
34 971 74 None -9 29 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
60795 971 74 None -9 29 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
CHEMBL1112 971 74 None -9 29 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
DB01238 971 74 None -9 29 Human 7.0 pAC50 = 7.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1038/s41467-023-40064-9
213046 4852 48 None -61 16 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
4168 4852 48 None -61 16 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
7461 4852 48 None -61 16 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
CHEMBL1237021 4852 48 None -61 16 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
DB08815 4852 48 None -61 16 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 10.1038/s41467-023-40064-9
443955 461801 61 None 2 8 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 350 3 0 4 4.1 CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32 10.1038/s41467-023-40064-9
CHEMBL71752 461801 61 None 2 8 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 350 3 0 4 4.1 CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32 10.1038/s41467-023-40064-9
DB12131 461801 61 None 2 8 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 350 3 0 4 4.1 CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32 10.1038/s41467-023-40064-9
1613 4786 46 None -97 29 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
205 4786 46 None -97 29 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
3964 4786 46 None -97 29 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL831 4786 46 None -97 29 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00408 4786 46 None -97 29 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
11626560 450637 63 None -1 14 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 449 5 2 6 5.0 C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl 10.1038/s41467-023-40064-9
CHEMBL601719 450637 63 None -1 14 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 449 5 2 6 5.0 C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl 10.1038/s41467-023-40064-9
DB08865 450637 63 None -1 14 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 449 5 2 6 5.0 C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl 10.1038/s41467-023-40064-9
55483 469961 31 None -7 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 356 13 4 4 3.6 Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O 10.1038/s41467-023-40064-9
CHEMBL77622 469961 31 None -7 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 356 13 4 4 3.6 Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O 10.1038/s41467-023-40064-9
DB12313 469961 31 None -7 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 356 13 4 4 3.6 Oc1ccc(CCNCCCCCCNCCc2ccccc2)cc1O 10.1038/s41467-023-40064-9
2540 18749 72 None -776 26 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
475 18749 72 None -776 26 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
CHEMBL1014 18749 72 None -776 26 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
DB00796 18749 72 None -776 26 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 610 10 1 11 6.3 CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 10.1038/s41467-023-40064-9
8550 38336 43 None -1 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 578 7 1 9 4.2 COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC 10.1038/s41467-023-40064-9
CHEMBL1200515 38336 43 None -1 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 578 7 1 9 4.2 COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC 10.1038/s41467-023-40064-9
DB01089 38336 43 None -1 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 578 7 1 9 4.2 COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC 10.1038/s41467-023-40064-9
131411 39284 53 None -4 10 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
28446253 39284 53 None -4 10 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
CHEMBL1214598 39284 53 None -4 10 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
DB13609 39284 53 None -4 10 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 476 7 1 6 5.2 CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12 10.1038/s41467-023-40064-9
11291 199038 20 None -1 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
2129 199038 20 None -1 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
CHEMBL278398 199038 20 None -1 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
DB01619 199038 20 None -1 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 261 1 0 1 3.9 CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12 10.1038/s41467-023-40064-9
2583 8231 75 None -12589 13 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
592 8231 75 None -12589 13 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
65999 8231 75 None -12589 13 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
CHEMBL1017 8231 75 None -12589 13 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
DB00966 8231 75 None -12589 13 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 514 7 1 5 7.3 CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2 10.1038/s41467-023-40064-9
71496458 234502 70 None -33 16 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 499 10 2 8 4.5 C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C 10.1038/s41467-023-40064-9
CHEMBL3353410 234502 70 None -33 16 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 499 10 2 8 4.5 C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C 10.1038/s41467-023-40064-9
DB09330 234502 70 None -33 16 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 499 10 2 8 4.5 C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C 10.1038/s41467-023-40064-9
104850 6773 56 None -85 22 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
4150 6773 56 None -85 22 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
743 6773 56 None -85 22 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL111 6773 56 None -85 22 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
DB06155 6773 56 None -85 22 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 462 4 1 4 5.9 Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1 10.1038/s41467-023-40064-9
5282175 38344 24 None -14 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 424 16 2 5 5.1 CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O 10.1038/s41467-023-40064-9
CHEMBL1200661 38344 24 None -14 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 424 16 2 5 5.1 CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]1O 10.1038/s41467-023-40064-9
65948 42417 69 None -5 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 582 9 2 9 4.7 CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1 10.1038/s41467-023-40064-9
CHEMBL1275868 42417 69 None -5 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 582 9 2 9 4.7 CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1 10.1038/s41467-023-40064-9
DB09230 42417 69 None -5 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 582 9 2 9 4.7 CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1 10.1038/s41467-023-40064-9
2794 43235 59 None -14 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 472 4 1 4 7.5 CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1292 43235 59 None -14 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 472 4 1 4 7.5 CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
DB00845 43235 59 None -14 7 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 472 4 1 4 7.5 CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
7028 97082 10 None -7 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1590 97082 10 None -7 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
DB00852 97082 10 None -7 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 165 3 2 2 1.3 CN[C@@H](C)[C@@H](O)c1ccccc1 10.1038/s41467-023-40064-9
2467 139708 33 None -3 5 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 8 0 5 2.8 COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 10.1038/s41467-023-40064-9
CHEMBL188921 139708 33 None -3 5 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 8 0 5 2.8 COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 10.1038/s41467-023-40064-9
DB13510 139708 33 None -3 5 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 8 0 5 2.8 COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1 10.1038/s41467-023-40064-9
2375 314268 80 None -5 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 430 5 2 5 2.9 CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 10.1038/s41467-023-40064-9
CHEMBL409 314268 80 None -5 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 430 5 2 5 2.9 CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 10.1038/s41467-023-40064-9
DB01128 314268 80 None -5 2 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 430 5 2 5 2.9 CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1 10.1038/s41467-023-40064-9
37264 372552 17 None -8 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 435 6 2 10 1.3 COc1cc2c(N)nc(N3CCN(C(=O)OCC(C)(C)O)CC3)nc2c(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL513301 372552 17 None -8 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 435 6 2 10 1.3 COc1cc2c(N)nc(N3CCN(C(=O)OCC(C)(C)O)CC3)nc2c(OC)c1OC 10.1038/s41467-023-40064-9
DB09206 372552 17 None -8 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 435 6 2 10 1.3 COc1cc2c(N)nc(N3CCN(C(=O)OCC(C)(C)O)CC3)nc2c(OC)c1OC 10.1038/s41467-023-40064-9
68867 159750 36 None -61 13 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
CHEMBL2104523 159750 36 None -61 13 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
DB08810 159750 36 None -61 13 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 402 7 2 6 3.1 CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1 10.1038/s41467-023-40064-9
1655 461831 57 None -11 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
68602 461831 57 None -11 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
CHEMBL77921 461831 57 None -11 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
DB11428 461831 57 None -11 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 200 2 1 1 3.2 Cc1cccc(C(C)c2c[nH]cn2)c1C 10.1038/s41467-023-40064-9
2683 8346 48 None -4 5 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
5487 8346 48 None -4 5 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
7308 8346 48 None -4 5 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
CHEMBL1079 8346 48 None -4 5 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
DB00697 8346 48 None -4 5 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 10.1038/s41467-023-40064-9
1707 469523 59 None -870 15 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
4066 469523 59 None -870 15 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL73451 469523 59 None -870 15 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
DB01071 469523 59 None -870 15 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 2 0 3 4.6 c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2 10.1038/s41467-023-40064-9
1043 3255 6 None -3 10 Human 6.9 pAC50 = 6.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
149 3255 6 None -3 10 Human 6.9 pAC50 = 6.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
8223 3255 6 None -3 10 Human 6.9 pAC50 = 6.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
CHEMBL442 3255 6 None -3 10 Human 6.9 pAC50 = 6.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
DB00696 3255 6 None -3 10 Human 6.9 pAC50 = 6.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
202 3105 49 None 1 17 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
60835 3105 49 None 1 17 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
972 3105 49 None 1 17 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL1175 3105 49 None 1 17 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
DB00476 3105 49 None 1 17 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 297 6 1 3 4.6 CNCC[C@@H](c1cccs1)Oc1cccc2c1cccc2 10.1038/s41467-023-40064-9
124 6070 37 None -741 10 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
2032 6070 37 None -741 10 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
4636 6070 37 None -741 10 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
CHEMBL762 6070 37 None -741 10 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
DB00935 6070 37 None -741 10 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1038/s41467-023-40064-9
2274 6448 36 None -32 20 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4917 6448 36 None -32 20 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
7279 6448 36 None -32 20 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL728 6448 36 None -32 20 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00433 6448 36 None -32 20 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
212 8291 39 None -524 21 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
2639 8291 39 None -524 21 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
941651 8291 39 None -524 21 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
CHEMBL1201 8291 39 None -524 21 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
DB01623 8291 39 None -524 21 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C 10.1038/s41467-023-40064-9
56959 65183 65 None 3 8 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
CHEMBL1404 65183 65 None 3 8 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
DB00243 65183 65 None 3 8 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 427 9 2 6 2.3 COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 10.1038/s41467-023-40064-9
70691408 155097 0 None 3 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 1 2 4 1.6 CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O 10.1038/s41467-023-40064-9
CHEMBL2105617 155097 0 None 3 4 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 1 2 4 1.6 CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O 10.1038/s41467-023-40064-9
4640 159843 24 None -11 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 1 4 3.9 COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC 10.1038/s41467-023-40064-9
CHEMBL2107011 159843 24 None -11 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 1 4 3.9 COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC 10.1038/s41467-023-40064-9
DB13403 159843 24 None -11 11 Human 5.9 pAC50 = 5.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 1 4 3.9 COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC 10.1038/s41467-023-40064-9
243 6507 68 None -2 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
3052762 6507 68 None -2 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
3502 6507 68 None -2 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
CHEMBL117287 6507 68 None -2 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
DB06480 6507 68 None -2 3 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 367 6 2 5 2.1 COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N 10.1038/s41467-023-40064-9
67462786 239159 61 None -3 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 9 1 8 4.2 COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 10.1038/s41467-023-40064-9
CHEMBL3545376 239159 61 None -3 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 9 1 8 4.2 COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 10.1038/s41467-023-40064-9
DB12147 239159 61 None -3 6 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 9 1 8 4.2 COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 10.1038/s41467-023-40064-9
122282 270994 52 None None None Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 198 0 0 2 -0.4 CN1C(=O)N(C)C2C1N(C)C(=O)N2C 10.1038/s41467-023-40064-9
CHEMBL3707390 270994 52 None None None Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 198 0 0 2 -0.4 CN1C(=O)N(C)C2C1N(C)C(=O)N2C 10.1038/s41467-023-40064-9
3198 461850 54 None -6 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
983 461850 54 None -6 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL808 461850 54 None -6 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
DB01127 461850 54 None -6 4 Human 4.9 pAC50 = 4.9 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 6 0 3 5.8 Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
137 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
2119 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
563 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
66368 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
CHEMBL266195 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
DB00866 765 35 None -13182 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 249 8 2 3 2.2 C=CCc1ccccc1OCC(CNC(C)C)O 10.1038/s41467-023-40064-9
2343 38367 48 None 1 3 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 5 2 6 2.2 NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O 10.1038/s41467-023-40064-9
CHEMBL1201039 38367 48 None 1 3 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 5 2 6 2.2 NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O 10.1038/s41467-023-40064-9
DB00562 38367 48 None 1 3 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 5 2 6 2.2 NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O 10.1038/s41467-023-40064-9
2303 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
4946 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
564 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
63 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
91536 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
CHEMBL27 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
CHEMBL452861 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
DB00571 6476 48 None -3311 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 6 2 3 2.6 O[C@H](COc1cccc2c1cccc2)CNC(C)C 10.1038/s41467-023-40064-9
65859 42903 61 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 236 4 2 4 0.2 OC[C@@H](O)CN1CCN(c2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL1288810 42903 61 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 236 4 2 4 0.2 OC[C@@H](O)CN1CCN(c2ccccc2)CC1 10.1038/s41467-023-40064-9
DB12472 42903 61 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 236 4 2 4 0.2 OC[C@@H](O)CN1CCN(c2ccccc2)CC1 10.1038/s41467-023-40064-9
5468 255191 64 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 4 1 3 3.2 CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1 10.1038/s41467-023-40064-9
CHEMBL365795 255191 64 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 4 1 3 3.2 CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1 10.1038/s41467-023-40064-9
DB01600 255191 64 None -1 3 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 260 4 1 3 3.2 CC(C(=O)O)c1ccc(C(=O)c2ccccc2)s1 10.1038/s41467-023-40064-9
31101 1504 27 None -57 22 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
35 1504 27 None -57 22 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
403 1504 27 None -57 22 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
CHEMBL493 1504 27 None -57 22 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
DB01200 1504 27 None -57 22 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 10.1038/s41467-023-40064-9
2877 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
4397 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
5311507 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL53904 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
DB01624 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
DB13841 387290 38 None -13 12 Human 6.8 pAC50 = 6.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 400 5 1 4 4.2 OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
216416 221077 40 None -18 23 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 413 6 1 3 5.7 Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL328190 221077 40 None -18 23 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 413 6 1 3 5.7 Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1 10.1038/s41467-023-40064-9
DB06202 221077 40 None -18 23 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 413 6 1 3 5.7 Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1 10.1038/s41467-023-40064-9
1547484 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
2761 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
654 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
9072 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL43064 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
DB00568 1937 56 None -47 15 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
2600 8239 59 None -144 25 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
2608 8239 59 None -144 25 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
5405 8239 59 None -144 25 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
CHEMBL17157 8239 59 None -144 25 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
DB00342 8239 59 None -144 25 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O 10.1038/s41467-023-40064-9
2812 19119 69 None -21 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
719 19119 69 None -21 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
CHEMBL104 19119 69 None -21 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
DB00257 19119 69 None -21 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 344 4 0 2 5.4 Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1 10.1038/s41467-023-40064-9
54454 19595 56 None -6 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 6 1 5 4.6 CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 10.1038/s41467-023-40064-9
CHEMBL1064 19595 56 None -6 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 6 1 5 4.6 CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 10.1038/s41467-023-40064-9
DB00641 19595 56 None -6 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 6 1 5 4.6 CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 10.1038/s41467-023-40064-9
4260 105780 20 None -14 8 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
CHEMBL159226 105780 20 None -14 8 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
DB09205 105780 20 None -14 8 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 6 0 4 3.0 CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C 10.1038/s41467-023-40064-9
1891 346760 41 None -24 11 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
4450 346760 41 None -24 11 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
CHEMBL465026 346760 41 None -24 11 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
DB12293 346760 41 None -24 11 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 253 1 0 2 3.2 CN1CCOC(c2ccccc2)c2ccccc2C1 10.1038/s41467-023-40064-9
2106 461821 25 None -3 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
4746 461821 25 None -3 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
CHEMBL75880 461821 25 None -3 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
DB01074 461821 25 None -3 14 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 5.3 C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1 10.1038/s41467-023-40064-9
168871 179987 10 None -1 13 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 563 4 3 6 2.1 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 10.1038/s41467-023-40064-9
CHEMBL2365712 179987 10 None -1 13 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 563 4 3 6 2.1 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 10.1038/s41467-023-40064-9
DB11273 179987 10 None -1 13 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 563 4 3 6 2.1 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 10.1038/s41467-023-40064-9
2342 1238 31 None -5 8 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
331 1238 31 None -5 8 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
7124 1238 31 None -5 8 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
CHEMBL1201250 1238 31 None -5 8 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
DB00767 1238 31 None -5 8 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC 10.1038/s41467-023-40064-9
150 5099 16 None -549 13 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
1764 5099 16 None -549 13 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
8226 5099 16 None -549 13 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
CHEMBL1201356 5099 16 None -549 13 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
DB00353 5099 16 None -549 13 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 339 4 3 3 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO 10.1038/s41467-023-40064-9
1234 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
2358 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
3001055 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
5039 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
CHEMBL1790041 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
CHEMBL512 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
DB00863 6694 58 None -74 7 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 10 2 7 1.5 CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C 10.1038/s41467-023-40064-9
24826799 25079 69 None -53 20 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 532 4 1 6 4.5 Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 10.1038/s41467-023-40064-9
CHEMBL1171837 25079 69 None -53 20 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 532 4 1 6 4.5 Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 10.1038/s41467-023-40064-9
DB08901 25079 69 None -53 20 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 532 4 1 6 4.5 Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 10.1038/s41467-023-40064-9
49846579 215849 72 None -7 2 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 867 13 3 11 8.7 CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 10.1038/s41467-023-40064-9
CHEMBL3137309 215849 72 None -7 2 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 867 13 3 11 8.7 CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 10.1038/s41467-023-40064-9
DB11581 215849 72 None -7 2 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 867 13 3 11 8.7 CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 10.1038/s41467-023-40064-9
1592 473362 45 None -26 16 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
3947 473362 45 None -26 16 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL87708 473362 45 None -26 16 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
DB13411 473362 45 None -26 16 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 418 7 0 3 5.8 CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1 10.1038/s41467-023-40064-9
30323 125224 40 None -4 19 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
CHEMBL178 125224 40 None -4 19 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
DB00694 125224 40 None -4 19 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 527 4 5 11 1.0 COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 10.1038/s41467-023-40064-9
5329102 387203 55 None -16 37 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 398 7 3 3 3.3 CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C 10.1038/s41467-023-40064-9
CHEMBL535 387203 55 None -16 37 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 398 7 3 3 3.3 CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C 10.1038/s41467-023-40064-9
DB01268 387203 55 None -16 37 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 398 7 3 3 3.3 CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C 10.1038/s41467-023-40064-9
124087 2860 75 None -5370 21 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
7157 2860 75 None -5370 21 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
814 2860 75 None -5370 21 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
CHEMBL1172 2860 75 None -5370 21 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
DB00967 2860 75 None -5370 21 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 310 0 1 2 4.0 Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1 10.1038/s41467-023-40064-9
2346 37972 49 None -13 10 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
441074 37972 49 None -13 10 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
CHEMBL1294 37972 49 None -13 10 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
DB00908 37972 49 None -13 10 Human 4.8 pAC50 = 4.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 4 1 4 3.2 C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12 10.1038/s41467-023-40064-9
3294 4099 60 None -18 18 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
71360 4099 60 None -18 18 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
87 4099 60 None -18 18 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
CHEMBL14376 4099 60 None -18 18 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
DB04946 4099 60 None -18 18 Human 7.8 pAC50 = 7.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C 10.1038/s41467-023-40064-9
2713 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
5353524 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
5360566 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
88536661 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
9552079 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL790 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
DB00878 470127 64 None -6 26 Human 5.8 pAC50 = 5.8 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 504 9 10 4 4.2 N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1 10.1038/s41467-023-40064-9
103 8980 49 None -316 22 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2875 8980 49 None -316 22 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
5736 8980 49 None -316 22 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL285802 8980 49 None -316 22 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB09225 8980 49 None -316 22 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
1201549 1234 18 None -295 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
333 1234 18 None -295 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
7601 1234 18 None -295 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1201203 1234 18 None -295 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
DB00245 1234 18 None -295 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
12574 5302 68 None -218 6 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
1856 5302 68 None -218 6 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
4810 5302 68 None -218 6 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
CHEMBL19236 5302 68 None -218 6 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
DB09242 5302 68 None -218 6 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1038/s41467-023-40064-9
5318 39468 43 None -11 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
CHEMBL1221 39468 43 None -11 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
DB06820 39468 43 None -11 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 10.1038/s41467-023-40064-9
3062316 67191 73 None -3 10 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 487 7 3 9 3.3 Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 10.1038/s41467-023-40064-9
CHEMBL1421 67191 73 None -3 10 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 487 7 3 9 3.3 Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 10.1038/s41467-023-40064-9
DB01254 67191 73 None -3 10 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 487 7 3 9 3.3 Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1 10.1038/s41467-023-40064-9
16363 1232 41 None -363 21 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
312 1232 41 None -363 21 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
9215 1232 41 None -363 21 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL297302 1232 41 None -363 21 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB12867 1232 41 None -363 21 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 6 1 4 3.8 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
135398737 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
2818 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
38 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
722 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL253391 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL42 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
DB00363 1973 61 None -4 25 Human 7.7 pAC50 = 7.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1038/s41467-023-40064-9
1873 77714 61 None -1 16 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
4418 77714 61 None -1 16 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
CHEMBL142635 77714 61 None -1 16 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
DB12092 77714 61 None -1 16 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 392 7 1 5 3.4 COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1 10.1038/s41467-023-40064-9
1887 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
189562 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
71301 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
7246 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
9844194 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL2365658 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL3526436 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
CHEMBL434394 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
DB04861 5630 45 None -660 23 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 405 6 3 5 2.4 OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O 10.1038/s41467-023-40064-9
214 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
2740 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
5566 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
66064 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL422 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
DB00831 8400 48 None -134 24 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
2335 26122 15 None -2 30 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
3018 26122 15 None -2 30 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL1182210 26122 15 None -2 30 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
DB11125 26122 15 None -2 30 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 10.1038/s41467-023-40064-9
CHEMBL2103737 159717 0 None -3 8 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None None 10.1038/s41467-023-40064-9
1830 5270 37 None -22 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
207 5270 37 None -22 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
23897 5270 37 None -22 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
CHEMBL460 5270 37 None -22 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
DB01618 5270 37 None -22 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 10.1038/s41467-023-40064-9
2393 6783 45 None -8 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
5078 6783 45 None -8 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
51 6783 45 None -8 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
CHEMBL905 6783 45 None -8 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
DB00953 6783 45 None -8 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 269 5 1 4 1.9 CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C 10.1038/s41467-023-40064-9
1022 139888 29 None -1 7 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
3236 139888 29 None -1 7 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL1902981 139888 29 None -1 7 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
DB08992 139888 29 None -1 7 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 259 5 0 2 3.6 CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1 10.1038/s41467-023-40064-9
1427 4113 43 None -123 26 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
357 4113 43 None -123 26 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
3696 4113 43 None -123 26 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL11 4113 43 None -123 26 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00458 4113 43 None -123 26 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 280 4 0 2 3.9 CN(CCCN1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2136 6299 27 None -6 19 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
4768 6299 27 None -6 19 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
7268 6299 27 None -6 19 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL753 6299 27 None -6 19 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
DB00925 6299 27 None -6 19 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 303 8 0 2 4.2 ClCCN(C(COc1ccccc1)C)Cc1ccccc1 10.1038/s41467-023-40064-9
2220 6375 66 None -758 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
27400 6375 66 None -758 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
93 6375 66 None -758 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
CHEMBL294951 6375 66 None -758 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
DB06153 6375 66 None -758 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 0 0 2 4.4 CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1 10.1038/s41467-023-40064-9
4031 193725 29 None -3 12 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 429 13 0 6 4.6 CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1 10.1038/s41467-023-40064-9
CHEMBL282121 193725 29 None -3 12 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 429 13 0 6 4.6 CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1 10.1038/s41467-023-40064-9
DB12554 193725 29 None -3 12 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 429 13 0 6 4.6 CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1 10.1038/s41467-023-40064-9
16351 202790 37 None -338 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
717 202790 37 None -338 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL304902 202790 37 None -338 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
DB13256 202790 37 None -338 17 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 0 0 4 4.1 CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1 10.1038/s41467-023-40064-9
2780 220059 25 None -218 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
670 220059 25 None -218 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL325109 220059 25 None -218 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
DB13511 220059 25 None -218 10 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 2 4 3.3 COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
11511120 159957 64 None -2 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 7 2 6 5.2 COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL2110732 159957 64 None -2 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 7 2 6 5.2 COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 10.1038/s41467-023-40064-9
DB11963 159957 64 None -2 5 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 7 2 6 5.2 COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 10.1038/s41467-023-40064-9
107771 238918 50 None -1 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
5485198 238918 50 None -1 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
CHEMBL35228 238918 50 None -1 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
DB12975 238918 50 None -1 9 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 517 7 2 7 6.1 COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1 10.1038/s41467-023-40064-9
3052776 473513 55 None -2 3 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 171 2 1 1 1.9 C#CCN[C@@H]1CCc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL887 473513 55 None -2 3 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 171 2 1 1 1.9 C#CCN[C@@H]1CCc2ccccc21 10.1038/s41467-023-40064-9
DB01367 473513 55 None -2 3 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 171 2 1 1 1.9 C#CCN[C@@H]1CCc2ccccc21 10.1038/s41467-023-40064-9
65709 122659 38 None -8 13 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 365 8 0 5 3.3 CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1729803 122659 38 None -8 13 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 365 8 0 5 3.3 CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21 10.1038/s41467-023-40064-9
DB13835 122659 38 None -8 13 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 365 8 0 5 3.3 CCN(CC)CCn1c(=O)c(Cc2ccc(OC)cc2)nc2ccccc21 10.1038/s41467-023-40064-9
25025298 159796 46 None -7 8 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
25181577 159796 46 None -7 8 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
CHEMBL2105695 159796 46 None -7 8 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
DB12095 159796 46 None -7 8 Human 4.7 pAC50 = 4.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 574 9 2 9 5.0 CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1 10.1038/s41467-023-40064-9
2435 7889 70 None -912 5 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
395 7889 70 None -912 5 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
5386 7889 70 None -912 5 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL844 7889 70 None -912 5 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1038/s41467-023-40064-9
2630 62383 30 None -707 16 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
5440 62383 30 None -707 16 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1378 62383 30 None -707 16 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
DB00372 62383 30 None -707 16 Human 5.7 pAC50 = 5.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 399 6 0 5 5.0 CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
154257 352530 47 None 4 19 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 470 7 2 5 6.3 Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 10.1038/s41467-023-40064-9
CHEMBL46740 352530 47 None 4 19 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 470 7 2 5 6.3 Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 10.1038/s41467-023-40064-9
DB06401 352530 47 None 4 19 Human 6.7 pAC50 = 6.7 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 470 7 2 5 6.3 Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12 10.1038/s41467-023-40064-9
1001 365921 35 None 1 7 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
10219 365921 35 None 1 7 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
CHEMBL50588 365921 35 None 1 7 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
DB13393 365921 35 None 1 7 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 10.1038/s41467-023-40064-9
1400 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
3658 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
7199 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
91513 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL896 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
DB00557 4003 50 None -17 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 374 8 1 4 3.1 OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1 10.1038/s41467-023-40064-9
123707 98133 32 None -38 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 9 3 6 1.4 COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1 10.1038/s41467-023-40064-9
2169 98133 32 None -38 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 9 3 6 1.4 COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1 10.1038/s41467-023-40064-9
CHEMBL152231 98133 32 None -38 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 9 3 6 1.4 COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1 10.1038/s41467-023-40064-9
9801 174427 27 None -6 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 8 1 1 5.4 CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL24072 174427 27 None -6 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 8 1 1 5.4 CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
DB04825 174427 27 None -6 16 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 8 1 1 5.4 CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 10.1038/s41467-023-40064-9
1164 3353 10 None -1621 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
1626 3353 10 None -1621 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
3345 3353 10 None -1621 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL596 3353 10 None -1621 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
DB00813 3353 10 None -1621 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 336 6 0 2 4.1 CCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1 10.1038/s41467-023-40064-9
3658 8894 44 None -25 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
517 8894 44 None -25 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
5709 8894 44 None -25 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
CHEMBL312448 8894 44 None -25 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
DB06694 8894 44 None -25 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 10.1038/s41467-023-40064-9
2767 313429 63 None -12 17 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
5591 313429 63 None -12 17 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
CHEMBL408 313429 63 None -12 17 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
DB00197 313429 63 None -12 17 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 441 5 2 6 4.4 Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2 10.1038/s41467-023-40064-9
2267 1156 50 None -100 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
271 1156 50 None -100 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
7121 1156 50 None -100 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL639 1156 50 None -100 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
DB00972 1156 50 None -100 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 381 3 0 4 4.3 CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
2318 310871 17 None -3 15 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 351 7 1 3 4.1 CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL400599 310871 17 None -3 15 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 351 7 1 3 4.1 CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1 10.1038/s41467-023-40064-9
DB09022 310871 17 None -3 15 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 351 7 1 3 4.1 CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1 10.1038/s41467-023-40064-9
13162 7899 43 None -16 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1038/s41467-023-40064-9
2803 7899 43 None -16 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1038/s41467-023-40064-9
CHEMBL134 7899 43 None -16 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1038/s41467-023-40064-9
11434515 536 9 None -3162 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
4484 536 9 None -3162 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
7449 536 9 None -3162 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL1194325 536 9 None -3162 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
DB08897 536 9 None -3162 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 9 1 6 4.7 O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2 10.1038/s41467-023-40064-9
2131 120202 17 None -3 7 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 536 14 2 2 4.6 CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl 10.1038/s41467-023-40064-9
CHEMBL1652 120202 17 None -3 7 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 536 14 2 2 4.6 CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl 10.1038/s41467-023-40064-9
DB01122 120202 17 None -3 7 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 536 14 2 2 4.6 CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl 10.1038/s41467-023-40064-9
54682461 175643 46 None -5 12 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 602 11 2 6 7.3 CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1 10.1038/s41467-023-40064-9
CHEMBL222559 175643 46 None -5 12 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 602 11 2 6 7.3 CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1 10.1038/s41467-023-40064-9
DB00932 175643 46 None -5 12 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 602 11 2 6 7.3 CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1 10.1038/s41467-023-40064-9
1343 3863 47 None -21 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
3519 3863 47 None -21 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
522 3863 47 None -21 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
CHEMBL862 3863 47 None -21 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
DB01018 3863 47 None -21 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1038/s41467-023-40064-9
25102847 159798 69 None -21 10 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 501 8 2 6 5.5 COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC 10.1038/s41467-023-40064-9
CHEMBL2105717 159798 69 None -21 10 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 501 8 2 6 5.5 COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC 10.1038/s41467-023-40064-9
DB08875 159798 69 None -21 10 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 501 8 2 6 5.5 COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC 10.1038/s41467-023-40064-9
65700 159837 25 None -77 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 238 1 1 2 3.3 CNC1Cc2ccccc2N(C)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL2106919 159837 25 None -77 8 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 238 1 1 2 3.3 CNC1Cc2ccccc2N(C)c2ccccc21 10.1038/s41467-023-40064-9
2333 279489 72 None -22 13 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
318 279489 72 None -22 13 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
CHEMBL388590 279489 72 None -22 13 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
DB12319 279489 72 None -22 13 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 422 3 1 3 5.5 CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1 10.1038/s41467-023-40064-9
10531 2923 15 None 1 17 Human 7.6 pAC50 = 7.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
121 2923 15 None 1 17 Human 7.6 pAC50 = 7.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
888 2923 15 None 1 17 Human 7.6 pAC50 = 7.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
CHEMBL1732 2923 15 None 1 17 Human 7.6 pAC50 = 7.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
DB00320 2923 15 None 1 17 Human 7.6 pAC50 = 7.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.1038/s41467-023-40064-9
1960 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
439260 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
505 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
6921840 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL1437 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00368 5823 49 None -31 6 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5282136 123054 51 None None None Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
CHEMBL1742461 123054 51 None None None Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
DB12770 123054 51 None None None Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 431 11 1 6 2.7 O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1 10.1038/s41467-023-40064-9
2635 465641 44 None -275 18 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
9429 465641 44 None -275 18 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
CHEMBL609109 465641 44 None -275 18 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
DB01622 465641 44 None -275 18 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 446 6 0 6 3.2 CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1 10.1038/s41467-023-40064-9
260 8417 32 None -5 6 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
2775 8417 32 None -5 6 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
656665 8417 32 None -5 6 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL56564 8417 32 None -5 6 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB11699 8417 32 None -5 6 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 2 1 3 3.0 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
2324 158740 18 None -17 11 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 505 7 1 8 4.2 COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1 10.1038/s41467-023-40064-9
CHEMBL2074972 158740 18 None -17 11 Human 4.6 pAC50 = 4.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 505 7 1 8 4.2 COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1 10.1038/s41467-023-40064-9
CHEMBL6066864 479735 0 None -89 15 Human 6.6 pAC50 = 6.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL None None None None 10.1038/s41467-023-40064-9
1028 599 43 None -1122 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
479 599 43 None -1122 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
5816 599 43 None -1122 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
CHEMBL679 599 43 None -1122 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
DB00668 599 43 None -1122 9 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.1038/s41467-023-40064-9
3151 3013 70 None -446 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
945 3013 70 None -446 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
965 3013 70 None -446 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL219916 3013 70 None -446 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB01184 3013 70 None -446 14 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
47319 60138 23 None 1 6 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
47320 60138 23 None 1 6 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
CHEMBL1360 60138 23 None 1 6 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
DB00732 60138 23 None 1 6 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 929 24 0 12 8.1 COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC 10.1038/s41467-023-40064-9
4846 61650 43 None -1 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 308 1 2 6 2.2 O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1 10.1038/s41467-023-40064-9
CHEMBL1372341 61650 43 None -1 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 308 1 2 6 2.2 O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1 10.1038/s41467-023-40064-9
DB15945 61650 43 None -1 10 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 308 1 2 6 2.2 O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1 10.1038/s41467-023-40064-9
2796 199133 56 None -53 11 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
5639 199133 56 None -53 11 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
CHEMBL279229 199133 56 None -53 11 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
DB12661 199133 56 None -53 11 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 7 1 8 0.7 COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1 10.1038/s41467-023-40064-9
2179 332289 56 None -2 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
CHEMBL43 332289 56 None -2 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
DB00276 332289 56 None -2 12 Human 5.6 pAC50 = 5.6 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 393 5 2 5 4.5 COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 10.1038/s41467-023-40064-9
180 829 44 None -22 27 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
200 829 44 None -22 27 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2160 829 44 None -22 27 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL629 829 44 None -22 27 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00321 829 44 None -22 27 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C 10.1038/s41467-023-40064-9
2429 473124 19 None 2 3 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
26757 473124 19 None 2 3 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL972 473124 19 None 2 3 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
DB01037 473124 19 None 2 3 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 187 4 0 1 2.2 C#CCN(C)[C@H](C)Cc1ccccc1 10.1038/s41467-023-40064-9
1402 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
154417 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
174174 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
260 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
320 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
CHEMBL1331216 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
CHEMBL517712 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
DB00424 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
DB00572 1082 53 None -7079 7 Human 4.5 pAC50 = 4.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 4 1 4 1.9 OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C 10.1038/s41467-023-40064-9
2601 8241 23 None 1 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
443951 8241 23 None 1 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
56 8241 23 None 1 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
CHEMBL73151 8241 23 None 1 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
DB13399 8241 23 None 1 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 10.1038/s41467-023-40064-9
102 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
3659 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
8969 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
92766 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
CHEMBL15245 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
CHEMBL31410 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
DB01392 8930 44 None 2 14 Human 8.5 pAC50 = 8.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1038/s41467-023-40064-9
37 1606 47 None -63 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
460 1606 47 None -63 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
54746 1606 47 None -63 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
CHEMBL1201087 1606 47 None -63 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
DB00248 1606 47 None -63 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 10.1038/s41467-023-40064-9
129211 8177 49 None -177 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
2562 8177 49 None -177 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
488 8177 49 None -177 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
CHEMBL836 8177 49 None -177 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
DB00706 8177 49 None -177 12 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1038/s41467-023-40064-9
11954293 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
3036780 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
4115 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
9903970 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
CHEMBL3187365 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
CHEMBL504548 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
DB06216 212936 14 None -1513 14 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 10.1038/s41467-023-40064-9
1782 5116 63 None -39 7 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
241 5116 63 None -39 7 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
4168 5116 63 None -39 7 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
CHEMBL86 5116 63 None -39 7 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
DB01233 5116 63 None -39 7 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 2 4 2.0 CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC 10.1038/s41467-023-40064-9
2286 6468 43 None -426 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
4927 6468 43 None -426 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
7282 6468 43 None -426 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
CHEMBL643 6468 43 None -426 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
DB01069 6468 43 None -426 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C 10.1038/s41467-023-40064-9
389 239896 36 None -630 10 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
44112 239896 36 None -630 10 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
CHEMBL357995 239896 36 None -630 10 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
DB08807 239896 36 None -630 10 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 380 7 2 4 4.5 Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 10.1038/s41467-023-40064-9
2726 1895 54 None -213 26 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
621 1895 54 None -213 26 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
83 1895 54 None -213 26 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL71 1895 54 None -213 26 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB00477 1895 54 None -213 26 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
191 833 62 None -281 30 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
201 833 62 None -281 30 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
2170 833 62 None -281 30 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
CHEMBL1113 833 62 None -281 30 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
DB00543 833 62 None -281 30 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 10.1038/s41467-023-40064-9
228 919 20 None -16 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
33 919 20 None -16 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
6005 919 20 None -16 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
CHEMBL53 919 20 None -16 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
DB00714 919 20 None -16 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1038/s41467-023-40064-9
4413 198369 45 None 1 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 347 4 5 4 2.6 N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 10.1038/s41467-023-40064-9
CHEMBL273264 198369 45 None 1 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 347 4 5 4 2.6 N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 10.1038/s41467-023-40064-9
DB12598 198369 45 None 1 15 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 347 4 5 4 2.6 N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 10.1038/s41467-023-40064-9
60753 387164 32 None 1 6 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 384 14 2 4 4.2 CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1 10.1038/s41467-023-40064-9
CHEMBL533 387164 32 None 1 6 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 384 14 2 4 4.2 CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1 10.1038/s41467-023-40064-9
DB00308 387164 32 None 1 6 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 384 14 2 4 4.2 CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1 10.1038/s41467-023-40064-9
11079 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
3369 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
4436 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
5509 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL761 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
DB06711 5576 48 None -363 6 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1038/s41467-023-40064-9
2865 8961 54 None -58 19 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
59 8961 54 None -58 19 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
60854 8961 54 None -58 19 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL708 8961 54 None -58 19 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
DB00246 8961 54 None -58 19 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 10.1038/s41467-023-40064-9
2351 18649 37 None -1 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
CHEMBL1008 18649 37 None -1 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
DB01244 18649 37 None -1 21 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 366 10 0 3 4.8 CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 10.1038/s41467-023-40064-9
3157 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
6604102 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
6604576 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
7170 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
954 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
CHEMBL1363589 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
CHEMBL707 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
DB00590 3031 53 None -11 18 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1038/s41467-023-40064-9
100 8289 46 None -38 23 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
2637 8289 46 None -38 23 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
5452 8289 46 None -38 23 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
CHEMBL479 8289 46 None -38 23 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
DB00679 8289 46 None -38 23 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 10.1038/s41467-023-40064-9
1398859 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
3584 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
5401 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
7302 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
CHEMBL1481149 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
CHEMBL611 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
DB01162 8235 54 None -5 7 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1038/s41467-023-40064-9
213 8386 39 None -2 15 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
2717 8386 39 None -2 15 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
5533 8386 39 None -2 15 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL621 8386 39 None -2 15 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
DB00656 8386 39 None -2 15 Human 6.5 pAC50 = 6.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 10.1038/s41467-023-40064-9
134 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
1775 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
6604697 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
9681 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
CHEMBL1065 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
CHEMBL1397576 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
DB00247 5109 16 None -1000 14 Human 5.5 pAC50 = 5.5 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO 10.1038/s41467-023-40064-9
11658860 4776 23 None -17 10 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
2941 4776 23 None -17 10 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
4374 4776 23 None -17 10 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
CHEMBL360328 4776 23 None -17 10 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
DB04871 4776 23 None -17 10 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 195 0 1 1 2.6 Clc1ccc2c(c1)[C@@H](C)CNCC2 10.1038/s41467-023-40064-9
2470 8060 43 None -933 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
3300 8060 43 None -933 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
5265 8060 43 None -933 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL267930 8060 43 None -933 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 6 1 4 3.2 Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.1038/s41467-023-40064-9
19675 104902 43 None -28 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 7 1 5 5.0 CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1584 104902 43 None -28 15 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 7 1 5 5.0 CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
4756 40533 39 None -1 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
CHEMBL1242 40533 39 None -1 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
DB01438 40533 39 None -1 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 213 2 2 5 2.7 Nc1ccc(/N=N/c2ccccc2)c(N)n1 10.1038/s41467-023-40064-9
2440 66954 24 None -1 7 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
5210 66954 24 None -1 7 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1419 66954 24 None -1 7 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
DB01105 66954 24 None -1 7 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
2895 468596 27 None -186 13 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
751 468596 27 None -186 13 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL669 468596 27 None -186 13 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
DB00924 468596 27 None -186 13 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 275 3 0 1 4.6 CN(C)CCC=C1c2ccccc2C=Cc2ccccc21 10.1038/s41467-023-40064-9
2436 470362 35 None -11 24 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
68617 470362 35 None -11 24 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL809 470362 35 None -11 24 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
DB01104 470362 35 None -11 24 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 10.1038/s41467-023-40064-9
2407 6859 55 None -120 17 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
59227 6859 55 None -120 17 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
941 6859 55 None -120 17 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
CHEMBL1303 6859 55 None -120 17 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
DB05271 6859 55 None -120 17 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 315 6 1 3 4.3 CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1 10.1038/s41467-023-40064-9
6337614 27257 41 None -3 6 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 296 1 0 2 2.7 O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2 10.1038/s41467-023-40064-9
CHEMBL1189679 27257 41 None -3 6 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 296 1 0 2 2.7 O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2 10.1038/s41467-023-40064-9
DB00377 27257 41 None -3 6 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 296 1 0 2 2.7 O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2 10.1038/s41467-023-40064-9
319 7908 34 None -22 14 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
444031 7908 34 None -22 14 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
784 7908 34 None -22 14 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
CHEMBL1346 7908 34 None -22 14 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 3 4.0 NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2 10.1038/s41467-023-40064-9
1593 4768 42 None -9 6 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
30668 4768 42 None -9 6 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
9868 4768 42 None -9 6 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
CHEMBL17860 4768 42 None -9 6 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
DB04948 4768 42 None -9 6 Human 6.4 pAC50 = 6.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1038/s41467-023-40064-9
3149 26881 13 None -11 26 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 334 15 0 1 6.1 CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL1187011 26881 13 None -11 26 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 334 15 0 1 6.1 CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1 10.1038/s41467-023-40064-9
DB11594 26881 13 None -11 26 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 334 15 0 1 6.1 CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1 10.1038/s41467-023-40064-9
3949 200764 33 None -4 16 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 468 8 0 5 4.9 COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC 10.1038/s41467-023-40064-9
CHEMBL29188 200764 33 None -4 16 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 468 8 0 5 4.9 COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC 10.1038/s41467-023-40064-9
DB14065 200764 33 None -4 16 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 468 8 0 5 4.9 COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC 10.1038/s41467-023-40064-9
2520 461768 56 None -17 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
2815 461768 56 None -17 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL6966 461768 56 None -17 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
DB00661 461768 56 None -17 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 454 13 0 6 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
5453 468619 62 None -100 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 189 3 0 1 0.2 S=P(N1CC1)(N1CC1)N1CC1 10.1038/s41467-023-40064-9
CHEMBL671 468619 62 None -100 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 189 3 0 1 0.2 S=P(N1CC1)(N1CC1)N1CC1 10.1038/s41467-023-40064-9
DB04572 468619 62 None -100 14 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 189 3 0 1 0.2 S=P(N1CC1)(N1CC1)N1CC1 10.1038/s41467-023-40064-9
2398 1965 48 None -67 25 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
2801 1965 48 None -67 25 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
701 1965 48 None -67 25 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
CHEMBL415 1965 48 None -67 25 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
DB01242 1965 48 None -67 25 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C 10.1038/s41467-023-40064-9
4940 38383 29 None -151 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 5 0 4 4.8 CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1201210 38383 29 None -151 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 5 0 4 4.8 CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2 10.1038/s41467-023-40064-9
DB00777 38383 29 None -151 15 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 340 5 0 4 4.8 CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2 10.1038/s41467-023-40064-9
2541 198983 33 None -407 5 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
5357 198983 33 None -407 5 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
CHEMBL277945 198983 33 None -407 5 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
DB13273 198983 33 None -407 5 Human 5.4 pAC50 = 5.4 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 354 7 1 5 1.7 CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC 10.1038/s41467-023-40064-9
4452 5640 12 None -1513 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
983 5640 12 None -1513 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
CHEMBL20734 5640 12 None -1513 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 387 6 2 4 3.8 COc1cc(NC)c(cc1C(=O)NC1CCN(C1C)Cc1ccccc1)Cl 10.1038/s41467-023-40064-9
209 6223 60 None -26 11 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
2113 6223 60 None -26 11 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
4748 6223 60 None -26 11 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
CHEMBL567 6223 60 None -26 11 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
DB00850 6223 60 None -26 11 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 10.1038/s41467-023-40064-9
2351 6685 46 None -2 14 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
2820 6685 46 None -2 14 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
5035 6685 46 None -2 14 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
CHEMBL81 6685 46 None -2 14 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
DB00481 6685 46 None -2 14 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O 10.1038/s41467-023-40064-9
16362 6358 55 None -52 31 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
2172 6358 55 None -52 31 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
90 6358 55 None -52 31 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL1423 6358 55 None -52 31 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB01100 6358 55 None -52 31 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 10.1038/s41467-023-40064-9
47641 461669 24 None -2 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
73342 461669 24 None -2 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
CHEMBL626 461669 24 None -2 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
DB00735 461669 24 None -2 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 5 0 1 5.0 CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12 10.1038/s41467-023-40064-9
2165 468769 54 None -3 8 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
3647519 468769 54 None -3 8 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
CHEMBL682 468769 54 None -3 8 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
DB00613 468769 54 None -3 8 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 355 6 2 4 5.2 CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O 10.1038/s41467-023-40064-9
1353 3909 69 None -426 28 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
3559 3909 69 None -426 28 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
86 3909 69 None -426 28 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
CHEMBL54 3909 69 None -426 28 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
DB00502 3909 69 None -426 28 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1038/s41467-023-40064-9
1212 3415 38 None -128 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
204 3415 38 None -128 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
3372 3415 38 None -128 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL726 3415 38 None -128 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
DB00623 3415 38 None -128 18 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1038/s41467-023-40064-9
135 5144 38 None -27 22 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
1796 5144 38 None -27 22 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
4184 5144 38 None -27 22 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
CHEMBL6437 5144 38 None -27 22 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
DB06148 5144 38 None -27 22 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1038/s41467-023-40064-9
2695 8361 59 None -6 4 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
5504 8361 59 None -6 4 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
7310 8361 59 None -6 4 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL770 8361 59 None -6 4 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
DB00797 8361 59 None -6 4 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 10.1038/s41467-023-40064-9
240 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
2769 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
44279790 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
660 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
6917698 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
CHEMBL1729 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
DB00604 1945 27 None -263 10 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N 10.1038/s41467-023-40064-9
2995 469311 34 None -36 14 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
812 469311 34 None -36 14 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL72 469311 34 None -36 14 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
DB01151 469311 34 None -36 14 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 266 4 1 2 3.5 CNCCCN1c2ccccc2CCc2ccccc21 10.1038/s41467-023-40064-9
26987 1955 32 None -158 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
6063 1955 32 None -158 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
671 1955 32 None -158 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
CHEMBL1626 1955 32 None -158 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
DB00283 1955 32 None -158 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41467-023-40064-9
20628 196884 24 None -13 13 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 6 1 5 3.7 CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12 10.1038/s41467-023-40064-9
CHEMBL26291 196884 24 None -13 13 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 324 6 1 5 3.7 CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12 10.1038/s41467-023-40064-9
2389 6775 83 None -36 19 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
5073 6775 83 None -36 19 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
96 6775 83 None -36 19 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
CHEMBL85 6775 83 None -36 19 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
DB00734 6775 83 None -36 19 Human 7.3 pAC50 = 7.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1038/s41467-023-40064-9
2472 139567 41 None 3 4 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 1 7 2.1 CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1 10.1038/s41467-023-40064-9
CHEMBL188185 139567 41 None 3 4 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 1 7 2.1 CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1 10.1038/s41467-023-40064-9
DB12230 139567 41 None 3 4 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 373 5 1 7 2.1 CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1 10.1038/s41467-023-40064-9
4034 118640 42 None -13 18 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
CHEMBL1623 118640 42 None -13 18 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
DB00737 118640 42 None -13 18 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 390 5 0 2 5.6 Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 10.1038/s41467-023-40064-9
2365 175610 23 None -4 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
54477 175610 23 None -4 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
CHEMBL22242 175610 23 None -4 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
DB00409 175610 23 None -4 6 Human 5.3 pAC50 = 5.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 370 6 1 4 2.7 CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC 10.1038/s41467-023-40064-9
1971 5840 38 None -30 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
2404 5840 38 None -30 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
4543 5840 38 None -30 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL445 5840 38 None -30 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
DB00540 5840 38 None -30 22 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 10.1038/s41467-023-40064-9
1816 5164 69 None -87 10 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
4205 5164 69 None -87 10 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
7241 5164 69 None -87 10 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
CHEMBL654 5164 69 None -87 10 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
DB00370 5164 69 None -87 10 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1038/s41467-023-40064-9
135398745 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
1982 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
4585 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
47 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
CHEMBL715 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
DB00334 5933 69 None -69 26 Human 6.3 pAC50 = 6.3 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1038/s41467-023-40064-9
5048 6373 55 None -208 4 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
8924 6373 55 None -208 4 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
9948102 6373 55 None -208 4 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
CHEMBL462605 6373 55 None -208 4 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
DB11642 6373 55 None -208 4 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 8 0 2 4.2 Clc1ccc(cc1)CCCOCCCN1CCCCC1 10.1038/s41467-023-40064-9
2585 1662 62 None -18 28 Human 7.2 pAC50 = 7.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
522 1662 62 None -18 28 Human 7.2 pAC50 = 7.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
551 1662 62 None -18 28 Human 7.2 pAC50 = 7.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
CHEMBL723 1662 62 None -18 28 Human 7.2 pAC50 = 7.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
DB01136 1662 62 None -18 28 Human 7.2 pAC50 = 7.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O 10.1038/s41467-023-40064-9
1150567 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
3152 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
946 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
CHEMBL502 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
DB00843 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
DB07701 371619 67 None -7 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 379 6 0 4 4.4 COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2 10.1038/s41467-023-40064-9
2863 270513 30 None -4 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
41987 270513 30 None -4 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
5365247 270513 30 None -4 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
CHEMBL37744 270513 30 None -4 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
DB04832 270513 30 None -4 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 316 4 0 2 3.8 CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1 10.1038/s41467-023-40064-9
1890 5634 35 None -4 23 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
4449 5634 35 None -4 23 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
7247 5634 35 None -4 23 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
CHEMBL623 5634 35 None -4 23 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
DB01149 5634 35 None -4 23 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.1038/s41467-023-40064-9
2435 7298 64 None -74 19 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
60149 7298 64 None -74 19 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
98 7298 64 None -74 19 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
CHEMBL12713 7298 64 None -74 19 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
DB06144 7298 64 None -74 19 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O 10.1038/s41467-023-40064-9
1976 24250 34 None -11 12 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
4567 24250 34 None -11 12 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
CHEMBL114655 24250 34 None -11 12 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
DB06152 24250 34 None -11 12 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 299 7 3 3 3.4 CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1 10.1038/s41467-023-40064-9
1530 4450 49 None -363 12 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
3827 4450 49 None -363 12 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
7206 4450 49 None -363 12 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
CHEMBL534 4450 49 None -363 12 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
DB00920 4450 49 None -363 12 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 309 0 0 3 4.0 CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1 10.1038/s41467-023-40064-9
5482 38332 59 None -3 13 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 386 6 0 4 5.9 Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 10.1038/s41467-023-40064-9
CHEMBL1200438 38332 59 None -3 13 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 386 6 0 4 5.9 Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 10.1038/s41467-023-40064-9
DB01007 38332 59 None -3 13 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 386 6 0 4 5.9 Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 10.1038/s41467-023-40064-9
1524 7961 66 None -2511 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
197 7961 66 None -2511 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
3822 7961 66 None -2511 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
CHEMBL51 7961 66 None -2511 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 395 5 1 5 2.4 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2 10.1038/s41467-023-40064-9
1634 163834 36 None -851 15 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
4011 163834 36 None -851 15 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
CHEMBL21731 163834 36 None -851 15 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
DB00934 163834 36 None -851 15 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 10.1038/s41467-023-40064-9
9417 270997 45 None -83 14 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
CHEMBL370753 270997 45 None -83 14 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
DB12930 270997 45 None -83 14 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 363 6 1 4 3.3 OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1 10.1038/s41467-023-40064-9
5311017 239242 5 None 2 5 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
CHEMBL3545985 239242 5 None 2 5 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
DB00865 239242 5 None 2 5 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 239 5 0 1 3.8 C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1 10.1038/s41467-023-40064-9
2381 200503 44 None -3 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
68712 200503 44 None -3 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
CHEMBL289480 200503 44 None -3 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
DB11738 200503 44 None -3 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1038/s41467-023-40064-9
3926 474146 33 None -1 18 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 491 9 1 3 5.8 Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1038/s41467-023-40064-9
CHEMBL92870 474146 33 None -1 18 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 491 9 1 3 5.8 Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1038/s41467-023-40064-9
DB13766 474146 33 None -1 18 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 491 9 1 3 5.8 Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1038/s41467-023-40064-9
21772 159962 24 None -457 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 293 4 0 1 4.5 CC(CC1c2ccccc2CCc2ccccc21)CN(C)C 10.1038/s41467-023-40064-9
CHEMBL2110816 159962 24 None -457 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 293 4 0 1 4.5 CC(CC1c2ccccc2CCc2ccccc21)CN(C)C 10.1038/s41467-023-40064-9
DB09016 159962 24 None -457 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 293 4 0 1 4.5 CC(CC1c2ccccc2CCc2ccccc21)CN(C)C 10.1038/s41467-023-40064-9
179 827 77 None -46 7 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
2159 827 77 None -46 7 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
963 827 77 None -46 7 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
CHEMBL243712 827 77 None -46 7 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
DB06288 827 77 None -46 7 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC 10.1038/s41467-023-40064-9
104870 199119 37 None -2 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
2558 199119 37 None -2 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
5374 199119 37 None -2 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
CHEMBL279085 199119 37 None -2 10 Human 6.2 pAC50 = 6.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 10.1038/s41467-023-40064-9
2291 6470 51 None -18 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
2561 6470 51 None -18 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
4932 6470 51 None -18 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
CHEMBL631 6470 51 None -18 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
DB01182 6470 51 None -18 6 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 341 11 2 4 3.2 CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O 10.1038/s41467-023-40064-9
19910 80865 69 None -1 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 190 1 1 4 1.8 O=[N+]([O-])c1ccc(O)c2ncccc12 10.1038/s41467-023-40064-9
CHEMBL1454910 80865 69 None -1 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 190 1 1 4 1.8 O=[N+]([O-])c1ccc(O)c2ncccc12 10.1038/s41467-023-40064-9
DB01422 80865 69 None -1 10 Human 5.2 pAC50 = 5.2 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 190 1 1 4 1.8 O=[N+]([O-])c1ccc(O)c2ncccc12 10.1038/s41467-023-40064-9
17676 21398 27 None -165 13 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
5281082 21398 27 None -165 13 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
CHEMBL1085 21398 27 None -165 13 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
DB01063 21398 27 None -165 13 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 411 7 1 6 3.5 CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2 10.1038/s41467-023-40064-9
2477 1536 44 None -151 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
36 1536 44 None -151 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
437 1536 44 None -151 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
CHEMBL49 1536 44 None -151 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
DB00490 1536 44 None -151 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 385 6 0 6 2.1 O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 10.1038/s41467-023-40064-9
2149 461549 10 None None None Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
26934 461549 10 None None None Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
4786 461549 10 None None None Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL61006 461549 10 None None None Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
DB00397 461549 10 None None None Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 10.1038/s41467-023-40064-9
16722836 42842 62 None -6 13 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 524 10 3 8 4.8 Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1 10.1038/s41467-023-40064-9
CHEMBL1287853 42842 62 None -6 13 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 524 10 3 8 4.8 Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1 10.1038/s41467-023-40064-9
DB12500 42842 62 None -6 13 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 524 10 3 8 4.8 Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1 10.1038/s41467-023-40064-9
2440 66954 24 None -1 7 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
5210 66954 24 None -1 7 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
CHEMBL1419 66954 24 None -1 7 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
DB01105 66954 24 None -1 7 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 5 0 1 4.7 CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1 10.1038/s41467-023-40064-9
1234 365939 35 None -28 9 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
CHEMBL51149 365939 35 None -28 9 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
DB12923 365939 35 None -28 9 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 484 14 0 7 5.1 COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC 10.1038/s41467-023-40064-9
135409453 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
226 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
2579 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
5362436 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
CHEMBL76370 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
DB01079 8225 26 None -9 33 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 3 3 2.6 CCCCCN=C(N/N=C/c1c[nH]c2c1cc(OC)cc2)N 10.1038/s41467-023-40064-9
2068 370177 47 None -42 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
43815 370177 47 None -42 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
CHEMBL490 370177 47 None -42 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
DB00715 370177 47 None -42 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 329 4 1 4 3.3 Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1 10.1038/s41467-023-40064-9
2218 39180 23 None -10 12 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 8 0 2 4.4 CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1 10.1038/s41467-023-40064-9
CHEMBL1213033 39180 23 None -10 12 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 8 0 2 4.4 CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1 10.1038/s41467-023-40064-9
DB01429 39180 23 None -10 12 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 322 8 0 2 4.4 CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1 10.1038/s41467-023-40064-9
36811 2998 34 None -17 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
535 2998 34 None -17 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
937 2998 34 None -17 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
CHEMBL926 2998 34 None -17 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
DB00841 2998 34 None -17 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 301 7 4 4 3.0 CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O 10.1038/s41467-023-40064-9
2146 6309 49 None -53 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
485 6309 49 None -53 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
6041 6309 49 None -53 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
CHEMBL1215 6309 49 None -53 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
DB00388 6309 49 None -53 8 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O 10.1038/s41467-023-40064-9
2448 199534 52 None -363 15 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
407 199534 52 None -363 15 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
CHEMBL28218 199534 52 None -363 15 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
DB12401 199534 52 None -363 15 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 419 6 1 3 4.5 O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1 10.1038/s41467-023-40064-9
115 706 55 None -14 5 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
2092 706 55 None -14 5 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
7109 706 55 None -14 5 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
CHEMBL709 706 55 None -14 5 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
DB00346 706 55 None -14 5 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 389 8 3 7 2.0 COc1cc2nc([nH]c(=N)c2cc1OC)N(CCCN=C(C1CCCO1)O)C 10.1038/s41467-023-40064-9
3158 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
667468 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
956 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL101740 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1628227 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
DB01142 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
DB14750 18465 32 None -812 24 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 10.1038/s41467-023-40064-9
2142 6301 41 None -21 11 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
502 6301 41 None -21 11 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
5775 6301 41 None -21 11 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
CHEMBL597 6301 41 None -21 11 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
DB00692 6301 41 None -21 11 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1038/s41467-023-40064-9
72093 78550 5 None -7 28 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
CHEMBL1433361 78550 5 None -7 28 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
DB13500 78550 5 None -7 28 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 483 16 1 4 6.3 CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1 10.1038/s41467-023-40064-9
1549120 393450 55 None -5 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 319 4 1 4 2.9 CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1 10.1038/s41467-023-40064-9
CHEMBL56337 393450 55 None -5 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 319 4 1 4 2.9 CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1 10.1038/s41467-023-40064-9
DB15293 393450 55 None -5 19 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 319 4 1 4 2.9 CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1 10.1038/s41467-023-40064-9
2284 6466 25 None -263 26 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
4926 6466 25 None -263 26 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
7281 6466 25 None -263 26 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
CHEMBL564 6466 25 None -263 26 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
DB00420 6466 25 None -263 26 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C 10.1038/s41467-023-40064-9
156419 1933 51 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
3308 1933 51 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
647 1933 51 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
CHEMBL1201284 1933 51 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
DB01012 1933 51 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.1038/s41467-023-40064-9
3180 38385 30 None -2 10 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 8 0 3 3.9 CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1 10.1038/s41467-023-40064-9
CHEMBL1201217 38385 30 None -2 10 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 8 0 3 3.9 CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1 10.1038/s41467-023-40064-9
DB00645 38385 30 None -2 10 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 289 8 0 3 3.9 CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1 10.1038/s41467-023-40064-9
68555 203162 13 None -190 7 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 7 1 5 2.6 CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1 10.1038/s41467-023-40064-9
CHEMBL307739 203162 13 None -190 7 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 7 1 5 2.6 CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1 10.1038/s41467-023-40064-9
DB13316 203162 13 None -190 7 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 307 7 1 5 2.6 CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1 10.1038/s41467-023-40064-9
3081361 194350 71 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 474 5 1 5 4.4 COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 10.1038/s41467-023-40064-9
CHEMBL24828 194350 71 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 474 5 1 5 4.4 COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 10.1038/s41467-023-40064-9
DB05294 194350 71 None -1 14 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 474 5 1 5 4.4 COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 10.1038/s41467-023-40064-9
1385580 62931 59 None -6 17 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
2014 62931 59 None -6 17 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
4615 62931 59 None -6 17 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL13828 62931 59 None -6 17 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
DB12877 62931 59 None -6 17 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 426 7 1 4 4.1 O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 10.1038/s41467-023-40064-9
1419 193823 38 None -2 12 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
3689 193823 38 None -2 12 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
CHEMBL305187 193823 38 None -2 12 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
DB08954 193823 38 None -2 12 Human 6.1 pAC50 = 6.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 325 5 2 3 3.8 CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 10.1038/s41467-023-40064-9
2018 6124 31 None -169 17 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 1047 17 9 11 3.4 NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
4329 6124 31 None -169 17 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 1047 17 9 11 3.4 NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
9941444 6124 31 None -169 17 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 1047 17 9 11 3.4 NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
CHEMBL3349607 6124 31 None -169 17 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 1047 17 9 11 3.4 NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
DB06663 6124 31 None -169 17 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 1047 17 9 11 3.4 NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2 10.1038/s41467-023-40064-9
22323 39196 30 None -5 11 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
9571037 39196 30 None -5 11 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
CHEMBL1213553 39196 30 None -5 11 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
DB12314 39196 30 None -5 11 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 287 2 5 2 2.9 CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1 10.1038/s41467-023-40064-9
1478 41858 30 None -22 21 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
21722 41858 30 None -22 21 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
CHEMBL126224 41858 30 None -22 21 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
DB13496 41858 30 None -22 21 Human 5.1 pAC50 = 5.1 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 284 4 0 2 4.3 CN(C)CCCn1c2c(c3ccccc31)CCCCCC2 10.1038/s41467-023-40064-9
129 23612 35 None -120 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
2099 23612 35 None -120 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
CHEMBL1110 23612 35 None -120 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
DB00969 23612 35 None -120 5 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 294 2 1 3 2.4 Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O 10.1038/s41467-023-40064-9
2762 8406 24 None -117 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
5587 8406 24 None -117 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
7318 8406 24 None -117 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
CHEMBL1241 8406 24 None -117 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
DB00792 8406 24 None -117 9 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 255 6 0 3 2.7 CN(CCN(c1ccccn1)Cc1ccccc1)C 10.1038/s41467-023-40064-9
2372 216137 33 None -354 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 345 10 2 5 2.6 COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC 10.1038/s41467-023-40064-9
CHEMBL314010 216137 33 None -354 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 345 10 2 5 2.6 COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC 10.1038/s41467-023-40064-9
DB01295 216137 33 None -354 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 345 10 2 5 2.6 COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC 10.1038/s41467-023-40064-9
1150 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
3337 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
65801 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
66264 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
91452 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
CHEMBL87493 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
DB00574 473039 11 None -2 6 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 10.1038/s41467-023-40064-9
2202 6371 70 None -16 9 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
4850 6371 70 None -16 9 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
49 6371 70 None -16 9 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
CHEMBL1371770 6371 70 None -16 9 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
DB12478 6371 70 None -16 9 Human 6.0 pAC50 = 6.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 10.1038/s41467-023-40064-9
25382 23462 27 None -263 21 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 3 0 1 4.7 CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21 10.1038/s41467-023-40064-9
CHEMBL110094 23462 27 None -263 21 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 3 0 1 4.7 CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21 10.1038/s41467-023-40064-9
DB13384 23462 27 None -263 21 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 291 3 0 1 4.7 CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21 10.1038/s41467-023-40064-9
135564886 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
135673376 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
137157436 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
145948239 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
71587099 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
CHEMBL1201304 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
DB16024 38403 5 None -3 25 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 752 14 1 6 8.7 CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21 10.1038/s41467-023-40064-9
3191 202914 68 None -61 14 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
977 202914 68 None -61 14 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
CHEMBL305660 202914 68 None -61 14 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
DB11742 202914 68 None -61 14 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 10.1038/s41467-023-40064-9
2247 1042 63 None -37 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
249 1042 63 None -37 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
2603 1042 63 None -37 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
CHEMBL296419 1042 63 None -37 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
DB00637 1042 63 None -37 27 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 10.1038/s41467-023-40064-9
3155 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
5284550 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
951 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL108947 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
CHEMBL1492500 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
DB09167 77368 13 None -512 16 Human 5.0 pAC50 = 5.0 Functional
Compound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtrationCompound was evaluated for inhibition of human ADRA2C in an in vitro assay with cellular components measured by membrane filtration
ChEMBL 295 3 0 2 4.7 CN(C)CC/C=C1\c2ccccc2CSc2ccccc21 10.1038/s41467-023-40064-9
521 2888 53 None -2 5 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
5311068 2888 53 None -2 5 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
835 2888 53 None -2 5 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
CHEMBL778 2888 53 None -2 5 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
DB00633 2888 53 None -2 5 Human 9.3 pEC50 = 9.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C nan
1593 4768 42 None 4 3 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668 4768 42 None 4 3 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9868 4768 42 None 4 3 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
CHEMBL17860 4768 42 None 4 3 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
DB04948 4768 42 None 4 3 Human 8.9 pEC50 = 8.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
57345628 143414 0 None 1659 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956195 143414 0 None 1659 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 143414 0 None 1659 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL1956195 143414 0 None 1659 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
70695474 155061 0 None 794 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089156 155061 0 None 794 2 Human 8.7 pEC50 = 8.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
44292386 201605 0 None 35 2 Human 8.7 pEC50 = 8.7 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297827 201605 0 None 35 2 Human 8.7 pEC50 = 8.7 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
16757089 183100 1 None None None Human 8.0 pEC50 = 8 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL242693 183100 1 None None None Human 8.0 pEC50 = 8 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
57345626 143411 0 None 31 2 Human 8.0 pEC50 = 8 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956192 143411 0 None 31 2 Human 8.0 pEC50 = 8 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906199 370898 17 None 6 3 Human 8.0 pEC50 = 8 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL495096 370898 17 None 6 3 Human 8.0 pEC50 = 8 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
16757089 183100 1 None None None Human 8.0 pEC50 = 8 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 183100 1 None None None Human 8.0 pEC50 = 8 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
49836306 42436 0 None 31 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276247 42436 0 None 31 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11361608 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL222928 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
11361608 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
44269140 67169 0 None 17 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL14208 67169 0 None 17 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44371745 102531 0 None 100 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL156336 102531 0 None 100 2 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57402718 143420 0 None -3 3 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956201 143420 0 None -3 3 Human 7.0 pEC50 = 7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
11097789 203048 1 None -16 5 Human 7.0 pEC50 = 7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL306792 203048 1 None -16 5 Human 7.0 pEC50 = 7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
11361608 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL222928 175702 0 None None None Human 7.0 pEC50 = 7 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
24906196 370494 0 None None None Human 6.0 pEC50 = 6 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL492639 370494 0 None None None Human 6.0 pEC50 = 6 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
135453290 271080 30 None -5011 7 Human 5.0 pEC50 = 5 Functional
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL371300 271080 30 None -5011 7 Human 5.0 pEC50 = 5 Functional
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
57399145 143415 0 None -3 2 Human 5.0 pEC50 = 5 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956196 143415 0 None -3 2 Human 5.0 pEC50 = 5 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
131829 469612 14 None -37 3 Human 7.0 pEC50 = 7.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
CHEMBL74283 469612 14 None -37 3 Human 7.0 pEC50 = 7.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
9859437 332763 0 None 1 3 Human 7.0 pEC50 = 7.0 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
CHEMBL432155 332763 0 None 1 3 Human 7.0 pEC50 = 7.0 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
11043720 174435 0 None 257 3 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL242265 174435 0 None 257 3 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
11043720 174435 0 None 257 3 Human 7.0 pEC50 = 7.0 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL242265 174435 0 None 257 3 Human 7.0 pEC50 = 7.0 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
10221005 469239 0 None -575 3 Human 6.0 pEC50 = 6.0 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 267 4 2 5 0.8 Cc1ccc(S(C)(=O)=O)c(NCC2=NCCN2)c1 10.1021/jm000542r
CHEMBL71479 469239 0 None -575 3 Human 6.0 pEC50 = 6.0 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 267 4 2 5 0.8 Cc1ccc(S(C)(=O)=O)c(NCC2=NCCN2)c1 10.1021/jm000542r
57345627 143413 0 None 13 2 Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956194 143413 0 None 13 2 Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
2683 8346 48 None -2 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
5487 8346 48 None -2 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
7308 8346 48 None -2 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
CHEMBL1079 8346 48 None -2 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
DB00697 8346 48 None -2 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 nan
49836304 42432 0 None None None Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276219 42432 0 None None None Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
24906159 370643 13 None 3 3 Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
CHEMBL493675 370643 13 None 3 3 Human 6.9 pEC50 = 6.9 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
44292385 201255 0 None None None Human 7.9 pEC50 = 7.9 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL295186 201255 0 None None None Human 7.9 pEC50 = 7.9 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
1242 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
6603799 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
6852376 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
935 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL24077 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL284746 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL286080 7344 19 None -14 4 Human 5.9 pEC50 = 5.9 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
185076 370341 2 None -11 3 Human 7.9 pEC50 = 7.9 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL49137 370341 2 None -11 3 Human 7.9 pEC50 = 7.9 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
42669828 240316 1 None None None Human 3.8 pEC50 = 3.8 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
CHEMBL3588911 240316 1 None None None Human 3.8 pEC50 = 3.8 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
11140345 469103 0 None -2 5 Human 7.8 pEC50 = 7.8 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70692 469103 0 None -2 5 Human 7.8 pEC50 = 7.8 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
45487962 394570 0 None -2 2 Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL569933 394570 0 None -2 2 Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
11361608 175702 0 None None None Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 175702 0 None None None Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
11277479 175707 0 None None None Human 5.8 pEC50 = 5.8 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
CHEMBL222973 175707 0 None None None Human 5.8 pEC50 = 5.8 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
57345625 143410 0 None -1 2 Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956191 143410 0 None -1 2 Human 6.8 pEC50 = 6.8 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
13178306 240307 1 None None None Human 6.8 pEC50 = 6.8 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
CHEMBL3588902 240307 1 None None None Human 6.8 pEC50 = 6.8 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
10333157 289829 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL396013 289829 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
10333157 289829 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL396013 289829 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
49836302 42427 0 None None None Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276139 42427 0 None None None Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
49836302 42427 0 None None None Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276139 42427 0 None None None Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
2381 200503 44 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
68712 200503 44 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL289480 200503 44 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
DB11738 200503 44 None 1 3 Human 6.7 pEC50 = 6.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
57395731 143421 0 None -3 3 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956202 143421 0 None -3 3 Human 6.7 pEC50 = 6.7 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
481 5888 5 None -8 2 Human 5.7 pEC50 = 5.7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
9838763 5888 5 None -8 2 Human 5.7 pEC50 = 5.7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
CHEMBL72958 5888 5 None -8 2 Human 5.7 pEC50 = 5.7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 248 4 3 4 0.2 NC[C@@H](c1cc(ccc1F)NS(=O)(=O)C)O 10.1021/jm000542r
10199335 469632 0 None -120 2 Human 5.7 pEC50 = 5.7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74467 469632 0 None -120 2 Human 5.7 pEC50 = 5.7 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
218362 469682 1 None -1 3 Human 8.7 pEC50 = 8.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL75030 469682 1 None -1 3 Human 8.7 pEC50 = 8.7 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
11109088 469109 0 None -6 5 Human 8.6 pEC50 = 8.6 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70751 469109 0 None -6 5 Human 8.6 pEC50 = 8.6 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
23622576 346901 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL451229 346901 0 None 3 3 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
169087997 390383 7 None -93 4 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 278 1 1 2 3.1 Brc1cccc2c1OCCC2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
CHEMBL5532450 390383 7 None -93 4 Human 7.7 pEC50 = 7.7 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 278 1 1 2 3.1 Brc1cccc2c1OCCC2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
44292232 201451 0 None -1 3 Human 7.7 pEC50 = 7.7 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL296660 201451 0 None -1 3 Human 7.7 pEC50 = 7.7 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
44314200 203002 0 None 1 3 Human 7.6 pEC50 = 7.6 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
CHEMBL306377 203002 0 None 1 3 Human 7.6 pEC50 = 7.6 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
45487955 406965 0 None 125 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL576078 406965 0 None 125 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
49836301 42428 0 None 39 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276140 42428 0 None 39 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
49836308 42643 0 None None None Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278084 42643 0 None None None Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
49836301 42428 0 None 39 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276140 42428 0 None 39 2 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
49836307 42644 0 None None None Human 5.6 pEC50 = 5.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278085 42644 0 None None None Human 5.6 pEC50 = 5.6 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
10266032 372056 0 None None None Human 7.6 pEC50 = 7.6 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50720 372056 0 None None None Human 7.6 pEC50 = 7.6 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
44421258 175703 0 None 1 2 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 175703 0 None 1 2 Human 5.6 pEC50 = 5.6 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
44371755 102024 0 None -1 3 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL155866 102024 0 None -1 3 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44371864 104375 0 None -2 3 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157955 104375 0 None -2 3 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
169087981 390037 0 None -24 4 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 294 1 1 2 3.1 Fc1cc(Br)c2c(c1)C(c1c[nH]cn1)=CCO2 10.1021/acs.jmedchem.4c01239
CHEMBL5512438 390037 0 None -24 4 Human 7.6 pEC50 = 7.6 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 294 1 1 2 3.1 Fc1cc(Br)c2c(c1)C(c1c[nH]cn1)=CCO2 10.1021/acs.jmedchem.4c01239
11000184 27313 0 None -8 5 Human 7.6 pEC50 = 7.6 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1190038 27313 0 None -8 5 Human 7.6 pEC50 = 7.6 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
10859076 27933 0 None -5 4 Human 7.6 pEC50 = 7.6 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1194763 27933 0 None -5 4 Human 7.6 pEC50 = 7.6 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
521 2888 53 None -2 5 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human alpha2C-adrenoceptorAgonist activity at human alpha2C-adrenoceptor
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
5311068 2888 53 None -2 5 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human alpha2C-adrenoceptorAgonist activity at human alpha2C-adrenoceptor
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
835 2888 53 None -2 5 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human alpha2C-adrenoceptorAgonist activity at human alpha2C-adrenoceptor
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
CHEMBL778 2888 53 None -2 5 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human alpha2C-adrenoceptorAgonist activity at human alpha2C-adrenoceptor
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
DB00633 2888 53 None -2 5 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human alpha2C-adrenoceptorAgonist activity at human alpha2C-adrenoceptor
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
45487958 407710 0 None -1 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL576819 407710 0 None -1 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
2435 7889 70 None -4 5 Human 8.5 pEC50 = 8.5 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
395 7889 70 None -4 5 Human 8.5 pEC50 = 8.5 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
5386 7889 70 None -4 5 Human 8.5 pEC50 = 8.5 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
CHEMBL844 7889 70 None -4 5 Human 8.5 pEC50 = 8.5 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
3086326 469431 25 None -13 3 Human 7.5 pEC50 = 7.5 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL72753 469431 25 None -13 3 Human 7.5 pEC50 = 7.5 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
57400959 143419 0 None 1 3 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956200 143419 0 None 1 3 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
70693375 155060 0 None 12 2 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089155 155060 0 None 12 2 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
24906241 385360 0 None 7 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL522151 385360 0 None 7 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
434526 159196 20 None None None Human 5.5 pEC50 = 5.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
CHEMBL2087646 159196 20 None None None Human 5.5 pEC50 = 5.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
9816461 25000 4 None -60 2 Human 5.5 pEC50 = 5.5 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 253 4 2 5 0.5 CS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117094 25000 4 None -60 2 Human 5.5 pEC50 = 5.5 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 253 4 2 5 0.5 CS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
32238 46484 69 None None None Human 3.5 pEC50 = 3.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
CHEMBL1327 46484 69 None None None Human 3.5 pEC50 = 3.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
2146 6309 49 None -199 9 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
485 6309 49 None -199 9 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
6041 6309 49 None -199 9 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
CHEMBL1215 6309 49 None -199 9 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
DB00388 6309 49 None -199 9 Human 6.5 pEC50 = 6.5 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 167 3 3 3 0.6 CNC[C@@H](c1cccc(c1)O)O nan
122180567 240309 0 None None None Human 5.5 pEC50 = 5.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588904 240309 0 None None None Human 5.5 pEC50 = 5.5 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
49836303 42433 0 None 89 2 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276220 42433 0 None 89 2 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
169087993 390741 0 None -15 4 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 234 1 1 2 3.0 Clc1cccc2c1OCCC2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
CHEMBL5557226 390741 0 None -15 4 Human 7.5 pEC50 = 7.5 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 234 1 1 2 3.0 Clc1cccc2c1OCCC2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
24906197 370899 0 None 8 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL495097 370899 0 None 8 2 Human 5.5 pEC50 = 5.5 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
11300487 175956 0 None None None Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
CHEMBL223830 175956 0 None None None Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
169088005 390801 0 None -47 4 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 276 1 1 2 3.0 Brc1cccc2c1OCC=C2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
CHEMBL5558235 390801 0 None -47 4 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 276 1 1 2 3.0 Brc1cccc2c1OCC=C2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
16757089 183100 1 None None None Human 7.4 pEC50 = 7.4 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 183100 1 None None None Human 7.4 pEC50 = 7.4 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
45487956 407512 0 None 25 2 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
CHEMBL576623 407512 0 None 25 2 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
44549156 42431 0 None 79 2 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276218 42431 0 None 79 2 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
11265631 273853 0 None 9 3 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 273853 0 None 9 3 Human 7.4 pEC50 = 7.4 Functional
Agonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulationAgonist activity at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
2765 1943 17 None -95 5 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
515 1943 17 None -95 5 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
CHEMBL13852 1943 17 None -95 5 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
DB09202 1943 17 None -95 5 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
44269089 197328 0 None -1 2 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL266613 197328 0 None -1 2 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
44314198 212867 0 None -2 3 Human 8.4 pEC50 = 8.4 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL310335 212867 0 None -2 3 Human 8.4 pEC50 = 8.4 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
9815707 201592 0 None -2 3 Human 8.4 pEC50 = 8.4 Functional
Alpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297752 201592 0 None -2 3 Human 8.4 pEC50 = 8.4 Functional
Alpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha-2C adrenergic receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
1960 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
439260 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
505 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
6921840 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
CHEMBL1437 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
DB00368 5823 49 None -380 15 Human 6.4 pEC50 = 6.4 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/acs.jmedchem.4c01239
11058166 469593 0 None -10 2 Human 6.4 pEC50 = 6.4 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74114 469593 0 None -10 2 Human 6.4 pEC50 = 6.4 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
11346584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL374584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
11346584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL374584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
11346584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL374584 270477 0 None 112 2 Human 7.3 pEC50 = 7.3 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
57345629 143416 0 None 269 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956197 143416 0 None 269 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
46743607 240310 0 None None None Human 3.3 pEC50 = 3.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588905 240310 0 None None None Human 3.3 pEC50 = 3.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
169087989 390840 0 None -23 4 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 212 1 1 2 2.5 Cc1cccc2c1OCC=C2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
CHEMBL5558705 390840 0 None -23 4 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 212 1 1 2 2.5 Cc1cccc2c1OCC=C2c1c[nH]cn1 10.1021/acs.jmedchem.4c01239
521 2888 53 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
5311068 2888 53 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
835 2888 53 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
CHEMBL778 2888 53 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
DB00633 2888 53 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopyAgonist activity at alpha2C-adrenoceptor (unknown origin) expressed in CHO-alpha2C-PKAcatEGFP cells assessed as increase in intracellular calcium level measured after 15 mins incubation by Micro automated microscopy
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/acs.jmedchem.4c01239
11140347 469433 1 None -3 5 Human 8.3 pEC50 = 8.3 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72768 469433 1 None -3 5 Human 8.3 pEC50 = 8.3 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
11108001 25153 0 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117248 25153 0 None -2 5 Human 8.3 pEC50 = 8.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
45487145 404442 0 None 19 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570973 404442 0 None 19 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
24906198 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
CHEMBL495095 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
11265631 273853 0 None 9 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 273853 0 None 9 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
24906198 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
CHEMBL495095 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2C adrenoceptor expressed in CHO cells assessed as extracellular acidification measured after 4 mins by cytosensor microphysiometric analysis
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
24906198 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL495095 365892 3 None None None Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
11265631 273853 0 None 9 3 Human 7.3 pEC50 = 7.3 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
CHEMBL373535 273853 0 None 9 3 Human 7.3 pEC50 = 7.3 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
11173568 175598 0 None -1 2 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222371 175598 0 None -1 2 Human 6.3 pEC50 = 6.3 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
24906160 334032 0 None None None Human 6.3 pEC50 = 6.3 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL442815 334032 0 None None None Human 6.3 pEC50 = 6.3 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
11090351 328369 0 None -20 2 Human 6.3 pEC50 = 6.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL419448 328369 0 None -20 2 Human 6.3 pEC50 = 6.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
10221004 469156 0 None -20 2 Human 5.3 pEC50 = 5.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70973 469156 0 None -20 2 Human 5.3 pEC50 = 5.3 Functional
Agonist potency at Alpha-2C adrenergic receptor expressed in CHO cellsAgonist potency at Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
11079 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
3369 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
5509 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
CHEMBL761 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
DB06711 5576 48 None -3 3 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
13162 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
2803 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
CHEMBL134 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
10382537 469100 7 None -4 2 Human 7.3 pEC50 = 7.3 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL70676 469100 7 None -4 2 Human 7.3 pEC50 = 7.3 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
13162 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl nan
2803 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl nan
CHEMBL134 7899 43 None -19 4 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl nan
44371744 103556 0 None 8 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157206 103556 0 None 8 2 Human 7.3 pEC50 = 7.3 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
135399666 327759 4 None -66 6 Human 5.3 pEC50 = 5.3 Functional
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL437314 327759 4 None -66 6 Human 5.3 pEC50 = 5.3 Functional
Activity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assayActivity at adrenergic Alpha-2C receptor expressed in rat-mouse hybrid NH108-15 cell by adenylyl cyclase assay
ChEMBL 191 2 2 4 1.1 C[C@@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
13162 7899 43 None -19 4 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm100977d
2803 7899 43 None -19 4 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm100977d
CHEMBL134 7899 43 None -19 4 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm100977d
44352207 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL128168 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
44352207 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL128168 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
44352207 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL128168 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
44352207 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL128168 42715 0 None 1 3 Human 7.2 pEC50 = 7.2 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
11360447 175955 0 None -1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
CHEMBL223829 175955 0 None -1 3 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
49836305 42437 0 None 9 3 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276248 42437 0 None 9 3 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
10176999 213281 29 None 1 3 Human 8.2 pEC50 = 8.2 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
CHEMBL308570 213281 29 None 1 3 Human 8.2 pEC50 = 8.2 Functional
Effective concentration at Alpha-2C adrenergic receptor from CHO-C4 cellsEffective concentration at Alpha-2C adrenergic receptor from CHO-C4 cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
11211035 175957 0 None 1 2 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL223836 175957 0 None 1 2 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
11211035 175957 0 None 1 2 Human 7.2 pEC50 = 7.2 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL223836 175957 0 None 1 2 Human 7.2 pEC50 = 7.2 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
9971924 367543 0 None -1 2 Human 7.2 pEC50 = 7.2 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL48341 367543 0 None -1 2 Human 7.2 pEC50 = 7.2 Functional
Alpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMPAlpha2c receptor agonism measured as ability to inhibit forskolin-stimulated synthesis of cAMP
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
1343 3863 47 None -1 3 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1021/acs.jmedchem.4c01239
3519 3863 47 None -1 3 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1021/acs.jmedchem.4c01239
522 3863 47 None -1 3 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1021/acs.jmedchem.4c01239
CHEMBL862 3863 47 None -1 3 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1021/acs.jmedchem.4c01239
DB01018 3863 47 None -1 3 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 10.1021/acs.jmedchem.4c01239
45487089 394723 0 None 79 2 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570863 394723 0 None 79 2 Human 7.2 pEC50 = 7.2 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
57393922 143417 0 None 5 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 5 1 4 2.0 C=COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956198 143417 0 None 5 2 Human 6.2 pEC50 = 6.2 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 232 5 1 4 2.0 C=COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
10923927 469107 0 None None None Human 5.2 pEC50 = 5.2 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
CHEMBL70740 469107 0 None None None Human 5.2 pEC50 = 5.2 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
770500 240314 1 None None None Human 3.2 pEC50 = 3.2 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588909 240314 1 None None None Human 3.2 pEC50 = 3.2 Functional
Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysisAgonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
11034737 469428 0 None -1 4 Human 8.1 pEC50 = 8.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72724 469428 0 None -1 4 Human 8.1 pEC50 = 8.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
16757182 308630 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL397753 308630 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
16757182 308630 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL397753 308630 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
294234 202947 0 None -2 3 Human 7.1 pEC50 = 7.1 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
CHEMBL305928 202947 0 None -2 3 Human 7.1 pEC50 = 7.1 Functional
Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphateAgonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
24906200 385690 0 None 1 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL523048 385690 0 None 1 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
57395732 143422 0 None 2 2 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956203 143422 0 None 2 2 Human 7.1 pEC50 = 7.1 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
1960 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
439260 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
505 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
6921840 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
CHEMBL1437 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
DB00368 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm901262f
1960 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
439260 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
505 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
6921840 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
CHEMBL1437 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
DB00368 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm0408215
57395663 143412 0 None -3 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956193 143412 0 None -3 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
1960 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
439260 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
505 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
6921840 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
CHEMBL1437 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
DB00368 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm800250z
24906201 370595 0 None 15 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL493272 370595 0 None 15 2 Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidificationAgonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as stimulation of extracellular acidification
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
9947861 469097 0 None -281 3 Human 6.1 pEC50 = 6.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70634 469097 0 None -281 3 Human 6.1 pEC50 = 6.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
1960 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
439260 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
505 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
6921840 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
CHEMBL1437 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
DB00368 5823 49 None -380 15 Human 6.1 pEC50 = 6.1 Functional
Agonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulationAgonistic potency at human adrenergic Alpha-2C receptor expressed in CHO cells assessed as forskolin-induced cAMP accumulation
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm061487a
2435 7889 70 None -4 5 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
395 7889 70 None -4 5 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
5386 7889 70 None -4 5 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
CHEMBL844 7889 70 None -4 5 Human 8.1 pEC50 = 8.1 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 nan
10934575 469388 0 None -81 5 Human 8.1 pEC50 = 8.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72441 469388 0 None -81 5 Human 8.1 pEC50 = 8.1 Functional
Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptorAgonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
11173544 331095 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL426900 331095 0 None None None Human 6.1 pEC50 = 6.1 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
15675860 469334 0 None 1 2 Human 6.1 pEC50 = 6.1 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL72147 469334 0 None 1 2 Human 6.1 pEC50 = 6.1 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
44312036 469463 1 None 19 2 Human 6.1 pEC50 = 6.1 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
CHEMBL72995 469463 1 None 19 2 Human 6.1 pEC50 = 6.1 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
2435 7889 70 None -4 5 Human 8.0 pEC50 = 8.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
395 7889 70 None -4 5 Human 8.0 pEC50 = 8.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
5386 7889 70 None -4 5 Human 8.0 pEC50 = 8.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
CHEMBL844 7889 70 None -4 5 Human 8.0 pEC50 = 8.0 Functional
Alpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesisAlpha-2C adrenergic receptor agonistic potency as inhibition of forskolin-stimulated cyclic adenosine monophosphate synthesis
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
13162 7899 43 None -19 4 Human 6.0 pEC50 = 6.0 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/acs.jmedchem.4c01239
2803 7899 43 None -19 4 Human 6.0 pEC50 = 6.0 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/acs.jmedchem.4c01239
CHEMBL134 7899 43 None -19 4 Human 6.0 pEC50 = 6.0 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assayAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cells assessed as forskolin-stimulated intracellular cAMP accumulation incubated for 15 mins by Scintillation proximity assay
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/acs.jmedchem.4c01239
11371902 270611 0 None -1 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL385310 270611 0 None -1 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometryAgonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11140033 44532 0 None 4 3 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL130884 44532 0 None 4 3 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
11371902 270611 0 None -1 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
CHEMBL385310 270611 0 None -1 2 Human 7.0 pEC50 = 7.0 Functional
Agonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometryAgonist activity at human adrenergic alpha-2C receptor expressed in CHO cells assessed as extracellular acidification by cytosensor microphysiometry
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
57402717 143418 0 None 10 2 Human 5.0 pEC50 = 5.0 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956199 143418 0 None 10 2 Human 5.0 pEC50 = 5.0 Functional
Agonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysisAgonist activity at human adrenoceptor aplha 2C expressed in CHO cells assessed as rate of extracellular acidification by cytosensor microphysiometric analysis
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
156735109 369871 0 None None None Human 10.1 pIC50 = 10.1 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(COC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4878875 369871 0 None None None Human 10.1 pIC50 = 10.1 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(COC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
156735161 369638 0 None None None Human 9.6 pIC50 = 9.6 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 465 5 1 6 3.5 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC4(CC4)C3)C(F)C2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4875484 369638 0 None None None Human 9.6 pIC50 = 9.6 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 465 5 1 6 3.5 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC4(CC4)C3)C(F)C2)s1 10.1021/acsmedchemlett.1c00423
164617361 368144 0 None None None Human 9.5 pIC50 = 9.5 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 499 6 1 7 3.8 COc1cccc2c1CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
CHEMBL4852159 368144 0 None None None Human 9.5 pIC50 = 9.5 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 499 6 1 7 3.8 COc1cccc2c1CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
156735115 369694 0 None None None Human 9.4 pIC50 = 9.4 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 527 8 1 7 3.9 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CC4(F)F)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4876214 369694 0 None None None Human 9.4 pIC50 = 9.4 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 527 8 1 7 3.9 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CC4(F)F)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
156735204 369192 0 None None None Human 9.4 pIC50 = 9.4 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 483 5 1 6 4.1 Cc1ccc2c(c1)CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
CHEMBL4868807 369192 0 None None None Human 9.4 pIC50 = 9.4 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 483 5 1 6 4.1 Cc1ccc2c(c1)CN(C1CCN(c3ncc(C(=O)NCc4ncc(F)cc4F)s3)CC1)CC2 10.1021/acsmedchemlett.1c00423
156735188 369044 0 None None None Human 9.3 pIC50 = 9.3 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
CHEMBL4866383 369044 0 None None None Human 9.3 pIC50 = 9.3 Functional
Inhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assayInhibition of human alpha 2C adrenergic receptor expressed in CHO-K1 cells coexpressing Gaq and aequorin assessed as suppression of noradrenaline-induced intracellular calcium release by bioluminescence assay
ChEMBL 505 8 1 7 4.0 O=C(NCc1ncc(F)cc1F)c1cnc(N2CCC(N3CCCC(OCC4CCC4)C3)CC2)s1 10.1021/acsmedchemlett.1c00423
136 6696 31 None -1 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
643606 6696 31 None -1 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
CHEMBL10347 6696 31 None -1 2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulationAntagonist activity at human recombinant alpha2C adrenoceptor assessed as inhibition of epinephrine-induced cAMP accumulation
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
171714111 389958 1 None 2 3 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 409 2 3 5 2.5 N[C@H]1C[C@H](OC(=O)[C@@H]2[C@H]3C[C@H]4c5[nH]c6ccccc6c5CCN4C[C@@H]3CC[C@@H]2O)C1 10.1021/acs.jmedchem.4c00323
CHEMBL5505942 389958 1 None 2 3 Human 8.4 pIC50 = 8.4 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 409 2 3 5 2.5 N[C@H]1C[C@H](OC(=O)[C@@H]2[C@H]3C[C@H]4c5[nH]c6ccccc6c5CCN4C[C@@H]3CC[C@@H]2O)C1 10.1021/acs.jmedchem.4c00323
102 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
3659 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
8969 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
92766 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
CHEMBL15245 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
CHEMBL31410 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
DB01392 8930 44 None -3 15 Human 8.1 pIC50 = 8.1 Functional
Antagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assayAntagonist activity at ADRA2C (unknown origin) expressed in CHO cells coexpressing Gqi5 assessed as inhibition of brimonidine induced calcium mobilization preincubated for 15 mins followed by brimonidine addition at EC80 and measured for 180 secs by FLIPR assay
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
11306100 333185 0 None None None Human 10.5 pKi = 10.5 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 477 9 0 7 3.5 COCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL435352 333185 0 None None None Human 10.5 pKi = 10.5 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 477 9 0 7 3.5 COCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11271808 123755 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 490 9 0 7 3.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OCCN(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL176261 123755 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 490 9 0 7 3.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OCCN(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
135519400 136227 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 419 5 1 6 3.2 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(O)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL180470 136227 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 419 5 1 6 3.2 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(O)cc4OC[C@H]32)CC1 10.1021/jm049619s
135440165 160438 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112985 160438 0 None None None Human 10.0 pKi = 10 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
11214030 123311 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 491 8 0 8 3.1 COCC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL175853 123311 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 491 8 0 8 3.1 COCC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
44387789 123342 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 433 6 0 6 3.5 COc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL176002 123342 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 433 6 0 6 3.5 COc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11259744 123560 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 461 6 0 7 3.4 CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL176116 123560 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 461 6 0 7 3.4 CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11785961 125991 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 535 13 0 8 4.0 CCOCCOCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL179237 125991 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 535 13 0 8 4.0 CCOCCOCCOc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
44324800 473881 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL91157 473881 0 None None None Human 9.7 pKi = 9.7 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
11785068 123323 0 None None None Human 9.5 pKi = 9.5 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 7 3.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C5CC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL175911 123323 0 None None None Human 9.5 pKi = 9.5 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 7 3.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C5CC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
11260018 136194 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 473 7 0 7 3.6 C=CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL180322 136194 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 473 7 0 7 3.6 C=CC(=O)Oc1ccc2c(c1)OC[C@@H]1C2=NO[C@H]1CN1CCN(C/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11190988 259685 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 6 4.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC5CCCC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL369378 259685 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 487 7 0 6 4.8 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC5CCCC5)cc4OC[C@H]32)CC1 10.1021/jm049619s
11318438 330845 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 524 7 0 8 4.1 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)c5ccncc5)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL425324 330845 0 None None None Human 9.3 pKi = 9.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 524 7 0 8 4.1 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)c5ccncc5)cc4OC[C@H]32)CC1 10.1021/jm049619s
44324972 327521 0 None None None Human 9.2 pKi = 9.2 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL419316 327521 0 None None None Human 9.2 pKi = 9.2 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
11191321 125721 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 503 6 0 7 4.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C(C)(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL178588 125721 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 503 6 0 7 4.5 C/C(=C\c1ccccc1)CN1CCN(C[C@@H]2ON=C3c4ccc(OC(=O)C(C)(C)C)cc4OC[C@H]32)CC1 10.1021/jm049619s
135405894 160424 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 470 8 1 8 2.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(CCOc4ccc(F)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112969 160424 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 470 8 1 8 2.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(CCOc4ccc(F)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579272 370346 0 None None None Human 8.8 pKi = 8.8 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491420 370346 0 None None None Human 8.8 pKi = 8.8 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
71450907 160432 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4OC[C@H]32)CC1 10.1021/jm049619s
CHEMBL2112978 160432 0 None None None Human 8.8 pKi = 8.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4OC[C@H]32)CC1 10.1021/jm049619s
44579187 372797 0 None None None Human 8.7 pKi = 8.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
CHEMBL515331 372797 0 None None None Human 8.7 pKi = 8.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
25110718 384962 0 None None None Human 8.7 pKi = 8.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL524153 384962 0 None None None Human 8.7 pKi = 8.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44387798 331107 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 458 7 0 5 3.9 CC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(CCC/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL426959 331107 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 458 7 0 5 3.9 CC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(CCC/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
71456239 160433 0 None None None Human 7.0 pKi = 7.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 385 5 0 4 3.8 C1=C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112979 160433 0 None None None Human 7.0 pKi = 7.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 385 5 0 4 3.8 C1=C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
136044137 160430 0 None None None Human 7.9 pKi = 7.9 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 472 6 1 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112976 160430 0 None None None Human 7.9 pKi = 7.9 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 472 6 1 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CN2 10.1021/jm049619s
135499867 160434 0 None None None Human 7.8 pKi = 7.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 388 5 1 5 3.2 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4NC[C@H]32)CC1 10.1021/jm049619s
CHEMBL2112981 160434 0 None None None Human 7.8 pKi = 7.8 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 388 5 1 5 3.2 C(=C/c1ccccc1)\CN1CCN(C[C@@H]2ON=C3c4ccccc4NC[C@H]32)CC1 10.1021/jm049619s
3038503 155098 19 None None None Human 6.8 pKi = 6.8 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cell membrane assessed as increase in [35S]GTPgammaS binding incubated for 60 mins by liquid scintillation counting analysisAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cell membrane assessed as increase in [35S]GTPgammaS binding incubated for 60 mins by liquid scintillation counting analysis
ChEMBL 258 3 1 3 2.8 C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 10.1021/acs.jmedchem.4c01239
CHEMBL2107417 155098 19 None None None Human 6.8 pKi = 6.8 Functional
Agonist activity at human alpha2C-adrenoceptor expressed in HEK293 cell membrane assessed as increase in [35S]GTPgammaS binding incubated for 60 mins by liquid scintillation counting analysisAgonist activity at human alpha2C-adrenoceptor expressed in HEK293 cell membrane assessed as increase in [35S]GTPgammaS binding incubated for 60 mins by liquid scintillation counting analysis
ChEMBL 258 3 1 3 2.8 C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 10.1021/acs.jmedchem.4c01239
11224953 160427 0 None None None Human 8.6 pKi = 8.6 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 459 6 1 5 3.3 CCNC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112973 160427 0 None None None Human 8.6 pKi = 8.6 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 459 6 1 5 3.3 CCNC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
10758200 126125 0 None None None Human 7.7 pKi = 7.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL179648 126125 0 None None None Human 7.7 pKi = 7.7 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
44579184 374027 3 None None None Human 7.6 pKi = 7.6 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL518592 374027 3 None None None Human 7.6 pKi = 7.6 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
135519421 160428 0 None None None Human 7.6 pKi = 7.6 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 456 6 1 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc(Cl)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112974 160428 0 None None None Human 7.6 pKi = 7.6 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 456 6 1 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc(Cl)cc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579185 355653 1 None None None Human 7.6 pKi = 7.6 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL477816 355653 1 None None None Human 7.6 pKi = 7.6 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44324737 474143 0 None None None Human 8.5 pKi = 8.5 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL92860 474143 0 None None None Human 8.5 pKi = 8.5 Functional
Binding affinity for alpha-2C-adrenergic receptorBinding affinity for alpha-2C-adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
135477797 160425 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112971 160425 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44579230 355391 0 None None None Human 8.4 pKi = 8.4 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
CHEMBL476569 355391 0 None None None Human 8.4 pKi = 8.4 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
71456240 160435 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 415 6 0 5 3.8 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(C/C=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL2112982 160435 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 415 6 0 5 3.8 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(C/C=C/c2ccccc2)CC1 10.1021/jm049619s
44579228 355501 0 None None None Human 7.5 pKi = 7.5 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL477608 355501 0 None None None Human 7.5 pKi = 7.5 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
71456238 160431 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 504 9 0 7 4.4 COc1cc2c(cc1OC)N(C)C[C@@H]1C2=NO[C@H]1CN1CCN(CCC/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
CHEMBL2112977 160431 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 504 9 0 7 4.4 COc1cc2c(cc1OC)N(C)C[C@@H]1C2=NO[C@H]1CN1CCN(CCC/C(C)=C/c2ccccc2)CC1 10.1021/jm049619s
11200476 155162 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 402 5 0 5 3.2 CN1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112970 155162 0 None None None Human 8.4 pKi = 8.4 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 402 5 0 5 3.2 CN1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
44579229 372738 0 None None None Human 8.3 pKi = 8.3 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL514837 372738 0 None None None Human 8.3 pKi = 8.3 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
135545454 160436 0 None None None Human 8.3 pKi = 8.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 448 7 1 7 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
CHEMBL2112983 160436 0 None None None Human 8.3 pKi = 8.3 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 448 7 1 7 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CN2 10.1021/jm049619s
44324765 221065 0 None None None Human 8.2 pKi = 8.2 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 221065 0 None None None Human 8.2 pKi = 8.2 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
71461647 160426 0 None None None Human 8.2 pKi = 8.2 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 439 5 0 5 4.4 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
CHEMBL2112972 160426 0 None None None Human 8.2 pKi = 8.2 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 439 5 0 5 4.4 COc1ccc2c(c1)C=C[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
44579271 370345 0 None None None Human 8.2 pKi = 8.2 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491419 370345 0 None None None Human 8.2 pKi = 8.2 Functional
Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPRAntagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells assessed as inhibition of NE-induced calcium mobilization by FLIPR
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
10073773 316679 27 None None None Human 6.2 pKi = 6.2 Functional
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
CHEMBL4117187 316679 27 None None None Human 6.2 pKi = 6.2 Functional
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
DB06140 316679 27 None None None Human 6.2 pKi = 6.2 Functional
Inhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assayInhibition of recombinant human adrenergic alpha 2C receptor expressed in CHO cells assessed as inhibition of 5-HT stimulated cAMP accumulation after 4 hrs by luciferase reporter gene assay
ChEMBL 477 5 0 6 3.4 COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br 10.1021/acs.jmedchem.6b01662
44324765 221065 0 None None None Human 8.1 pKi = 8.1 Functional
Binding affinity for Alpha-2C adrenergic receptorBinding affinity for Alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 221065 0 None None None Human 8.1 pKi = 8.1 Functional
Binding affinity for Alpha-2C adrenergic receptorBinding affinity for Alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
136274357 160437 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 412 4 1 5 3.8 c1ccc2c(c1)NC[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
CHEMBL2112984 160437 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 412 4 1 5 3.8 c1ccc2c(c1)NC[C@@H]1C2=NO[C@H]1CN1CCN(Cc2ccc3ccccc3c2)CC1 10.1021/jm049619s
11385652 160429 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 460 6 0 6 3.7 CCOC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
CHEMBL2112975 160429 0 None None None Human 8.0 pKi = 8.0 Functional
Binding affinity for alpha-2C adrenergic receptorBinding affinity for alpha-2C adrenergic receptor
ChEMBL 460 6 0 6 3.7 CCOC(=O)N1C[C@@H]2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1021/jm049619s
1343 3863 47 None -1 3 Human 8.3 pEC50 = 8.3 Functional
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
3519 3863 47 None -1 3 Human 8.3 pEC50 = 8.3 Functional
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
522 3863 47 None -1 3 Human 8.3 pEC50 = 8.3 Functional
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
CHEMBL862 3863 47 None -1 3 Human 8.3 pEC50 = 8.3 Functional
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
DB01018 3863 47 None -1 3 Human 8.3 pEC50 = 8.3 Functional
NoneNone
Drug Central 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N None
2683 8346 48 None -2 4 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
5487 8346 48 None -2 4 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
7308 8346 48 None -2 4 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
CHEMBL1079 8346 48 None -2 4 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
DB00697 8346 48 None -2 4 Human 8.2 pEC50 = 8.2 Functional
Agonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassayAgonist activity at human recombinant alpha-2C receptor expressed in PC12 cells assessed as inhibition of forskolin-stimulated intracellular cAMP accumulation measured after 10 mins by cAMP enzyme immunoassay
Drug Central 253 1 2 6 1.7 Clc1ccc2c(c1NC1=NCCN1)nsn2 None
2803 1967 0 None -8 4 Human 8.2 pEC50 = 8.2 Functional
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
516 1967 0 None -8 4 Human 8.2 pEC50 = 8.2 Functional
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
704 1967 0 None -8 4 Human 8.2 pEC50 = 8.2 Functional
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
CHEMBL134 1967 0 None -8 4 Human 8.2 pEC50 = 8.2 Functional
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
DB00575 1967 0 None -8 4 Human 8.2 pEC50 = 8.2 Functional
NoneNone
Drug Central 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl None
2435 1490 0 None -10 4 Human 8.1 pEC50 = 8.1 Functional
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
395 1490 0 None -10 4 Human 8.1 pEC50 = 8.1 Functional
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
520 1490 0 None -10 4 Human 8.1 pEC50 = 8.1 Functional
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
CHEMBL844 1490 0 None -10 4 Human 8.1 pEC50 = 8.1 Functional
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
DB00484 1490 0 None -10 4 Human 8.1 pEC50 = 8.1 Functional
NoneNone
Drug Central 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 None
124 6070 37 None -36 11 Human 6.9 pEC50 = 6.9 Functional
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 6070 37 None -36 11 Human 6.9 pEC50 = 6.9 Functional
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 6070 37 None -36 11 Human 6.9 pEC50 = 6.9 Functional
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 6070 37 None -36 11 Human 6.9 pEC50 = 6.9 Functional
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 6070 37 None -36 11 Human 6.9 pEC50 = 6.9 Functional
β-arrestin recruitment and internalizationβ-arrestin recruitment and internalization
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2803 1967 0 None -8 4 Human 5.7 pEC50 = 5.7 Functional
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
516 1967 0 None -8 4 Human 5.7 pEC50 = 5.7 Functional
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
704 1967 0 None -8 4 Human 5.7 pEC50 = 5.7 Functional
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
CHEMBL134 1967 0 None -8 4 Human 5.7 pEC50 = 5.7 Functional
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
DB00575 1967 0 None -8 4 Human 5.7 pEC50 = 5.7 Functional
4.64 =value for β-arrestin recruitment and internalization4.64 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
12574 5302 68 None -15 3 Human 5.0 pEC50 = 5.0 Functional
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
1856 5302 68 None -15 3 Human 5.0 pEC50 = 5.0 Functional
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810 5302 68 None -15 3 Human 5.0 pEC50 = 5.0 Functional
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
CHEMBL19236 5302 68 None -15 3 Human 5.0 pEC50 = 5.0 Functional
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
DB09242 5302 68 None -15 3 Human 5.0 pEC50 = 5.0 Functional
4.73 =value for β-arrestin recruitment and internalization4.73 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
3952 3861 3 None -37 3 Human 5.9 pEC50 = 5.9 Functional
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646 3861 3 None -37 3 Human 5.9 pEC50 = 5.9 Functional
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5443 3861 3 None -37 3 Human 5.9 pEC50 = 5.9 Functional
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL1331786 3861 3 None -37 3 Human 5.9 pEC50 = 5.9 Functional
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
DB00629 3861 3 None -37 3 Human 5.9 pEC50 = 5.9 Functional
5.14 =value for β-arrestin recruitment and internalization5.14 =value for β-arrestin recruitment and internalization
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
2435 1490 0 None -10 4 Human 6.4 pEC50 = 6.4 Functional
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
395 1490 0 None -10 4 Human 6.4 pEC50 = 6.4 Functional
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
520 1490 0 None -10 4 Human 6.4 pEC50 = 6.4 Functional
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
CHEMBL844 1490 0 None -10 4 Human 6.4 pEC50 = 6.4 Functional
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
DB00484 1490 0 None -10 4 Human 6.4 pEC50 = 6.4 Functional
5.88 = value for β-arrestin recruitment and internalization5.88 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
1960 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
6921840 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 5823 49 None -380 15 Human 6.3 pEC50 = 6.3 Functional
6.02 = value for β-arrestin recruitment and internalization6.02 = value for β-arrestin recruitment and internalization
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
12574 5302 68 None -15 3 Human 6.9 pEC50 = 6.9 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
1856 5302 68 None -15 3 Human 6.9 pEC50 = 6.9 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 5302 68 None -15 3 Human 6.9 pEC50 = 6.9 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 5302 68 None -15 3 Human 6.9 pEC50 = 6.9 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 5302 68 None -15 3 Human 6.9 pEC50 = 6.9 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
523 8892 50 None 1 3 Human 7.1 pEC50 = 7.1 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 8892 50 None 1 3 Human 7.1 pEC50 = 7.1 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 8892 50 None 1 3 Human 7.1 pEC50 = 7.1 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 8892 50 None 1 3 Human 7.1 pEC50 = 7.1 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
1028 599 43 None -4 11 Human 7.6 pEC50 = 7.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 599 43 None -4 11 Human 7.6 pEC50 = 7.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 599 43 None -4 11 Human 7.6 pEC50 = 7.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 599 43 None -4 11 Human 7.6 pEC50 = 7.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 599 43 None -4 11 Human 7.6 pEC50 = 7.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
11079 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 5576 48 None -3 3 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
1960 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
6921840 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 5823 49 None -380 15 Human 7.7 pEC50 = 7.7 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
2803 1967 0 None -8 4 Human 7.8 pEC50 = 7.8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 1967 0 None -8 4 Human 7.8 pEC50 = 7.8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 1967 0 None -8 4 Human 7.8 pEC50 = 7.8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 1967 0 None -8 4 Human 7.8 pEC50 = 7.8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 1967 0 None -8 4 Human 7.8 pEC50 = 7.8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
1343 3863 47 None -1 3 Human 8.0 pEC50 = 8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 3863 47 None -1 3 Human 8.0 pEC50 = 8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 3863 47 None -1 3 Human 8.0 pEC50 = 8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 3863 47 None -1 3 Human 8.0 pEC50 = 8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 3863 47 None -1 3 Human 8.0 pEC50 = 8 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
2435 1490 0 None -10 4 Human 8.2 pEC50 = 8.2 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 1490 0 None -10 4 Human 8.2 pEC50 = 8.2 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 1490 0 None -10 4 Human 8.2 pEC50 = 8.2 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 1490 0 None -10 4 Human 8.2 pEC50 = 8.2 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 1490 0 None -10 4 Human 8.2 pEC50 = 8.2 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
3952 3861 3 None -37 3 Human 8.4 pEC50 = 8.4 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 3861 3 None -37 3 Human 8.4 pEC50 = 8.4 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 3861 3 None -37 3 Human 8.4 pEC50 = 8.4 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 3861 3 None -37 3 Human 8.4 pEC50 = 8.4 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 3861 3 None -37 3 Human 8.4 pEC50 = 8.4 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
521 2888 53 None -2 5 Human 9.6 pEC50 = 9.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 2888 53 None -2 5 Human 9.6 pEC50 = 9.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 2888 53 None -2 5 Human 9.6 pEC50 = 9.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 2888 53 None -2 5 Human 9.6 pEC50 = 9.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 2888 53 None -2 5 Human 9.6 pEC50 = 9.6 Functional
ERK1/2 phosphorylationERK1/2 phosphorylation
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
30699 490155 0 None -1 14 Human 8.3 pIC50 = 8.3 Functional
NoneNone
Drug Central 423 7 2 8 0.5 [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O None
575 490155 0 None -1 14 Human 8.3 pIC50 = 8.3 Functional
NoneNone
Drug Central 423 7 2 8 0.5 [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O None
DB01139 490155 0 None -1 14 Human 8.3 pIC50 = 8.3 Functional
NoneNone
Drug Central 423 7 2 8 0.5 [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O None
2337 6622 53 None -7 22 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
50 6622 53 None -7 22 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
5002 6622 53 None -7 22 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
CHEMBL716 6622 53 None -7 22 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
DB01224 6622 53 None -7 22 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 None
3158 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
667468 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
956 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
CHEMBL101740 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
CHEMBL1628227 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
DB01142 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
DB14750 18465 32 None -147 21 Human 8.2 pIC50 = 8.2 Functional
NoneNone
Drug Central 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 None
1816 5164 69 None -5 4 Human 6.7 pIC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
4205 5164 69 None -5 4 Human 6.7 pIC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
7241 5164 69 None -5 4 Human 6.7 pIC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
CHEMBL654 5164 69 None -5 4 Human 6.7 pIC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
DB00370 5164 69 None -5 4 Human 6.7 pIC50 = 6.7 Functional
UnclassifiedUnclassified
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10636247
102 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
3659 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
8969 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
92766 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
CHEMBL15245 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
CHEMBL31410 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
DB01392 8930 44 None -3 15 Human 7.4 pIC50 = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 25080296
12577 5214 0 None None None Human 8.9 pIC50 = 8.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
189711 5214 0 None None None Human 8.9 pIC50 = 8.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
CHEMBL1257057 5214 0 None None None Human 8.9 pIC50 = 8.9 Functional
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 25080296
12574 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
12574 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
1856 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
1856 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
4810 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
CHEMBL19236 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 25080296
DB09242 5302 68 None -11 4 Human 6.5 pIC50 = 6.5 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
1028 599 43 None -11 7 Human 6.7 pIC50 = 6.7 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 599 43 None -11 7 Human 6.7 pIC50 = 6.7 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 599 43 None -11 7 Human 6.7 pIC50 = 6.7 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 599 43 None -11 7 Human 6.7 pIC50 = 6.7 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 599 43 None -11 7 Human 6.7 pIC50 = 6.7 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
523 8892 50 None -7 3 Human 6.8 pIC50 = 6.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 8892 50 None -7 3 Human 6.8 pIC50 = 6.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 8892 50 None -7 3 Human 6.8 pIC50 = 6.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 8892 50 None -7 3 Human 6.8 pIC50 = 6.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
3952 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
3952 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5353646 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
5443 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
CHEMBL1331786 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 25080296
DB00629 3861 3 None -112 3 Human 7.0 pIC50 = 7.0 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
11079 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 5576 48 None -5 3 Human 7.1 pIC50 = 7.1 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
1343 3863 47 None -28 7 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 3863 47 None -28 7 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 3863 47 None -28 7 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 3863 47 None -28 7 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 3863 47 None -28 7 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3658 8894 44 None -39 3 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
517 8894 44 None -39 3 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709 8894 44 None -39 3 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
CHEMBL312448 8894 44 None -39 3 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
DB06694 8894 44 None -39 3 Human 7.2 pIC50 = 7.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
1960 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
1960 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
6921840 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
6921840 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 5823 49 None -1 3 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
2803 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
2803 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
516 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
704 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
CHEMBL134 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 25080296
DB00575 1967 0 None -10 5 Human 7.6 pIC50 = 7.6 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
124 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
124 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2032 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
CHEMBL762 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
DB00935 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 6070 37 None -102 14 Human 7.8 pIC50 = 7.8 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2435 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
2435 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
395 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
520 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
CHEMBL844 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 25080296
DB00484 1490 0 None -4 4 Human 8.3 pIC50 = 8.3 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
521 2888 53 None -50 3 Human 9.2 pIC50 = 9.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 2888 53 None -50 3 Human 9.2 pIC50 = 9.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 2888 53 None -50 3 Human 9.2 pIC50 = 9.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 2888 53 None -50 3 Human 9.2 pIC50 = 9.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 2888 53 None -50 3 Human 9.2 pIC50 = 9.2 Functional
inhibition of cAMP productioninhibition of cAMP production
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
3930 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
3930 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
540335 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
540335 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
CHEMBL106525 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 17220913
CHEMBL106525 4392 42 None None None Human 7.4 pKB = 7.4 Functional
UnclassifiedUnclassified
Guide to Pharmacology 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 35224877
13130 6036 0 None None None Human 9.8 pKB = 9.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
171037438 6036 0 None None None Human 9.8 pKB = 9.8 Functional
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812




Ligands (move mouse cursor over ligand name to see structure) Receptor Assay information Chemical information
Sel. page Similar-
ity
Common
name
GPCRdb
ID
#Vendors

Reference
ligand
Fold
selectivity
# Tested
GPCRs
Species

p-value
(-log)
Activity
Type
Activity
Relation
Activity
Value
Assay
Type
Assay
Description
Source

Mol
weight
Rot
Bonds
H don

H acc

LogP

Smiles

DOI

57345628 143414 0 None None None Human 8.7 pEC50 = 8.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956195 143414 0 None None None Human 8.7 pEC50 = 8.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
70695474 155061 0 None None None Human 8.7 pEC50 = 8.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089156 155061 0 None None None Human 8.7 pEC50 = 8.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
57345626 143411 0 None None None Human 8.0 pEC50 = 8 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
CHEMBL1956192 143411 0 None None None Human 8.0 pEC50 = 8 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
72947315 183297 0 None None None Human 6.0 pEC50 = 6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
CHEMBL2431280 183297 0 None None None Human 6.0 pEC50 = 6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
134137108 279870 0 None None None Human 6.9 pEC50 = 6.9 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 217 5 2 3 2.1 CCCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3892351 279870 0 None None None Human 6.9 pEC50 = 6.9 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 217 5 2 3 2.1 CCCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
49836304 42432 0 None None None Human 6.9 pEC50 = 6.9 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276219 42432 0 None None None Human 6.9 pEC50 = 6.9 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
44352155 235695 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 251 4 2 3 2.8 c1ccc(-c2ccccc2NCC2=NCCN2)cc1 10.1021/acsmedchemlett.6b00290
CHEMBL337862 235695 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 251 4 2 3 2.8 c1ccc(-c2ccccc2NCC2=NCCN2)cc1 10.1021/acsmedchemlett.6b00290
44269013 63990 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL13917 63990 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
134156190 298012 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 215 5 2 3 1.8 C=CCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3961335 298012 0 None None None Human 6.8 pEC50 = 6.8 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 215 5 2 3 1.8 C=CCc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
49836302 42427 0 None None None Human 6.7 pEC50 = 6.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276139 42427 0 None None None Human 6.7 pEC50 = 6.7 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
129928082 290951 1 None None None Human 7.7 pEC50 = 7.7 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 189 3 2 3 1.4 Cc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL3904276 290951 1 None None None Human 7.7 pEC50 = 7.7 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 189 3 2 3 1.4 Cc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
13123534 372580 1 None None None Human 6.7 pEC50 = 6.7 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 209 3 2 3 1.8 Clc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
CHEMBL51358 372580 1 None None None Human 6.7 pEC50 = 6.7 Binding
Agonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysisAgonist activity at human alpha2c-AR expressed in CHO cells assessed as rate of acidification after 240 mins by cytosensor microphysiometric analysis
ChEMBL 209 3 2 3 1.8 Clc1ccccc1NCC1=NCCN1 10.1021/acsmedchemlett.6b00290
72947314 183298 0 None None None Human 6.6 pEC50 = 6.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
CHEMBL2431281 183298 0 None None None Human 6.6 pEC50 = 6.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
49836301 42428 0 None None None Human 7.6 pEC50 = 7.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276140 42428 0 None None None Human 7.6 pEC50 = 7.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
73291731 183299 0 None None None Human 7.6 pEC50 = 7.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL2431282 183299 0 None None None Human 7.6 pEC50 = 7.6 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
70693375 155060 0 None None None Human 6.5 pEC50 = 6.5 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089155 155060 0 None None None Human 6.5 pEC50 = 6.5 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
49836303 42433 0 None None None Human 7.5 pEC50 = 7.5 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276220 42433 0 None None None Human 7.5 pEC50 = 7.5 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
44549156 42431 0 None None None Human 7.4 pEC50 = 7.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276218 42431 0 None None None Human 7.4 pEC50 = 7.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
2765 1943 17 None None None Human 6.4 pEC50 = 6.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
515 1943 17 None None None Human 6.4 pEC50 = 6.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
CHEMBL13852 1943 17 None None None Human 6.4 pEC50 = 6.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
DB09202 1943 17 None None None Human 6.4 pEC50 = 6.4 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
57345629 143416 0 None None None Human 7.3 pEC50 = 7.3 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956197 143416 0 None None None Human 7.3 pEC50 = 7.3 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
24906198 365892 3 None None None Human 7.3 pEC50 = 7.3 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL495095 365892 3 None None None Human 7.3 pEC50 = 7.3 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
44269006 65978 0 None None None Human 7.2 pEC50 = 7.2 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL14107 65978 0 None None None Human 7.2 pEC50 = 7.2 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
28918670 183295 1 None None None Human 7.0 pEC50 = 7.0 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL2431279 183295 1 None None None Human 7.0 pEC50 = 7.0 Binding
Agonist activity at human alpha2C ARAgonist activity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
44376984 119032 0 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 485 3 0 5 4.0 Cc1nc2ccc(I)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162682 119032 0 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 485 3 0 5 4.0 Cc1nc2ccc(I)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44377200 120216 1 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 437 3 0 5 4.1 Cc1nc2ccc(Br)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165350 120216 1 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 437 3 0 5 4.1 Cc1nc2ccc(Br)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
22120332 118860 0 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 389 4 0 6 3.4 COc1cccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc12 10.1016/s0960-894x(99)00591-0
CHEMBL162490 118860 0 None None None Human 9.2 pIC50 = 9.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 389 4 0 6 3.4 COc1cccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc12 10.1016/s0960-894x(99)00591-0
44377036 238834 0 None None None Human 9.1 pIC50 = 9.1 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL351483 238834 0 None None None Human 9.1 pIC50 = 9.1 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376954 118560 0 None None None Human 9.1 pIC50 = 9.1 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 387 3 0 5 4.0 Cc1cc(C)n2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
CHEMBL162232 118560 0 None None None Human 9.1 pIC50 = 9.1 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 387 3 0 5 4.0 Cc1cc(C)n2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
44376923 119227 0 None None None Human 9.0 pIC50 = 9.0 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2cccc(C)n2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL163190 119227 0 None None None Human 9.0 pIC50 = 9.0 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2cccc(C)n2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376958 120275 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
CHEMBL165796 120275 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccn2c(=O)c(CCN3CCc4oc5ccccc5c4C3)c(C)nc2c1 10.1016/s0960-894x(99)00591-0
22120322 118738 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2c1 10.1016/s0960-894x(99)00591-0
CHEMBL162370 118738 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1ccc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2c1 10.1016/s0960-894x(99)00591-0
44377035 238812 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2c(C)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL351200 238812 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 3 0 5 3.7 Cc1nc2c(C)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376993 119283 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 427 3 0 5 4.7 Cc1nc2c(Cl)cc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL163247 119283 0 None None None Human 8.9 pIC50 = 8.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 427 3 0 5 4.7 Cc1nc2c(Cl)cc(Cl)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
44376900 119074 0 None None None Human 8.8 pIC50 = 8.8 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 1 6 3.1 Cc1nc2c(O)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162826 119074 0 None None None Human 8.8 pIC50 = 8.8 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 1 6 3.1 Cc1nc2c(O)cccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
3045401 118874 35 None None None Human 8.8 pIC50 = 8.8 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 359 3 0 5 3.4 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162501 118874 35 None None None Human 8.8 pIC50 = 8.8 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 359 3 0 5 3.4 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
10531 2923 15 None None None Human 8.0 pIC50 = 8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
121 2923 15 None None None Human 8.0 pIC50 = 8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
888 2923 15 None None None Human 8.0 pIC50 = 8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL1732 2923 15 None None None Human 8.0 pIC50 = 8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00320 2923 15 None None None Human 8.0 pIC50 = 8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
3151 3013 70 None None None Human 6.0 pIC50 = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
945 3013 70 None None None Human 6.0 pIC50 = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
965 3013 70 None None None Human 6.0 pIC50 = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
CHEMBL219916 3013 70 None None None Human 6.0 pIC50 = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
DB01184 3013 70 None None None Human 6.0 pIC50 = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
3158 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
667468 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
956 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
CHEMBL101740 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
CHEMBL1628227 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
DB01142 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
DB14750 18465 32 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
16220269 372781 0 None None None Human 5.0 pIC50 = 5.0 Binding
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 361 3 1 2 4.4 CC[C@@H]1O[C@](/C=C/C2CC2)(C(F)(F)F)c2c(ccc(F)c2F)NC1=O 10.1073/pnas.0605125104
CHEMBL515170 372781 0 None None None Human 5.0 pIC50 = 5.0 Binding
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 361 3 1 2 4.4 CC[C@@H]1O[C@](/C=C/C2CC2)(C(F)(F)F)c2c(ccc(F)c2F)NC1=O 10.1073/pnas.0605125104
2142 6301 41 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
502 6301 41 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775 6301 41 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
CHEMBL597 6301 41 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
DB00692 6301 41 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
25014630 174539 1 None None None Human 5.0 pIC50 = 5.0 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 326 3 3 4 3.3 N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1 10.1016/j.ejmech.2012.07.006
CHEMBL2203713 174539 1 None None None Human 5.0 pIC50 = 5.0 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 326 3 3 4 3.3 N=C(Nc1ccc2c(c1)CCN2C1CCNCC1)c1cccs1 10.1016/j.ejmech.2012.07.006
3952 327526 35 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
5702063 327526 35 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
CHEMBL420 327526 35 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
DB00629 327526 35 None None None Human 6.0 pIC50 = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
44318454 470803 0 None None None Human 5.9 pIC50 = 5.9 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 312 2 0 3 3.5 CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL84931 470803 0 None None None Human 5.9 pIC50 = 5.9 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 312 2 0 3 3.5 CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1 10.1016/s0960-894x(01)00721-1
2657 470626 56 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
5472 470626 56 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL833 470626 56 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
DB00208 470626 56 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
1043 3255 6 None None None Human 7.9 pIC50 = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
149 3255 6 None None None Human 7.9 pIC50 = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223 3255 6 None None None Human 7.9 pIC50 = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL442 3255 6 None None None Human 7.9 pIC50 = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00696 3255 6 None None None Human 7.9 pIC50 = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
277 2680 45 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913 2680 45 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
765 2680 45 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL516 2680 45 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
DB00434 2680 45 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL5070958 478459 3 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 365 7 2 5 2.6 NCCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21 10.1021/acs.jmedchem.1c01564
9951544 120172 0 None None None Human 7.9 pIC50 = 7.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 0 5 3.8 Cc1nc2ccccn2c(=O)c1CCN1CCc2sc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165181 120172 0 None None None Human 7.9 pIC50 = 7.9 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 375 3 0 5 3.8 Cc1nc2ccccn2c(=O)c1CCN1CCc2sc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
123132228 312229 54 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 369 5 1 8 2.4 CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1 10.1021/acs.jmedchem.1c02148
CHEMBL4065484 312229 54 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 369 5 1 8 2.4 CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1 10.1021/acs.jmedchem.1c02148
10331436 666 9 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
160 666 9 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
CHEMBL133455 666 9 None None None Human 4.9 pIC50 = 4.9 Binding
Inhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligandInhibitory concentration required against Alpha-2A adrenergic receptor using [3H]clonidine radioligand
ChEMBL 230 2 2 2 2.4 C[C@@H](Cc1c[nH]c2c1c1CCCOc1cc2)N 10.1021/jm030205t
2105 6217 26 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
47811 6217 26 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
48 6217 26 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
CHEMBL531 6217 26 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
DB01186 6217 26 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
2398 1965 48 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801 1965 48 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
701 1965 48 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
CHEMBL415 1965 48 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
DB01242 1965 48 None None None Human 5.9 pIC50 = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
15730 143349 64 None None None Human 4.9 pIC50 = 4.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
CHEMBL195437 143349 64 None None None Human 4.9 pIC50 = 4.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
1548953 473104 29 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
CHEMBL954 473104 29 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
DB06735 473104 29 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
2683 202943 22 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL305906 202943 22 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
DB11073 202943 22 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
3054 315981 60 None None None Human 4.8 pIC50 = 4.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
448537 315981 60 None None None Human 4.8 pIC50 = 4.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
875 315981 60 None None None Human 4.8 pIC50 = 4.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
CHEMBL411 315981 60 None None None Human 4.8 pIC50 = 4.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
DB00255 315981 60 None None None Human 4.8 pIC50 = 4.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
1212 3415 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
204 3415 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372 3415 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
CHEMBL726 3415 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
DB00623 3415 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
138753276 351130 0 None None None Human 4.8 pIC50 = 4.8 Binding
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 302 4 2 3 2.8 CO[C@H]1CCN(Cc2c(C)cc(C)c3[nH]ccc23)[C@H](CO)C1 10.1021/acs.jmedchem.9b01870
CHEMBL4634827 351130 0 None None None Human 4.8 pIC50 = 4.8 Binding
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 302 4 2 3 2.8 CO[C@H]1CCN(Cc2c(C)cc(C)c3[nH]ccc23)[C@H](CO)C1 10.1021/acs.jmedchem.9b01870
196129 140073 12 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
CHEMBL1909065 140073 12 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
DB11525 140073 12 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
8447 372118 60 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
CHEMBL508112 372118 60 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
DB14201 372118 60 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
73453 63270 20 None None None Human 7.8 pIC50 = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
CHEMBL1385840 63270 20 None None None Human 7.8 pIC50 = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
100 8289 46 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
2637 8289 46 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
5452 8289 46 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
CHEMBL479 8289 46 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
DB00679 8289 46 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
3168 23567 68 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
966 23567 68 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
CHEMBL1108 23567 68 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
DB00450 23567 68 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
135 5144 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
1796 5144 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184 5144 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
CHEMBL6437 5144 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
DB06148 5144 38 None None None Human 6.8 pIC50 = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
138753277 351247 1 None None None Human 6.8 pIC50 = 6.8 Binding
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 303 1 2 3 3.3 Cc1cc(Br)c(NC2=NCCN2)c2ccccc12 10.1021/acs.jmedchem.9b01870
CHEMBL4636550 351247 1 None None None Human 6.8 pIC50 = 6.8 Binding
Inhibition of adrenergic receptor alpha2c (unknown origin)Inhibition of adrenergic receptor alpha2c (unknown origin)
ChEMBL 303 1 2 3 3.3 Cc1cc(Br)c(NC2=NCCN2)c2ccccc12 10.1021/acs.jmedchem.9b01870
183 84935 67 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
2162 84935 67 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
CHEMBL1491 84935 67 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
DB00381 84935 67 None None None Human 5.8 pIC50 = 5.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
1001 365921 35 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
10219 365921 35 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL50588 365921 35 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
DB13393 365921 35 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
1353 3909 69 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559 3909 69 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
86 3909 69 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
CHEMBL54 3909 69 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
DB00502 3909 69 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
9904205 461874 0 None None None Human 5.7 pIC50 = 5.7 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 294 2 0 3 3.4 CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL83658 461874 0 None None None Human 5.7 pIC50 = 5.7 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 294 2 0 3 3.4 CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1 10.1016/s0960-894x(01)00721-1
3468 350117 13 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
4138 350117 13 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL459265 350117 13 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
DB00406 350117 13 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
133 5073 43 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
1723 5073 43 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
28693 5073 43 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
CHEMBL19215 5073 43 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
DB13520 5073 43 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
213 8386 39 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2717 8386 39 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533 8386 39 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
CHEMBL621 8386 39 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
DB00656 8386 39 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2247 1042 63 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
249 1042 63 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2603 1042 63 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
CHEMBL296419 1042 63 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
DB00637 1042 63 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2335 26122 15 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
3018 26122 15 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL1182210 26122 15 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
DB11125 26122 15 None None None Human 5.7 pIC50 = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
1816 5164 69 None None None Human 6.7 pIC50 = 6.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
4205 5164 69 None None None Human 6.7 pIC50 = 6.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
7241 5164 69 None None None Human 6.7 pIC50 = 6.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
CHEMBL654 5164 69 None None None Human 6.7 pIC50 = 6.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
DB00370 5164 69 None None None Human 6.7 pIC50 = 6.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1016/s0960-894x(99)00591-0
44377007 119946 0 None None None Human 8.7 pIC50 = 8.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3c(Cl)cccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL164612 119946 0 None None None Human 8.7 pIC50 = 8.7 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3c(Cl)cccc3c2C1 10.1016/s0960-894x(99)00591-0
44376975 118801 0 None None None Human 8.6 pIC50 = 8.6 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 435 5 0 5 4.6 O=c1c(CCN2CCc3oc4ccccc4c3C2)c(Cc2ccccc2)nc2ccccn12 10.1016/s0960-894x(99)00591-0
CHEMBL162436 118801 0 None None None Human 8.6 pIC50 = 8.6 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 435 5 0 5 4.6 O=c1c(CCN2CCc3oc4ccccc4c3C2)c(Cc2ccccc2)nc2ccccn12 10.1016/s0960-894x(99)00591-0
CHEMBL5082142 478966 0 None None None Human 4.7 pIC50 = 4.7 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 435 8 1 6 3.0 c1cnc2c(c1)CN[C@@H](CN(CCCCN1CCOCC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
1971 5840 38 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
2404 5840 38 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543 5840 38 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
CHEMBL445 5840 38 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
DB00540 5840 38 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
45482789 424681 0 None None None Human 6.7 pIC50 = 6.7 Binding
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 428 4 2 2 4.5 CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1 10.1016/j.bmcl.2009.09.002
CHEMBL584554 424681 0 None None None Human 6.7 pIC50 = 6.7 Binding
Inhibition of adrenergic Alpha-2C receptorInhibition of adrenergic Alpha-2C receptor
ChEMBL 428 4 2 2 4.5 CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1 10.1016/j.bmcl.2009.09.002
CHEMBL5081505 478929 0 None None None Human 5.7 pIC50 = 5.7 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 419 7 2 5 3.7 c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
1200 3405 44 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
12488 3405 44 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
941361 3405 44 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
CHEMBL30008 3405 44 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
DB04841 3405 44 None None None Human 6.7 pIC50 = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
57345320 8342 12 None None None Human 4.6 pIC50 = 4.6 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
9882 8342 12 None None None Human 4.6 pIC50 = 4.6 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
CHEMBL3091687 8342 12 None None None Human 4.6 pIC50 = 4.6 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 364 7 2 4 3.2 NCCCCN([C@H]1CCCc2c1nccc2)C[C@@H]1NCc2c(C1)cccc2 10.1021/acs.jmedchem.1c01564
28417 83476 34 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
779 83476 34 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
CHEMBL1479 83476 34 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
DB01406 83476 34 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
2286 6468 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927 6468 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
7282 6468 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
CHEMBL643 6468 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
DB01069 6468 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
1028 599 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
479 599 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816 599 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL679 599 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
DB00668 599 43 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
1058 199583 51 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
222757 199583 51 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
CHEMBL282575 199583 51 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
DB13953 199583 51 None None None Human 4.6 pIC50 = 4.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
2284 6466 25 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
4926 6466 25 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
7281 6466 25 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
CHEMBL564 6466 25 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
DB00420 6466 25 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
124 6070 37 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
2032 6070 37 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636 6070 37 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
CHEMBL762 6070 37 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
DB00935 6070 37 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
102 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
3659 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
8969 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
92766 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
CHEMBL15245 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
CHEMBL31410 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
DB01392 8930 44 None None None Human 7.6 pIC50 = 7.6 Binding
Displacement of radioligand from human adrenergic Alpha-2C receptor after 60 minsDisplacement of radioligand from human adrenergic Alpha-2C receptor after 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm900458r
44377006 120259 0 None None None Human 7.6 pIC50 = 7.6 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccc(Cl)cc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165677 120259 0 None None None Human 7.6 pIC50 = 7.6 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 393 3 0 5 4.0 Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccc(Cl)cc3c2C1 10.1016/s0960-894x(99)00591-0
3191 202914 68 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
977 202914 68 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
CHEMBL305660 202914 68 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
DB11742 202914 68 None None None Human 6.6 pIC50 = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
2353 201246 55 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL295124 201246 55 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
DB04115 201246 55 None None None Human 5.6 pIC50 = 5.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
44376927 118459 0 None None None Human 8.4 pIC50 = 8.4 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 461 3 0 5 5.0 Cc1nc2c(Cl)cc(C(F)(F)F)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL162147 118459 0 None None None Human 8.4 pIC50 = 8.4 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 461 3 0 5 5.0 Cc1nc2c(Cl)cc(C(F)(F)F)cn2c(=O)c1CCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL5076569 478641 0 None None None Human 4.5 pIC50 = 4.5 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 365 7 2 5 2.6 NCCCCN(C[C@H]1Cc2cccnc2CN1)[C@H]1CCCc2cccnc21 10.1021/acs.jmedchem.1c01564
1634 163834 36 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
4011 163834 36 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
CHEMBL21731 163834 36 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
DB00934 163834 36 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
176516508 467778 0 None None None Human 5.5 pIC50 = 5.5 Binding
Inhibition of Adrenergic alpha2C at compound concentration of 10.0 uM in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_203810)Inhibition of Adrenergic alpha2C at compound concentration of 10.0 uM in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_203810)
ChEMBL 364 4 2 4 2.8 CCNc1cc(C#Cc2ccc(OC3CCN(C(N)=O)CC3)cc2)ccn1 10.6019/CHEMBL6193870
CHEMBL6195034 467778 0 None None None Human 5.5 pIC50 = 5.5 Binding
Inhibition of Adrenergic alpha2C at compound concentration of 10.0 uM in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_203810)Inhibition of Adrenergic alpha2C at compound concentration of 10.0 uM in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_203810)
ChEMBL 364 4 2 4 2.8 CCNc1cc(C#Cc2ccc(OC3CCN(C(N)=O)CC3)cc2)ccn1 10.6019/CHEMBL6193870
6918276 39502 6 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
CHEMBL1221512 39502 6 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
1482 367203 61 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
60838 367203 61 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
CHEMBL481 367203 61 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
DB00762 367203 61 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
191 833 62 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
201 833 62 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170 833 62 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
CHEMBL1113 833 62 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
DB00543 833 62 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2536 308773 12 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
5354 308773 12 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
CHEMBL404849 308773 12 None None None Human 5.5 pIC50 = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
102 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
3659 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
92766 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL15245 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL31410 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
DB01392 8930 44 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
2726 1895 54 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
621 1895 54 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
83 1895 54 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
CHEMBL71 1895 54 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
DB00477 1895 54 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2600 8239 59 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2608 8239 59 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
5405 8239 59 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
CHEMBL17157 8239 59 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
DB00342 8239 59 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
134551 741 18 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
271 741 18 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
885 741 18 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
CHEMBL1403281 741 18 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
2338 461820 42 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
237 461820 42 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL7568 461820 42 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
DB01103 461820 42 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
121432827 375281 0 None None None Human 5.4 pIC50 = 5.4 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 344 4 1 7 2.7 c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1 10.1021/acs.jmedchem.1c02148
CHEMBL5205327 375281 0 None None None Human 5.4 pIC50 = 5.4 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 344 4 1 7 2.7 c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1 10.1021/acs.jmedchem.1c02148
CHEMBL6067487 479737 0 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
1201549 1234 18 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
333 1234 18 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
7601 1234 18 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL1201203 1234 18 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
DB00245 1234 18 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
1588 4738 26 None None None Human 8.4 pIC50 = 8.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864 4738 26 None None None Human 8.4 pIC50 = 8.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
43 4738 26 None None None Human 8.4 pIC50 = 8.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
CHEMBL157138 4738 26 None None None Human 8.4 pIC50 = 8.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
DB00589 4738 26 None None None Human 8.4 pIC50 = 8.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
1355 42931 34 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
3561 42931 34 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
CHEMBL1289 42931 34 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
DB00793 42931 34 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
3408 41852 27 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
5353853 41852 27 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
CHEMBL1262 41852 27 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
DB00239 41852 27 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
2599 116531 16 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
5404 116531 16 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
CHEMBL1714574 116531 16 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
135 5144 38 None None None Human 7.4 pIC50 = 7.4 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
1796 5144 38 None None None Human 7.4 pIC50 = 7.4 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
4184 5144 38 None None None Human 7.4 pIC50 = 7.4 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
CHEMBL6437 5144 38 None None None Human 7.4 pIC50 = 7.4 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
DB06148 5144 38 None None None Human 7.4 pIC50 = 7.4 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1016/s0960-894x(01)00721-1
2337 6622 53 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
50 6622 53 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002 6622 53 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
CHEMBL716 6622 53 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
DB01224 6622 53 None None None Human 6.4 pIC50 = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
2406 200565 63 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
3032 200565 63 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
CHEMBL290106 200565 63 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
DB04813 200565 63 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
2436 470362 35 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
68617 470362 35 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL809 470362 35 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
DB01104 470362 35 None None None Human 5.4 pIC50 = 5.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
2180 140074 14 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
6761 140074 14 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
CHEMBL1909072 140074 14 None None None Human 7.4 pIC50 = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
5318 39468 43 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1221 39468 43 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
DB06820 39468 43 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL508338 372132 0 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
31101 1504 27 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
35 1504 27 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
403 1504 27 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
CHEMBL493 1504 27 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
DB01200 1504 27 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
1836 5276 50 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
3340 5276 50 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040 5276 50 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
CHEMBL787 5276 50 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
DB00471 5276 50 None None None Human 5.3 pIC50 = 5.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
12575 4064 28 None None None Human 7.3 pIC50 = 7.3 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
54459 4064 28 None None None Human 7.3 pIC50 = 7.3 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
CHEMBL10316 4064 28 None None None Human 7.3 pIC50 = 7.3 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
DB12551 4064 28 None None None Human 7.3 pIC50 = 7.3 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/s0960-894x(99)00591-0
135398745 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
1982 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
4585 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
47 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
CHEMBL715 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
DB00334 5933 69 None None None Human 6.3 pIC50 = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
11080 62743 48 None None None Human 4.3 pIC50 = 4.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
CHEMBL1381098 62743 48 None None None Human 4.3 pIC50 = 4.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
44376845 118370 1 None None None Human 7.2 pIC50 = 7.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 419 5 0 7 3.4 COc1cc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2cc1OC 10.1016/s0960-894x(99)00591-0
CHEMBL162058 118370 1 None None None Human 7.2 pIC50 = 7.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 419 5 0 7 3.4 COc1cc2nc(C)c(CCN3CCc4oc5ccccc5c4C3)c(=O)n2cc1OC 10.1016/s0960-894x(99)00591-0
180 829 44 None None None Human 7.2 pIC50 = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
200 829 44 None None None Human 7.2 pIC50 = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160 829 44 None None None Human 7.2 pIC50 = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
CHEMBL629 829 44 None None None Human 7.2 pIC50 = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
DB00321 829 44 None None None Human 7.2 pIC50 = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
44376936 120270 0 None None None Human 8.2 pIC50 = 8.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 4 0 5 3.7 Cc1nc2ccccn2c(=O)c1CCCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
CHEMBL165776 120270 0 None None None Human 8.2 pIC50 = 8.2 Binding
Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.
ChEMBL 373 4 0 5 3.7 Cc1nc2ccccn2c(=O)c1CCCN1CCc2oc3ccccc3c2C1 10.1016/s0960-894x(99)00591-0
1398859 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
3584 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
7302 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL1481149 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL611 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
DB01162 8235 54 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
141 2941 18 None None None Human 5.2 pIC50 = 5.2 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
6089 2941 18 None None None Human 5.2 pIC50 = 5.2 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
CHEMBL12420 2941 18 None None None Human 5.2 pIC50 = 5.2 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
DB01488 2941 18 None None None Human 5.2 pIC50 = 5.2 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
1343 3863 47 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519 3863 47 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
522 3863 47 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
CHEMBL862 3863 47 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
DB01018 3863 47 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
4209 8026 58 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893 8026 58 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
5385 8026 58 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
CHEMBL2 8026 58 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
1547484 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
2761 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
654 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
9072 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL43064 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
DB00568 1937 56 None None None Human 6.2 pIC50 = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
42611190 6416 21 None None None Human 5.2 pIC50 = 5.2 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
5802 6416 21 None None None Human 5.2 pIC50 = 5.2 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
CHEMBL1800685 6416 21 None None None Human 5.2 pIC50 = 5.2 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
1364 371049 49 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
3598 371049 49 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
CHEMBL496 371049 49 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
DB00756 371049 49 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
135398737 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
2818 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
38 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
722 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL253391 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL42 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
DB00363 1973 61 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
42574 39184 56 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
CHEMBL12131 39184 56 None None None Human 5.2 pIC50 = 5.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
2351 6685 46 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
2820 6685 46 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
5035 6685 46 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
CHEMBL81 6685 46 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
DB00481 6685 46 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
42636941 352851 0 None None None Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptorDisplacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptor
ChEMBL 343 5 0 5 4.4 CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1 10.1016/j.bmc.2008.11.045
CHEMBL470432 352851 0 None None None Human 6.1 pIC50 = 6.1 Binding
Displacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptorDisplacement of [3H]RX821002 form human recombinant Alpha-2C adrenergic receptor
ChEMBL 343 5 0 5 4.4 CCCN1CCC(COc2nc3scc(C)c3n3cccc23)CC1 10.1016/j.bmc.2008.11.045
240 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
2769 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
44279790 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
660 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
6917698 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL1729 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
DB00604 1945 27 None None None Human 6.1 pIC50 = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
104903 119144 14 None None None Human 5.1 pIC50 = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
4063 119144 14 None None None Human 5.1 pIC50 = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
CHEMBL1630578 119144 14 None None None Human 5.1 pIC50 = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
DB13050 119144 14 None None None Human 5.1 pIC50 = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
107715 443066 16 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
887 443066 16 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL601773 443066 16 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
DB13345 443066 16 None None None Human 8.1 pIC50 = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
2274 6448 36 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917 6448 36 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
7279 6448 36 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL728 6448 36 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
DB00433 6448 36 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL5077132 478675 0 None None None Human 5.1 pIC50 = 5.1 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 463 9 1 6 3.8 CN(CCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21)C1CCOCC1 10.1021/acs.jmedchem.1c01564
10381889 216717 0 None None None Human 6.1 pIC50 = 6.1 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 328 2 0 3 4.1 CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1 10.1016/s0960-894x(01)00721-1
CHEMBL315772 216717 0 None None None Human 6.1 pIC50 = 6.1 Binding
Binding affinity for human cloned Alpha-2C adrenergic receptorBinding affinity for human cloned Alpha-2C adrenergic receptor
ChEMBL 328 2 0 3 4.1 CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1 10.1016/s0960-894x(01)00721-1
132256889 373535 0 None None None Human 5.1 pIC50 = 5.1 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 378 5 1 7 3.6 COc1cccc(F)c1CNc1ccc(-c2cnc(C)nc2C)c2nncn12 10.1021/acs.jmedchem.1c02148
CHEMBL5178464 373535 0 None None None Human 5.1 pIC50 = 5.1 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 378 5 1 7 3.6 COc1cccc(F)c1CNc1ccc(-c2cnc(C)nc2C)c2nncn12 10.1021/acs.jmedchem.1c02148
CHEMBL5083458 479043 0 None None None Human 5.1 pIC50 = 5.1 Binding
Inhibition of alpha 2C adrenergic receptor (unknown origin)Inhibition of alpha 2C adrenergic receptor (unknown origin)
ChEMBL 421 9 2 6 2.6 c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2 10.1021/acs.jmedchem.1c01564
2389 6775 83 None None None Human 8.0 pIC50 = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073 6775 83 None None None Human 8.0 pIC50 = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
96 6775 83 None None None Human 8.0 pIC50 = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
CHEMBL85 6775 83 None None None Human 8.0 pIC50 = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
DB00734 6775 83 None None None Human 8.0 pIC50 = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
2585 1662 62 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
522 1662 62 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
551 1662 62 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
CHEMBL723 1662 62 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
DB01136 1662 62 None None None Human 7.1 pIC50 = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
141 2941 18 None None None Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
6089 2941 18 None None None Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
CHEMBL12420 2941 18 None None None Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
DB01488 2941 18 None None None Human 5.0 pIC50 = 5.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
26987 1955 32 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
6063 1955 32 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
671 1955 32 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
CHEMBL1626 1955 32 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
DB00283 1955 32 None None None Human 7.0 pIC50 = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
46209194 327673 7 None 6 3 Human 8.4 pKd = 8.4 Binding
Binding affinity to alpha2C receptor (unknown origin)Binding affinity to alpha2C receptor (unknown origin)
ChEMBL 355 5 0 6 2.2 COCc1cccnc1N1CCN(C[C@H]2COc3ccccc3O2)CC1 10.1021/acs.jmedchem.2c01965
CHEMBL4302506 327673 7 None 6 3 Human 8.4 pKd = 8.4 Binding
Binding affinity to alpha2C receptor (unknown origin)Binding affinity to alpha2C receptor (unknown origin)
ChEMBL 355 5 0 6 2.2 COCc1cccnc1N1CCN(C[C@H]2COc3ccccc3O2)CC1 10.1021/acs.jmedchem.2c01965
136019934 289714 0 None 7 3 Human 10.0 pKi = 10 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 289714 0 None 7 3 Human 10.0 pKi = 10 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
44324800 473881 0 None 5 7 Human 10.0 pKi = 10 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91157 473881 0 None 5 7 Human 10.0 pKi = 10 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324800 473881 0 None 5 7 Human 10.0 pKi = 10 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL91157 473881 0 None 5 7 Human 10.0 pKi = 10 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
49781228 41080 0 None -3 4 Human 9.9 pKi = 9.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 41080 0 None -3 4 Human 9.9 pKi = 9.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
52944548 41028 0 None -1 4 Human 9.8 pKi = 9.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.0 CC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255723 41028 0 None -1 4 Human 9.8 pKi = 9.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.0 CC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
49781228 41080 0 None -3 4 Human 9.8 pKi = 9.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 41080 0 None -3 4 Human 9.8 pKi = 9.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
44330168 18668 0 None 1 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL100879 18668 0 None 1 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330668 18784 0 None 5 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101596 18784 0 None 5 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330617 196954 0 None 5 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL263424 196954 0 None 5 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
11225779 217362 0 None 1 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cc(F)ccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319119 217362 0 None 1 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cc(F)ccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419316 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324800 473881 0 None 5 7 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL91157 473881 0 None 5 7 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330653 475065 0 None 8 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98646 475065 0 None 8 2 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccs4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL419316 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44325050 474185 0 None 3 3 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93171 474185 0 None 3 3 Human 9.7 pKi = 9.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324972 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL419316 327521 0 None 2 4 Human 9.7 pKi = 9.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
102 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
3659 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
8969 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
92766 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
CHEMBL15245 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
CHEMBL31410 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
DB01392 8930 44 None -60 31 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]RX821,002 from human ADRA2C expressed in CHO cellsDisplacement of [3H]RX821,002 from human ADRA2C expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.4c00323
49781228 41080 0 None -3 4 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
CHEMBL1256414 41080 0 None -3 4 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 196 1 1 1 2.4 c1ccc2c(c1)C[C@]1(c3c[nH]cn3)C[C@H]21 10.1021/jm1006269
16655023 217063 2 None 5 7 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 217063 2 None 5 7 Human 9.6 pKi = 9.6 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
52941512 41074 0 None -1 4 Human 9.5 pKi = 9.5 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256378 41074 0 None -1 4 Human 9.5 pKi = 9.5 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
44330369 221078 0 None 4 2 Human 9.5 pKi = 9.5 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328195 221078 0 None 4 2 Human 9.5 pKi = 9.5 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 469 7 0 8 3.6 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccsc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
10480357 475052 0 None 9 2 Human 9.5 pKi = 9.5 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98541 475052 0 None 9 2 Human 9.5 pKi = 9.5 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
177639257 390148 0 None -1 6 Human 9.5 pKi = 9.5 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 236 0 1 3 1.9 NC1=N[C@]2(CCc3cccc(Cl)c3C2)OC1 10.1021/acs.jmedchem.4c01239
CHEMBL5517941 390148 0 None -1 6 Human 9.5 pKi = 9.5 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 236 0 1 3 1.9 NC1=N[C@]2(CCc3cccc(Cl)c3C2)OC1 10.1021/acs.jmedchem.4c01239
44330114 217702 0 None 1 2 Human 9.4 pKi = 9.4 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319530 217702 0 None 1 2 Human 9.4 pKi = 9.4 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330635 475240 0 None 2 2 Human 9.4 pKi = 9.4 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1ccccc1/C=C(\C)CN1CCN(C[C@@H]2ON=C3c4cc(OC)c(OC)cc4OC[C@H]32)CC1 10.1016/j.bmcl.2004.03.031
CHEMBL99868 475240 0 None 2 2 Human 9.4 pKi = 9.4 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1ccccc1/C=C(\C)CN1CCN(C[C@@H]2ON=C3c4cc(OC)c(OC)cc4OC[C@H]32)CC1 10.1016/j.bmcl.2004.03.031
52948958 41029 0 None -1 4 Human 9.4 pKi = 9.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.4 CCC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255724 41029 0 None -1 4 Human 9.4 pKi = 9.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.4 CCC[C@H]1[C@@H]2c3ccccc3C[C@]12c1c[nH]cn1 10.1021/jm1006269
44579228 355501 0 None 13 3 Human 9.3 pKi = 9.3 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL477608 355501 0 None 13 3 Human 9.3 pKi = 9.3 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 467 7 2 7 2.9 CC(C)(C)Nc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
102 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
3659 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
8969 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
92766 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
CHEMBL15245 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
CHEMBL31410 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
DB01392 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.ejmech.2014.12.045
102 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
3659 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
8969 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
92766 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
CHEMBL15245 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
CHEMBL31410 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
DB01392 8930 44 None -60 31 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm401895u
44330645 475248 0 None 3 2 Human 9.3 pKi = 9.3 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL99916 475248 0 None 3 2 Human 9.3 pKi = 9.3 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 453 7 0 8 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccco4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324765 221065 0 None 2 5 Human 9.3 pKi = 9.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328114 221065 0 None 2 5 Human 9.3 pKi = 9.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324765 221065 0 None 2 5 Human 9.3 pKi = 9.3 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL328114 221065 0 None 2 5 Human 9.3 pKi = 9.3 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1021/jm049619s
49781222 41126 0 None -2 4 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 3.0 C[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256609 41126 0 None -2 4 Human 9.3 pKi = 9.3 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 3.0 C[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
44579230 355391 0 None 8 3 Human 9.2 pKi = 9.2 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
CHEMBL476569 355391 0 None 8 3 Human 9.2 pKi = 9.2 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1cccc(C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)n1 10.1016/j.bmcl.2008.08.055
44330368 221679 0 None 3 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 479 7 1 8 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(O)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL329065 221679 0 None 3 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 479 7 1 8 3.2 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(O)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44325049 221022 0 None 2 3 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C(\C)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL327875 221022 0 None 2 3 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C(\C)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
1588 4738 26 None -4 28 Human 9.2 pKi = 9.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
28864 4738 26 None -4 28 Human 9.2 pKi = 9.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
43 4738 26 None -4 28 Human 9.2 pKi = 9.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
CHEMBL157138 4738 26 None -4 28 Human 9.2 pKi = 9.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
DB00589 4738 26 None -4 28 Human 9.2 pKi = 9.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC nan
11203101 143911 0 None 44 3 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 515 7 3 5 4.1 O=C(CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
CHEMBL196451 143911 0 None 44 3 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 515 7 3 5 4.1 O=C(CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
16655023 217063 2 None 5 7 Human 9.2 pKi = 9.2 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 217063 2 None 5 7 Human 9.2 pKi = 9.2 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
16655023 217063 2 None 5 7 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL318235 217063 2 None 5 7 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330427 328354 0 None 4 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419336 328354 0 None 4 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccc(F)c4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330598 474521 0 None 8 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL95218 474521 0 None 8 2 Human 9.2 pKi = 9.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4cccc(F)c4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
108094 8046 24 None 1 3 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
528 8046 24 None 1 3 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
CHEMBL10332 8046 24 None 1 3 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 10.1021/jm800250z
499 8838 14 None -4 15 Human 9.1 pKi = 9.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
5685 8838 14 None -4 15 Human 9.1 pKi = 9.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
CHEMBL25554 8838 14 None -4 15 Human 9.1 pKi = 9.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 10.1021/jm00018a001
44579229 372738 0 None 6 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL514837 372738 0 None 6 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 468 10 1 7 2.8 CCCCOc1ncccc1C(=O)NCCN1CCCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
44579187 372797 0 None 25 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
CHEMBL515331 372797 0 None 25 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 513 8 1 8 3.3 N#Cc1cccc(Oc2ncccc2C(=O)NCCN2CCCN(CC3COc4ccccc4O3)CC2)c1 10.1016/j.bmcl.2008.08.055
44438167 295649 0 None 52 3 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL394218 295649 0 None 52 3 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 505 7 1 7 3.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NC4CN5CCC4CC5)cc13)CC2 10.1016/j.bmcl.2006.12.094
102 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
3659 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
8969 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
92766 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
CHEMBL15245 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
CHEMBL31410 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
DB01392 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.9b01465
10028898 221148 0 None 11 2 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328631 221148 0 None 11 2 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 499 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccc(F)cc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324737 474143 0 None 2 5 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92860 474143 0 None 2 5 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324737 474143 0 None 2 5 Human 9.1 pKi = 9.1 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
CHEMBL92860 474143 0 None 2 5 Human 9.1 pKi = 9.1 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1021/jm049619s
102 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
3659 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
8969 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
92766 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
CHEMBL15245 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
CHEMBL31410 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
DB01392 8930 44 None -60 31 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2005.03.116
25110718 384962 0 None 16 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL524153 384962 0 None 16 3 Human 9.1 pKi = 9.1 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44330857 18742 0 None 5 2 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4OC)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101361 18742 0 None 5 2 Human 9.1 pKi = 9.1 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 493 8 0 8 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4OC)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
136019934 289714 0 None 7 3 Human 9.0 pKi = 9.0 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 289714 0 None 7 3 Human 9.0 pKi = 9.0 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
124 6070 37 None -26 25 Human 9.0 pKi = 9 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
2032 6070 37 None -26 25 Human 9.0 pKi = 9 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636 6070 37 None -26 25 Human 9.0 pKi = 9 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
CHEMBL762 6070 37 None -26 25 Human 9.0 pKi = 9 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
DB00935 6070 37 None -26 25 Human 9.0 pKi = 9 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
136 6696 31 None 3 17 Human 9.0 pKi = 9 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
643606 6696 31 None 3 17 Human 9.0 pKi = 9 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL10347 6696 31 None 3 17 Human 9.0 pKi = 9 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
44402346 260602 0 None None None Human 9.0 pKi = 9.0 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 530 7 4 5 3.9 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
CHEMBL369938 260602 0 None None None Human 9.0 pKi = 9.0 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 530 7 4 5 3.9 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)OCc1ccccc1 10.1016/j.bmcl.2005.03.116
135398737 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
2818 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
38 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
722 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL253391 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
CHEMBL42 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
DB00363 1973 61 None -3 61 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 nan
52950140 41034 0 None -1 4 Human 8.9 pKi = 8.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 1 1 1 3.0 CC1(C)[C@@H]2c3ccccc3C[C@@]21c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255770 41034 0 None -1 4 Human 8.9 pKi = 8.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 1 1 1 3.0 CC1(C)[C@@H]2c3ccccc3C[C@@]21c1c[nH]cn1 10.1021/jm1006269
107715 443066 16 None -7 21 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
887 443066 16 None -7 21 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
CHEMBL601773 443066 16 None -7 21 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
DB13345 443066 16 None -7 21 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O nan
49781223 41127 0 None -2 4 Human 8.9 pKi = 8.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.3 CC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256610 41127 0 None -2 4 Human 8.9 pKi = 8.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 224 2 1 1 3.3 CC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
2389 6775 83 None -12 45 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
5073 6775 83 None -12 45 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
96 6775 83 None -12 45 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
CHEMBL85 6775 83 None -12 45 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
DB00734 6775 83 None -12 45 Human 8.9 pKi = 8.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 nan
10824121 239126 0 None None None Rat 8.9 pKi = 8.9 Binding
In vitro binding affinity against alpha-2C adrenergic receptor of male Wistar ratIn vitro binding affinity against alpha-2C adrenergic receptor of male Wistar rat
ChEMBL 242 2 1 2 2.8 Brc1csc(Cc2c[nH]cn2)c1 10.1021/jm0003891
CHEMBL354272 239126 0 None None None Rat 8.9 pKi = 8.9 Binding
In vitro binding affinity against alpha-2C adrenergic receptor of male Wistar ratIn vitro binding affinity against alpha-2C adrenergic receptor of male Wistar rat
ChEMBL 242 2 1 2 2.8 Brc1csc(Cc2c[nH]cn2)c1 10.1021/jm0003891
44324800 473881 0 None 5 7 Human 8.9 pKi = 8.9 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91157 473881 0 None 5 7 Human 8.9 pKi = 8.9 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
49781224 41019 0 None -1 4 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.7 CCC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1255616 41019 0 None -1 4 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 238 3 1 1 3.7 CCC[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10531 2923 15 None -16 30 Human 8.8 pKi = 8.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
121 2923 15 None -16 30 Human 8.8 pKi = 8.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
888 2923 15 None -16 30 Human 8.8 pKi = 8.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL1732 2923 15 None -16 30 Human 8.8 pKi = 8.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00320 2923 15 None -16 30 Human 8.8 pKi = 8.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
49781007 41116 0 None 2 4 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 4 1 2 3.3 CCCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256566 41116 0 None 2 4 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 4 1 2 3.3 CCCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
102 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
3659 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
8969 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
92766 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
CHEMBL15245 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
CHEMBL31410 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
DB01392 8930 44 None -60 31 Human 8.8 pKi = 8.8 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
44324937 473068 0 None -1 3 Human 8.8 pKi = 8.8 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(CC2ON=C3c4ccccc4OCC32)CC1 10.1016/s0960-894x(03)00525-0
CHEMBL90943 473068 0 None -1 3 Human 8.8 pKi = 8.8 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 389 5 0 5 3.1 C(=C/c1ccccc1)\CN1CCN(CC2ON=C3c4ccccc4OCC32)CC1 10.1016/s0960-894x(03)00525-0
1043 3255 6 None -8 33 Human 8.7 pKi = 8.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
149 3255 6 None -8 33 Human 8.7 pKi = 8.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
8223 3255 6 None -8 33 Human 8.7 pKi = 8.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
CHEMBL442 3255 6 None -8 33 Human 8.7 pKi = 8.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
DB00696 3255 6 None -8 33 Human 8.7 pKi = 8.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O nan
44579272 370346 0 None 5 3 Human 8.7 pKi = 8.7 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491420 370346 0 None 5 3 Human 8.7 pKi = 8.7 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 499 7 0 9 4.3 c1ccc(Oc2ncccc2-c2noc(CN3CCCN(CC4COc5ccccc5O4)CC3)n2)cc1 10.1016/j.bmcl.2008.08.055
102 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
3659 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
8969 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
92766 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
CHEMBL15245 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
CHEMBL31410 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
DB01392 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1016/j.bmcl.2006.12.094
56944383 221606 0 None -3 12 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 487 8 1 6 5.1 O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1 10.1021/jm401895u
CHEMBL3290012 221606 0 None -3 12 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
ChEMBL 487 8 1 6 5.1 O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1 10.1021/jm401895u
44324906 473732 0 None -3 3 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)OCC1C2=NOC1CN1CCN(C/C=C/c2ccccc2)CC1 10.1016/s0960-894x(03)00525-0
CHEMBL90247 473732 0 None -3 3 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)OCC1C2=NOC1CN1CCN(C/C=C/c2ccccc2)CC1 10.1016/s0960-894x(03)00525-0
44324725 473760 0 None 13 3 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 451 8 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90419 473760 0 None 13 3 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 451 8 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
49781005 41089 0 None -3 4 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 41089 0 None -3 4 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
2389 6775 83 None -12 45 Human 8.0 pKi = 8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
5073 6775 83 None -12 45 Human 8.0 pKi = 8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
96 6775 83 None -12 45 Human 8.0 pKi = 8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
CHEMBL85 6775 83 None -12 45 Human 8.0 pKi = 8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
DB00734 6775 83 None -12 45 Human 8.0 pKi = 8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1039/C2MD00311B
16655023 217063 2 None 5 7 Human 8.0 pKi = 8 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
CHEMBL318235 217063 2 None 5 7 Human 8.0 pKi = 8 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 481 7 0 7 3.7 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmc.2007.03.053
44330621 18750 0 None 6 2 Human 8.0 pKi = 8 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 483 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(Cl)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL101411 18750 0 None 6 2 Human 8.0 pKi = 8 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 483 7 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(Cl)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44324972 327521 0 None 2 4 Human 8.0 pKi = 8 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL419316 327521 0 None 2 4 Human 8.0 pKi = 8 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 463 7 0 7 3.5 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
49781006 41115 0 None -3 4 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 240 3 1 2 2.9 CCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256565 41115 0 None -3 4 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 240 3 1 2 2.9 CCO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
441082 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
8981 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
CHEMBL191703 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
441082 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
8981 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
CHEMBL191703 2406 38 None -2 7 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 356 1 0 2 4.8 CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C 10.1021/jm8003625
10707358 353178 0 None -7 3 Human 8.0 pKi = 8.0 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 272 4 1 3 3.2 c1ccc(CC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL47313 353178 0 None -7 3 Human 8.0 pKi = 8.0 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 272 4 1 3 3.2 c1ccc(CC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
242 971 74 None -16 38 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
34 971 74 None -16 38 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
60795 971 74 None -16 38 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
CHEMBL1112 971 74 None -16 38 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
DB01238 971 74 None -16 38 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1039/C2MD00311B
135398737 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
2818 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
38 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
722 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
CHEMBL253391 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
CHEMBL42 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
DB00363 1973 61 None -3 61 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1039/C2MD00311B
135398745 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
1982 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
4585 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
47 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
CHEMBL715 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
DB00334 5933 69 None -20 45 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1039/C2MD00311B
2337 6622 53 None -14 36 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
50 6622 53 None -14 36 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
5002 6622 53 None -14 36 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
CHEMBL716 6622 53 None -14 36 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
DB01224 6622 53 None -14 36 Human 7.0 pKi = 7 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 10.1039/C2MD00311B
16090600 333790 0 None 10 3 Human 7.0 pKi = 7 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL440594 333790 0 None 10 3 Human 7.0 pKi = 7 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
9982218 201875 5 None -12 6 Human 7.0 pKi = 7 Binding
Bnding affinity against cloned human Alpha-2C adrenergic receptor was evaluatedBnding affinity against cloned human Alpha-2C adrenergic receptor was evaluated
ChEMBL 471 9 2 5 4.1 O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1 10.1016/s0960-894x(02)00287-1
CHEMBL299879 201875 5 None -12 6 Human 7.0 pKi = 7 Binding
Bnding affinity against cloned human Alpha-2C adrenergic receptor was evaluatedBnding affinity against cloned human Alpha-2C adrenergic receptor was evaluated
ChEMBL 471 9 2 5 4.1 O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1 10.1016/s0960-894x(02)00287-1
16090600 333790 0 None 10 3 Human 7.0 pKi = 7 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1021/jm060262x
CHEMBL440594 333790 0 None 10 3 Human 7.0 pKi = 7 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 6 2 4 5.1 Cc1nc2ccccc2c(Nc2ccc(NCCN3CCCC3)cc2)c1C 10.1021/jm060262x
42611190 6416 21 None -2511 23 Human 6.0 pKi = 6 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
5802 6416 21 None -2511 23 Human 6.0 pKi = 6 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
CHEMBL1800685 6416 21 None -2511 23 Human 6.0 pKi = 6 Binding
Adrenergic alpha2C Eurofins-Panlabs radioligand binding assayAdrenergic alpha2C Eurofins-Panlabs radioligand binding assay
ChEMBL 475 4 2 2 7.4 OC(=O)c1cc2cc(ccc2c(c1)c1ccc(cc1)C1CCNCC1)c1ccc(cc1)C(F)(F)F 10.6019/CHEMBL4507292
10793665 176232 0 None -562 6 Human 6.0 pKi = 6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 597 9 2 5 6.3 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)cc1 10.1021/jm980077m
CHEMBL2260359 176232 0 None -562 6 Human 6.0 pKi = 6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 597 9 2 5 6.3 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)cc1 10.1021/jm980077m
CHEMBL314960 176232 0 None -562 6 Human 6.0 pKi = 6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 597 9 2 5 6.3 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)cc1 10.1021/jm980077m
42574 39184 56 None -18 3 Human 6.0 pKi = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
CHEMBL12131 39184 56 None -18 3 Human 6.0 pKi = 6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 662 4 2 3 7.1 Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O nan
153287553 335645 0 None -158 6 Human 6.0 pKi = 6 Binding
Displacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 264 1 1 2 3.7 C[C@@]12CN(c3ccccc3)c3ccccc3[C@@H]1CCN2 10.1021/acsmedchemlett.9b00225
CHEMBL4457754 335645 0 None -158 6 Human 6.0 pKi = 6 Binding
Displacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human recombinant adrenergic Alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 264 1 1 2 3.7 C[C@@]12CN(c3ccccc3)c3ccccc3[C@@H]1CCN2 10.1021/acsmedchemlett.9b00225
2719 1891 63 None -1 8 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
5535 1891 63 None -1 8 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
607 1891 63 None -1 8 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
CHEMBL76 1891 63 None -1 8 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
DB00608 1891 63 None -1 8 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC 10.1038/s41586-020-2286-9
9817231 314114 23 None -1 7 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 282 4 0 3 4.1 CCCN1CCC=C(c2cc(-c3ccc(C)cc3)no2)C1 10.1038/s41586-020-2286-9
CHEMBL4088272 314114 23 None -1 7 Human 5.0 pKi = 5 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 282 4 0 3 4.1 CCCN1CCC=C(c2cc(-c3ccc(C)cc3)no2)C1 10.1038/s41586-020-2286-9
72901200 238494 30 None -6918 33 Human 5.0 pKi = 5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 322 7 2 4 3.8 Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1 10.6019/CHEMBL4507309
CHEMBL3480577 238494 30 None -6918 33 Human 5.0 pKi = 5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 322 7 2 4 3.8 Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1 10.6019/CHEMBL4507309
CHEMBL4578164 478340 2 None -478 6 Human 5.0 pKi = 5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 549 5 1 6 5.8 CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O 10.6019/CHEMBL4507287
1364 371049 49 None -1 7 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
3598 371049 49 None -1 7 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
CHEMBL496 371049 49 None -1 7 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
DB00756 371049 49 None -1 7 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl nan
11801828 473502 0 None -63 6 Human 6.0 pKi = 6.0 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 606 9 3 6 5.0 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL88628 473502 0 None -63 6 Human 6.0 pKi = 6.0 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 606 9 3 6 5.0 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
3229 7931 37 None -2454 19 Human 6.0 pKi = 6.0 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 425 5 0 4 3.7 Fc1ccc(cc1)N1CCN(CC1)CCCN1c2cccc3c2c(S1(=O)=O)ccc3 10.6019/CHEMBL5442175
60785 7931 37 None -2454 19 Human 6.0 pKi = 6.0 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 425 5 0 4 3.7 Fc1ccc(cc1)N1CCN(CC1)CCCN1c2cccc3c2c(S1(=O)=O)ccc3 10.6019/CHEMBL5442175
CHEMBL83894 7931 37 None -2454 19 Human 6.0 pKi = 6.0 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 425 5 0 4 3.7 Fc1ccc(cc1)N1CCN(CC1)CCCN1c2cccc3c2c(S1(=O)=O)ccc3 10.6019/CHEMBL5442175
132584404 290123 0 None -2 5 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting methodDisplacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting method
ChEMBL 416 3 0 2 6.7 CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32 10.1016/j.bmcl.2016.10.065
CHEMBL3897499 290123 0 None -2 5 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting methodDisplacement of [3H]Rauwolscine from human Alpha2C receptor expressed in MDCK cells measured after 90 mins by microbeta scintillation counting method
ChEMBL 416 3 0 2 6.7 CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32 10.1016/j.bmcl.2016.10.065
11333552 240313 2 None None None Human 5.0 pKi = 5.0 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 223 4 1 4 1.1 COc1ccccc1OCC1CNCCO1 10.1016/j.bmc.2015.01.013
CHEMBL3588908 240313 2 None None None Human 5.0 pKi = 5.0 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 223 4 1 4 1.1 COc1ccccc1OCC1CNCCO1 10.1016/j.bmc.2015.01.013
2351 6685 46 None -4 21 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
2820 6685 46 None -4 21 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
5035 6685 46 None -4 21 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
CHEMBL81 6685 46 None -4 21 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
DB00481 6685 46 None -4 21 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O nan
171534638 465256 0 None -31 10 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 329 5 1 3 1.1 COc1cc([Se]C(F)(F)F)c(OC)cc1CCN 10.1021/acs.jmedchem.3c01961
CHEMBL6070400 465256 0 None -31 10 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 329 5 1 3 1.1 COc1cc([Se]C(F)(F)F)c(OC)cc1CCN 10.1021/acs.jmedchem.3c01961
122180567 240309 0 None None None Human 6.0 pKi = 6.0 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588904 240309 0 None None None Human 6.0 pKi = 6.0 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 261 4 1 3 3.8 c1cncc(-c2ccccc2NCc2ccncc2)c1 10.1016/j.bmc.2015.01.013
171534638 465256 0 None -31 10 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 329 5 1 3 1.1 COc1cc([Se]C(F)(F)F)c(OC)cc1CCN 10.1021/acs.jmedchem.3c01961
CHEMBL6070400 465256 0 None -31 10 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 329 5 1 3 1.1 COc1cc([Se]C(F)(F)F)c(OC)cc1CCN 10.1021/acs.jmedchem.3c01961
11948707 331012 0 None -269 13 Human 7.0 pKi = 7.0 Binding
Binding affinity to alpha 2C adrenergic receptor by radioligand binding assayBinding affinity to alpha 2C adrenergic receptor by radioligand binding assay
ChEMBL 373 7 0 8 0.6 COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1 10.1016/j.bmcl.2006.01.052
CHEMBL426317 331012 0 None -269 13 Human 7.0 pKi = 7.0 Binding
Binding affinity to alpha 2C adrenergic receptor by radioligand binding assayBinding affinity to alpha 2C adrenergic receptor by radioligand binding assay
ChEMBL 373 7 0 8 0.6 COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1 10.1016/j.bmcl.2006.01.052
16090635 163941 0 None 5 3 Human 7.0 pKi = 7.0 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1016/j.ejmech.2010.12.026
CHEMBL217768 163941 0 None 5 3 Human 7.0 pKi = 7.0 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1016/j.ejmech.2010.12.026
44289035 200668 0 None -575 7 Human 6.0 pKi = 6.0 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.4 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL291166 200668 0 None -575 7 Human 6.0 pKi = 6.0 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.4 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
127036186 274817 0 None -34 19 Human 6.0 pKi = 6.0 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 254 7 1 1 3.7 C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3753318 274817 0 None -34 19 Human 6.0 pKi = 6.0 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 254 7 1 1 3.7 C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12 10.1016/j.bmcl.2015.12.053
44210114 384932 16 None -6 3 Human 8.0 pKi = 8.0 Binding
Binding affinity to alpha2C AR (unknown origin) assessed as inhibition constantBinding affinity to alpha2C AR (unknown origin) assessed as inhibition constant
ChEMBL 492 5 0 6 4.3 O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1 10.1016/j.bmcl.2021.128275
CHEMBL5219924 384932 16 None -6 3 Human 8.0 pKi = 8.0 Binding
Binding affinity to alpha2C AR (unknown origin) assessed as inhibition constantBinding affinity to alpha2C AR (unknown origin) assessed as inhibition constant
ChEMBL 492 5 0 6 4.3 O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1 10.1016/j.bmcl.2021.128275
11293787 294899 0 None 27 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL393597 294899 0 None 27 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 447 6 0 5 5.8 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4F)cc13)CC2 10.1016/j.bmcl.2006.12.094
1393724 240495 0 None None None Human 7.9 pKi = 7.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 222 3 1 2 2.7 N#Cc1cccc(-c2ccccc2CCN)c1 10.1016/j.bmc.2015.01.013
CHEMBL3590203 240495 0 None None None Human 7.9 pKi = 7.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 222 3 1 2 2.7 N#Cc1cccc(-c2ccccc2CCN)c1 10.1016/j.bmc.2015.01.013
16090635 163941 0 None 5 3 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1021/jm060262x
CHEMBL217768 163941 0 None 5 3 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 4 1 4 4.7 CCc1c(C)nc2c(c1Nc1ccc(N3CCN(C)C(C)C3)cc1)CCCC2 10.1021/jm060262x
46869265 40147 0 None -5 7 Human 6.0 pKi = 6.0 Binding
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 295 1 3 3 3.1 Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21 10.1016/j.bmc.2010.07.052
CHEMBL1224527 40147 0 None -5 7 Human 6.0 pKi = 6.0 Binding
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 295 1 3 3 3.1 Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21 10.1016/j.bmc.2010.07.052
171357206 386311 0 None 1 5 Human 6.0 pKi = 6.0 Binding
Binding affinity to adrenergic alpha 2c receptor (unknown origin)Binding affinity to adrenergic alpha 2c receptor (unknown origin)
ChEMBL 383 4 0 3 5.0 CC[Si](C#Cc1cccc2c1OC(C(F)(F)F)C([N+](=O)[O-])=C2)(CC)CC 10.1016/j.bmcl.2022.128981
CHEMBL5274312 386311 0 None 1 5 Human 6.0 pKi = 6.0 Binding
Binding affinity to adrenergic alpha 2c receptor (unknown origin)Binding affinity to adrenergic alpha 2c receptor (unknown origin)
ChEMBL 383 4 0 3 5.0 CC[Si](C#Cc1cccc2c1OC(C(F)(F)F)C([N+](=O)[O-])=C2)(CC)CC 10.1016/j.bmcl.2022.128981
10489502 18864 1 None -11 3 Human 6.0 pKi = 6.0 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 2 2 2 3.5 Clc1cccc(Cl)c1Nc1ncc[nH]1 10.1021/jm9605142
CHEMBL1022 18864 1 None -11 3 Human 6.0 pKi = 6.0 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 2 2 2 3.5 Clc1cccc(Cl)c1Nc1ncc[nH]1 10.1021/jm9605142
49836307 42644 0 None -1 3 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278085 42644 0 None -1 3 Human 7.0 pKi = 7.0 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
240 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
2769 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
44279790 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
660 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
6917698 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
CHEMBL1729 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
DB00604 1945 27 None -7 23 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N nan
11386747 157157 17 None -1 3 Human 6.0 pKi = 6.0 Binding
Selectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2CSelectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2C
ChEMBL 513 4 1 5 6.4 CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12 10.6019/CHEMBL5212743
CHEMBL204232 157157 17 None -1 3 Human 6.0 pKi = 6.0 Binding
Selectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2CSelectivity interaction (Radioligand binding assay (MDS Pharma Service)) EUB0000296b ADRA2C
ChEMBL 513 4 1 5 6.4 CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12 10.6019/CHEMBL5212743
11140347 469433 1 None -18 6 Human 6.9 pKi = 6.9 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72768 469433 1 None -18 6 Human 6.9 pKi = 6.9 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1ccc(F)cc1NCC1=NCCN1 10.1021/jm000542r
71455894 174789 0 None 1 12 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205827 174789 0 None 1 12 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
71455894 174789 0 None 1 12 Human 5.9 pKi = 5.9 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmc.2013.07.045
CHEMBL2205827 174789 0 None 1 12 Human 5.9 pKi = 5.9 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 4 1 4 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmc.2013.07.045
104903 119144 14 None -1 6 Human 5.9 pKi = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
4063 119144 14 None -1 6 Human 5.9 pKi = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
CHEMBL1630578 119144 14 None -1 6 Human 5.9 pKi = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
DB13050 119144 14 None -1 6 Human 5.9 pKi = 5.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 nan
10841190 176224 0 None -162 6 Human 5.9 pKi = 5.9 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 2 6 5.7 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(OC)cc1 10.1021/jm980077m
CHEMBL2260150 176224 0 None -162 6 Human 5.9 pKi = 5.9 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 2 6 5.7 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(OC)cc1 10.1021/jm980077m
CHEMBL315538 176224 0 None -162 6 Human 5.9 pKi = 5.9 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 2 6 5.7 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(OC)cc1 10.1021/jm980077m
44311789 469620 0 None 1 5 Human 4.9 pKi = 4.9 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 345 1 2 5 3.1 Brc1c(NC2=N[C@@H]3CCCC[C@@H]3N2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL74342 469620 0 None 1 5 Human 4.9 pKi = 4.9 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 345 1 2 5 3.1 Brc1c(NC2=N[C@@H]3CCCC[C@@H]3N2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
1028 599 43 None -61 18 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
479 599 43 None -61 18 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
5816 599 43 None -61 18 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
CHEMBL679 599 43 None -61 18 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
DB00668 599 43 None -61 18 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
10220337 447503 31 None None None Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 236 2 0 2 2.7 Brc1cccc(Cn2ccnc2)c1 10.1016/j.bmc.2015.01.013
CHEMBL598391 447503 31 None None None Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 236 2 0 2 2.7 Brc1cccc(Cn2ccnc2)c1 10.1016/j.bmc.2015.01.013
2274 6448 36 None -2 25 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
4917 6448 36 None -2 25 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
7279 6448 36 None -2 25 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
CHEMBL728 6448 36 None -2 25 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
DB00433 6448 36 None -2 25 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 nan
218362 469682 1 None -5 4 Human 7.9 pKi = 7.9 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL75030 469682 1 None -5 4 Human 7.9 pKi = 7.9 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 216 1 1 3 2.0 c1ccc2c(c1)CCCC2NC1=NCCO1 10.1016/0960-894X(94)85032-1
2381 200503 44 None -1 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
68712 200503 44 None -1 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
CHEMBL289480 200503 44 None -1 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
DB11738 200503 44 None -1 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/j.bmc.2012.06.008
9883506 142807 0 None 1 6 Human 7.9 pKi = 7.9 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 282 3 3 5 2.3 Cc1ccc(N(NC2=NCCN2)c2cccc(O)c2)cc1 10.1016/j.bmcl.2005.07.083
CHEMBL194849 142807 0 None 1 6 Human 7.9 pKi = 7.9 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 282 3 3 5 2.3 Cc1ccc(N(NC2=NCCN2)c2cccc(O)c2)cc1 10.1016/j.bmcl.2005.07.083
9816048 370525 0 None -12 3 Human 6.9 pKi = 6.9 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 231 1 4 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCN2 10.1021/jm960359r
CHEMBL49284 370525 0 None -12 3 Human 6.9 pKi = 6.9 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 231 1 4 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCN2 10.1021/jm960359r
177381480 391538 0 None None None Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 277 1 1 1 4.4 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccc(F)c(F)c1)NC2(C)C 10.1021/acs.jmedchem.3c01758
CHEMBL5570620 391538 0 None None None Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 277 1 1 1 4.4 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccc(F)c(F)c1)NC2(C)C 10.1021/acs.jmedchem.3c01758
118717249 234112 0 None -18 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1cccc2cnn(N=C3NCCN3)c12 10.1016/j.ejmech.2014.09.083
CHEMBL3343700 234112 0 None -18 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1cccc2cnn(N=C3NCCN3)c12 10.1016/j.ejmech.2014.09.083
50985821 350185 38 None 2 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C receptor (unknown origin) by radioligand displacement assay
ChEMBL 474 5 2 5 6.2 N=c1c2c(-c3ccccc3)c(-c3ccccc3)n(Cc3ccccc3)c2ncn1[C@H]1CC[C@H](O)CC1 10.1021/acs.jmedchem.2c00204
CHEMBL4594433 350185 38 None 2 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C receptor (unknown origin) by radioligand displacement assay
ChEMBL 474 5 2 5 6.2 N=c1c2c(-c3ccccc3)c(-c3ccccc3)n(Cc3ccccc3)c2ncn1[C@H]1CC[C@H](O)CC1 10.1021/acs.jmedchem.2c00204
44292232 201451 0 None -4 3 Human 6.9 pKi = 6.9 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL296660 201451 0 None -4 3 Human 6.9 pKi = 6.9 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 222 3 1 3 2.2 CCC[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
9971924 367543 0 None -3 3 Human 6.9 pKi = 6.9 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL48341 367543 0 None -3 3 Human 6.9 pKi = 6.9 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 298 5 1 3 3.4 c1ccc(CCC[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
11221758 175577 0 None -7 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccccc1[N+](=O)[O-])C1=NCCN1 10.1021/jm0408215
CHEMBL222138 175577 0 None -7 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccccc1[N+](=O)[O-])C1=NCCN1 10.1021/jm0408215
49836304 42432 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276219 42432 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
49836304 42432 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276219 42432 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
49836305 42437 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276248 42437 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
56852956 221531 1 None -32 12 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
CHEMBL3289656 221531 1 None -32 12 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
24906203 370467 0 None -3 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL492445 370467 0 None -3 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
11380132 175383 0 None -1 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccccn1)C1=NCCN1 10.1021/jm0408215
CHEMBL221989 175383 0 None -1 3 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccccn1)C1=NCCN1 10.1021/jm0408215
662 7476 7 None -1778 6 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442175
9853583 7476 7 None -1778 6 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442175
CHEMBL2021721 7476 7 None -1778 6 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 756 14 2 8 6.3 COc1ccc2c(c1)ccc(c2)S(=O)(=O)N[C@@H](c1ccc2c(c1)OCO2)CC(=O)N[C@@H](C(=O)N(C(C)C)C)Cc1ccc(cc1)CN1[C@H](C)CCC[C@@H]1C 10.6019/CHEMBL5442175
56852956 221531 1 None -32 12 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
CHEMBL3289656 221531 1 None -32 12 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assayDisplacement of [3H]clonidine from human adrenergic-alpha2C receptor by PDSP assay
ChEMBL 339 5 0 6 2.8 c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1016/j.bmc.2014.04.026
44371744 103556 0 None -7 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157206 103556 0 None -7 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 270 7 1 3 2.9 C=CCc1cccc(CC=C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
2585 1662 62 None -24 22 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
522 1662 62 None -24 22 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
551 1662 62 None -24 22 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
CHEMBL723 1662 62 None -24 22 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
DB01136 1662 62 None -24 22 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O nan
44325044 474280 0 None 5 3 Human 7.9 pKi = 7.9 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4csc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93801 474280 0 None 5 3 Human 7.9 pKi = 7.9 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4csc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
136 6696 31 None 3 17 Human 7.9 pKi = 7.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.6019/CHEMBL5442175
643606 6696 31 None 3 17 Human 7.9 pKi = 7.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.6019/CHEMBL5442175
CHEMBL10347 6696 31 None 3 17 Human 7.9 pKi = 7.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.6019/CHEMBL5442175
213041 41010 26 None -2 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 230 2 1 1 3.0 CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1 10.1021/jm1006269
CHEMBL1255582 41010 26 None -2 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 230 2 1 1 3.0 CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1 10.1021/jm1006269
DB06585 41010 26 None -2 4 Human 7.9 pKi = 7.9 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 230 2 1 1 3.0 CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1 10.1021/jm1006269
CHEMBL4535474 478312 45 None -1 22 Human 6.9 pKi = 6.9 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL4507273
CHEMBL4535474 478312 45 None -1 22 Human 6.9 pKi = 6.9 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL4507273
CHEMBL4535474 478312 45 None -1 22 Human 6.9 pKi = 6.9 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000320b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000320b ADRA2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL5212743
489 297 25 None -154 9 Human 6.9 pKi = 6.9 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
5640 297 25 None -154 9 Human 6.9 pKi = 6.9 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
CHEMBL420060 297 25 None -154 9 Human 6.9 pKi = 6.9 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 401 7 1 8 1.0 COc1ccccc1N1CCN(CC1)CCCNc1c(C)c(=O)n(c(=O)n1C)C 10.1021/jm00018a001
11371902 270611 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL385310 270611 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
11371902 270611 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
CHEMBL385310 270611 0 None -2 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm0408215
11741010 164663 0 None 4 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL218730 164663 0 None 4 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
11741010 164663 0 None 4 3 Human 6.9 pKi = 6.9 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL218730 164663 0 None 4 3 Human 6.9 pKi = 6.9 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1cc(C)c2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
135356876 348140 0 None -7 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assayBinding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assay
ChEMBL 464 5 2 6 5.5 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-n2cc(-c3ccc(Cl)s3)nn2)c1 10.1021/acs.jmedchem.6b00044
CHEMBL4544251 348140 0 None -7 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assayBinding affinity to human alpha2C receptor expressed in MDCK cells by PDSP assay
ChEMBL 464 5 2 6 5.5 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-n2cc(-c3ccc(Cl)s3)nn2)c1 10.1021/acs.jmedchem.6b00044
9809007 327839 14 None -724 6 Human 5.9 pKi = 5.9 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL448620 327839 14 None -724 6 Human 5.9 pKi = 5.9 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
16090598 163881 0 None 5 3 Human 6.9 pKi = 6.9 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217568 163881 0 None 5 3 Human 6.9 pKi = 6.9 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090598 163881 0 None 5 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217568 163881 0 None 5 3 Human 6.9 pKi = 6.9 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cccc(Cl)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
71450548 174787 0 None 1 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
CHEMBL2205824 174787 0 None 1 3 Human 5.9 pKi = 5.9 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
4223 8657 61 None -512 17 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 441 7 2 5 4.0 N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 10.6019/CHEMBL5442175
6918314 8657 61 None -512 17 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 441 7 2 5 4.0 N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 10.6019/CHEMBL5442175
7427 8657 61 None -512 17 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 441 7 2 5 4.0 N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 10.6019/CHEMBL5442175
CHEMBL439849 8657 61 None -512 17 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 441 7 2 5 4.0 N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 10.6019/CHEMBL5442175
DB06684 8657 61 None -512 17 Human 5.9 pKi = 5.9 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 441 7 2 5 4.0 N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2 10.6019/CHEMBL5442175
42656257 240317 0 None None None Human 4.9 pKi = 4.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 2 1 3 2.6 COc1ccc(C2NCCCn3cccc32)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588912 240317 0 None None None Human 4.9 pKi = 4.9 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 2 1 3 2.6 COc1ccc(C2NCCCn3cccc32)cc1 10.1016/j.bmc.2015.01.013
26987 1955 32 None -107 21 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
6063 1955 32 None -107 21 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
671 1955 32 None -107 21 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
CHEMBL1626 1955 32 None -107 21 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
DB00283 1955 32 None -107 21 Human 7.9 pKi = 7.9 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C nan
164669024 391653 3 None 1 2 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 292 1 1 2 4.6 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccnc3ccccc13)NC2(C)C 10.1021/acs.jmedchem.3c01758
CHEMBL5572459 391653 3 None 1 2 Human 5.9 pKi = 5.9 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 292 1 1 2 4.6 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccnc3ccccc13)NC2(C)C 10.1021/acs.jmedchem.3c01758
10198248 370686 46 None -6 6 Human 5.9 pKi = 5.9 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 213 1 2 5 1.0 c1cnc2cc(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL49395 370686 46 None -6 6 Human 5.9 pKi = 5.9 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 213 1 2 5 1.0 c1cnc2cc(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
13091268 159801 0 None -208 14 Human 6.8 pKi = 6.8 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 401 6 1 3 5.0 O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL210578 159801 0 None -208 14 Human 6.8 pKi = 6.8 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 401 6 1 3 5.0 O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
44582678 355421 0 None 3 10 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 401 9 1 4 4.3 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL476839 355421 0 None 3 10 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 401 9 1 4 4.3 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
11108001 25153 0 None -12 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL117248 25153 0 None -12 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 221 4 2 4 1.8 CSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
11380133 333955 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccncc1)C1=NCCN1 10.1021/jm0408215
CHEMBL442045 333955 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1ccncc1)C1=NCCN1 10.1021/jm0408215
3151 3013 70 None -18 18 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
945 3013 70 None -18 18 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
965 3013 70 None -18 18 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
CHEMBL219916 3013 70 None -18 18 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
DB01184 3013 70 None -18 18 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 nan
73291731 183299 0 None -10 4 Human 6.8 pKi = 6.8 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL2431282 183299 0 None -10 4 Human 6.8 pKi = 6.8 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 3 2.4 CCCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
45487955 406965 0 None -2 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL576078 406965 0 None -2 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 232 4 1 3 2.7 CCCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
9827677 333115 0 None -7413 7 Human 5.8 pKi = 5.8 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 510 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL43491 333115 0 None -7413 7 Human 5.8 pKi = 5.8 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 510 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
50878551 181561 26 None -22 18 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL2391541 181561 26 None -22 18 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2015.12.053
44455426 311141 0 None -2 12 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 405 9 1 4 4.2 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL402143 311141 0 None -2 12 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 405 9 1 4 4.2 COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
144852560 335480 0 None -85 4 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 343 2 2 5 3.8 Clc1ccc(C#Cc2nc(NC3CCCC3)c3nc[nH]c3n2)s1 10.1039/C8MD00317C
CHEMBL4455344 335480 0 None -85 4 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 343 2 2 5 3.8 Clc1ccc(C#Cc2nc(NC3CCCC3)c3nc[nH]c3n2)s1 10.1039/C8MD00317C
71463063 174788 0 None -2 8 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
CHEMBL2205825 174788 0 None -2 8 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
21830793 182632 12 None -100 13 Human 7.8 pKi = 7.8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 10.1016/j.bmc.2013.05.050
CHEMBL2413154 182632 12 None -100 13 Human 7.8 pKi = 7.8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 373 7 0 8 0.6 COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1 10.1016/j.bmc.2013.05.050
10044968 193620 0 None 54 3 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL262901 193620 0 None 54 3 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
10044968 193620 0 None 54 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL262901 193620 0 None 54 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
44579231 355414 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 396 6 1 6 1.7 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1 10.1016/j.bmcl.2008.08.055
CHEMBL476774 355414 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 396 6 1 6 1.7 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1 10.1016/j.bmcl.2008.08.055
3158 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
667468 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
956 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
CHEMBL101740 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
CHEMBL1628227 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
DB01142 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
DB14750 18465 32 None -316 22 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 279 3 0 2 4.0 CN(C)CC/C=C1/c2ccccc2COc2ccccc21 nan
10609673 213499 0 None -11 3 Human 5.8 pKi = 5.8 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 233 4 2 4 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1OC 10.1021/jm9605142
CHEMBL308863 213499 0 None -11 3 Human 5.8 pKi = 5.8 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 233 4 2 4 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1OC 10.1021/jm9605142
118734875 237534 0 None -489 3 Human 5.8 pKi = 5.8 Binding
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1 10.1016/j.ejmech.2015.03.054
CHEMBL3417585 237534 0 None -489 3 Human 5.8 pKi = 5.8 Binding
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1 10.1016/j.ejmech.2015.03.054
73352414 183340 0 None -2 5 Human 5.8 pKi = 5.8 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 257 3 1 1 3.3 C1CCC(CN[C@H]2C3C4CC5C6C4CC3C6C52)CC1 10.1016/j.bmc.2013.07.045
CHEMBL2432038 183340 0 None -2 5 Human 5.8 pKi = 5.8 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 257 3 1 1 3.3 C1CCC(CN[C@H]2C3C4CC5C6C4CC3C6C52)CC1 10.1016/j.bmc.2013.07.045
737253 237300 78 None None None Human 5.8 pKi = 5.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccc(N)cc2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL341473 237300 78 None None None Human 5.8 pKi = 5.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccc(N)cc2)CC1 10.1016/j.bmc.2015.01.013
32238 46484 69 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
CHEMBL1327 46484 69 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 256 3 1 3 2.9 OC(Cn1ccnc1)c1ccc(Cl)cc1Cl 10.1016/j.bmc.2015.01.013
44582705 370251 0 None 3 13 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 399 9 0 4 4.5 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL490632 370251 0 None 3 13 Human 6.8 pKi = 6.8 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 399 9 0 4 4.5 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1 10.1016/j.bmc.2009.03.021
71463022 174688 7 None -1 4 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 436 8 0 5 5.3 COc1cc2oc(C(=O)N(CCCN3CCCCC3)c3ccccc3)c(C)c2cc1OC 10.1016/j.bmc.2012.09.044
CHEMBL2205362 174688 7 None -1 4 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 436 8 0 5 5.3 COc1cc2oc(C(=O)N(CCCN3CCCCC3)c3ccccc3)c(C)c2cc1OC 10.1016/j.bmc.2012.09.044
770500 240314 1 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588909 240314 1 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 242 4 2 3 2.4 NCC(=O)Nc1ccccc1Oc1ccccc1 10.1016/j.bmc.2015.01.013
4306793 240315 0 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 282 3 1 3 2.6 O=C(CCC1CCCC1)N1CCSC12CCNCC2 10.1016/j.bmc.2015.01.013
CHEMBL3588910 240315 0 None None None Human 4.8 pKi = 4.8 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 282 3 1 3 2.6 O=C(CCC1CCCC1)N1CCSC12CCNCC2 10.1016/j.bmc.2015.01.013
156419 1933 51 None -39 15 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442175
3308 1933 51 None -39 15 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442175
647 1933 51 None -39 15 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442175
CHEMBL1201284 1933 51 None -39 15 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442175
DB01012 1933 51 None -39 15 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 357 6 1 1 6.1 C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F 10.6019/CHEMBL5442175
10651654 176239 0 None -85 6 Human 6.8 pKi = 6.8 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 631 9 2 5 7.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)c(Cl)c1 10.1021/jm980077m
CHEMBL2260367 176239 0 None -85 6 Human 6.8 pKi = 6.8 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 631 9 2 5 7.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)c(Cl)c1 10.1021/jm980077m
CHEMBL327712 176239 0 None -85 6 Human 6.8 pKi = 6.8 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 631 9 2 5 7.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(Cl)c(Cl)c1 10.1021/jm980077m
158797 8221 22 None -37 13 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442175
718 8221 22 None -37 13 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442175
CHEMBL292376 8221 22 None -37 13 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 303 7 1 2 4.6 COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C 10.6019/CHEMBL5442175
24906202 370466 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL492444 370466 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2ccc3c(c2)OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
1395 99516 64 None -2 9 Human 4.8 pKi = 4.8 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
3652 99516 64 None -2 9 Human 4.8 pKi = 4.8 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
CHEMBL1535 99516 64 None -2 9 Human 4.8 pKi = 4.8 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
DB01611 99516 64 None -2 9 Human 4.8 pKi = 4.8 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 10.1038/s41586-020-2286-9
16090626 163562 0 None 77 3 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216727 163562 0 None 77 3 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
2142 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
502 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
5775 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
CHEMBL597 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
DB00692 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 nan
16090626 163562 0 None 77 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL216727 163562 0 None 77 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 378 3 1 4 4.9 Cc1nc2ccc(F)cc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
9906978 86128 1 None -1 12 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL150161 86128 1 None -1 12 Human 7.8 pKi = 7.8 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
10527469 312189 3 None -75 15 Human 7.8 pKi = 7.8 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 448 4 1 7 3.0 COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21 10.1021/jm970364a
CHEMBL40650 312189 3 None -75 15 Human 7.8 pKi = 7.8 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 448 4 1 7 3.0 COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21 10.1021/jm970364a
11211035 175957 0 None -1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL223836 175957 0 None -1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm061487a
11211035 175957 0 None -1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL223836 175957 0 None -1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 284 4 1 3 3.3 CC(Oc1ccccc1-c1cccc(F)c1)C1=NCCN1 10.1021/jm0408215
13162 7899 43 None -3 15 Human 6.8 pKi = 6.8 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm990569e
2803 7899 43 None -3 15 Human 6.8 pKi = 6.8 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm990569e
CHEMBL134 7899 43 None -3 15 Human 6.8 pKi = 6.8 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm990569e
11393666 385531 0 None -407 19 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 340 2 1 2 4.6 CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1 10.1016/j.bmcl.2022.128879
CHEMBL5222597 385531 0 None -407 19 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 340 2 1 2 4.6 CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1 10.1016/j.bmcl.2022.128879
3952 327526 35 None -5 11 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
5702063 327526 35 None -5 11 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
CHEMBL420 327526 35 None -5 11 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
DB00629 327526 35 None -5 11 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl nan
102 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
3659 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
8969 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
92766 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL15245 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL31410 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
DB01392 8930 44 None -60 31 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
44275807 193705 0 None -1995 10 Human 5.8 pKi = 5.8 Binding
Binding affinity towards human Alpha-2C adrenergic receptorBinding affinity towards human Alpha-2C adrenergic receptor
ChEMBL 422 7 0 4 4.5 C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1 10.1016/s0960-894x(03)00118-5
CHEMBL27979 193705 0 None -1995 10 Human 5.8 pKi = 5.8 Binding
Binding affinity towards human Alpha-2C adrenergic receptorBinding affinity towards human Alpha-2C adrenergic receptor
ChEMBL 422 7 0 4 4.5 C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1 10.1016/s0960-894x(03)00118-5
11199581 273989 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccccc1O)C1=NCCN1 10.1021/jm0408215
CHEMBL373830 273989 0 None -5 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccccc1O)C1=NCCN1 10.1021/jm0408215
132060746 328076 0 None -9 5 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 405 4 0 4 4.4 O=C(OCc1ccccc1)N1Cc2ccc(N3CCN(C4CCCC4)CC3)cc2C1 10.1016/j.ejmech.2018.02.024
CHEMBL4176474 328076 0 None -9 5 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 405 4 0 4 4.4 O=C(OCc1ccccc1)N1Cc2ccc(N3CCN(C4CCCC4)CC3)cc2C1 10.1016/j.ejmech.2018.02.024
9894818 199160 0 None -93 7 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm00019a001
CHEMBL279436 199160 0 None -93 7 Human 6.8 pKi = 6.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm00019a001
10859076 27933 0 None -2 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1194763 27933 0 None -2 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 249 5 2 4 2.6 CC(C)Sc1ccccc1NCC1=NCCN1 10.1021/jm000542r
9894818 199160 0 None -93 7 Human 6.8 pKi = 6.8 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 199160 0 None -93 7 Human 6.8 pKi = 6.8 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
21392988 469698 2 None -1 3 Human 4.8 pKi = 4.8 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 156 0 0 4 -0.3 C1COC(N2CCOCC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL75201 469698 2 None -1 3 Human 4.8 pKi = 4.8 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 156 0 0 4 -0.3 C1COC(N2CCOCC2)=N1 10.1016/0960-894X(94)85032-1
11109088 469109 0 None -36 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70751 469109 0 None -36 6 Human 6.8 pKi = 6.8 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 255 4 2 4 2.5 CSc1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
4567175 163902 4 None -2 3 Human 5.8 pKi = 5.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
CHEMBL217665 163902 4 None -2 3 Human 5.8 pKi = 5.8 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
15641841 385061 3 None -1 4 Human 7.8 pKi = 7.8 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 222 2 1 1 3.7 C[C@H](c1c[nH]cn1)c1cccc2ccccc12 10.1021/acs.jmedchem.4c01239
CHEMBL5542211 385061 3 None -1 4 Human 7.8 pKi = 7.8 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 222 2 1 1 3.7 C[C@H](c1c[nH]cn1)c1cccc2ccccc12 10.1021/acs.jmedchem.4c01239
12575 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
54459 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
CHEMBL10316 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
DB12551 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1021/jm800250z
11346584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
CHEMBL374584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm061487a
12575 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
54459 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
CHEMBL10316 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
DB12551 4064 28 None -19 5 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmc.2012.02.016
11346584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL374584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
11346584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL374584 270477 0 None 1 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm0408215
1398859 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
3584 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
5401 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
7302 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
CHEMBL1481149 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
CHEMBL611 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
DB01162 8235 54 None -50 13 Human 6.8 pKi = 6.8 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00010a001
4567175 163902 4 None -2 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1021/jm060262x
CHEMBL217665 163902 4 None -2 3 Human 5.8 pKi = 5.8 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 318 3 1 4 3.7 CN1CCN(c2ccc(Nc3ccnc4ccccc34)cc2)CC1 10.1021/jm060262x
9960497 200631 0 None -691 6 Human 5.8 pKi = 5.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL290860 200631 0 None -691 6 Human 5.8 pKi = 5.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL3392246 200631 0 None -691 6 Human 5.8 pKi = 5.8 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
171352812 386292 0 None -1 2 Human 4.8 pKi = 4.8 Binding
Displacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysisDisplacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysis
ChEMBL 305 3 2 2 4.1 C#Cc1cc(Nc2ccccc2C(=O)O)cc(C(F)(F)F)c1 10.1021/acs.jmedchem.2c01997
CHEMBL5273955 386292 0 None -1 2 Human 4.8 pKi = 4.8 Binding
Displacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysisDisplacement of [3H]RX821002 from human alpha2C receptor stably expressed in HEK293T cells by Cheng-Prusoff equation analysis
ChEMBL 305 3 2 2 4.1 C#Cc1cc(Nc2ccccc2C(=O)O)cc(C(F)(F)F)c1 10.1021/acs.jmedchem.2c01997
71452382 174781 0 None -53 10 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
CHEMBL2205812 174781 0 None -53 10 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1 10.1016/j.bmcl.2012.08.046
2657 470626 56 None -1 3 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
5472 470626 56 None -1 3 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
CHEMBL833 470626 56 None -1 3 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
DB00208 470626 56 None -1 3 Human 6.8 pKi = 6.8 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 nan
91826086 233928 48 None -2 8 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 418 7 3 7 3.2 CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1 10.6019/CHEMBL5442175
CHEMBL3342358 233928 48 None -2 8 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 418 7 3 7 3.2 CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1 10.6019/CHEMBL5442175
9815633 199829 1 None -44 6 Human 6.8 pKi = 6.8 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm990569e
CHEMBL284213 199829 1 None -44 6 Human 6.8 pKi = 6.8 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm990569e
9815633 199829 1 None -44 6 Rat 6.8 pKi = 6.8 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm000128r
CHEMBL284213 199829 1 None -44 6 Rat 6.8 pKi = 6.8 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 204 1 1 2 2.9 c1nc(C2CCCc3sccc32)c[nH]1 10.1021/jm000128r
21509921 214176 0 None -16 24 Human 6.8 pKi = 6.8 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104091 214176 0 None -16 24 Human 6.8 pKi = 6.8 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
73346042 182631 8 None -1737 17 Human 6.8 pKi = 6.8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 405 9 0 8 0.9 Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O 10.1016/j.bmc.2013.05.050
CHEMBL2413153 182631 8 None -1737 17 Human 6.8 pKi = 6.8 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 405 9 0 8 0.9 Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O 10.1016/j.bmc.2013.05.050
21509921 214176 0 None -16 24 Human 6.8 pKi = 6.8 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104091 214176 0 None -16 24 Human 6.8 pKi = 6.8 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.7 CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1 10.1016/j.bmcl.2013.12.024
599482 468039 5 None -12 5 Human 5.8 pKi = 5.8 Binding
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 202 1 2 2 1.8 COc1ccc2c3c([nH]c2c1)CNCC3 10.1016/j.bmcl.2003.09.027
CHEMBL6310 468039 5 None -12 5 Human 5.8 pKi = 5.8 Binding
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 202 1 2 2 1.8 COc1ccc2c3c([nH]c2c1)CNCC3 10.1016/j.bmcl.2003.09.027
3247 8052 26 None -1698 16 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 352 5 1 4 2.7 CC1CCN(CC1)CC[C@H]1CCCN1S(=O)(=O)c1cccc(c1)O 10.6019/CHEMBL5442175
6604889 8052 26 None -1698 16 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 352 5 1 4 2.7 CC1CCN(CC1)CC[C@H]1CCCN1S(=O)(=O)c1cccc(c1)O 10.6019/CHEMBL5442175
CHEMBL282199 8052 26 None -1698 16 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 352 5 1 4 2.7 CC1CCN(CC1)CC[C@H]1CCCN1S(=O)(=O)c1cccc(c1)O 10.6019/CHEMBL5442175
49836302 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276139 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml400232p
49836302 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276139 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/jm100977d
49836302 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276139 42427 0 None -1 3 Human 6.8 pKi = 6.8 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@H](C)C1=NCCN1 10.1021/ml300064v
4410 6381 68 None -645 5 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 502 4 6 8 0.4 C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1 10.6019/CHEMBL5442175
65015 6381 68 None -645 5 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 502 4 6 8 0.4 C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1 10.6019/CHEMBL5442175
844 6381 68 None -645 5 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 502 4 6 8 0.4 C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1 10.6019/CHEMBL5442175
CHEMBL18442 6381 68 None -645 5 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 502 4 6 8 0.4 C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1 10.6019/CHEMBL5442175
DB06809 6381 68 None -645 5 Human 5.8 pKi = 5.8 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 502 4 6 8 0.4 C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1 10.6019/CHEMBL5442175
71452387 174790 0 None -1 7 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmcl.2012.08.046
CHEMBL2205829 174790 0 None -1 7 Human 5.8 pKi = 5.8 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmcl.2012.08.046
71452387 174790 0 None -1 7 Human 5.8 pKi = 5.8 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmc.2013.07.045
CHEMBL2205829 174790 0 None -1 7 Human 5.8 pKi = 5.8 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 309 2 1 4 1.7 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2 10.1016/j.bmc.2013.07.045
11225732 194074 0 None 16 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246852 194074 0 None 16 3 Human 7.8 pKi = 7.8 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 497 6 0 5 6.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4C(F)(F)F)cc13)CC2 10.1016/j.bmcl.2006.12.094
1816 5164 69 None -4 15 Human 7.8 pKi = 7.8 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
4205 5164 69 None -4 15 Human 7.8 pKi = 7.8 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
7241 5164 69 None -4 15 Human 7.8 pKi = 7.8 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
CHEMBL654 5164 69 None -4 15 Human 7.8 pKi = 7.8 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
DB00370 5164 69 None -4 15 Human 7.8 pKi = 7.8 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 10.1021/jm049632c
118734876 237535 0 None -398 3 Human 5.8 pKi = 5.8 Binding
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1 10.1016/j.ejmech.2015.03.054
CHEMBL3417586 237535 0 None -398 3 Human 5.8 pKi = 5.8 Binding
Inhibition of alpha-2C adrenergic receptor (unknown origin)Inhibition of alpha-2C adrenergic receptor (unknown origin)
ChEMBL 327 6 1 4 2.4 C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1 10.1016/j.ejmech.2015.03.054
181743 346764 4 None -91 22 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]Clonidine from human adrenergic Alpha-2C receptorDisplacement of [3H]Clonidine from human adrenergic Alpha-2C receptor
ChEMBL 339 2 0 5 3.2 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4 10.1016/j.bmcl.2009.11.053
CHEMBL467094 346764 4 None -91 22 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]Clonidine from human adrenergic Alpha-2C receptorDisplacement of [3H]Clonidine from human adrenergic Alpha-2C receptor
ChEMBL 339 2 0 5 3.2 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4 10.1016/j.bmcl.2009.11.053
71452384 174784 0 None -8 5 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmcl.2012.08.046
CHEMBL2205816 174784 0 None -8 5 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmcl.2012.08.046
71452384 174784 0 None -8 5 Human 5.7 pKi = 5.7 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmc.2013.07.045
CHEMBL2205816 174784 0 None -8 5 Human 5.7 pKi = 5.7 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 280 3 1 3 1.4 OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccn1 10.1016/j.bmc.2013.07.045
277 2680 45 None -66 34 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
2913 2680 45 None -66 34 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
765 2680 45 None -66 34 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
CHEMBL516 2680 45 None -66 34 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
DB00434 2680 45 None -66 34 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 nan
71452383 174783 0 None -1 3 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205814 174783 0 None -1 3 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC 10.1016/j.bmcl.2012.08.046
12575 4064 28 None -19 5 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
54459 4064 28 None -19 5 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
CHEMBL10316 4064 28 None -19 5 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
DB12551 4064 28 None -19 5 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 10.1016/j.bmcl.2006.12.094
44438147 193906 0 None 19 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246228 193906 0 None 19 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 406 5 1 9 2.5 COc1cc2c(cc1OC)CN(Cc1cnc(N)n3nc(-c4ccco4)nc13)CC2 10.1016/j.bmcl.2006.12.094
44438152 194025 0 None 42 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 10.1016/j.bmcl.2006.12.094
CHEMBL246639 194025 0 None 42 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 459 7 0 6 5.7 COc1cccc(-c2cc3c(CN4CCc5cc(OC)c(OC)cc5C4)ccc(OC)c3o2)c1 10.1016/j.bmcl.2006.12.094
10176999 213281 29 None -11 3 Human 7.7 pKi = 7.7 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
CHEMBL308570 213281 29 None -11 3 Human 7.7 pKi = 7.7 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 231 2 2 4 2.2 Cc1c(Nc2ncc[nH]2)ccc2c1OCCO2 10.1021/jm9605142
44402344 270588 0 None None None Human 7.7 pKi = 7.7 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 340 1 3 3 2.6 O=C(O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL382310 270588 0 None None None Human 7.7 pKi = 7.7 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 340 1 3 3 2.6 O=C(O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10220053 473854 0 None -3 3 Human 7.7 pKi = 7.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1016/s0960-894x(03)00525-0
CHEMBL90997 473854 0 None -3 3 Human 7.7 pKi = 7.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1016/s0960-894x(03)00525-0
10220053 473854 0 None -3 3 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1021/jm049619s
CHEMBL90997 473854 0 None -3 3 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 218 2 1 2 1.9 Fc1ccc2c(c1)CC(CC1CN=CN1)C2 10.1021/jm049619s
10758200 126125 0 None -5 5 Human 7.7 pKi = 7.7 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL179648 126125 0 None -5 5 Human 7.7 pKi = 7.7 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 322 4 0 3 3.2 c1ccc(CN2CCN(CC3CCc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
10531 2923 15 None -16 30 Human 7.7 pKi = 7.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.6019/CHEMBL5442175
121 2923 15 None -16 30 Human 7.7 pKi = 7.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.6019/CHEMBL5442175
888 2923 15 None -16 30 Human 7.7 pKi = 7.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.6019/CHEMBL5442175
CHEMBL1732 2923 15 None -16 30 Human 7.7 pKi = 7.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.6019/CHEMBL5442175
DB00320 2923 15 None -16 30 Human 7.7 pKi = 7.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O 10.6019/CHEMBL5442175
71151588 237081 0 None -1905 10 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 518 9 1 7 3.6 NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1 10.1016/j.ejmech.2014.12.045
CHEMBL3409256 237081 0 None -1905 10 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cellsDisplacement of [3H]RX-821002 from human adrenergic alpha2C receptor expressed in CHO cells
ChEMBL 518 9 1 7 3.6 NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1 10.1016/j.ejmech.2014.12.045
9895326 473954 0 None -177 6 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 12 3 6 5.7 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CC)N1 10.1021/jm980077m
CHEMBL91550 473954 0 None -177 6 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 12 3 6 5.7 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CC)N1 10.1021/jm980077m
44288769 201282 0 None -1737 7 Human 5.7 pKi = 5.7 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 542 7 1 4 4.5 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL295395 201282 0 None -1737 7 Human 5.7 pKi = 5.7 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 542 7 1 4 4.5 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
11301655 411 40 None -1258 4 Human 5.7 pKi = 5.7 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
8441 411 40 None -1258 4 Human 5.7 pKi = 5.7 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
CHEMBL127257 411 40 None -1258 4 Human 5.7 pKi = 5.7 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 320 3 1 3 3.5 Cc1ccc(cc1C)N1CCN(CC1)Cc1nc2c([nH]1)cccc2 10.1021/acs.jmedchem.7b00151
44209472 142418 1 None -107 11 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 315 6 0 4 2.8 Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940420 142418 1 None -107 11 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 315 6 0 4 2.8 Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
3086326 469431 25 None -5 6 Human 6.7 pKi = 6.7 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL72753 469431 25 None -5 6 Human 6.7 pKi = 6.7 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 247 1 2 5 1.7 Clc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
49781005 41089 0 None -3 4 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 41089 0 None -3 4 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10934575 469388 0 None -11 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72441 469388 0 None -11 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 4 2 4 2.1 CSc1ccc(C)cc1NCC1=NCCN1 10.1021/jm000542r
44352207 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL128168 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm800250z
44352207 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL128168 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
44352207 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL128168 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
44352207 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL128168 42715 0 None -4 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 CC(Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
44288874 201230 0 None -1995 7 Human 5.7 pKi = 5.7 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 528 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL295001 201230 0 None -1995 7 Human 5.7 pKi = 5.7 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 528 7 2 4 4.2 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
25142456 155194 1 None 3 9 Human 8.7 pKi = 8.7 Binding
Binding affinity to human cloned adrenergic alpha 2C receptor receptorBinding affinity to human cloned adrenergic alpha 2C receptor receptor
ChEMBL 269 0 3 4 2.1 Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2 10.1021/jm0604979
CHEMBL217299 155194 1 None 3 9 Human 8.7 pKi = 8.7 Binding
Binding affinity to human cloned adrenergic alpha 2C receptor receptorBinding affinity to human cloned adrenergic alpha 2C receptor receptor
ChEMBL 269 0 3 4 2.1 Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2 10.1021/jm0604979
102 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
3659 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
8969 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
92766 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
CHEMBL15245 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
CHEMBL31410 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
DB01392 8930 44 None -60 31 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to controlDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2C receptor expressed in CHO-K1 cells incubated for 60 mins by spectrophotometric analysis relative to control
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/acs.jmedchem.3c01961
44330679 475102 0 None 10 2 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 464 7 0 8 2.9 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccnc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL98889 475102 0 None 10 2 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 464 7 0 8 2.9 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4cccnc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
9928332 197495 3 None -1 9 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1016/s0960-894x(03)00525-0
CHEMBL268258 197495 3 None -1 9 Human 8.7 pKi = 8.7 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1016/s0960-894x(03)00525-0
9928332 197495 3 None -1 9 Human 8.7 pKi = 8.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1021/jm049619s
CHEMBL268258 197495 3 None -1 9 Human 8.7 pKi = 8.7 Binding
Inhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptorInhibition of [3H]- rauwolscine binding to alpha-2C adrenergic receptor
ChEMBL 349 6 0 3 5.0 COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1 10.1021/jm049619s
49781887 41020 0 None -5 4 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 41020 0 None -5 4 Human 8.7 pKi = 8.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
11079 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
3369 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
4436 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
5509 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
CHEMBL761 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
DB06711 5576 48 None -2 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 10.1016/j.bmc.2015.01.013
10045713 330953 0 None 309 3 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1021/jm060262x
CHEMBL425983 330953 0 None 309 3 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1021/jm060262x
44324887 329927 0 None -2 3 Human 8.6 pKi = 8.6 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL422597 329927 0 None -2 3 Human 8.6 pKi = 8.6 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 419 6 0 6 3.1 COc1ccc2c(c1)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
102 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
3659 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
8969 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
92766 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL15245 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
CHEMBL31410 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
DB01392 8930 44 None -60 31 Human 8.6 pKi = 8.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 10.1021/jm00019a001
10045713 330953 0 None 309 3 Human 8.6 pKi = 8.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL425983 330953 0 None 309 3 Human 8.6 pKi = 8.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 386 3 1 4 5.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN4CCCCC4C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
9805944 119035 30 None -3 9 Human 8.6 pKi = 8.6 Binding
Displacement of [125I]HEAT from adrenergic Alpha-2C receptorDisplacement of [125I]HEAT from adrenergic Alpha-2C receptor
ChEMBL 462 7 2 3 4.7 CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1 10.1021/jm800510m
CHEMBL1627 119035 30 None -3 9 Human 8.6 pKi = 8.6 Binding
Displacement of [125I]HEAT from adrenergic Alpha-2C receptorDisplacement of [125I]HEAT from adrenergic Alpha-2C receptor
ChEMBL 462 7 2 3 4.7 CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1 10.1021/jm800510m
73453 63270 20 None -2 15 Human 8.6 pKi = 8.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
CHEMBL1385840 63270 20 None -2 15 Human 8.6 pKi = 8.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 561 4 3 6 2.0 CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 nan
44579271 370345 0 None 22 3 Human 8.6 pKi = 8.6 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
CHEMBL491419 370345 0 None 22 3 Human 8.6 pKi = 8.6 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 475 9 0 7 4.2 c1ccc(Oc2ncccc2COCCN2CCCN(CC3COc4ccccc4O3)CC2)cc1 10.1016/j.bmcl.2008.08.055
49781887 41020 0 None -5 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 41020 0 None -5 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
115237 118408 70 None -1 26 Human 8.6 pKi = 8.6 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O 10.1021/acs.jmedchem.4c00537
4137 118408 70 None -1 26 Human 8.6 pKi = 8.6 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O 10.1021/acs.jmedchem.4c00537
CHEMBL1621 118408 70 None -1 26 Human 8.6 pKi = 8.6 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O 10.1021/acs.jmedchem.4c00537
DB01267 118408 70 None -1 26 Human 8.6 pKi = 8.6 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O 10.1021/acs.jmedchem.4c00537
44402345 143660 0 None None None Human 8.6 pKi = 8.6 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 496 5 4 5 3.5 CC(C)(C)OC(=O)NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL196064 143660 0 None None None Human 8.6 pKi = 8.6 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 496 5 4 5 3.5 CC(C)(C)OC(=O)NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44330584 217739 0 None 1 2 Human 8.6 pKi = 8.6 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL319573 217739 0 None 1 2 Human 8.6 pKi = 8.6 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4F)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
52943739 41035 0 None -6 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@]12C[C@@]1(c1c[nH]cn1)Cc1ccccc12 10.1021/jm1006269
CHEMBL1255771 41035 0 None -6 4 Human 8.6 pKi = 8.6 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 210 1 1 1 2.6 C[C@]12C[C@@]1(c1c[nH]cn1)Cc1ccccc12 10.1021/jm1006269
135398737 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
2818 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
38 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
722 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
CHEMBL253391 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
CHEMBL42 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
DB00363 1973 61 None -3 61 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 10.1021/jm049632c
46225029 430300 0 None None None Human 7.7 pKi = 7.7 Binding
Binding affinity to Alpha2C adrenoceptor receptorBinding affinity to Alpha2C adrenoceptor receptor
ChEMBL 297 4 1 2 2.4 Fc1cccc(CCNC23OC4C5C6CC(C7C6C4C72)C53)c1 10.1016/j.bmcl.2009.11.019
CHEMBL590615 430300 0 None None None Human 7.7 pKi = 7.7 Binding
Binding affinity to Alpha2C adrenoceptor receptorBinding affinity to Alpha2C adrenoceptor receptor
ChEMBL 297 4 1 2 2.4 Fc1cccc(CCNC23OC4C5C6CC(C7C6C4C72)C53)c1 10.1016/j.bmcl.2009.11.019
16725934 294123 0 None 38 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392992 294123 0 None 38 3 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 429 6 0 5 5.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccc4)cc13)CC2 10.1016/j.bmcl.2006.12.094
123981 40347 12 None -2 7 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 10.1021/jm00019a001
CHEMBL123349 40347 12 None -2 7 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 195 0 0 1 2.4 CN1CCc2cccc(Cl)c2CC1 10.1021/jm00019a001
49781887 41020 0 None -5 4 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
CHEMBL1255617 41020 0 None -5 4 Human 7.7 pKi = 7.7 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 222 1 1 1 2.9 c1ccc2c(c1)[C@H]1C[C@@]1(c1c[nH]cn1)C21CC1 10.1021/jm1006269
118656529 239326 0 None 2 4 Human 6.7 pKi = 6.7 Binding
Binding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assayBinding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assay
ChEMBL 325 8 1 5 2.6 Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1 10.1021/jm501719e
CHEMBL3547107 239326 0 None 2 4 Human 6.7 pKi = 6.7 Binding
Binding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assayBinding affinity to human adrenergic alpha-2C receptor after 90 mins by radioligand displacement assay
ChEMBL 325 8 1 5 2.6 Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1 10.1021/jm501719e
44401041 142731 0 None -46 7 Human 6.7 pKi = 6.7 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL194659 142731 0 None -46 7 Human 6.7 pKi = 6.7 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
12574 5302 68 None -87 6 Human 5.7 pKi = 5.7 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
1856 5302 68 None -87 6 Human 5.7 pKi = 5.7 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
4810 5302 68 None -87 6 Human 5.7 pKi = 5.7 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
CHEMBL19236 5302 68 None -87 6 Human 5.7 pKi = 5.7 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
DB09242 5302 68 None -87 6 Human 5.7 pKi = 5.7 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 10.1021/jm960012o
10032383 213007 0 None -194 6 Human 6.7 pKi = 6.7 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
136680387 213007 0 None -194 6 Human 6.7 pKi = 6.7 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
CHEMBL323579 213007 0 None -194 6 Human 6.7 pKi = 6.7 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 666 15 4 8 4.2 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN)N1 10.1016/s0960-894x(99)00484-9
24906200 385690 0 None 1 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL523048 385690 0 None 1 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 328 5 1 3 4.5 c1ccc(-c2ccccc2OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
9816063 203123 0 None -14 6 Human 6.7 pKi = 6.7 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm990569e
CHEMBL30739 203123 0 None -14 6 Human 6.7 pKi = 6.7 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm990569e
2398 1965 48 None -4 22 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2801 1965 48 None -4 22 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
701 1965 48 None -4 22 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
CHEMBL415 1965 48 None -4 22 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
DB01242 1965 48 None -4 22 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C nan
2105 6217 26 None -45 25 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
47811 6217 26 None -45 25 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
48 6217 26 None -45 25 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
CHEMBL531 6217 26 None -45 25 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
DB01186 6217 26 None -45 25 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 nan
16090632 278917 0 None 46 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1021/jm060262x
CHEMBL385722 278917 0 None 46 3 Human 6.7 pKi = 6.7 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1021/jm060262x
9816063 203123 0 None -14 6 Rat 6.7 pKi = 6.7 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm000128r
CHEMBL30739 203123 0 None -14 6 Rat 6.7 pKi = 6.7 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 232 1 1 2 3.6 Cc1sc(C)c2c1CCCC2c1c[nH]cn1 10.1021/jm000128r
16090632 278917 0 None 46 3 Human 6.7 pKi = 6.7 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1016/j.ejmech.2010.12.026
CHEMBL385722 278917 0 None 46 3 Human 6.7 pKi = 6.7 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 348 4 3 5 3.3 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1 10.1016/j.ejmech.2010.12.026
15730 143349 64 None 1 10 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
CHEMBL195437 143349 64 None 1 10 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 206 7 1 1 4.3 CCCCCCCCc1ccc(O)cc1 nan
53325861 119654 0 None 2 3 Human 5.7 pKi = 5.7 Binding
Inhibition of Alpha-2C adrenergic receptorInhibition of Alpha-2C adrenergic receptor
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmcl.2010.11.075
CHEMBL1643902 119654 0 None 2 3 Human 5.7 pKi = 5.7 Binding
Inhibition of Alpha-2C adrenergic receptorInhibition of Alpha-2C adrenergic receptor
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmcl.2010.11.075
53325861 119654 0 None 2 3 Human 5.7 pKi = 5.7 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL1643902 119654 0 None 2 3 Human 5.7 pKi = 5.7 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 4 0 1 3.4 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
126225 195355 2 None -9 6 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 263 1 0 2 4.2 C=Cc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
CHEMBL25467 195355 2 None -9 6 Human 7.7 pKi = 7.7 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 263 1 0 2 4.2 C=Cc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
176190998 393374 0 None -11 6 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C receptor (unknown origin) assessed as inhibition constant
ChEMBL 505 8 3 8 4.7 CCSC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CCCC4)C4CCCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O 10.1016/j.ejmech.2023.115691
CHEMBL5632374 393374 0 None -11 6 Human 5.7 pKi = 5.7 Binding
Binding affinity to alpha2C receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C receptor (unknown origin) assessed as inhibition constant
ChEMBL 505 8 3 8 4.7 CCSC[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CCCC4)C4CCCC4)nc(Cl)nc31)[C@H](O)[C@@H]2O 10.1016/j.ejmech.2023.115691
1398859 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
3584 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
5401 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
7302 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
CHEMBL1481149 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
CHEMBL611 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
DB01162 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.The compound was tested for binding affinity against alpha-2C-adrenoceptor, from human clones.
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm00018a001
131829 469612 14 None -33 6 Human 6.7 pKi = 6.7 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
CHEMBL74283 469612 14 None -33 6 Human 6.7 pKi = 6.7 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 295 1 4 5 1.7 Brc1c(NC2=NCCN2)ccc2c1NCCN2 10.1016/0960-894X(95)00391-6
1548953 473104 29 None 1 17 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
CHEMBL954 473104 29 None 1 17 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
DB06735 473104 29 None 1 17 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 405 9 0 2 6.6 CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1 nan
2683 202943 22 None -30 16 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
CHEMBL305906 202943 22 None -30 16 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
DB11073 202943 22 None -30 16 Human 6.7 pKi = 6.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 304 15 0 0 6.5 CCCCCCCCCCCCCCCC[n+]1ccccc1 nan
11097789 203048 1 None -43 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL306792 203048 1 None -43 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1cc(F)ccc1NCC1=NCCN1 10.1021/jm000542r
11140345 469103 0 None -1 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70692 469103 0 None -1 6 Human 6.7 pKi = 6.7 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 239 4 2 4 2.0 CSc1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
44401194 143525 0 None -28 7 Human 6.7 pKi = 6.7 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL195706 143525 0 None -28 7 Human 6.7 pKi = 6.7 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 313 2 0 3 4.1 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
1212 3415 38 None -9 41 Human 7.7 pKi = 7.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
204 3415 38 None -9 41 Human 7.7 pKi = 7.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3372 3415 38 None -9 41 Human 7.7 pKi = 7.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
CHEMBL726 3415 38 None -9 41 Human 7.7 pKi = 7.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
DB00623 3415 38 None -9 41 Human 7.7 pKi = 7.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F nan
3054 315981 60 None -21 25 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
448537 315981 60 None -21 25 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
875 315981 60 None -21 25 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
CHEMBL411 315981 60 None -21 25 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
DB00255 315981 60 None -21 25 Human 5.7 pKi = 5.7 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 nan
44634573 5612 1 None -2 12 Human 6.7 pKi = 6.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442175
9168 5612 1 None -2 12 Human 6.7 pKi = 6.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442175
CHEMBL1474387 5612 1 None -2 12 Human 6.7 pKi = 6.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442175
CHEMBL1622930 5612 1 None -2 12 Human 6.7 pKi = 6.7 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 465 6 0 2 5.0 Cc1n(C/C=C/c2ccccc2)c2[n+](c1P(=S)(c1ccccc1)c1ccccc1)cccc2 10.6019/CHEMBL5442175
26987 1955 32 None -107 21 Human 6.7 pKi = 6.7 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
6063 1955 32 None -107 21 Human 6.7 pKi = 6.7 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
671 1955 32 None -107 21 Human 6.7 pKi = 6.7 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
CHEMBL1626 1955 32 None -107 21 Human 6.7 pKi = 6.7 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
DB00283 1955 32 None -107 21 Human 6.7 pKi = 6.7 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C 10.1038/s41586-020-2286-9
1398859 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
3584 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
5401 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
7302 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
CHEMBL1481149 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
CHEMBL611 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
DB01162 8235 54 None -50 13 Human 6.7 pKi = 6.7 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm980077m
42669828 240316 1 None None None Human 4.7 pKi = 4.7 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
CHEMBL3588911 240316 1 None None None Human 4.7 pKi = 4.7 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 243 5 1 3 2.7 Cc1ccccc1Cn1ccnc1CNC(C)C 10.1016/j.bmc.2015.01.013
15853467 474980 0 None -67 6 Human 6.7 pKi = 6.7 Binding
Binding affinity against human Alpha-2C adrenergic receptorBinding affinity against human Alpha-2C adrenergic receptor
ChEMBL 692 16 3 8 5.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN=[N+]=[N-])N1 10.1016/s0960-894x(99)00484-9
CHEMBL98063 474980 0 None -67 6 Human 6.7 pKi = 6.7 Binding
Binding affinity against human Alpha-2C adrenergic receptorBinding affinity against human Alpha-2C adrenergic receptor
ChEMBL 692 16 3 8 5.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCN=[N+]=[N-])N1 10.1016/s0960-894x(99)00484-9
10326069 82746 1 None -125 9 Human 5.7 pKi = 5.7 Binding
Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.
ChEMBL 589 10 3 8 3.3 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980506g
CHEMBL147077 82746 1 None -125 9 Human 5.7 pKi = 5.7 Binding
Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.Binding affinity for recombinant human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand.
ChEMBL 589 10 3 8 3.3 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980506g
73349359 183351 0 None -3 8 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 341 6 1 4 2.9 COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432051 183351 0 None -3 8 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 341 6 1 4 2.9 COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
44424855 176398 0 None 1 3 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 176398 0 None 1 3 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
44330609 327524 0 None -2 2 Human 7.6 pKi = 7.6 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL419894 327524 0 None -2 2 Human 7.6 pKi = 7.6 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccc(F)cc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
10324985 158429 6 None -17 17 Human 7.6 pKi = 7.6 Binding
Binding affinity to adrenergic alpha-2C receptorBinding affinity to adrenergic alpha-2C receptor
ChEMBL 423 7 0 8 1.7 COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1 10.1021/jm050725j
CHEMBL2068762 158429 6 None -17 17 Human 7.6 pKi = 7.6 Binding
Binding affinity to adrenergic alpha-2C receptorBinding affinity to adrenergic alpha-2C receptor
ChEMBL 423 7 0 8 1.7 COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1 10.1021/jm050725j
9859437 332763 0 None -38 3 Human 6.6 pKi = 6.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
CHEMBL432155 332763 0 None -38 3 Human 6.6 pKi = 6.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 230 2 3 4 2.3 Cc1c(Nc2ncc[nH]2)ccc2c1NCCO2 10.1021/jm9605142
3303 4574 46 None -309 15 Human 6.6 pKi = 6.6 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
3853 4574 46 None -309 15 Human 6.6 pKi = 6.6 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
5311200 4574 46 None -309 15 Human 6.6 pKi = 6.6 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
CHEMBL267014 4574 46 None -309 15 Human 6.6 pKi = 6.6 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 326 3 1 3 3.5 Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2 10.1021/acs.jmedchem.7b00151
13149 5176 19 None -38 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
3034396 5176 19 None -38 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
CHEMBL299031 5176 19 None -38 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 minsDisplacement of [3H]RX 821002 from human recombinant adrenergic alpha-2C receptor expressed in CHO cell membranes incubated for 60 mins
ChEMBL 398 5 1 5 3.8 CC[C@@H]1CN2CCC3=C([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC 10.1021/acs.jmedchem.9b01465
196129 140073 12 None -295 15 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
CHEMBL1909065 140073 12 None -295 15 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
DB11525 140073 12 None -295 15 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 917 13 4 16 4.3 CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC nan
11154555 1656 51 None -831 24 Human 6.6 pKi = 6.6 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 426 5 1 3 4.3 O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl 10.6019/CHEMBL5442175
5037 1656 51 None -831 24 Human 6.6 pKi = 6.6 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 426 5 1 3 4.3 O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl 10.6019/CHEMBL5442175
7671 1656 51 None -831 24 Human 6.6 pKi = 6.6 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 426 5 1 3 4.3 O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl 10.6019/CHEMBL5442175
CHEMBL2028019 1656 51 None -831 24 Human 6.6 pKi = 6.6 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 426 5 1 3 4.3 O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl 10.6019/CHEMBL5442175
DB06016 1656 51 None -831 24 Human 6.6 pKi = 6.6 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 426 5 1 3 4.3 O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl 10.6019/CHEMBL5442175
70693375 155060 0 None -5 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089155 155060 0 None -5 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
11361608 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL222928 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
11361608 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL222928 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
11361608 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222928 175702 0 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm0408215
11300487 175956 0 None -5 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
CHEMBL223830 175956 0 None -5 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccccc1-c1ccccc1OC(C)C1=NCCN1 10.1021/jm0408215
70693375 155060 0 None -5 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089155 155060 0 None -5 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
286547 139526 63 None None None Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccccc2N)CC1 10.1016/j.bmc.2015.01.013
CHEMBL1879790 139526 63 None None None Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2ccccc2N)CC1 10.1016/j.bmc.2015.01.013
4209 8026 58 None -389 20 Human 7.6 pKi = 7.6 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
4893 8026 58 None -389 20 Human 7.6 pKi = 7.6 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
5385 8026 58 None -389 20 Human 7.6 pKi = 7.6 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
CHEMBL2 8026 58 None -389 20 Human 7.6 pKi = 7.6 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00010a001
44314198 212867 0 None -8 4 Human 7.6 pKi = 7.6 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
CHEMBL310335 212867 0 None -8 4 Human 7.6 pKi = 7.6 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCCC1NC1=NCCO1 10.1016/0960-894X(94)85032-1
9815707 201592 0 None -8 3 Human 7.6 pKi = 7.6 Binding
Inhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297752 201592 0 None -8 3 Human 7.6 pKi = 7.6 Binding
Inhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant determined using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 210 3 1 3 2.3 CCC[C@H]1CCCC[C@@H]1NC1=NCCO1 10.1021/jm9905256
10490084 469825 0 None -11 3 Human 5.6 pKi = 5.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 237 2 2 2 2.9 Brc1ccccc1Nc1ncc[nH]1 10.1021/jm9605142
CHEMBL76457 469825 0 None -11 3 Human 5.6 pKi = 5.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 237 2 2 2 2.9 Brc1ccccc1Nc1ncc[nH]1 10.1021/jm9605142
8447 372118 60 None -3 13 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
CHEMBL508112 372118 60 None -3 13 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
DB14201 372118 60 None -3 13 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 332 3 0 6 5.7 c1ccc2sc(SSc3nc4ccccc4s3)nc2c1 nan
10603951 176222 0 None -12 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 10 1 7 5.9 COC(=O)C1=C(C)NC(C)=C(C(=O)N(C)CCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL2260148 176222 0 None -12 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 10 1 7 5.9 COC(=O)C1=C(C)NC(C)=C(C(=O)N(C)CCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL88448 176222 0 None -12 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 10 1 7 5.9 COC(=O)C1=C(C)NC(C)=C(C(=O)N(C)CCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
10531532 176243 0 None -28 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 594 9 2 7 5.2 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL2260371 176243 0 None -28 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 594 9 2 7 5.2 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL91956 176243 0 None -28 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 594 9 2 7 5.2 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
24906243 370496 0 None -1 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 310 3 1 5 2.5 COC1(C2=NCCN2)COc2cccc(-c3ccccc3)c2O1 10.1021/jm800250z
CHEMBL492648 370496 0 None -1 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 310 3 1 5 2.5 COC1(C2=NCCN2)COc2cccc(-c3ccccc3)c2O1 10.1021/jm800250z
11277479 175707 0 None -4 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
CHEMBL222973 175707 0 None -4 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1cccc(-c2ccccc2OC(C)C2=NCCN2)c1 10.1021/jm0408215
132060733 317622 0 None -1 3 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 294 3 0 3 3.0 c1ccc(CN2Cc3ccc(N4CCOCC4)cc3C2)cc1 10.1016/j.ejmech.2018.02.024
CHEMBL4161503 317622 0 None -1 3 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 294 3 0 3 3.0 c1ccc(CN2Cc3ccc(N4CCOCC4)cc3C2)cc1 10.1016/j.ejmech.2018.02.024
71452341 174687 8 None 3 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 376 6 0 3 5.3 Cc1c(C(=O)N(CCCN2CCCCC2)c2ccccc2)oc2ccccc12 10.1016/j.bmc.2012.09.044
CHEMBL2205361 174687 8 None 3 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysisDisplacement of [3H]clonidine from alpha2C adrenergic receptor after 40 mins by scintillation counting analysis
ChEMBL 376 6 0 3 5.3 Cc1c(C(=O)N(CCCN2CCCCC2)c2ccccc2)oc2ccccc12 10.1016/j.bmc.2012.09.044
10109188 330925 0 None 43 2 Human 7.6 pKi = 7.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL425803 330925 0 None 43 2 Human 7.6 pKi = 7.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
100 8289 46 None -6 34 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
2637 8289 46 None -6 34 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
5452 8289 46 None -6 34 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
CHEMBL479 8289 46 None -6 34 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
DB00679 8289 46 None -6 34 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 nan
10109188 330925 0 None 43 2 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1021/jm060262x
CHEMBL425803 330925 0 None 43 2 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 4 1 4 4.6 CCc1c(C)nc2ccccc2c1Nc1ccc(N2CCN(C)CC2)cc1 10.1021/jm060262x
176190960 393402 0 None -5 8 Human 5.6 pKi = 5.6 Binding
Binding affinity to alpha2C receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C receptor (unknown origin) assessed as inhibition constant
ChEMBL 479 6 3 7 4.2 O[C@H]1[C@H](n2cnc3c(NC(C4CCCC4)C4CCCC4)nc(Cl)nc32)[C@H]2C[C@@]2(CCl)[C@H]1O 10.1016/j.ejmech.2023.115691
CHEMBL5632857 393402 0 None -5 8 Human 5.6 pKi = 5.6 Binding
Binding affinity to alpha2C receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C receptor (unknown origin) assessed as inhibition constant
ChEMBL 479 6 3 7 4.2 O[C@H]1[C@H](n2cnc3c(NC(C4CCCC4)C4CCCC4)nc(Cl)nc32)[C@H]2C[C@@]2(CCl)[C@H]1O 10.1016/j.ejmech.2023.115691
172452565 388088 0 None -5 4 Human 5.6 pKi = 5.6 Binding
Inhibition of human alpha 2C adrenergic receptor assessed as inhibition constant by microbeta scintillation counting methodInhibition of human alpha 2C adrenergic receptor assessed as inhibition constant by microbeta scintillation counting method
ChEMBL 424 5 4 8 1.7 OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O 10.1021/acsmedchemlett.3c00427
CHEMBL5409958 388088 0 None -5 4 Human 5.6 pKi = 5.6 Binding
Inhibition of human alpha 2C adrenergic receptor assessed as inhibition constant by microbeta scintillation counting methodInhibition of human alpha 2C adrenergic receptor assessed as inhibition constant by microbeta scintillation counting method
ChEMBL 424 5 4 8 1.7 OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O 10.1021/acsmedchemlett.3c00427
44371755 102024 0 None -21 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL155866 102024 0 None -21 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 3 1 3 2.1 Cc1cccc(C)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
11173544 331095 0 None -6 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL426900 331095 0 None -6 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 4 1 3 3.4 Cc1ccc(-c2ccccc2OC(C)C2=NCCN2)cc1 10.1021/jm0408215
10221004 469156 0 None -2 5 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70973 469156 0 None -2 5 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 267 5 2 5 0.9 CCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
73355420 183359 0 None 2 2 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 355 6 0 4 3.3 COc1cc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432061 183359 0 None 2 2 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 355 6 0 4 3.3 COc1cc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC 10.1016/j.bmc.2013.07.045
132060743 317732 0 None 1 13 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 351 3 0 4 3.1 CN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)C3)CC1 10.1016/j.ejmech.2018.02.024
CHEMBL4163428 317732 0 None 1 13 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 351 3 0 4 3.1 CN1CCN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)C3)CC1 10.1016/j.ejmech.2018.02.024
3168 23567 68 None -63 19 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
966 23567 68 None -63 19 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
CHEMBL1108 23567 68 None -63 19 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
DB00450 23567 68 None -63 19 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 nan
11090351 328369 0 None 2 4 Human 6.6 pKi = 6.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL419448 328369 0 None 2 4 Human 6.6 pKi = 6.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1c(F)cccc1NCC1=NCCN1 10.1021/jm000542r
16757089 183100 1 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 183100 1 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
16757089 183100 1 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL242693 183100 1 None -3 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
10220232 199910 5 None -1 6 Human 7.6 pKi = 7.6 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm990569e
CHEMBL284795 199910 5 None -1 6 Human 7.6 pKi = 7.6 Binding
Binding affinity towards alpha-2C adrenergic receptorBinding affinity towards alpha-2C adrenergic receptor
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm990569e
135 5144 38 None -6 42 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
1796 5144 38 None -6 42 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
4184 5144 38 None -6 42 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
CHEMBL6437 5144 38 None -6 42 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
DB06148 5144 38 None -6 42 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 nan
1001 365921 35 None -2 5 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
10219 365921 35 None -2 5 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
CHEMBL50588 365921 35 None -2 5 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
DB13393 365921 35 None -2 5 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 nan
44401243 327740 0 None -10 9 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL435301 327740 0 None -10 9 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
10220232 199910 5 None -1 6 Rat 7.6 pKi = 7.6 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm000128r
CHEMBL284795 199910 5 None -1 6 Rat 7.6 pKi = 7.6 Binding
in vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligandin vitro alpha-2C adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand
ChEMBL 230 1 1 2 3.5 Cc1sc(C)c2c1CCC=C2c1c[nH]cn1 10.1021/jm000128r
24906199 370898 17 None 1 3 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL495096 370898 17 None 1 3 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 258 4 1 3 3.1 CC(Oc1ccccc1C1CCCC1)C1=NCCN1 10.1021/jm800250z
164615845 368488 0 None -2 6 Human 5.6 pKi = 5.6 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 389 2 1 4 3.7 O=C(O)c1ccc(C#Cc2ccc3c(c2)C=C([N+](=O)[O-])C(C(F)(F)F)O3)cc1 10.1016/j.bmcl.2021.128008
CHEMBL4857492 368488 0 None -2 6 Human 5.6 pKi = 5.6 Binding
Inhibition of alpha2c adrenergic receptor (unknown origin)Inhibition of alpha2c adrenergic receptor (unknown origin)
ChEMBL 389 2 1 4 3.7 O=C(O)c1ccc(C#Cc2ccc3c(c2)C=C([N+](=O)[O-])C(C(F)(F)F)O3)cc1 10.1016/j.bmcl.2021.128008
183 84935 67 None -1 6 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
2162 84935 67 None -1 6 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
CHEMBL1491 84935 67 None -1 6 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
DB00381 84935 67 None -1 6 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl nan
44269122 198403 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL273485 198403 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm800250z
45487144 404483 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.7 CC(OC1=NCCN1)c1ccccc1 10.1021/jm901262f
CHEMBL571314 404483 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.7 CC(OC1=NCCN1)c1ccccc1 10.1021/jm901262f
44269122 198403 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL273485 198403 0 None -9 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 190 3 1 3 1.5 CC(Oc1ccccc1)C1=NCCN1 10.1021/jm100977d
10903226 28019 0 None -3 4 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 281 6 2 5 1.3 CCCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1195368 28019 0 None -3 4 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 281 6 2 5 1.3 CCCS(=O)(=O)c1ccccc1NCC1=NCCN1 10.1021/jm000542r
1353 3909 69 None -54 49 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
3559 3909 69 None -54 49 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
86 3909 69 None -54 49 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
CHEMBL54 3909 69 None -54 49 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
DB00502 3909 69 None -54 49 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl nan
11000184 27313 0 None -6 6 Human 6.6 pKi = 6.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL1190038 27313 0 None -6 6 Human 6.6 pKi = 6.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 235 5 2 4 2.2 CCSc1ccccc1NCC1=NCCN1 10.1021/jm000542r
45487089 394723 0 None -10 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570863 394723 0 None -10 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 204 2 1 3 2.0 Cc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
10923927 469107 0 None -4 4 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
CHEMBL70740 469107 0 None -4 4 Human 5.6 pKi = 5.6 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 279 3 2 5 0.8 O=S1(=O)CCCc2cccc(NCC3=NCCN3)c21 10.1021/jm000542r
3080926 311542 22 None -10 3 Human 4.6 pKi = 4.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 186 1 1 3 1.8 c1ccc2oc(C3=NCCN3)cc2c1 10.1021/ml400232p
CHEMBL404505 311542 22 None -10 3 Human 4.6 pKi = 4.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 186 1 1 3 1.8 c1ccc2oc(C3=NCCN3)cc2c1 10.1021/ml400232p
185076 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm960359r
CHEMBL49137 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm960359r
133 5073 43 None -11 30 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
1723 5073 43 None -11 30 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
28693 5073 43 None -11 30 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
CHEMBL19215 5073 43 None -11 30 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
DB13520 5073 43 None -11 30 Human 7.6 pKi = 7.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C nan
185076 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm9605142
CHEMBL49137 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1021/jm9605142
164946675 390476 1 None -15 4 Human 7.6 pKi = 7.6 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 221 2 1 3 3.4 c1ccc2c(Nc3ccncc3)cncc2c1 10.1021/acs.jmedchem.4c01239
CHEMBL5542553 390476 1 None -15 4 Human 7.6 pKi = 7.6 Binding
Binding affinity to human alpha2C-adrenoceptorBinding affinity to human alpha2C-adrenoceptor
ChEMBL 221 2 1 3 3.4 c1ccc2c(Nc3ccncc3)cncc2c1 10.1021/acs.jmedchem.4c01239
3930 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
540335 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
CHEMBL106525 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1016/j.ejmech.2010.12.026
139406787 351099 0 None -2 4 Human 5.6 pKi = 5.6 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 492 5 2 5 5.8 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-c2cn(-c3ccc(C(F)(F)F)cc3)nn2)c1 10.1021/acs.jmedchem.0c00745
CHEMBL4633982 351099 0 None -2 4 Human 5.6 pKi = 5.6 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin)Binding affinity to adrenergic alpha2C receptor (unknown origin)
ChEMBL 492 5 2 5 5.8 O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)cc(-c2cn(-c3ccc(C(F)(F)F)cc3)nn2)c1 10.1021/acs.jmedchem.0c00745
141 2941 18 None -57 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
6089 2941 18 None -57 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
CHEMBL12420 2941 18 None -57 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
DB01488 2941 18 None -57 17 Human 5.6 pKi = 5.6 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
3468 350117 13 None -1 20 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
4138 350117 13 None -1 20 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
CHEMBL459265 350117 13 None -1 20 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
DB00406 350117 13 None -1 20 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 nan
57345628 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956195 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
70695474 155061 0 None -47 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL2089156 155061 0 None -47 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml400232p
122442272 275722 0 None -9 15 Human 6.6 pKi = 6.6 Binding
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3771384 275722 0 None -9 15 Human 6.6 pKi = 6.6 Binding
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
44371864 104375 0 None -8 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL157955 104375 0 None -8 3 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 3 2.6 CCc1cccc(CC)c1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956195 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
57345628 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL1956195 143414 0 None -26 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 CC(Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
70695474 155061 0 None -47 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
CHEMBL2089156 155061 0 None -47 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 244 5 1 3 2.4 C[C@H](Oc1ccccc1CC1CC1)C1=NCCN1 10.1021/ml300064v
122442272 275722 0 None -9 15 Human 6.6 pKi = 6.6 Binding
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
CHEMBL3771384 275722 0 None -9 15 Human 6.6 pKi = 6.6 Binding
Binding affinity to human alpha-2C adrenergic receptor by radioligand binding assayBinding affinity to human alpha-2C adrenergic receptor by radioligand binding assay
ChEMBL 239 5 1 2 2.6 C=CCOc1cc(F)c(F)cc1C1CC1CN 10.1021/acs.jmedchem.5b01153
73346336 183353 0 None -5 6 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 2 3.0 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432054 183353 0 None -5 6 Human 5.6 pKi = 5.6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 2 3.0 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
3930 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
540335 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
CHEMBL106525 4392 42 None 2 15 Human 7.6 pKi = 7.6 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.1021/jm060262x
518 7342 1 None -1 6 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
9839317 7342 1 None -1 6 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
CHEMBL123138 7342 1 None -1 6 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 299 0 0 2 3.8 CN1CCc2c3c(C1)c(Br)oc3ccc2Cl 10.1021/jm00019a001
1268096 40055 24 None 3 4 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]12 10.1021/jm00019a001
CHEMBL122404 40055 24 None 3 4 Human 7.6 pKi = 7.6 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 352 1 1 4 3.2 COC(=O)C1=CO[C@@H](C)[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]12 10.1021/jm00019a001
185076 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL49137 370341 2 None -7 7 Human 7.6 pKi = 7.6 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 227 1 2 5 1.3 Cc1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
1212 3415 38 None -9 41 Human 7.5 pKi = 7.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1021/acs.jmedchem.4c00537
204 3415 38 None -9 41 Human 7.5 pKi = 7.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1021/acs.jmedchem.4c00537
3372 3415 38 None -9 41 Human 7.5 pKi = 7.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1021/acs.jmedchem.4c00537
CHEMBL726 3415 38 None -9 41 Human 7.5 pKi = 7.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1021/acs.jmedchem.4c00537
DB00623 3415 38 None -9 41 Human 7.5 pKi = 7.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F 10.1021/acs.jmedchem.4c00537
3157 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
6604102 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
6604576 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
7170 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
954 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
CHEMBL1363589 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
CHEMBL707 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
DB00590 3031 53 None -67 11 Human 6.6 pKi = 6.6 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 10.1021/jm00018a001
177381479 392391 0 None 1 2 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 327 1 1 1 5.2 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccc(F)c(C(F)(F)F)c1)NC2(C)C 10.1021/acs.jmedchem.3c01758
CHEMBL5595517 392391 0 None 1 2 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 327 1 1 1 5.2 CC1=CC[C@@H]2C[C@H]1[C@H](c1ccc(F)c(C(F)(F)F)c1)NC2(C)C 10.1021/acs.jmedchem.3c01758
10793963 176221 0 None -30 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 11 2 7 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL2260147 176221 0 None -30 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 11 2 7 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL284470 176221 0 None -30 6 Human 6.6 pKi = 6.6 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 622 11 2 7 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
57345626 143411 0 None -12 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
CHEMBL1956192 143411 0 None -12 4 Human 6.6 pKi = 6.6 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1021/ml400232p
57345626 143411 0 None -12 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956192 143411 0 None -12 4 Human 6.6 pKi = 6.6 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 3 1 3 2.2 CC(Oc1ccccc1Br)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL4549667 478320 13 None -1 4 Human 5.6 pKi = 5.6 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 480 3 0 5 3.1 CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21 10.6019/CHEMBL4507326
44312037 469516 0 None -2 6 Human 4.6 pKi = 4.6 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 308 1 1 5 2.9 Brc1c(NC2=NCCS2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL73392 469516 0 None -2 6 Human 4.6 pKi = 4.6 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 308 1 1 5 2.9 Brc1c(NC2=NCCS2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
213 8386 39 None -8 22 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2717 8386 39 None -8 22 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
5533 8386 39 None -8 22 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
CHEMBL621 8386 39 None -8 22 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
DB00656 8386 39 None -8 22 Human 6.6 pKi = 6.6 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 nan
2247 1042 63 None -18 37 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
249 1042 63 None -18 37 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2603 1042 63 None -18 37 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
CHEMBL296419 1042 63 None -18 37 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
DB00637 1042 63 None -18 37 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 nan
2335 26122 15 None -2 12 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
3018 26122 15 None -2 12 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
CHEMBL1182210 26122 15 None -2 12 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
DB11125 26122 15 None -2 12 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 nan
136680386 474581 0 None -60 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
44328801 474581 0 None -60 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
CHEMBL95578 474581 0 None -60 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 680 16 4 8 4.6 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCCCN)N1 10.1016/s0960-894x(99)00484-9
178298264 466495 0 None -9772 11 Human 5.5 pKi = 5.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 448 1 1 4 3.4 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccc(I)cc14 10.1021/acs.jmedchem.4c00736
CHEMBL6146975 466495 0 None -9772 11 Human 5.5 pKi = 5.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 448 1 1 4 3.4 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccc(I)cc14 10.1021/acs.jmedchem.4c00736
132060720 317981 0 None -7 9 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 315 4 0 2 4.9 COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1 10.1016/j.ejmech.2018.02.024
CHEMBL4167315 317981 0 None -7 9 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting methodDisplacement of [3H]-Rauwolscine from human adrenergic alpha2C receptor expressed in stable MDCK cells after 90 mins by microbeta scintillation counting method
ChEMBL 315 4 0 2 4.9 COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1 10.1016/j.ejmech.2018.02.024
2381 200503 44 None -1 4 Human 6.5 pKi = 6.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
68712 200503 44 None -1 4 Human 6.5 pKi = 6.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
CHEMBL289480 200503 44 None -1 4 Human 6.5 pKi = 6.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
DB11738 200503 44 None -1 4 Human 6.5 pKi = 6.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 10.1016/0960-894X(94)85032-1
44371745 102531 0 None -12 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL156336 102531 0 None -12 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 3 2.0 CCc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
25130235 370821 1 None -8 11 Human 6.5 pKi = 6.5 Binding
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 294 2 1 6 1.3 CN1CCN(c2cc(-c3ccc(C#N)cc3)nc(N)n2)CC1 10.1021/jm8005959
CHEMBL494678 370821 1 None -8 11 Human 6.5 pKi = 6.5 Binding
Binding affinity to adrenergic Alpha-2C receptorBinding affinity to adrenergic Alpha-2C receptor
ChEMBL 294 2 1 6 1.3 CN1CCN(c2cc(-c3ccc(C#N)cc3)nc(N)n2)CC1 10.1021/jm8005959
10682720 470024 0 None -7 3 Human 6.5 pKi = 6.5 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 259 3 2 3 3.8 COc1cc(C)c(Nc2ncc[nH]2)cc1C(C)(C)C 10.1021/jm9605142
CHEMBL78190 470024 0 None -7 3 Human 6.5 pKi = 6.5 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 259 3 2 3 3.8 COc1cc(C)c(Nc2ncc[nH]2)cc1C(C)(C)C 10.1021/jm9605142
178297314 466216 0 None -4786 9 Human 5.5 pKi = 5.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 400 1 1 4 3.6 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccc(Br)cc14 10.1021/acs.jmedchem.4c00736
CHEMBL6133333 466216 0 None -4786 9 Human 5.5 pKi = 5.5 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 400 1 1 4 3.6 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccc(Br)cc14 10.1021/acs.jmedchem.4c00736
197033 429048 47 None -269 18 Human 5.5 pKi = 5.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 319 3 0 3 3.9 Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1 10.6019/CHEMBL5442175
CHEMBL589390 429048 47 None -269 18 Human 5.5 pKi = 5.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 319 3 0 3 3.9 Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1 10.6019/CHEMBL5442175
DB11725 429048 47 None -269 18 Human 5.5 pKi = 5.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 319 3 0 3 3.9 Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1 10.6019/CHEMBL5442175
CHEMBL4549667 478320 13 None -1 4 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 480 3 0 5 3.1 CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21 10.6019/CHEMBL4507326
44579186 355813 0 None 2 3 Human 8.5 pKi = 8.5 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 474 8 1 7 3.1 O=C(NCCN1CCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL478026 355813 0 None 2 3 Human 8.5 pKi = 8.5 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 474 8 1 7 3.1 O=C(NCCN1CCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
44402583 143644 0 None None None Human 8.5 pKi = 8.5 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 425 5 4 4 2.5 O=C(O)CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL195925 143644 0 None None None Human 8.5 pKi = 8.5 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 425 5 4 4 2.5 O=C(O)CCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44215744 474334 0 None 1 3 Human 8.5 pKi = 8.5 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL94129 474334 0 None 1 3 Human 8.5 pKi = 8.5 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
2389 6775 83 None -12 45 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
5073 6775 83 None -12 45 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
96 6775 83 None -12 45 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
CHEMBL85 6775 83 None -12 45 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
DB00734 6775 83 None -12 45 Human 8.5 pKi = 8.5 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 10.1021/jm049632c
44438168 194235 0 None 53 3 Human 8.5 pKi = 8.5 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL247665 194235 0 None 53 3 Human 8.5 pKi = 8.5 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 533 7 0 7 4.7 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)N4CCC(N5CCCC5)CC4)cc13)CC2 10.1016/j.bmcl.2006.12.094
11653915 252061 0 None 1 6 Human 8.4 pKi = 8.4 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 296 4 2 5 2.6 COc1cccc(N(NC2=NCCN2)c2ccc(C)cc2)c1 10.1016/j.bmcl.2005.07.083
CHEMBL362954 252061 0 None 1 6 Human 8.4 pKi = 8.4 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 296 4 2 5 2.6 COc1cccc(N(NC2=NCCN2)c2ccc(C)cc2)c1 10.1016/j.bmcl.2005.07.083
16090630 164649 0 None 309 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1021/jm060262x
CHEMBL218675 164649 0 None 309 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1021/jm060262x
135 5144 38 None -6 42 Human 8.4 pKi = 8.4 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
1796 5144 38 None -6 42 Human 8.4 pKi = 8.4 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
4184 5144 38 None -6 42 Human 8.4 pKi = 8.4 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
CHEMBL6437 5144 38 None -6 42 Human 8.4 pKi = 8.4 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
DB06148 5144 38 None -6 42 Human 8.4 pKi = 8.4 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 10.1021/jm049632c
16090630 164649 0 None 309 3 Human 8.4 pKi = 8.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
CHEMBL218675 164649 0 None 309 3 Human 8.4 pKi = 8.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
13162 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960012o
2803 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960012o
CHEMBL134 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960012o
2216 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
229 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
7117 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
CHEMBL647 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
DB00964 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 10.1021/jm960359r
13162 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960359r
2803 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960359r
CHEMBL134 7899 43 None -3 15 Human 7.5 pKi = 7.5 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1021/jm960359r
1971 5840 38 None -2 24 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
2404 5840 38 None -2 24 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
4543 5840 38 None -2 24 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
CHEMBL445 5840 38 None -2 24 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
DB00540 5840 38 None -2 24 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 nan
44325027 473998 0 None 1 2 Human 7.5 pKi = 7.5 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cnc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91824 473998 0 None 1 2 Human 7.5 pKi = 7.5 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cnc5ccccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
521 2888 53 None -17 8 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
5311068 2888 53 None -17 8 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
835 2888 53 None -17 8 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
CHEMBL778 2888 53 None -17 8 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
DB00633 2888 53 None -17 8 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.1021/jm061487a
9960497 200631 0 None -691 6 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL290860 200631 0 None -691 6 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL3392246 200631 0 None -691 6 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.9 CO/C(O)=C1\C(C)=NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
9894818 199160 0 None -93 7 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 199160 0 None -93 7 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
10333157 289829 0 None -3 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL396013 289829 0 None -3 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
10333157 289829 0 None -3 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL396013 289829 0 None -3 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
11246610 175282 0 None -2 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccc([N+](=O)[O-])cc1)C1=NCCN1 10.1021/jm0408215
CHEMBL221523 175282 0 None -2 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 CC(Oc1ccccc1-c1ccc([N+](=O)[O-])cc1)C1=NCCN1 10.1021/jm0408215
44209480 142416 1 None -281 11 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 313 6 0 3 3.4 Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940418 142416 1 None -281 11 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 313 6 0 3 3.4 Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
73353884 183131 0 None -2 8 Human 5.5 pKi = 5.5 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 295 3 1 3 2.7 c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2 10.1016/j.bmc.2013.07.045
CHEMBL2429890 183131 0 None -2 8 Human 5.5 pKi = 5.5 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 295 3 1 3 2.7 c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2 10.1016/j.bmc.2013.07.045
11173568 175598 0 None -8 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
CHEMBL222371 175598 0 None -8 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 281 4 2 4 2.7 CC(Oc1ccccc1-c1cccc(N)c1)C1=NCCN1 10.1021/jm0408215
24906160 334032 0 None -4 3 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL442815 334032 0 None -4 3 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 247 5 1 5 1.4 CO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
75306277 218830 0 None -15 23 Human 7.5 pKi = 7.5 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 308 0 0 3 4.2 CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3 10.1039/C2MD00311B
CHEMBL3217984 218830 0 None -15 23 Human 7.5 pKi = 7.5 Binding
Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assayBinding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 308 0 0 3 4.2 CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3 10.1039/C2MD00311B
49836308 42643 0 None 1 3 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
CHEMBL1278084 42643 0 None 1 3 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 C[C@@H](Oc1ccccc1-c1cccc(O)c1)C1=NCCN1 10.1021/jm100977d
44288945 333550 0 None -794 7 Human 6.5 pKi = 6.5 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 485 7 2 3 4.4 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL43860 333550 0 None -794 7 Human 6.5 pKi = 6.5 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 485 7 2 3 4.4 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
49836306 42436 0 None -1 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276247 42436 0 None -1 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 C[C@@H](Oc1ccccc1-c1ccsc1)C1=NCCN1 10.1021/jm100977d
1200 3405 44 None -2 23 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
12488 3405 44 None -2 23 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
941361 3405 44 None -2 23 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
CHEMBL30008 3405 44 None -2 23 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
DB04841 3405 44 None -2 23 Human 7.5 pKi = 7.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F nan
44402352 143854 0 None None None Human 7.5 pKi = 7.5 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 396 4 4 4 1.9 NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL196344 143854 0 None None None Human 7.5 pKi = 7.5 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 396 4 4 4 1.9 NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10266032 372056 0 None -2 3 Human 7.5 pKi = 7.5 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50720 372056 0 None -2 3 Human 7.5 pKi = 7.5 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 286 5 1 3 3.5 c1ccc(CCC[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
487 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442175
60602 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442175
CHEMBL405355 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442175
DB09239 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.6019/CHEMBL5442175
10841387 199812 0 None -91 6 Human 6.5 pKi = 6.5 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
CHEMBL284103 199812 0 None -91 6 Human 6.5 pKi = 6.5 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00019a001
9894818 199160 0 None -93 7 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL279436 199160 0 None -93 7 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 10 3 6 4.9 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
10841387 199812 0 None -91 6 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL284103 199812 0 None -91 6 Human 6.5 pKi = 6.5 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 10 3 6 5.2 CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL4588900 478347 0 None 1 3 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 816 9 4 11 6.1 COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C 10.6019/CHEMBL4507284
44390749 136243 0 None -173 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 607 11 3 6 5.3 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1016/s0960-894x(99)00484-9
CHEMBL180561 136243 0 None -173 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 607 11 3 6 5.3 CC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1016/s0960-894x(99)00484-9
CHEMBL4588900 478347 0 None 1 3 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 816 9 4 11 6.1 COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C 10.6019/CHEMBL4507284
44579184 374027 3 None 2 3 Human 7.5 pKi = 7.5 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
CHEMBL518592 374027 3 None 2 3 Human 7.5 pKi = 7.5 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 340 4 0 5 2.7 COc1ccccc1N1CCN(CC2COc3ccccc3O2)CC1 10.1016/j.bmcl.2008.08.055
294234 202947 0 None -6 4 Human 7.5 pKi = 7.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
CHEMBL305928 202947 0 None -6 4 Human 7.5 pKi = 7.5 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 182 1 1 3 1.7 C1CCCC(NC2=NCCO2)CC1 10.1016/0960-894X(94)85032-1
487 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
60602 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
CHEMBL405355 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
DB09239 7383 17 None -891 29 Human 6.5 pKi = 6.5 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
11186227 175679 0 None -9 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccc(O)cc1)C1=NCCN1 10.1021/jm0408215
CHEMBL222798 175679 0 None -9 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 2 4 2.8 CC(Oc1ccccc1-c1ccc(O)cc1)C1=NCCN1 10.1021/jm0408215
44582676 372889 0 None -2 17 Human 6.5 pKi = 6.5 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 403 9 0 4 4.3 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
CHEMBL516088 372889 0 None -2 17 Human 6.5 pKi = 6.5 Binding
Inhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experimentInhibition of human cloned Alpha-2C adrenergic receptor by competitive binding experiment
ChEMBL 403 9 0 4 4.3 COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1 10.1016/j.bmc.2009.03.021
9884781 82124 1 None -1 5 Human 6.5 pKi = 6.5 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 350 3 0 4 3.0 c1ccc2c(c1)CC(CN1CCN(c3ccc4c(c3)OCCO4)CC1)C2 10.1021/acs.jmedchem.7b00151
CHEMBL146556 82124 1 None -1 5 Human 6.5 pKi = 6.5 Binding
Inhibition of alpha2C adrenergic receptor (unknown origin)Inhibition of alpha2C adrenergic receptor (unknown origin)
ChEMBL 350 3 0 4 3.0 c1ccc2c(c1)CC(CN1CCN(c3ccc4c(c3)OCCO4)CC1)C2 10.1021/acs.jmedchem.7b00151
24906196 370494 0 None 1 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL492639 370494 0 None 1 3 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 261 6 1 5 1.8 CCO/N=C/c1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL4778870 478378 15 None -9 5 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 286 4 1 6 2.1 CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1 10.6019/CHEMBL4800732
10319299 163021 0 None 48 2 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL216290 163021 0 None 48 2 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
10132386 197419 1 None 63 2 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL267464 197419 1 None 63 2 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090621 278789 0 None 2 3 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL384925 278789 0 None 2 3 Human 7.5 pKi = 7.5 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1016/j.ejmech.2010.12.026
9794524 469722 0 None -10 3 Human 6.5 pKi = 6.5 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 225 2 2 4 2.4 Cc1c(Nc2ncc[nH]2)ccc2nccnc12 10.1021/jm9605142
CHEMBL75491 469722 0 None -10 3 Human 6.5 pKi = 6.5 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 225 2 2 4 2.4 Cc1c(Nc2ncc[nH]2)ccc2nccnc12 10.1021/jm9605142
CHEMBL4778870 478378 15 None -9 5 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 286 4 1 6 2.1 CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1 10.6019/CHEMBL4800732
28417 83476 34 None -1 12 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
779 83476 34 None -1 12 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
CHEMBL1479 83476 34 None -1 12 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
DB01406 83476 34 None -1 12 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C nan
1267 8287 36 None -112 9 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
3035905 8287 36 None -112 9 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
CHEMBL260374 8287 36 None -112 9 Human 6.5 pKi = 6.5 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 292 2 2 2 2.8 S=C(N1CCC(CC1)c1cnc[nH]1)NC1CCCCC1 10.1021/jm8003625
CHEMBL4798829 478387 23 None -6 4 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 415 4 1 6 5.2 c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1 10.6019/CHEMBL4507313
CHEMBL4798829 478387 23 None -6 4 Human 5.5 pKi = 5.5 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 415 4 1 6 5.2 c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1 10.6019/CHEMBL4507313
CHEMBL4798829 478387 23 None -6 4 Human 5.5 pKi = 5.5 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000752a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000752a ADRA2C
ChEMBL 415 4 1 6 5.2 c1ccc2oc(-c3csc(C4CCN(Cc5nc6ncccc6[nH]5)CC4)n3)cc2c1 10.6019/CHEMBL5212743
10319299 163021 0 None 48 2 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1021/jm060262x
CHEMBL216290 163021 0 None 48 2 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 408 4 1 4 5.7 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1-c1ccccc1 10.1021/jm060262x
10132386 197419 1 None 63 2 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1021/jm060262x
CHEMBL267464 197419 1 None 63 2 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.3 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C 10.1021/jm060262x
16090621 278789 0 None 2 3 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1021/jm060262x
CHEMBL384925 278789 0 None 2 3 Human 7.5 pKi = 7.5 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 5 1 4 5.6 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1Cc1ccccc1 10.1021/jm060262x
10946567 40357 0 None -28 6 Human 7.5 pKi = 7.5 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 265 1 0 2 4.1 CCc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
CHEMBL123448 40357 0 None -28 6 Human 7.5 pKi = 7.5 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 265 1 0 2 4.1 CCc1sc2ccc(Cl)c3c2c1CN(C)CC3 10.1021/jm00019a001
155561439 349658 0 None -2 2 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 411 4 4 7 3.5 Oc1ccc(CCNc2nc(C#Cc3ccc(Cl)s3)nc3[nH]cnc23)cc1O 10.1039/C8MD00317C
CHEMBL4581568 349658 0 None -2 2 Human 5.5 pKi = 5.5 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 411 4 4 7 3.5 Oc1ccc(CCNc2nc(C#Cc3ccc(Cl)s3)nc3[nH]cnc23)cc1O 10.1039/C8MD00317C
2286 6468 43 None -52 24 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
4927 6468 43 None -52 24 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
7282 6468 43 None -52 24 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
CHEMBL643 6468 43 None -52 24 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
DB01069 6468 43 None -52 24 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C nan
44329026 475239 0 None -69 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 679 16 3 7 6.1 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CCCCOC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL99864 475239 0 None -69 6 Human 6.5 pKi = 6.5 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 679 16 3 7 6.1 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(CCCCOC)N1 10.1016/s0960-894x(99)00484-9
1028 599 43 None -61 18 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
479 599 43 None -61 18 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
5816 599 43 None -61 18 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL679 599 43 None -61 18 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
DB00668 599 43 None -61 18 Human 6.5 pKi = 6.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O nan
1890 5634 35 None -50 21 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442175
4449 5634 35 None -50 21 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442175
7247 5634 35 None -50 21 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442175
CHEMBL623 5634 35 None -50 21 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442175
DB01149 5634 35 None -50 21 Human 6.5 pKi = 6.5 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 469 10 0 7 3.6 CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl 10.6019/CHEMBL5442175
1058 199583 51 None 1 3 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
222757 199583 51 None 1 3 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
CHEMBL282575 199583 51 None 1 3 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
DB13953 199583 51 None 1 3 Human 5.5 pKi = 5.5 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O nan
44325038 473850 0 None 3 3 Human 7.4 pKi = 7.4 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ncccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90966 473850 0 None 3 3 Human 7.4 pKi = 7.4 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 474 6 0 8 3.2 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccc5ncccc5c4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
228 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
Binding affinity to human alpha2C adrenergic receptor assessed as inhibition constantBinding affinity to human alpha2C adrenergic receptor assessed as inhibition constant
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1021/acs.jmedchem.4c00537
33 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
Binding affinity to human alpha2C adrenergic receptor assessed as inhibition constantBinding affinity to human alpha2C adrenergic receptor assessed as inhibition constant
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1021/acs.jmedchem.4c00537
6005 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
Binding affinity to human alpha2C adrenergic receptor assessed as inhibition constantBinding affinity to human alpha2C adrenergic receptor assessed as inhibition constant
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1021/acs.jmedchem.4c00537
CHEMBL53 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
Binding affinity to human alpha2C adrenergic receptor assessed as inhibition constantBinding affinity to human alpha2C adrenergic receptor assessed as inhibition constant
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1021/acs.jmedchem.4c00537
DB00714 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
Binding affinity to human alpha2C adrenergic receptor assessed as inhibition constantBinding affinity to human alpha2C adrenergic receptor assessed as inhibition constant
ChEMBL 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 10.1021/acs.jmedchem.4c00537
3072540 163841 6 None 32 3 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
CHEMBL217366 163841 6 None 32 3 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1016/j.ejmech.2010.12.026
4151 7332 65 None -645 16 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 495 13 3 6 3.1 OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N 10.6019/CHEMBL5442175
493 7332 65 None -645 16 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 495 13 3 6 3.1 OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N 10.6019/CHEMBL5442175
5312125 7332 65 None -645 16 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 495 13 3 6 3.1 OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N 10.6019/CHEMBL5442175
CHEMBL24778 7332 65 None -645 16 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 495 13 3 6 3.1 OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N 10.6019/CHEMBL5442175
DB06207 7332 65 None -645 16 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 495 13 3 6 3.1 OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N 10.6019/CHEMBL5442175
16757089 183100 1 None -3 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL242693 183100 1 None -3 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/NaDisplacement of [3H]RX 821002 from human adrenergic alpha-2c receptor expressed in CHO cells in presence of GppNHp/Na
ChEMBL 311 5 1 5 3.0 C[C@@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
2284 6466 25 None -8 23 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
4926 6466 25 None -8 23 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
7281 6466 25 None -8 23 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
CHEMBL564 6466 25 None -8 23 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
DB00420 6466 25 None -8 23 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C nan
3072540 163841 6 None 32 3 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1021/jm060262x
CHEMBL217366 163841 6 None 32 3 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 382 4 1 4 5.3 CCN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1 10.1021/jm060262x
242 971 74 None -16 38 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
34 971 74 None -16 38 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
60795 971 74 None -16 38 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
CHEMBL1112 971 74 None -16 38 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
DB01238 971 74 None -16 38 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting methodDisplacement of [3H]-clonidine from human alpha 2C receptor incubated for 1 hr by liquid scintillation counting method
ChEMBL 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl 10.1016/j.ejmech.2021.113931
9809007 327839 14 None -724 6 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL448620 327839 14 None -724 6 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
487 7383 17 None -891 29 Human 6.4 pKi = 6.4 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
60602 7383 17 None -891 29 Human 6.4 pKi = 6.4 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
CHEMBL405355 7383 17 None -891 29 Human 6.4 pKi = 6.4 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
DB09239 7383 17 None -891 29 Human 6.4 pKi = 6.4 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00019a001
4150 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
5288 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
644019 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
9852188 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
CHEMBL190461 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
CHEMBL3833333 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
DB09061 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
DB14011 1630 28 None -275 14 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C receptor (unknown origin)Inhibition of alpha2C receptor (unknown origin)
ChEMBL 314 6 2 2 5.8 CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C 10.1021/acs.jmedchem.0c00724
9809007 327839 14 None -724 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL448620 327839 14 None -724 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
9851486 473647 0 None -316 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 10 2 6 6.0 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL89685 473647 0 None -316 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 10 2 6 6.0 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
73349362 183358 0 None 1 2 Human 5.4 pKi = 5.4 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 5 0 1 3.8 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL2432060 183358 0 None 1 2 Human 5.4 pKi = 5.4 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 5 0 1 3.8 CN(CCCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
5074 6777 51 None -588 31 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 10.6019/CHEMBL5442175
97 6777 51 None -588 31 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 10.6019/CHEMBL5442175
CHEMBL267777 6777 51 None -588 31 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 10.6019/CHEMBL5442175
DB12693 6777 51 None -588 31 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 477 5 0 5 5.5 Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F 10.6019/CHEMBL5442175
16090633 161915 0 None 25 3 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL214661 161915 0 None 25 3 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
16090633 161915 0 None 25 3 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL214661 161915 0 None 25 3 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
57400959 143419 0 None -1 3 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956200 143419 0 None -1 3 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 268 4 1 5 0.9 CC(Oc1ccccc1S(C)(=O)=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
124 6070 37 None -26 25 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
2032 6070 37 None -26 25 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
4636 6070 37 None -26 25 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
CHEMBL762 6070 37 None -26 25 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
DB00935 6070 37 None -26 25 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C nan
10436842 200425 0 None -4786 7 Human 5.4 pKi = 5.4 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.6 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL288772 200425 0 None -4786 7 Human 5.4 pKi = 5.4 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 524 7 1 4 4.6 CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
1960 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
439260 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
505 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
6921840 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
CHEMBL1437 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
DB00368 5823 49 None -28 26 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.6019/CHEMBL5442175
16090597 278692 0 None 5 3 Human 6.4 pKi = 6.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL384318 278692 0 None 5 3 Human 6.4 pKi = 6.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
521 2888 53 None -17 8 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.6019/CHEMBL5442175
5311068 2888 53 None -17 8 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.6019/CHEMBL5442175
835 2888 53 None -17 8 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.6019/CHEMBL5442175
CHEMBL778 2888 53 None -17 8 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.6019/CHEMBL5442175
DB00633 2888 53 None -17 8 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 10.6019/CHEMBL5442175
3930 4392 42 None 2 15 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442175
540335 4392 42 None 2 15 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442175
CHEMBL106525 4392 42 None 2 15 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 368 3 1 4 4.9 CN1CCN(CC1)c1ccc(cc1)Nc1c2ccccc2nc2c1cccc2 10.6019/CHEMBL5442175
16090597 278692 0 None 5 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL384318 278692 0 None 5 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1nc2c(C)ccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
10508332 176240 0 None -269 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 638 11 2 8 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])c(OC)c1 10.1021/jm980077m
CHEMBL2260368 176240 0 None -269 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 638 11 2 8 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])c(OC)c1 10.1021/jm980077m
CHEMBL313160 176240 0 None -269 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 638 11 2 8 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])c(OC)c1 10.1021/jm980077m
28918670 183295 1 None -4 4 Human 6.4 pKi = 6.4 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL2431279 183295 1 None -4 4 Human 6.4 pKi = 6.4 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 254 3 1 3 1.8 Brc1ccccc1OCC1=NCCN1 10.1021/ml400232p
127036953 274918 0 None -39 22 Human 6.4 pKi = 6.4 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 318 7 1 1 4.1 C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3754166 274918 0 None -39 22 Human 6.4 pKi = 6.4 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 318 7 1 1 4.1 C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2015.12.053
44269140 67169 0 None -4 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL14208 67169 0 None -4 3 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 248 5 1 4 2.2 CC(C)Oc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
73352415 183346 0 None -2 4 Human 5.4 pKi = 5.4 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 293 4 0 2 2.5 CN(CCc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432044 183346 0 None -2 4 Human 5.4 pKi = 5.4 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 293 4 0 2 2.5 CN(CCc1ccccc1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
10916464 469091 0 None -8 5 Human 5.4 pKi = 5.4 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1cc(Cl)ccc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70563 469091 0 None -8 5 Human 5.4 pKi = 5.4 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1cc(Cl)ccc1NCC1=NCCN1 10.1021/jm000542r
12576 1064 66 None -1 4 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
71310 1064 66 None -1 4 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
CHEMBL353972 1064 66 None -1 4 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
DB11481 1064 66 None -1 4 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 10.1021/jm1006269
44438166 194234 0 None 33 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL247664 194234 0 None 33 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 8 2 7 3.5 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCC(C)(C)N)cc13)CC2 10.1016/j.bmcl.2006.12.094
46891598 21498 0 None -2 2 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rauwolscine from adrenergic Alpha-2C receptorDisplacement of [3H]rauwolscine from adrenergic Alpha-2C receptor
ChEMBL 402 5 0 5 3.2 CN1CC2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1016/j.bmcl.2010.04.099
CHEMBL1085510 21498 0 None -2 2 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rauwolscine from adrenergic Alpha-2C receptorDisplacement of [3H]rauwolscine from adrenergic Alpha-2C receptor
ChEMBL 402 5 0 5 3.2 CN1CC2C(=NO[C@H]2CN2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21 10.1016/j.bmcl.2010.04.099
44424855 176398 0 None 1 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 176398 0 None 1 3 Human 8.4 pKi = 8.4 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
44324859 221108 0 None 4 3 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 461 6 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CC4=Cc5ccccc5C4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328377 221108 0 None 4 3 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 461 6 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CC4=Cc5ccccc5C4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324765 221065 0 None 2 5 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328114 221065 0 None 2 5 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
16090631 163818 0 None 630 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1016/j.ejmech.2010.12.026
CHEMBL217253 163818 0 None 630 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1016/j.ejmech.2010.12.026
16090631 163818 0 None 630 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1021/jm060262x
CHEMBL217253 163818 0 None 630 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 4 2 5 4.5 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C(C)O 10.1021/jm060262x
3191 202914 68 None -3 25 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
977 202914 68 None -3 25 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
CHEMBL305660 202914 68 None -3 25 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
DB11742 202914 68 None -3 25 Human 7.4 pKi = 7.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 nan
10655607 469640 2 None -5 3 Human 6.4 pKi = 6.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 199 2 3 3 2.0 c1c[nH]c(Nc2ccc3[nH]cnc3c2)n1 10.1021/jm9605142
CHEMBL74544 469640 2 None -5 3 Human 6.4 pKi = 6.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 199 2 3 3 2.0 c1c[nH]c(Nc2ccc3[nH]cnc3c2)n1 10.1021/jm9605142
46224516 40316 54 None -1 6 Human 6.4 pKi = 6.4 Binding
Selectivity interaction (US National Institute of Mental Health's Psychoactive Drug Screen Program Selectivity Panel) EUB0001125a ADRA2CSelectivity interaction (US National Institute of Mental Health's Psychoactive Drug Screen Program Selectivity Panel) EUB0001125a ADRA2C
ChEMBL 509 10 1 7 5.8 COc1cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1 10.6019/CHEMBL5715260
CHEMBL1231795 40316 54 None -1 6 Human 6.4 pKi = 6.4 Binding
Selectivity interaction (US National Institute of Mental Health's Psychoactive Drug Screen Program Selectivity Panel) EUB0001125a ADRA2CSelectivity interaction (US National Institute of Mental Health's Psychoactive Drug Screen Program Selectivity Panel) EUB0001125a ADRA2C
ChEMBL 509 10 1 7 5.8 COc1cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1 10.6019/CHEMBL5715260
12304323 23355 3 None None None Human 5.4 pKi = 5.4 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 464 4 8 12 -0.5 O=c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 10.1021/np1000329
CHEMBL1098724 23355 3 None None None Human 5.4 pKi = 5.4 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 464 4 8 12 -0.5 O=c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12 10.1021/np1000329
10507651 473467 0 None -45 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 591 9 2 6 5.8 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL88388 473467 0 None -45 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 591 9 2 6 5.8 CC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
10382537 469100 7 None -60 6 Human 6.4 pKi = 6.4 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL70676 469100 7 None -60 6 Human 6.4 pKi = 6.4 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 339 1 2 5 1.6 Ic1c(NC2=NCCN2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL4748908 478366 0 None -4 12 Human 6.4 pKi = 6.4 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 297 5 1 5 1.9 CN1CCN(c2ccnc(NCCc3ccccc3)n2)CC1 10.6019/CHEMBL4800732
2353 201246 55 None -1 5 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL295124 201246 55 None -1 5 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
DB04115 201246 55 None -1 5 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 336 2 0 4 3.1 COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2 nan
CHEMBL4748908 478366 0 None -4 12 Human 6.4 pKi = 6.4 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 297 5 1 5 1.9 CN1CCN(c2ccnc(NCCc3ccccc3)n2)CC1 10.6019/CHEMBL4800732
10627021 176237 0 None -301 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 577 9 2 5 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C)cc1 10.1021/jm980077m
CHEMBL2260365 176237 0 None -301 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 577 9 2 5 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C)cc1 10.1021/jm980077m
CHEMBL315914 176237 0 None -301 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 577 9 2 5 6.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C)cc1 10.1021/jm980077m
10317643 193682 0 None 32 2 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL276417 193682 0 None 32 2 Human 7.4 pKi = 7.4 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
141 2941 18 None -57 17 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
6089 2941 18 None -57 17 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
CHEMBL12420 2941 18 None -57 17 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
DB01488 2941 18 None -57 17 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysisDisplacement of [3H]-rauwolscine from human recombinant adrenergic alpha-2c receptor expressed in CHO-K1 cells assessed as inhibition constant incubated for 60 mins by spectrophotometric analysis
ChEMBL 188 3 1 1 2.3 CN(CCc1c[nH]c2c1cccc2)C 10.1021/acsmedchemlett.3c00143
10818003 216093 0 None -7 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 649 12 3 6 6.2 CC(C)C1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C(C)C)N1 10.1021/jm980077m
CHEMBL313953 216093 0 None -7 6 Human 6.4 pKi = 6.4 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 649 12 3 6 6.2 CC(C)C1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C(C)C)N1 10.1021/jm980077m
66561967 156373 0 None -6 7 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 213 2 0 1 2.0 C1CC2CCC1N2CC12C3C4C5C3C1C5C42 10.1016/j.bmcl.2012.04.077
CHEMBL2030626 156373 0 None -6 7 Human 5.4 pKi = 5.4 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 213 2 0 1 2.0 C1CC2CCC1N2CC12C3C4C5C3C1C5C42 10.1016/j.bmcl.2012.04.077
44421258 175703 0 None -3 3 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 175703 0 None -3 3 Human 5.4 pKi = 5.4 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
127035062 273890 0 None -16 19 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting methodDisplacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting method
ChEMBL 447 12 0 5 5.2 COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC 10.1039/C4MD00418C
CHEMBL3735756 273890 0 None -16 19 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting methodDisplacement of [3H]Rauwolscine from human recombinant alpha 2C receptor stably expressed in MDCK cells after 90 mins by scintillation counting method
ChEMBL 447 12 0 5 5.2 COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC 10.1039/C4MD00418C
10317643 193682 0 None 32 2 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL276417 193682 0 None 32 2 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 380 4 2 5 3.8 CC1CN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CCN1C 10.1021/jm060262x
13162 7899 43 None -3 15 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.6019/CHEMBL5442175
2803 7899 43 None -3 15 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.6019/CHEMBL5442175
CHEMBL134 7899 43 None -3 15 Human 6.4 pKi = 6.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.6019/CHEMBL5442175
155770281 351683 0 None -5 9 Human 5.4 pKi = 5.4 Binding
Binding affinity to alpha2c (unknown origin)Binding affinity to alpha2c (unknown origin)
ChEMBL 517 4 1 2 7.6 CC(=O)N1CCC(c2ccc(-c3cc(C(=O)O)cc4cc(-c5ccc(C(F)(F)F)cc5)ccc34)cc2)CC1 10.1021/acs.jmedchem.1c00164
CHEMBL4642592 351683 0 None -5 9 Human 5.4 pKi = 5.4 Binding
Binding affinity to alpha2c (unknown origin)Binding affinity to alpha2c (unknown origin)
ChEMBL 517 4 1 2 7.6 CC(=O)N1CCC(c2ccc(-c3cc(C(=O)O)cc4cc(-c5ccc(C(F)(F)F)cc5)ccc34)cc2)CC1 10.1021/acs.jmedchem.1c00164
122186880 241541 0 None -4 5 Human 6.4 pKi = 6.4 Binding
Binding affinity to alpha2C adrenoceptor (unknown origin)Binding affinity to alpha2C adrenoceptor (unknown origin)
ChEMBL 415 3 0 5 4.8 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4 10.1016/j.bmcl.2015.07.012
CHEMBL3608450 241541 0 None -4 5 Human 6.4 pKi = 6.4 Binding
Binding affinity to alpha2C adrenoceptor (unknown origin)Binding affinity to alpha2C adrenoceptor (unknown origin)
ChEMBL 415 3 0 5 4.8 COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2c1ccccc1)OCO4 10.1016/j.bmcl.2015.07.012
71463061 174782 0 None -5 9 Human 5.4 pKi = 5.4 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC 10.1016/j.bmcl.2012.08.046
CHEMBL2205813 174782 0 None -5 9 Human 5.4 pKi = 5.4 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 339 5 1 4 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC 10.1016/j.bmcl.2012.08.046
2435 7889 70 None -5 10 Human 7.4 pKi = 7.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
395 7889 70 None -5 10 Human 7.4 pKi = 7.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
5386 7889 70 None -5 10 Human 7.4 pKi = 7.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
CHEMBL844 7889 70 None -5 10 Human 7.4 pKi = 7.4 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1021/jm9605142
3929516 212927 4 None -7 17 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 343 4 0 2 4.7 CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2 10.6019/CHEMBL5442175
CHEMBL317757 212927 4 None -7 17 Human 7.4 pKi = 7.4 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 343 4 0 2 4.7 CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2 10.6019/CHEMBL5442175
44328654 216825 0 None -114 6 Human 6.4 pKi = 6.4 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 663 14 3 6 6.7 CCCC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCC)=C(CC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL316495 216825 0 None -114 6 Human 6.4 pKi = 6.4 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 663 14 3 6 6.7 CCCC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCC)=C(CC)N1 10.1016/s0960-894x(99)00484-9
1634 163834 36 None -21 21 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
4011 163834 36 None -21 21 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
CHEMBL21731 163834 36 None -21 21 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
DB00934 163834 36 None -21 21 Human 6.4 pKi = 6.4 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 nan
2080 352858 63 None -1 22 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
33630 352858 63 None -1 22 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
CHEMBL47050 352858 63 None -1 22 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
DB13791 352858 63 None -1 22 Human 6.4 pKi = 6.4 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
ChEMBL 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 10.1016/j.bmcl.2018.10.036
73213196 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Binding affinity to adrenergic alpha 2C receptor (unknown origin)Binding affinity to adrenergic alpha 2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2014.05.016
CHEMBL3104093 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Binding affinity to adrenergic alpha 2C receptor (unknown origin)Binding affinity to adrenergic alpha 2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2014.05.016
73213196 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104093 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
73213196 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104093 214178 5 None -4 13 Human 6.4 pKi = 6.4 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.9 CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1 10.1016/j.bmcl.2013.12.024
57401706 142417 0 None -7 11 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 331 6 0 4 3.5 Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
CHEMBL1940419 142417 0 None -7 11 Human 7.4 pKi = 7.4 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 331 6 0 4 3.5 Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1 10.1016/j.bmc.2011.12.019
463 2890 18 None -48 13 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
6918097 2890 18 None -48 13 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
837 2890 18 None -48 13 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
CHEMBL2051956 2890 18 None -48 13 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
DB14068 2890 18 None -48 13 Human 6.4 pKi = 6.4 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
6918276 39502 6 None -47 8 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
CHEMBL1221512 39502 6 None -47 8 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 559 18 4 9 1.7 CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS nan
44269089 197328 0 None -6 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL266613 197328 0 None -6 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 3 2.6 CC(Oc1ccccc1C(C)C)C1=NCCN1 10.1016/j.bmc.2012.01.035
9809007 327839 14 None -724 6 Human 6.3 pKi = 6.3 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
CHEMBL448620 327839 14 None -724 6 Human 6.3 pKi = 6.3 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm00010a001
191 833 62 None -28 26 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
201 833 62 None -28 26 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
2170 833 62 None -28 26 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
CHEMBL1113 833 62 None -28 26 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
DB00543 833 62 None -28 26 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 nan
1482 367203 61 None -1 2 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
60838 367203 61 None -1 2 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
CHEMBL481 367203 61 None -1 2 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
DB00762 367203 61 None -1 2 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC nan
44288847 330198 0 None -3311 5 Human 5.3 pKi = 5.3 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 535 7 2 5 3.9 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
CHEMBL42335 330198 0 None -3311 5 Human 5.3 pKi = 5.3 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 535 7 2 5 3.9 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1 10.1016/s0960-894x(99)00696-4
10769331 176242 0 None -91 6 Human 7.3 pKi = 7.3 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 566 9 2 7 5.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc(Cl)c([N+](=O)[O-])c1 10.1021/jm980077m
CHEMBL2260370 176242 0 None -91 6 Human 7.3 pKi = 7.3 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 566 9 2 7 5.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc(Cl)c([N+](=O)[O-])c1 10.1021/jm980077m
CHEMBL327931 176242 0 None -91 6 Human 7.3 pKi = 7.3 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 566 9 2 7 5.0 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc(Cl)c([N+](=O)[O-])c1 10.1021/jm980077m
135453290 271080 30 None -1548 8 Human 5.3 pKi = 5.3 Binding
Displacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cellsDisplacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cells
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
CHEMBL371300 271080 30 None -1548 8 Human 5.3 pKi = 5.3 Binding
Displacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cellsDisplacement of [3H]clonidine from cloned human adrenergic Alpha-2C receptor expressed in Sf9 cells
ChEMBL 191 2 2 4 1.1 C[C@H](N)Cn1ncc2ccc(O)cc21 10.1021/jm050663x
136680384 474537 0 None -104 6 Human 6.3 pKi = 6.3 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
44328799 474537 0 None -104 6 Human 6.3 pKi = 6.3 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
CHEMBL95290 474537 0 None -104 6 Human 6.3 pKi = 6.3 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 694 16 4 8 4.9 CCNC(=O)C1=C(CC)NC(COCCN)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
71461344 174793 0 None None None Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 266 2 1 3 1.3 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1 10.1016/j.bmc.2013.07.045
CHEMBL2205833 174793 0 None None None Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 266 2 1 3 1.3 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccnc1 10.1016/j.bmc.2013.07.045
73347827 183352 0 None -2 4 Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 4 0 2 2.6 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432052 183352 0 None -2 4 Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 311 4 0 2 2.6 CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
1443 4143 26 None -11 9 Human 6.3 pKi = 6.3 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
33625 4143 26 None -11 9 Human 6.3 pKi = 6.3 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
501 4143 26 None -11 9 Human 6.3 pKi = 6.3 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
CHEMBL279516 4143 26 None -11 9 Human 6.3 pKi = 6.3 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
DB08950 4143 26 None -11 9 Human 6.3 pKi = 6.3 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 10.1021/jm00018a001
10474335 387172 20 None -16 10 Human 6.3 pKi = 6.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 370 6 0 3 4.8 COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1 10.1038/s41586-020-2286-9
CHEMBL53325 387172 20 None -16 10 Human 6.3 pKi = 6.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
ChEMBL 370 6 0 3 4.8 COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1 10.1038/s41586-020-2286-9
10626982 220994 0 None -8 6 Human 6.3 pKi = 6.3 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 575 9 2 6 5.9 CC1=C(C#N)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL327775 220994 0 None -8 6 Human 6.3 pKi = 6.3 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 575 9 2 6 5.9 CC1=C(C#N)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
9947861 469097 0 None -8 4 Human 5.3 pKi = 5.3 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL70634 469097 0 None -8 4 Human 5.3 pKi = 5.3 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 287 4 2 5 1.2 CS(=O)(=O)c1ccc(Cl)cc1NCC1=NCCN1 10.1021/jm000542r
10314057 372174 5 None -45 8 Human 5.3 pKi = 5.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 322 1 1 4 2.8 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14 10.1021/acs.jmedchem.4c00736
CHEMBL508955 372174 5 None -45 8 Human 5.3 pKi = 5.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assayBinding affinity to alpha2C adrenergic receptor (unknown origin) by radioligand displacement assay
ChEMBL 322 1 1 4 2.8 C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14 10.1021/acs.jmedchem.4c00736
44269013 63990 0 None -10 4 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL13917 63990 0 None -10 4 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 218 5 1 3 2.0 CCCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
57345625 143410 0 None -16 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956191 143410 0 None -16 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 224 3 1 3 2.1 CC(Oc1ccccc1Cl)C1=NCCN1 10.1016/j.bmc.2012.01.035
45487962 394570 0 None -10 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL569933 394570 0 None -10 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 218 4 1 3 2.1 CCCc1ccccc1COC1=NCCN1 10.1021/jm901262f
44312198 469487 0 None -1 4 Human 4.3 pKi = 4.3 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 292 1 1 5 2.2 Brc1c(NC2=NCCO2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
CHEMBL73164 469487 0 None -1 4 Human 4.3 pKi = 4.3 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 292 1 1 5 2.2 Brc1c(NC2=NCCO2)ccc2nccnc12 10.1016/0960-894X(95)00391-6
44579185 355653 1 None 7 3 Human 8.3 pKi = 8.3 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL477816 355653 1 None 7 3 Human 8.3 pKi = 8.3 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(CC2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
10362866 163727 0 None 114 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217203 163727 0 None 114 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
10070896 164610 0 None 281 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
CHEMBL218457 164610 0 None 281 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1016/j.ejmech.2010.12.026
10362866 163727 0 None 114 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL217203 163727 0 None 114 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)C(C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
10070896 164610 0 None 281 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1021/jm060262x
CHEMBL218457 164610 0 None 281 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 422 4 1 4 6.1 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1-c1ccccc1 10.1021/jm060262x
CHEMBL3559672 477901 0 None 1 3 Human 8.3 pKi = 8.3 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL None None None None 10.1021/jm00019a001
124 6070 37 None -26 25 Human 8.3 pKi = 8.3 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
2032 6070 37 None -26 25 Human 8.3 pKi = 8.3 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
4636 6070 37 None -26 25 Human 8.3 pKi = 8.3 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
CHEMBL762 6070 37 None -26 25 Human 8.3 pKi = 8.3 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
DB00935 6070 37 None -26 25 Human 8.3 pKi = 8.3 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1016/j.bmcl.2013.12.024
102 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
3659 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
8969 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
92766 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL15245 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
CHEMBL31410 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
DB01392 8930 44 None -60 31 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 nan
44402531 141860 0 None None None Human 8.3 pKi = 8.3 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 468 5 4 6 0.9 COC(=O)CNC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL193458 141860 0 None None None Human 8.3 pKi = 8.3 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 468 5 4 6 0.9 COC(=O)CNC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
44325075 221255 0 None 2 2 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 465 8 0 8 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCC(=O)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL328735 221255 0 None 2 2 Human 8.3 pKi = 8.3 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 465 8 0 8 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCC(=O)c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
10473701 164650 0 None 165 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL218679 164650 0 None 165 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1016/j.ejmech.2010.12.026
10473701 164650 0 None 165 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1021/jm060262x
CHEMBL218679 164650 0 None 165 3 Human 8.3 pKi = 8.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 4.8 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)(C)C2)cc1 10.1021/jm060262x
134551 741 18 None -4 19 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
271 741 18 None -4 19 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
885 741 18 None -4 19 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
CHEMBL1403281 741 18 None -4 19 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C nan
49781005 41089 0 None -3 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256503 41089 0 None -3 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
10251036 163313 0 None 70 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL216464 163313 0 None 70 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1021/jm060262x
10251036 163313 0 None 70 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL216464 163313 0 None 70 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 410 4 2 5 4.7 CN1CCN(c2ccc(Nc3c(CO)cnc4cc(Cl)ccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10475736 330726 0 None 26 3 Human 7.3 pKi = 7.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL424917 330726 0 None 26 3 Human 7.3 pKi = 7.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10475736 330726 0 None 26 3 Human 7.3 pKi = 7.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL424917 330726 0 None 26 3 Human 7.3 pKi = 7.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 4 2 5 4.1 CN1CCN(c2ccc(Nc3c(CO)cnc4ccc(F)cc34)cc2)CC1(C)C 10.1021/jm060262x
2536 308773 12 None -8 15 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
5354 308773 12 None -8 15 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
CHEMBL404849 308773 12 None -8 15 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 nan
16090599 162979 0 None 1 2 Human 5.3 pKi = 5.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216072 162979 0 None 1 2 Human 5.3 pKi = 5.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
50878551 181561 26 None -22 18 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
CHEMBL2391541 181561 26 None -22 18 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
45487958 407710 0 None -14 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
CHEMBL576819 407710 0 None -14 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 190 2 1 3 1.5 Cc1ccccc1COC1=NCCN1 10.1021/jm901262f
7059292 157958 2 None -5 3 Human 5.3 pKi = 5.3 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 194 1 1 2 2.9 Clc1ccccc1NC1=NCCC1 10.1016/j.bmc.2012.06.008
CHEMBL2058633 157958 2 None -5 3 Human 5.3 pKi = 5.3 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 194 1 1 2 2.9 Clc1ccccc1NC1=NCCC1 10.1016/j.bmc.2012.06.008
73346332 183343 0 None -2 4 Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 3 0 2 2.6 CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
CHEMBL2432041 183343 0 None -2 4 Human 5.3 pKi = 5.3 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 297 3 0 2 2.6 CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21 10.1016/j.bmc.2013.07.045
50878551 181561 26 None -22 18 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
CHEMBL2391541 181561 26 None -22 18 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysisDisplacement of [3H]Clonidine from human recombinant adrenergic alpha2C receptor expressed in MDCK cells after 1 to 1.5 hrs by scintillation counting analysis
ChEMBL 270 8 1 2 3.4 C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12 10.1016/j.bmcl.2013.03.066
10198135 469988 0 None -51 3 Human 6.3 pKi = 6.3 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 203 3 2 3 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1 10.1021/jm9605142
CHEMBL77913 469988 0 None -51 3 Human 6.3 pKi = 6.3 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 203 3 2 3 2.5 COc1ccc(Nc2ncc[nH]2)c(C)c1 10.1021/jm9605142
44329027 18517 0 None -26 6 Human 6.3 pKi = 6.3 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 637 13 3 7 4.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COC)N1 10.1016/s0960-894x(99)00484-9
CHEMBL100045 18517 0 None -26 6 Human 6.3 pKi = 6.3 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 637 13 3 7 4.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COC)N1 10.1016/s0960-894x(99)00484-9
10177445 330896 0 None 32 3 Human 7.3 pKi = 7.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL425622 330896 0 None 32 3 Human 7.3 pKi = 7.3 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1016/j.ejmech.2010.12.026
10177445 330896 0 None 32 3 Human 7.3 pKi = 7.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1021/jm060262x
CHEMBL425622 330896 0 None 32 3 Human 7.3 pKi = 7.3 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 4 1 4 5.2 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)CC3)cc2)c1C(C)C 10.1021/jm060262x
44292381 201522 0 None -2 3 Human 7.3 pKi = 7.3 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 244 2 1 3 2.7 c1ccc([C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL297228 201522 0 None -2 3 Human 7.3 pKi = 7.3 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 244 2 1 3 2.7 c1ccc([C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
46743607 240310 0 None None None Human 5.3 pKi = 5.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
CHEMBL3588905 240310 0 None None None Human 5.3 pKi = 5.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 264 5 2 3 2.8 c1ccc(-c2nc(CNCc3cccnc3)c[nH]2)cc1 10.1016/j.bmc.2015.01.013
71450550 174794 0 None -1 16 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
CHEMBL2205836 174794 0 None -1 16 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
9893924 19088 27 None -21 22 Human 6.3 pKi = 6.3 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442175
CHEMBL103769 19088 27 None -21 22 Human 6.3 pKi = 6.3 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 554 11 3 4 5.4 S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1 10.6019/CHEMBL5442175
8032110 240308 13 None None None Human 6.3 pKi = 6.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 198 3 1 2 3.0 Cc1ccccc1NCc1ccncc1 10.1016/j.bmc.2015.01.013
CHEMBL3588903 240308 13 None None None Human 6.3 pKi = 6.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 198 3 1 2 3.0 Cc1ccccc1NCc1ccncc1 10.1016/j.bmc.2015.01.013
16757182 308630 0 None -7 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
CHEMBL397753 308630 0 None -7 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm061487a
16757182 308630 0 None -7 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
CHEMBL397753 308630 0 None -7 3 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 311 5 1 5 3.0 C[C@H](Oc1ccccc1-c1cccc([N+](=O)[O-])c1)C1=NCCN1 10.1021/jm100977d
2726 1895 54 None -21 48 Human 7.3 pKi = 7.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
621 1895 54 None -21 48 Human 7.3 pKi = 7.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
83 1895 54 None -21 48 Human 7.3 pKi = 7.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
CHEMBL71 1895 54 None -21 48 Human 7.3 pKi = 7.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
DB00477 1895 54 None -21 48 Human 7.3 pKi = 7.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C nan
2600 8239 59 None -3 12 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2608 8239 59 None -3 12 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
5405 8239 59 None -3 12 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
CHEMBL17157 8239 59 None -3 12 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
DB00342 8239 59 None -3 12 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O nan
2765 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
515 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
CHEMBL13852 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
DB09202 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/ml400232p
2765 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
515 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
CHEMBL13852 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
DB09202 1943 17 None -15 8 Human 6.3 pKi = 6.3 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 216 4 1 3 1.9 C1CN=C(N1)COc1ccccc1C1CC1 10.1021/jm901262f
1353 3909 69 None -54 49 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1021/acs.jmedchem.4c00537
3559 3909 69 None -54 49 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1021/acs.jmedchem.4c00537
86 3909 69 None -54 49 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1021/acs.jmedchem.4c00537
CHEMBL54 3909 69 None -54 49 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1021/acs.jmedchem.4c00537
DB00502 3909 69 None -54 49 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl 10.1021/acs.jmedchem.4c00537
49783209 41478 0 None -977 27 Human 6.3 pKi = 6.3 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 396 7 1 6 3.8 CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1 10.1021/jm100668r
CHEMBL1258223 41478 0 None -977 27 Human 6.3 pKi = 6.3 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 396 7 1 6 3.8 CCCCN1CCC(COC(=O)c2cc(Cl)c(NC)c3c2OCCO3)CC1 10.1021/jm100668r
71459604 174780 0 None 1 14 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
CHEMBL2205811 174780 0 None 1 14 Human 6.3 pKi = 6.3 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 309 4 1 3 2.0 COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1 10.1016/j.bmcl.2012.08.046
13162 7899 43 None -3 15 Human 7.3 pKi = 7.3 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
2803 7899 43 None -3 15 Human 7.3 pKi = 7.3 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
CHEMBL134 7899 43 None -3 15 Human 7.3 pKi = 7.3 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/0960-894X(94)85032-1
2338 461820 42 None -1 13 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
237 461820 42 None -1 13 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
CHEMBL7568 461820 42 None -1 13 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
DB01103 461820 42 None -1 13 Human 6.3 pKi = 6.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 nan
101333429 235935 0 None -1412 6 Human 6.3 pKi = 6.3 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1 10.1021/jm00019a001
CHEMBL3392247 235935 0 None -1412 6 Human 6.3 pKi = 6.3 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1 10.1021/jm00019a001
11564613 43266 62 None None None Human 6.3 pKi = 6.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2cccc(N)c2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL129399 43266 62 None None None Human 6.3 pKi = 6.3 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 191 1 1 3 1.0 CN1CCN(c2cccc(N)c2)CC1 10.1016/j.bmc.2015.01.013
CHEMBL6067487 479737 0 None -1 8 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
1201549 1234 18 None -18 20 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
333 1234 18 None -18 20 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
7601 1234 18 None -18 20 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
CHEMBL1201203 1234 18 None -18 20 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
DB00245 1234 18 None -18 20 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 nan
2435 7889 70 None -5 10 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.6019/CHEMBL5442175
395 7889 70 None -5 10 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.6019/CHEMBL5442175
5386 7889 70 None -5 10 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.6019/CHEMBL5442175
CHEMBL844 7889 70 None -5 10 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.6019/CHEMBL5442175
10531766 176238 0 None -512 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 9 2 7 5.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL2260366 176238 0 None -512 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 9 2 7 5.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
CHEMBL91415 176238 0 None -512 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 607 9 2 7 5.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2c(c1)OCO2 10.1021/jm980077m
12699315 157956 0 None -4 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 243 1 2 3 2.8 CC1CNC(Nc2c(Cl)cccc2Cl)=N1 10.1016/j.bmc.2012.06.008
CHEMBL2058631 157956 0 None -4 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 243 1 2 3 2.8 CC1CNC(Nc2c(Cl)cccc2Cl)=N1 10.1016/j.bmc.2012.06.008
CHEMBL4513786 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL4507258
CHEMBL4796803 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL4507258
CHEMBL4513786 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL5212743
CHEMBL4796803 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl ADRA2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL5212743
124 6070 37 None -26 25 Human 7.2 pKi = 7.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
2032 6070 37 None -26 25 Human 7.2 pKi = 7.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
4636 6070 37 None -26 25 Human 7.2 pKi = 7.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
CHEMBL762 6070 37 None -26 25 Human 7.2 pKi = 7.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
DB00935 6070 37 None -26 25 Human 7.2 pKi = 7.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 10.1021/jm000542r
11498 6149 38 None -36 13 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 392 3 1 5 4.1 CCOC(=O)c1c(C)[nH]c2c1c1CN3CCc4c(C3Oc1cc2)ccc(c4)OC 10.6019/CHEMBL5442175
4995951 6149 38 None -36 13 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 392 3 1 5 4.1 CCOC(=O)c1c(C)[nH]c2c1c1CN3CCc4c(C3Oc1cc2)ccc(c4)OC 10.6019/CHEMBL5442175
CHEMBL59898 6149 38 None -36 13 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 392 3 1 5 4.1 CCOC(=O)c1c(C)[nH]c2c1c1CN3CCc4c(C3Oc1cc2)ccc(c4)OC 10.6019/CHEMBL5442175
1355 42931 34 None -2 11 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
3561 42931 34 None -2 11 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
CHEMBL1289 42931 34 None -2 11 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
DB00793 42931 34 None -2 11 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl nan
11448533 175648 0 None 1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 0 3 3.6 CC(Oc1ccccc1-c1ccccc1)C1=NCCO1 10.1021/jm0408215
CHEMBL222591 175648 0 None 1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 0 3 3.6 CC(Oc1ccccc1-c1ccccc1)C1=NCCO1 10.1021/jm0408215
11473729 175649 0 None 1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 0 2 4.4 CC(Oc1ccccc1-c1ccccc1)C1=NCCC1 10.1021/jm0408215
CHEMBL222593 175649 0 None 1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 0 2 4.4 CC(Oc1ccccc1-c1ccccc1)C1=NCCC1 10.1021/jm0408215
44401164 142064 0 None -309 9 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193639 142064 0 None -309 9 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
11978813 1488 62 None -25 28 Human 7.2 pKi = 7.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 10.6019/CHEMBL5442175
5014 1488 62 None -25 28 Human 7.2 pKi = 7.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 10.6019/CHEMBL5442175
7672 1488 62 None -25 28 Human 7.2 pKi = 7.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 10.6019/CHEMBL5442175
CHEMBL2105760 1488 62 None -25 28 Human 7.2 pKi = 7.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 10.6019/CHEMBL5442175
DB09128 1488 62 None -25 28 Human 7.2 pKi = 7.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 10.6019/CHEMBL5442175
49783419 41618 0 None -1778 13 Human 6.2 pKi = 6.2 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 366 6 1 6 2.8 CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1 10.1021/jm100668r
CHEMBL1258671 41618 0 None -1778 13 Human 6.2 pKi = 6.2 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 366 6 1 6 2.8 CCCCN1CCC(COC(=O)c2cc(F)c(N)c3c2OCCO3)CC1 10.1021/jm100668r
24771824 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
CHEMBL1651534 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
DB12012 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
24771824 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL5212743
CHEMBL1651534 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL5212743
DB12012 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000306b ADRA2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL5212743
CHEMBL4780458 478379 0 None -2 4 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000540a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000540a ADRA2C
ChEMBL 457 6 1 7 4.0 O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1 10.6019/CHEMBL5212743
44324765 221065 0 None 2 5 Human 8.2 pKi = 8.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL328114 221065 0 None 2 5 Human 8.2 pKi = 8.2 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
9846548 473089 0 None 1 3 Human 8.2 pKi = 8.2 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL93489 473089 0 None 1 3 Human 8.2 pKi = 8.2 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
10474679 197492 0 None 288 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
CHEMBL268217 197492 0 None 288 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1016/j.ejmech.2010.12.026
10474679 197492 0 None 288 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1021/jm060262x
CHEMBL268217 197492 0 None 288 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 4.0 CN1CCN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CC1(C)C 10.1021/jm060262x
2180 140074 14 None -3 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
6761 140074 14 None -3 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
CHEMBL1909072 140074 14 None -3 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 nan
16090596 163719 0 None 158 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217177 163719 0 None 158 3 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090596 163719 0 None 158 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217177 163719 0 None 158 3 Human 8.2 pKi = 8.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
44568347 374712 0 None -28 15 Human 6.2 pKi = 6.2 Binding
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 356 6 0 4 5.2 CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
CHEMBL519609 374712 0 None -28 15 Human 6.2 pKi = 6.2 Binding
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 356 6 0 4 5.2 CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
118717248 234111 0 None -18 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1ccc2cnn(N=C3NCCN3)c2c1 10.1016/j.ejmech.2014.09.083
CHEMBL3343699 234111 0 None -18 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 219 1 2 3 0.5 Fc1ccc2cnn(N=C3NCCN3)c2c1 10.1016/j.ejmech.2014.09.083
11098175 469102 0 None -5 5 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 251 5 2 5 1.8 COc1ccc(SC)c(NCC2=NCCN2)c1 10.1021/jm000542r
CHEMBL70691 469102 0 None -5 5 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 251 5 2 5 1.8 COc1ccc(SC)c(NCC2=NCCN2)c1 10.1021/jm000542r
11034737 469428 0 None -3 6 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
CHEMBL72724 469428 0 None -3 6 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 289 4 2 4 2.8 CSc1ccc(C(F)(F)F)cc1NCC1=NCCN1 10.1021/jm000542r
57345627 143413 0 None -8 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956194 143413 0 None -8 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 230 4 1 3 2.5 C=C(C)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
24771824 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
CHEMBL1651534 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
DB12012 120139 46 None 1 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 455 4 1 5 5.4 O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1 10.6019/CHEMBL4507297
3408 41852 27 None -11 15 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
5353853 41852 27 None -11 15 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
CHEMBL1262 41852 27 None -11 15 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
DB00239 41852 27 None -11 15 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 nan
2599 116531 16 None 2 17 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
5404 116531 16 None 2 17 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
CHEMBL1714574 116531 16 None 2 17 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 nan
2337 6622 53 None -14 36 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
50 6622 53 None -14 36 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
5002 6622 53 None -14 36 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
CHEMBL716 6622 53 None -14 36 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
DB01224 6622 53 None -14 36 Human 7.2 pKi = 7.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 5 1 6 2.9 OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2 nan
57401787 143483 0 None -1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COCC(C3=NCCN3)O2)cc1 10.1016/j.bmc.2012.02.016
CHEMBL1956906 143483 0 None -1 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COCC(C3=NCCN3)O2)cc1 10.1016/j.bmc.2012.02.016
4209 8026 58 None -389 20 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.6019/CHEMBL5442175
4893 8026 58 None -389 20 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.6019/CHEMBL5442175
5385 8026 58 None -389 20 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.6019/CHEMBL5442175
CHEMBL2 8026 58 None -389 20 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.6019/CHEMBL5442175
56645363 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL4507294
CHEMBL3582478 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL4507294
56645363 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL5212743
CHEMBL3582478 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000313b ADRA2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL5212743
1960 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
439260 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
505 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
6921840 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
CHEMBL1437 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
DB00368 5823 49 None -28 26 Human 7.2 pKi = 7.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 10.1021/jm960012o
49836303 42433 0 None -10 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276220 42433 0 None -10 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
49836303 42433 0 None -10 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276220 42433 0 None -10 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 C[C@H](Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
1265 1941 37 None -112 8 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
6422124 1941 37 None -112 8 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
CHEMBL14638 1941 37 None -112 8 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 270 7 1 3 3.0 O=C(c1ccc(cc1)OCCCc1[nH]cnc1)C1CC1 10.1021/jm8003625
10508016 176241 0 None -17 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 613 9 2 5 6.8 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2ccccc2c1 10.1021/jm980077m
CHEMBL2260369 176241 0 None -17 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 613 9 2 5 6.8 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2ccccc2c1 10.1021/jm980077m
CHEMBL92322 176241 0 None -17 6 Human 6.2 pKi = 6.2 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 613 9 2 5 6.8 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc2ccccc2c1 10.1021/jm980077m
72947314 183298 0 None -8 4 Human 6.2 pKi = 6.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
CHEMBL2431281 183298 0 None -8 4 Human 6.2 pKi = 6.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.0 c1ccc(OCC2=NCCN2)c(CC2CC2)c1 10.1021/ml400232p
127036932 274752 0 None -20 22 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 274 7 1 1 4.0 C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3752900 274752 0 None -20 22 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 274 7 1 1 4.0 C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12 10.1016/j.bmcl.2015.12.053
57395732 143422 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956203 143422 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 342 5 1 3 4.8 CC(Oc1c(-c2ccccc2)cccc1-c1ccccc1)C1=NCCN1 10.1016/j.bmc.2012.01.035
56645363 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL4507294
CHEMBL3582478 240095 21 None 2 6 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 311 3 1 4 3.8 CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1 10.6019/CHEMBL4507294
CHEMBL4513786 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL4507258
CHEMBL4796803 477449 5 None -1096 8 Human 5.2 pKi = 5.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 532 15 1 6 5.5 CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC 10.6019/CHEMBL4507258
2406 200565 63 None -11 12 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
3032 200565 63 None -11 12 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
CHEMBL290106 200565 63 None -11 12 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
DB04813 200565 63 None -11 12 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O nan
122295 24171 3 None -1 7 Human 7.2 pKi = 7.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00018a001
CHEMBL114166 24171 3 None -1 7 Human 7.2 pKi = 7.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00018a001
122295 24171 3 None -1 7 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00019a001
CHEMBL114166 24171 3 None -1 7 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine to CHO cells expressing the human Alpha-2C adrenergic receptor
ChEMBL 279 3 0 2 3.7 CC(C)=CCOc1ccc(Cl)c2c1CCN(C)CC2 10.1021/jm00019a001
44568614 370857 0 None -1 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 252 4 1 3 2.8 c1ccc(OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
CHEMBL494885 370857 0 None -1 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 252 4 1 3 2.8 c1ccc(OC(C2=NCCN2)c2ccccc2)cc1 10.1021/jm800250z
11265631 273853 0 None 2 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
CHEMBL373535 273853 0 None 2 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm061487a
11265631 273853 0 None 2 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
CHEMBL373535 273853 0 None 2 3 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 267 4 1 4 2.5 CC(Oc1ccccc1-c1cccnc1)C1=NCCN1 10.1021/jm0408215
24882007 26741 1 None -12 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 201 1 2 3 0.3 c1ccc2c(c1)cnn2N=C1NCCN1 10.1016/j.ejmech.2014.09.083
CHEMBL1186220 26741 1 None -12 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation countingDisplacement of [3H]RS-79948-197 from human alpha2C adrenoceptor expressed in CHO-K1 cells after 45 mins by liquid scintillation counting
ChEMBL 201 1 2 3 0.3 c1ccc2c(c1)cnn2N=C1NCCN1 10.1016/j.ejmech.2014.09.083
15675860 469334 0 None -8 4 Human 6.2 pKi = 6.2 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
CHEMBL72147 469334 0 None -8 4 Human 6.2 pKi = 6.2 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.1 Cc1cnc2c(Br)c(NC3=NCCN3)ccc2n1 10.1016/0960-894X(95)00391-6
44312036 469463 1 None 5 4 Human 6.2 pKi = 6.2 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
CHEMBL72995 469463 1 None 5 4 Human 6.2 pKi = 6.2 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 305 1 2 5 2.2 CC1CN=C(Nc2ccc3nccnc3c2Br)N1 10.1016/0960-894X(95)00391-6
434526 159196 20 None None None Human 6.2 pKi = 6.2 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
CHEMBL2087646 159196 20 None None None Human 6.2 pKi = 6.2 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 194 3 1 4 1.9 NCCSc1nc2ccccc2o1 10.1016/j.bmc.2015.01.013
44421258 175703 0 None -3 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
CHEMBL222933 175703 0 None -3 3 Human 5.2 pKi = 5.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 264 3 1 3 2.8 c1ccc(-c2ccccc2C2OC2C2=NCCN2)cc1 10.1021/jm0408215
1960 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
439260 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
505 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
6921840 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
CHEMBL1437 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
DB00368 5823 49 None -12 26 Mouse 6.2 pKi = 6.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
ChEMBL 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O nan
2436 470362 35 None -10 14 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
68617 470362 35 None -10 14 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL809 470362 35 None -10 14 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
DB01104 470362 35 None -10 14 Human 6.2 pKi = 6.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 nan
CHEMBL4558518 478328 0 None -30 14 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 568 6 1 5 6.2 CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1 10.6019/CHEMBL4507288
CHEMBL4558518 478328 0 None -30 14 Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000741a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000741a ADRA2C
ChEMBL 568 6 1 5 6.2 CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1 10.6019/CHEMBL5212743
44288877 333266 0 None -933 5 Human 5.2 pKi = 5.2 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 549 7 1 5 4.3 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL43594 333266 0 None -933 5 Human 5.2 pKi = 5.2 Binding
In vivo inhibitory effect against Alpha-2C adrenergic receptorIn vivo inhibitory effect against Alpha-2C adrenergic receptor
ChEMBL 549 7 1 5 4.3 CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C 10.1016/s0960-894x(99)00696-4
CHEMBL4516843 478297 2 None None None Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 476 6 2 4 5.1 NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1 10.6019/CHEMBL4507265
CHEMBL4516843 478297 2 None None None Human 6.2 pKi = 6.2 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000548a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000548a ADRA2C
ChEMBL 476 6 2 4 5.1 NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1 10.6019/CHEMBL5212743
49781004 41088 0 None -5 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@@H]1c2ccccc2[C@H]2C[C@]21c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256502 41088 0 None -5 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 226 2 1 2 2.5 CO[C@@H]1c2ccccc2[C@H]2C[C@]21c1c[nH]cn1 10.1021/jm1006269
10848826 372055 0 None -3 3 Human 7.2 pKi = 7.2 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 258 3 1 3 2.8 c1ccc(C[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL50719 372055 0 None -3 3 Human 7.2 pKi = 7.2 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 258 3 1 3 2.8 c1ccc(C[C@H]2CCCC[C@@H]2NC2=NCCO2)cc1 10.1021/jm9905256
177381463 391819 0 None None None Human 6.2 pKi = 6.2 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 292 1 1 2 4.6 CC1=CC[C@@H]2C[C@H]1[C@H](c1cccc3ncccc13)NC2(C)C 10.1021/acs.jmedchem.3c01758
CHEMBL5575320 391819 0 None None None Human 6.2 pKi = 6.2 Binding
Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)Displacement of [3H]-epibatidine from alpha2C receptor (unknown origin)
ChEMBL 292 1 1 2 4.6 CC1=CC[C@@H]2C[C@H]1[C@H](c1cccc3ncccc13)NC2(C)C 10.1021/acs.jmedchem.3c01758
CHEMBL4516843 478297 2 None None None Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 476 6 2 4 5.1 NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1 10.6019/CHEMBL4507265
CHEMBL4558518 478328 0 None -30 14 Human 6.2 pKi = 6.2 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 568 6 1 5 6.2 CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1 10.6019/CHEMBL4507288
121881 7096 27 None -52480 12 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 382 6 1 6 3.4 CCCCN1CCC(CC1)COC(=O)c1cc(Cl)c(c2c1OCCO2)N 10.6019/CHEMBL5442175
256 7096 27 None -52480 12 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 382 6 1 6 3.4 CCCCN1CCC(CC1)COC(=O)c1cc(Cl)c(c2c1OCCO2)N 10.6019/CHEMBL5442175
CHEMBL68131 7096 27 None -52480 12 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 382 6 1 6 3.4 CCCCN1CCC(CC1)COC(=O)c1cc(Cl)c(c2c1OCCO2)N 10.6019/CHEMBL5442175
57345629 143416 0 None -45 4 Human 6.2 pKi = 6.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1956197 143416 0 None -45 4 Human 6.2 pKi = 6.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1021/ml400232p
57345629 143416 0 None -45 4 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956197 143416 0 None -45 4 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 246 5 1 4 2.0 CC(Oc1ccccc1OC1CC1)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906197 370899 0 None -3 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
CHEMBL495097 370899 0 None -3 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 323 7 1 5 3.0 CC(Oc1ccccc1/C=N/OCc1ccccc1)C1=NCCN1 10.1021/jm800250z
44401042 252848 0 None -181 9 Human 6.2 pKi = 6.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL364270 252848 0 None -181 9 Human 6.2 pKi = 6.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.6 CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1 10.1021/jm049632c
498 7378 0 None -2238 6 Human 6.2 pKi = 6.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(=C([C@H]1c1ccc(cc1)[N+](=O)[O-])C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
5311437 7378 0 None -2238 6 Human 6.2 pKi = 6.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(=C([C@H]1c1ccc(cc1)[N+](=O)[O-])C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
CHEMBL179334 7378 0 None -2238 6 Human 6.2 pKi = 6.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(=C([C@H]1c1ccc(cc1)[N+](=O)[O-])C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C 10.1021/jm00010a001
36381 27204 1 None -1 6 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmcl.2012.08.046
CHEMBL1189234 27204 1 None -1 6 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmcl.2012.08.046
36381 27204 1 None -1 6 Human 6.2 pKi = 6.2 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmc.2013.07.045
CHEMBL1189234 27204 1 None -1 6 Human 6.2 pKi = 6.2 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 265 2 1 2 1.9 OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1 10.1016/j.bmc.2013.07.045
73355415 183341 0 None -3 13 Human 6.2 pKi = 6.2 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 277 3 1 1 2.1 C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42 10.1016/j.bmc.2013.07.045
CHEMBL2432039 183341 0 None -3 13 Human 6.2 pKi = 6.2 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 277 3 1 1 2.1 C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42 10.1016/j.bmc.2013.07.045
9839050 221864 0 None -144 9 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 293 2 0 2 3.8 CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1 10.1021/jm049632c
CHEMBL329566 221864 0 None -144 9 Human 7.2 pKi = 7.2 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 293 2 0 2 3.8 CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1 10.1021/jm049632c
1593 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
30668 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9868 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
CHEMBL17860 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
DB04948 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 10.1016/j.bmc.2012.01.035
9923679 163190 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1021/jm060262x
CHEMBL216399 163190 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1021/jm060262x
9923679 163190 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1016/j.ejmech.2010.12.026
CHEMBL216399 163190 0 None -1 3 Human 6.2 pKi = 6.2 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 332 3 1 4 4.0 Cc1cc(Nc2ccc(N3CCN(C)CC3)cc2)c2ccccc2n1 10.1016/j.ejmech.2010.12.026
11058166 469593 0 None -1 5 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
CHEMBL74114 469593 0 None -1 5 Human 6.2 pKi = 6.2 Binding
Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cellsAffinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells
ChEMBL 271 4 2 5 0.6 CS(=O)(=O)c1cccc(F)c1NCC1=NCCN1 10.1021/jm000542r
24906241 385360 0 None -2 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
CHEMBL522151 385360 0 None -2 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OC(C2=NCCN2)CO3)cc1 10.1021/jm800250z
71457691 174786 0 None -2 10 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
CHEMBL2205823 174786 0 None -2 10 Human 6.2 pKi = 6.2 Binding
Binding affinity to alpha2C adrenergic receptorBinding affinity to alpha2C adrenergic receptor
ChEMBL 295 3 1 3 2.0 COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53 10.1016/j.bmcl.2012.08.046
10045088 162042 0 None 407 2 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
CHEMBL214996 162042 0 None 407 2 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1016/j.ejmech.2010.12.026
10045088 162042 0 None 407 2 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1021/jm060262x
CHEMBL214996 162042 0 None 407 2 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1nc2ccccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1CO 10.1021/jm060262x
16090623 163880 0 None 77 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217567 163880 0 None 77 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
16090623 163880 0 None 77 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL217567 163880 0 None 77 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
129211 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
2562 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
488 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
CHEMBL836 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
DB00706 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C 10.1021/jm970364a
49836301 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
CHEMBL1276140 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml400232p
44269006 65978 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
CHEMBL14107 65978 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 216 5 1 3 1.8 C=CCc1ccccc1OCC1=NCCN1 10.1021/ml400232p
49836301 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
CHEMBL1276140 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/jm100977d
49836301 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
CHEMBL1276140 42428 0 None -1 4 Human 7.2 pKi = 7.2 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1O[C@@H](C)C1=NCCN1 10.1021/ml300064v
28 7108 39 None -676 15 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442175
3292447 7108 39 None -676 15 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442175
CHEMBL20963 7108 39 None -676 15 Human 6.2 pKi = 6.2 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 486 9 1 7 5.2 COc1ccc(cc1OCCN(C)C)NC(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C 10.6019/CHEMBL5442175
11140033 44532 0 None -7 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL130884 44532 0 None -7 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 265 4 2 3 3.2 CC(Nc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
11199593 274610 0 None -2 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 1 3 3.8 CC(Sc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
CHEMBL374954 274610 0 None -2 3 Human 6.2 pKi = 6.2 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 282 4 1 3 3.8 CC(Sc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm0408215
6603703 427 11 None -23 12 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442175
9637 427 11 None -23 12 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442175
CHEMBL291143 427 11 None -23 12 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 329 2 3 4 3.3 NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3 10.6019/CHEMBL5442175
5318 39468 43 None -1 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
CHEMBL1221 39468 43 None -1 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
DB06820 39468 43 None -1 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 396 6 0 3 6.5 Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 nan
164937988 387674 9 None -15 21 Human 7.1 pKi = 7.1 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 338 5 0 5 3.4 c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1021/acs.jmedchem.3c00734
CHEMBL5400876 387674 9 None -15 21 Human 7.1 pKi = 7.1 Binding
Binding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constantBinding affinity to alpha2C adrenergic receptor (unknown origin) assessed as inhibition constant
ChEMBL 338 5 0 5 3.4 c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1 10.1021/acs.jmedchem.3c00734
44424855 176398 0 None 1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
CHEMBL226636 176398 0 None 1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 467 7 0 7 3.3 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C=C/c4ccc(F)cc4)CC3)C1CO2 10.1016/j.bmc.2007.03.053
13178306 240307 1 None None None Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
CHEMBL3588902 240307 1 None None None Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 187 3 2 2 2.3 Cc1ccccc1NCc1cnc[nH]1 10.1016/j.bmc.2015.01.013
11360447 175955 0 None -4 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
CHEMBL223829 175955 0 None -4 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 4 3.2 CC(Oc1ccccc1-c1cccs1)C1=NCCN1 10.1021/jm0408215
10651080 215627 0 None -83 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 9 3 6 4.7 CC1=C(C(N)=O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL312871 215627 0 None -83 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 592 9 3 6 4.7 CC1=C(C(N)=O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
46743614 240311 0 None None None Human 5.1 pKi = 5.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 317 4 1 3 2.7 CCNCC(=O)N1CCn2cccc2C1c1cccc(Cl)c1 10.1016/j.bmc.2015.01.013
CHEMBL3588906 240311 0 None None None Human 5.1 pKi = 5.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 317 4 1 3 2.7 CCNCC(=O)N1CCn2cccc2C1c1cccc(Cl)c1 10.1016/j.bmc.2015.01.013
44401164 142064 0 None -309 9 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193639 142064 0 None -309 9 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL508338 372132 0 None -25 6 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL None None None None nan
490 389 17 None -354 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
9890547 389 17 None -354 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
CHEMBL268758 389 17 None -354 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 462 6 1 7 3.2 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1ccccc1 10.1016/s0960-894x(01)00159-7
57395731 143421 0 None -7 3 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956202 143421 0 None -7 3 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 232 4 1 4 1.7 CC(=O)c1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
57403508 143482 0 None -2 2 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COC(C3=NCCN3)CO2)cc1 10.1016/j.bmc.2012.02.016
CHEMBL1956905 143482 0 None -2 2 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 308 3 1 4 2.3 c1ccc(C2(c3ccccc3)COC(C3=NCCN3)CO2)cc1 10.1016/j.bmc.2012.02.016
44401105 141826 0 None -83 9 Human 6.1 pKi = 6.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 373 2 0 3 4.7 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL193435 141826 0 None -83 9 Human 6.1 pKi = 6.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 373 2 0 3 4.7 CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1 10.1021/jm049632c
57399145 143415 0 None -7 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956196 143415 0 None -7 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 234 5 1 4 1.9 CCOc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
31101 1504 27 None -8 28 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
35 1504 27 None -8 28 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
403 1504 27 None -8 28 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
CHEMBL493 1504 27 None -8 28 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
DB01200 1504 27 None -8 28 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C nan
16090624 163828 0 None 13 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL217278 163828 0 None 13 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
16090624 163828 0 None 13 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL217278 163828 0 None 13 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
175 7426 39 None -162 24 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 6 1 4 3.0 Fc1ccc(cc1)OCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.6019/CHEMBL5442175
68186 7426 39 None -162 24 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 6 1 4 3.0 Fc1ccc(cc1)OCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.6019/CHEMBL5442175
CHEMBL79834 7426 39 None -162 24 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 383 6 1 4 3.0 Fc1ccc(cc1)OCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 10.6019/CHEMBL5442175
1836 5276 50 None -31 15 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
3340 5276 50 None -31 15 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
5281040 5276 50 None -31 15 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
CHEMBL787 5276 50 None -31 15 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
DB00471 5276 50 None -31 15 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 nan
16090634 163722 0 None 4 2 Human 6.1 pKi = 6.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 296 3 1 4 3.2 Cc1cncc(C)c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217180 163722 0 None 4 2 Human 6.1 pKi = 6.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 296 3 1 4 3.2 Cc1cncc(C)c1Nc1ccc(N2CCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
135398745 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
1982 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
4585 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
47 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
CHEMBL715 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
DB00334 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C nan
25053351 347121 0 None -371 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 455 4 1 3 5.0 CN[C@@H](C(=O)N(C)[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]24CN(C)[C@@H](C)[C@H]2CC[C@@H]34)C1)C(C)C 10.1021/jm8003625
CHEMBL451821 347121 0 None -371 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cellsDisplacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells
ChEMBL 455 4 1 3 5.0 CN[C@@H](C(=O)N(C)[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]24CN(C)[C@@H](C)[C@H]2CC[C@@H]34)C1)C(C)C 10.1021/jm8003625
23622576 346901 0 None -1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
CHEMBL451229 346901 0 None -1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 272 4 1 3 3.5 CC(Oc1ccccc1C1CCCCC1)C1=NCCN1 10.1021/jm800250z
73213195 214177 0 None -26 12 Human 6.1 pKi = 6.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104092 214177 0 None -26 12 Human 6.1 pKi = 6.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
16090599 162979 0 None 1 2 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL216072 162979 0 None 1 2 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 360 3 1 4 5.0 Cc1nc2c(C)cccc2c(Nc2ccc(N3CCCN(C)C3)cc2)c1C 10.1021/jm060262x
10579368 215688 0 None -3 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 9 3 6 5.3 CC1=C(C(=O)O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
CHEMBL313251 215688 0 None -3 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 593 9 3 6 5.3 CC1=C(C(=O)O)C(c2ccc3c(c2)OCO3)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(C)N1 10.1021/jm980077m
73213195 214177 0 None -26 12 Human 6.1 pKi = 6.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
CHEMBL3104092 214177 0 None -26 12 Human 6.1 pKi = 6.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
ChEMBL 288 0 0 2 3.6 CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1 10.1016/j.bmcl.2013.12.024
1398859 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
3584 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
5401 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
7302 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
CHEMBL1481149 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
CHEMBL611 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
DB01162 8235 54 None -50 13 Human 7.1 pKi = 7.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 10.1021/jm970364a
44401106 251156 0 None -120 9 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL363581 251156 0 None -120 9 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
44549156 42431 0 None -10 4 Human 7.1 pKi = 7.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
CHEMBL1276218 42431 0 None -10 4 Human 7.1 pKi = 7.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/ml400232p
45487956 407512 0 None -3 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
CHEMBL576623 407512 0 None -3 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 3 1 3 2.6 CC(OC1=NCCN1)c1ccccc1C1CC1 10.1021/jm901262f
44549156 42431 0 None -10 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
CHEMBL1276218 42431 0 None -10 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 4 1 3 2.3 CC(Oc1ccccc1C1CC1)C1=NCCN1 10.1021/jm100977d
44292385 201255 0 None -5 3 Human 7.1 pKi = 7.1 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
CHEMBL295186 201255 0 None -5 3 Human 7.1 pKi = 7.1 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 270 3 1 3 2.6 c1ccc(C[C@H]2C3CCC(C3)[C@H]2NC2=NCCO2)cc1 10.1021/jm9905256
11080 62743 48 None -3 6 Human 5.1 pKi = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
CHEMBL1381098 62743 48 None -3 6 Human 5.1 pKi = 5.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 185 1 0 2 3.6 S=C=Nc1cccc2ccccc12 nan
72947315 183297 0 None -10 4 Human 6.1 pKi = 6.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
CHEMBL2431280 183297 0 None -10 4 Human 6.1 pKi = 6.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 232 5 1 4 1.6 c1ccc(OC2CC2)c(OCC2=NCCN2)c1 10.1021/ml400232p
127026052 274955 0 None -47 19 Human 6.1 pKi = 6.1 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 258 7 1 1 3.5 C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12 10.1016/j.bmcl.2015.12.053
CHEMBL3754496 274955 0 None -47 19 Human 6.1 pKi = 6.1 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 258 7 1 1 3.5 C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12 10.1016/j.bmcl.2015.12.053
44456400 27098 0 None -3 10 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL1188501 27098 0 None -3 10 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
11750482 294121 0 None 19 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392991 294121 0 None 19 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 419 6 0 6 5.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccco4)cc13)CC2 10.1016/j.bmcl.2006.12.094
44402579 260617 0 None None None Human 8.1 pKi = 8.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 411 3 3 5 1.8 COC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
CHEMBL370005 260617 0 None None None Human 8.1 pKi = 8.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 411 3 3 5 1.8 COC(=O)CNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O 10.1016/j.bmcl.2005.03.116
10318507 121737 0 None 104 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL1689423 121737 0 None 104 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
16090595 270602 0 None 109 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
CHEMBL383978 270602 0 None 109 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1016/j.ejmech.2010.12.026
10318507 121737 0 None 104 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL1689423 121737 0 None 104 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 394 3 1 4 5.4 Cc1nc2cc(Cl)ccc2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090595 270602 0 None 109 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
CHEMBL383978 270602 0 None 109 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C)c(C)nc2c1 10.1021/jm060262x
136019934 289714 0 None 7 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
CHEMBL390718 289714 0 None 7 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cellsDisplacement of [3H]rawolscine from human cloned adrenergic Alpha-2C receptor transfected in CHO cells
ChEMBL 462 7 1 7 3.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(C/C(C)=C/c4ccccc4)CC3)C1CN2 10.1016/j.bmc.2007.03.053
2142 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
502 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
5775 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
CHEMBL597 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
DB00692 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1021/jm00018a001
16090622 163726 0 None 165 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217202 163726 0 None 165 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1016/j.ejmech.2010.12.026
16090628 278983 0 None 309 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL386169 278983 0 None 309 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1016/j.ejmech.2010.12.026
16090622 163726 0 None 165 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1021/jm060262x
CHEMBL217202 163726 0 None 165 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 346 3 1 4 4.4 Cc1cnc2ccccc2c1Nc1ccc(N2CCN(C)C(C)C2)cc1 10.1021/jm060262x
16090628 278983 0 None 309 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1021/jm060262x
CHEMBL386169 278983 0 None 309 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 4 1 4 5.3 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(N2CCCN(C)CC2)cc1 10.1021/jm060262x
44402477 270432 0 None None None Human 8.1 pKi = 8.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 718 6 6 6 4.6 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)[C@@H]1[C@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]21 10.1016/j.bmcl.2005.03.116
CHEMBL371516 270432 0 None None None Human 8.1 pKi = 8.1 Binding
In vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamineIn vitro binding affinity measured by displacement of [3H]rauwolscine from alpha-2c adrenergic receptor expressed in CHO cells in presence of phentolamine
ChEMBL 718 6 6 6 4.6 O=C(NCCCNC(=O)[C@@H]1C2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O)[C@@H]1[C@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@H]21 10.1016/j.bmcl.2005.03.116
5268 7428 34 None -6 18 Human 8.1 pKi = 8.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 10.6019/CHEMBL5442175
53 7428 34 None -6 18 Human 8.1 pKi = 8.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 10.6019/CHEMBL5442175
CHEMBL300555 7428 34 None -6 18 Human 8.1 pKi = 8.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 10.6019/CHEMBL5442175
180 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
200 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
2160 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
CHEMBL629 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
DB00321 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C nan
9837551 201741 0 None -7 3 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 232 1 3 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCO2 10.1021/jm960359r
CHEMBL298936 201741 0 None -7 3 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
ChEMBL 232 1 3 5 1.2 Cc1c(NC2=NCCN2)ccc2c1NCCO2 10.1021/jm960359r
16090601 163819 0 None 199 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL217254 163819 0 None 199 3 Human 8.1 pKi = 8.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1016/j.ejmech.2010.12.026
10065083 65730 0 None -12 10 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 328 6 0 5 2.4 O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1 10.1016/j.bmc.2011.12.019
CHEMBL140872 65730 0 None -12 10 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation countingDisplacement of [3H]clonidine from human Alpha-2C receptor by liquid scintillation counting
ChEMBL 328 6 0 5 2.4 O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1 10.1016/j.bmc.2011.12.019
2142 6301 41 None -6 18 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
502 6301 41 None -6 18 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
5775 6301 41 None -6 18 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
CHEMBL597 6301 41 None -6 18 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
DB00692 6301 41 None -6 18 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cellsBinding affinity towards human alpha-2C adrenergic receptor expressed in Chinese Hamster ovary (CHO) cells
ChEMBL 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 10.1016/j.bmcl.2005.07.083
10088113 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
1243 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
6604885 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
944 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
CHEMBL1473849 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
CHEMBL324017 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
CHEMBL416401 7354 32 None -1258 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 331 1 1 2 3.8 CN1CCc2c(C(C1)c1ccccc1)cc(c(c2)Br)O 10.6019/CHEMBL5442175
9828476 176233 0 None -354 6 Human 7.1 pKi = 7.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 532 9 2 7 4.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL2260360 176233 0 None -354 6 Human 7.1 pKi = 7.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 532 9 2 7 4.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
CHEMBL91022 176233 0 None -354 6 Human 7.1 pKi = 7.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 532 9 2 7 4.4 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1021/jm980077m
5280953 197669 67 None 1 6 Human 6.1 pKi = 6.1 Binding
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 212 1 1 2 3.0 COc1ccc2c(c1)[nH]c1c(C)nccc12 10.1016/j.bmcl.2003.09.027
CHEMBL269538 197669 67 None 1 6 Human 6.1 pKi = 6.1 Binding
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 212 1 1 2 3.0 COc1ccc2c(c1)[nH]c1c(C)nccc12 10.1016/j.bmcl.2003.09.027
DB07919 197669 67 None 1 6 Human 6.1 pKi = 6.1 Binding
Binding affinity towards Alpha-2C adrenergic receptorBinding affinity towards Alpha-2C adrenergic receptor
ChEMBL 212 1 1 2 3.0 COc1ccc2c(c1)[nH]c1c(C)nccc12 10.1016/j.bmcl.2003.09.027
10508132 216670 0 None -13 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 10 2 6 5.5 CC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)N(C)C)=C(C)N1 10.1021/jm980077m
CHEMBL315392 216670 0 None -13 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 621 10 2 6 5.5 CC1=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)N(C)C)=C(C)N1 10.1021/jm980077m
491 391 11 None -501 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
9891167 391 11 None -501 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
CHEMBL13856 391 11 None -501 11 Human 7.1 pKi = 7.1 Binding
Ancillary Binding affinity to cloned human Alpha-2C adrenergic receptorAncillary Binding affinity to cloned human Alpha-2C adrenergic receptor
ChEMBL 476 6 1 7 3.6 COc1ccccc1N1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)c(cs2)c1cccc(c1)C 10.1016/s0960-894x(01)00159-7
16090627 163001 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1021/jm060262x
CHEMBL216197 163001 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1021/jm060262x
135398745 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
1982 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
4585 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
47 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
CHEMBL715 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
DB00334 5933 69 None -20 45 Human 7.1 pKi = 7.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C 10.1021/jm049632c
16090627 163001 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1016/j.ejmech.2010.12.026
CHEMBL216197 163001 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 390 9 2 4 5.9 CCc1c(C)nc2c(C)cccc2c1Nc1ccc(NCCN(CC)CC)cc1 10.1016/j.ejmech.2010.12.026
2435 7889 70 None -5 10 Human 7.1 pKi = 7.1 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
395 7889 70 None -5 10 Human 7.1 pKi = 7.1 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
5386 7889 70 None -5 10 Human 7.1 pKi = 7.1 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
CHEMBL844 7889 70 None -5 10 Human 7.1 pKi = 7.1 Binding
Binding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosinBinding affinity for human Alpha-2C adrenergic receptor from cultured LM(tk-) cells using [3H]- prazosin
ChEMBL 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 10.1016/0960-894X(95)00391-6
1242 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
6603799 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
6852376 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
935 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL24077 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL284746 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL286080 7344 19 None -2 6 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 255 1 3 3 2.4 Oc1cc2CCNCC(c2cc1O)c1ccccc1 10.1016/j.bmc.2015.01.013
3038495 1458 35 None -66 27 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 417 8 1 4 4.2 COc1ccccc1N1CCN(CC1)CCCCNC(=O)c1ccc2c(c1)cccc2 10.6019/CHEMBL5442175
7625 1458 35 None -66 27 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 417 8 1 4 4.2 COc1ccccc1N1CCN(CC1)CCCCNC(=O)c1ccc2c(c1)cccc2 10.6019/CHEMBL5442175
CHEMBL25236 1458 35 None -66 27 Human 7.1 pKi = 7.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 417 8 1 4 4.2 COc1ccccc1N1CCN(CC1)CCCCNC(=O)c1ccc2c(c1)cccc2 10.6019/CHEMBL5442175
16090594 163552 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
CHEMBL216674 163552 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1016/j.ejmech.2010.12.026
24841480 367228 0 None -416 20 Human 6.1 pKi = 6.1 Binding
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 340 3 0 4 4.5 O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
CHEMBL481153 367228 0 None -416 20 Human 6.1 pKi = 6.1 Binding
Antagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assayAntagonist activity at adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 340 3 0 4 4.5 O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21 10.1016/j.bmcl.2013.04.082
57402717 143418 0 None -14 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956199 143418 0 None -14 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 220 4 1 4 1.5 COc1ccccc1OC(C)C1=NCCN1 10.1016/j.bmc.2012.01.035
24906201 370595 0 None -1 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
CHEMBL493272 370595 0 None -1 3 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 280 2 1 4 2.5 c1ccc(-c2cccc3c2OCC(C2=NCCN2)O3)cc1 10.1021/jm800250z
4657799 240312 1 None None None Human 5.1 pKi = 5.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 254 5 1 2 2.7 NCCCN(C(=O)c1ccccc1)c1ccccc1 10.1016/j.bmc.2015.01.013
CHEMBL3588907 240312 1 None None None Human 5.1 pKi = 5.1 Binding
Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysisDisplacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis
ChEMBL 254 5 1 2 2.7 NCCCN(C(=O)c1ccccc1)c1ccccc1 10.1016/j.bmc.2015.01.013
16090594 163552 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
CHEMBL216674 163552 0 None 10 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 388 3 1 4 5.4 Cc1ccc2c(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C)c(C)nc2c1C 10.1021/jm060262x
44456400 27098 0 None -3 10 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
CHEMBL1188501 27098 0 None -3 10 Human 6.1 pKi = 6.1 Binding
Displacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysisDisplacement of [3H]Rauwolscine from human recombinant alpha2C-adrenoceptor expressed in MDCK cells after 90 mins by scintillation counting analysis
ChEMBL 181 0 2 3 1.4 NC1=Nc2ccc(Cl)cc2CN1 10.1016/j.bmcl.2013.08.072
52936725 124010 25 None -33884 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 432 6 2 4 6.3 Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1 10.6019/CHEMBL5442175
CHEMBL1766103 124010 25 None -33884 13 Human 6.1 pKi = 6.1 Binding
PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.PDSP Secondary Binding target: ADRA2C - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.
ChEMBL 432 6 2 4 6.3 Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1 10.6019/CHEMBL5442175
24906198 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
CHEMBL495095 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Binding affinity at human alpha2C ARBinding affinity at human alpha2C AR
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml400232p
44314200 203002 0 None -3 4 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
CHEMBL306377 203002 0 None -3 4 Human 7.1 pKi = 7.1 Binding
Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscineBinding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine
ChEMBL 230 1 1 3 2.4 c1ccc2c(c1)CCCC2NC1=NCCCO1 10.1016/0960-894X(94)85032-1
24906198 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
CHEMBL495095 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm800250z
45487145 404442 0 None -1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
CHEMBL570973 404442 0 None -1 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation countingDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cell membrane after 30 mins by liquid scintillation counting
ChEMBL 230 4 1 3 2.5 C=CCc1ccccc1C(C)OC1=NCCN1 10.1021/jm901262f
24906198 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
CHEMBL495095 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/jm100977d
24906198 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
CHEMBL495095 365892 3 None -3 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation countingDisplacement of [3H]RX821002 from human alpha2C adrenoceptor expressed in CHO cells after 30 mins by scintillation counting
ChEMBL 230 5 1 3 2.2 C=CCc1ccccc1OC(C)C1=NCCN1 10.1021/ml300064v
44292386 201605 0 None -5 3 Human 7.1 pKi = 7.1 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
CHEMBL297827 201605 0 None -5 3 Human 7.1 pKi = 7.1 Binding
Inhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptorInhibitory constant, using [3H]rauwolscine in LM(tk-) cells stably transfected with cloned human Alpha-2C adrenergic receptor
ChEMBL 296 4 1 3 3.5 C(=C/c1ccccc1)\C[C@H]1C2CCC(C2)[C@H]1NC1=NCCO1 10.1021/jm9905256
57339144 183047 56 None -11 7 Human 6.1 pKi = 6.1 Binding
Inhibition of alpha2C receptor (unknown origin) by radioligand binding assayInhibition of alpha2C receptor (unknown origin) by radioligand binding assay
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.1038/nchembio.1157
CHEMBL2426364 183047 56 None -11 7 Human 6.1 pKi = 6.1 Binding
Inhibition of alpha2C receptor (unknown origin) by radioligand binding assayInhibition of alpha2C receptor (unknown origin) by radioligand binding assay
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.1038/nchembio.1157
57339144 183047 56 None -11 7 Human 6.1 pKi = 6.1 Binding
Selectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2CSelectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2C
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.6019/CHEMBL5212743
CHEMBL2426364 183047 56 None -11 7 Human 6.1 pKi = 6.1 Binding
Selectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2CSelectivity interaction (NIMH Psychoactive Drug Screening Program Selectivity Panel (radioligand binding assay)) EUB0000214b ADRA2C
ChEMBL 529 6 1 5 4.8 O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1 10.6019/CHEMBL5212743
199798 156375 3 None 3 2 Human 6.1 pKi = 6.1 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 167 2 0 1 2.7 C1CCC(CN2CCCC2)CC1 10.1016/j.bmcl.2012.04.077
CHEMBL2030634 156375 3 None 3 2 Human 6.1 pKi = 6.1 Binding
Inhibition of alpha2C adrenergic receptorInhibition of alpha2C adrenergic receptor
ChEMBL 167 2 0 1 2.7 C1CCC(CN2CCCC2)CC1 10.1016/j.bmcl.2012.04.077
73349361 183356 0 None 1 7 Human 6.1 pKi = 6.1 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 279 4 0 1 3.3 CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
CHEMBL2432058 183356 0 None 1 7 Human 6.1 pKi = 6.1 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 279 4 0 1 3.3 CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41 10.1016/j.bmc.2013.07.045
16090625 163856 0 None 7 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
CHEMBL217452 163856 0 None 7 3 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1021/jm060262x
16090625 163856 0 None 7 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
CHEMBL217452 163856 0 None 7 3 Human 7.1 pKi = 7.1 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 374 3 1 4 5.0 Cc1nc2cccc(C)c2c(Nc2ccc(N3CCN(C)C(C)C3)cc2)c1C 10.1016/j.ejmech.2010.12.026
10674896 176223 0 None -478 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 588 9 2 6 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C#N)cc1 10.1021/jm980077m
CHEMBL2260149 176223 0 None -478 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 588 9 2 6 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C#N)cc1 10.1021/jm980077m
CHEMBL89243 176223 0 None -478 6 Human 6.1 pKi = 6.1 Binding
Binding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptorBinding affinity assayed by displacement of [3H]rauwolscine from human alpha-2C adrenergic receptor
ChEMBL 588 9 2 6 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc(C#N)cc1 10.1021/jm980077m
57402718 143420 0 None -8 3 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956201 143420 0 None -8 3 Human 5.1 pKi = 5.1 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 218 4 1 4 1.3 CC(Oc1ccccc1C=O)C1=NCCN1 10.1016/j.bmc.2012.01.035
1398859 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
3584 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
5401 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
7302 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL1481149 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
CHEMBL611 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
DB01162 8235 54 None -50 13 Human 6.1 pKi = 6.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 nan
9795515 469701 0 None -17 3 Human 7.1 pKi = 7.1 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 273 3 2 3 4.1 COc1c(C(C)(C)C)cc(C)c(Nc2ncc[nH]2)c1C 10.1021/jm9605142
CHEMBL75257 469701 0 None -17 3 Human 7.1 pKi = 7.1 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 273 3 2 3 4.1 COc1c(C(C)(C)C)cc(C)c(Nc2ncc[nH]2)c1C 10.1021/jm9605142
10632290 469631 6 None -2 3 Human 5.1 pKi = 5.1 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 211 2 2 4 2.1 c1c[nH]c(Nc2ccc3nccnc3c2)n1 10.1021/jm9605142
CHEMBL74449 469631 6 None -2 3 Human 5.1 pKi = 5.1 Binding
Displacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cellsDisplacement of rauwolscine from human Alpha-2C adrenergic receptor expressed in CHO cells
ChEMBL 211 2 2 4 2.1 c1c[nH]c(Nc2ccc3nccnc3c2)n1 10.1021/jm9605142
44328920 218233 0 None -77 6 Human 6.1 pKi = 6.1 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 705 14 3 7 5.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCC(F)(F)F)N1 10.1016/s0960-894x(99)00484-9
CHEMBL320736 218233 0 None -77 6 Human 6.1 pKi = 6.1 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 705 14 3 7 5.9 CCC1=C(C(N)=O)C(c2ccc([N+](=O)[O-])cc2)C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)=C(COCC(F)(F)F)N1 10.1016/s0960-894x(99)00484-9
44324900 473833 0 None 2 3 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 423 6 0 7 2.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL90843 473833 0 None 2 3 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 423 6 0 7 2.6 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44325028 473903 0 None 2 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cccc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL91297 473903 0 None 2 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cccc5ccccc45)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44325079 474099 0 None 2 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 437 7 0 7 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92496 474099 0 None 2 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 437 7 0 7 2.7 COc1cc2c(cc1OC)C1=NOC(CN3CCN(CCc4ccccc4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
44324860 474387 0 None 1 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cc5ccccc5s4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL94435 474387 0 None 1 2 Human 7.1 pKi = 7.1 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 479 6 0 8 3.8 COc1cc2c(cc1OC)C1=NOC(CN3CCN(Cc4cc5ccccc5s4)CC3)C1CO2 10.1016/s0960-894x(03)00525-0
49781008 41125 0 None -7 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 3 1 2 3.3 CC(C)O[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
CHEMBL1256608 41125 0 None -7 4 Human 7.1 pKi = 7.1 Binding
Displacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation countingDisplacement of [3H]-RX821002 from human adrenergic Alpha-2C receptor expressed in rat C6 cells after 120 mins by liquid scintillation counting
ChEMBL 254 3 1 2 3.3 CC(C)O[C@H]1c2ccccc2[C@H]2C[C@@]12c1c[nH]cn1 10.1021/jm1006269
24839550 274719 10 None -14 15 Human 6.1 pKi = 6.1 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 240 7 1 1 3.4 C=CCN(CC=C)CCc1c[nH]c2ccccc12 10.1016/j.bmcl.2015.12.053
CHEMBL3752576 274719 10 None -14 15 Human 6.1 pKi = 6.1 Binding
Binding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assayBinding affinity to alpha-2C adrenergic receptor (unknown origin) by competition binding assay
ChEMBL 240 7 1 1 3.4 C=CCN(CC=C)CCc1c[nH]c2ccccc12 10.1016/j.bmcl.2015.12.053
16090601 163819 0 None 199 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1021/jm060262x
CHEMBL217254 163819 0 None 199 3 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 376 4 2 5 3.9 Cc1c(CO)nc2ccccc2c1Nc1ccc(N2CCN(C)[C@H](C)C2)cc1 10.1021/jm060262x
44579303 365869 0 None None None Human 8.0 pKi = 8.0 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
CHEMBL488974 365869 0 None None None Human 8.0 pKi = 8.0 Binding
Binding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assayBinding affinity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells by radioligand binding assay
ChEMBL 488 8 1 7 3.5 O=C(NCCN1CCCN(C[C@@H]2COc3ccccc3O2)CC1)c1cccnc1Oc1ccccc1 10.1016/j.bmcl.2008.08.055
16090602 163874 0 None 239 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1021/jm060262x
CHEMBL217542 163874 0 None 239 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]rauwolscine from human ADRA2C expressed in S115 cellsDisplacement of [3H]rauwolscine from human ADRA2C expressed in S115 cells
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1021/jm060262x
16090602 163874 0 None 239 3 Human 8.0 pKi = 8.0 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
CHEMBL217542 163874 0 None 239 3 Human 8.0 pKi = 8.0 Binding
Binding affinity to human cloned Alpha-2C adrenergic receptorBinding affinity to human cloned Alpha-2C adrenergic receptor
ChEMBL 362 4 2 5 3.6 C[C@@H]1CN(c2ccc(Nc3c(CO)cnc4ccccc34)cc2)CCN1C 10.1016/j.ejmech.2010.12.026
13162 7899 43 None -3 15 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/j.bmc.2012.06.008
2803 7899 43 None -3 15 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/j.bmc.2012.06.008
CHEMBL134 7899 43 None -3 15 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
ChEMBL 229 1 2 3 2.4 ClC1=CC=CC(=C1NC2=NCCN2)Cl 10.1016/j.bmc.2012.06.008
44438161 293841 0 None 22 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL392771 293841 0 None 22 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 543 10 1 7 5.0 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4cccc(C(=O)NCCN(C)C)c4)cc13)CC2 10.1016/j.bmcl.2006.12.094
44438165 331596 0 None 48 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL428407 331596 0 None 48 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 467 9 1 7 3.3 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(C(=O)NCCN(C)C)cc13)CC2 10.1016/j.bmcl.2006.12.094
44330571 327537 0 None 2 2 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
CHEMBL420830 327537 0 None 2 2 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity to human alpha-2C adrenergic receptorIn vitro binding affinity to human alpha-2C adrenergic receptor
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/j.bmcl.2004.03.031
44330571 327537 0 None 2 2 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL420830 327537 0 None 2 2 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 449 7 0 7 3.1 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C\c4ccccc4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44324737 474143 0 None 2 5 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
CHEMBL92860 474143 0 None 2 5 Human 8.0 pKi = 8.0 Binding
In vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscineIn vitro binding affinity towards human adrenergic alpha-2C adrenergic receptor using [3H]rauwolscine
ChEMBL 473 6 0 7 3.8 COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2 10.1016/s0960-894x(03)00525-0
44438148 193907 0 None 14 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 10.1016/j.bmcl.2006.12.094
CHEMBL246229 193907 0 None 14 3 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cellsDisplacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells
ChEMBL 430 6 0 6 5.1 COc1cc2c(cc1OC)CN(Cc1ccc(OC)c3oc(-c4ccccn4)cc13)CC2 10.1016/j.bmcl.2006.12.094
11465618 193817 22 None -36 19 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
CHEMBL3039528 193817 22 None -36 19 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
DB12188 193817 22 None -36 19 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysisDisplacement of [3H]RX 821002 from recombinant human alpha2C receptor measured after 60 mins by scintillation counting analysis
ChEMBL 354 2 0 2 4.9 CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C 10.1016/j.bmcl.2022.128879
CHEMBL4520788 478301 14 None -4 26 Human 7.0 pKi = 7.0 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL4507273
9809007 327839 14 None -724 6 Human 6.0 pKi = 6.0 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
CHEMBL448620 327839 14 None -724 6 Human 6.0 pKi = 6.0 Binding
Binding affinity against human Alpha-2c adrenergic receptorBinding affinity against human Alpha-2c adrenergic receptor
ChEMBL 608 10 2 7 5.6 COC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1 10.1016/s0960-894x(99)00484-9
24906159 370643 13 None -3 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
CHEMBL493675 370643 13 None -3 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 233 4 2 5 1.3 CC(Oc1ccccc1/C=N/O)C1=NCCN1 10.1021/jm800250z
11186523 251223 0 None -66 9 Human 7.0 pKi = 7.0 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
CHEMBL366164 251223 0 None -66 9 Human 7.0 pKi = 7.0 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
ChEMBL 329 2 0 3 4.5 CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1 10.1021/jm049632c
1343 3863 47 None -17 9 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
3519 3863 47 None -17 9 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
522 3863 47 None -17 9 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
CHEMBL862 3863 47 None -17 9 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
DB01018 3863 47 None -17 9 Human 6.0 pKi = 6.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N nan
4209 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
4893 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
5385 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
CHEMBL2 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 nan
9906978 86128 1 None -1 12 Human 7.0 pKi = 7.0 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
CHEMBL150161 86128 1 None -1 12 Human 7.0 pKi = 7.0 Binding
Binding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assayBinding affinity to human cloned adrenergic alpha-2C receptor by radioligand binding assay
ChEMBL 361 6 1 3 4.0 O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1 10.1016/j.bmcl.2006.03.057
4209 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
4893 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
5385 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
CHEMBL2 8026 58 None -389 20 Human 7.0 pKi = 7.0 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
ChEMBL 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 10.1021/jm00018a001
1547484 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
2761 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
654 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
9072 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL43064 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
DB00568 1937 56 None -4 20 Human 7.0 pKi = 7.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
ChEMBL 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 nan
CHEMBL4520788 478301 14 None -4 26 Human 7.0 pKi = 7.0 Binding
GPCRScan assay: inhibition of Alpha2CGPCRScan assay: inhibition of Alpha2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL4507273
CHEMBL4520788 478301 14 None -4 26 Human 7.0 pKi = 7.0 Binding
Selectivity interaction (GPCR panel (PDSP screen)) EUB0000743a ADRA2CSelectivity interaction (GPCR panel (PDSP screen)) EUB0000743a ADRA2C
ChEMBL 448 8 2 7 5.6 CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1 10.6019/CHEMBL5212743
3535 176350 66 None -29 3 Human 5.0 pKi = 5.0 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
5280805 176350 66 None -29 3 Human 5.0 pKi = 5.0 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
CHEMBL226335 176350 66 None -29 3 Human 5.0 pKi = 5.0 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
DB01698 176350 66 None -29 3 Human 5.0 pKi = 5.0 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
ChEMBL 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O 10.1021/np1000329
4407909 385410 0 None -16 10 Human 6.0 pKi = 6.0 Binding
Binding affinity to alpha2c (unknown origin) assessed as inhibition constantBinding affinity to alpha2c (unknown origin) assessed as inhibition constant
ChEMBL 356 4 2 4 3.6 COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC 10.1021/acsmedchemlett.1c00694
CHEMBL5221893 385410 0 None -16 10 Human 6.0 pKi = 6.0 Binding
Binding affinity to alpha2c (unknown origin) assessed as inhibition constantBinding affinity to alpha2c (unknown origin) assessed as inhibition constant
ChEMBL 356 4 2 4 3.6 COc1cc(OC)c(C2NCCc3c2[nH]c2ccc(F)cc32)cc1OC 10.1021/acsmedchemlett.1c00694
57395663 143412 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
CHEMBL1956193 143412 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
ChEMBL 258 3 1 3 2.5 CC(Oc1ccccc1C(F)(F)F)C1=NCCN1 10.1016/j.bmc.2012.01.035
11043720 174435 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
CHEMBL242265 174435 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cellsDisplacement of [3H]RX 821002 from human adrenergic Alpha-2C receptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm061487a
11043720 174435 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
CHEMBL242265 174435 0 None -5 3 Human 6.0 pKi = 6.0 Binding
Displacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human Alpha-2C adrenoceptor expressed in CHO cells
ChEMBL 266 4 1 3 3.1 C[C@@H](Oc1ccccc1-c1ccccc1)C1=NCCN1 10.1021/jm100977d
49783415 41547 0 None -1348 13 Human 6.0 pKi = 6 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 320 7 1 5 2.9 CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1 10.1021/jm100668r
CHEMBL1258452 41547 0 None -1348 13 Human 6.0 pKi = 6 Binding
Binding affinity to human adrenergic Alpha-2C receptorBinding affinity to human adrenergic Alpha-2C receptor
ChEMBL 320 7 1 5 2.9 CCCCN1CCC(COC(=O)c2ccc(N)c(OC)c2)CC1 10.1021/jm100668r
73355418 183354 0 None 1 3 Human 6.0 pKi = 6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 3 3.3 COc1ccc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC 10.1016/j.bmc.2013.07.045
CHEMBL2432056 183354 0 None 1 3 Human 6.0 pKi = 6 Binding
Inhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assayInhibition of adrenergic alpha2C receptor (unknown origin) by PDSP assay
ChEMBL 325 5 0 3 3.3 COc1ccc(CN(C)[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC 10.1016/j.bmc.2013.07.045
527 7990 0 None 15 3 Human 10.1 pKd = 10.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 1 0 3 3.3 O=C1N(C)[C@]2(CCN3[C@H](C2)c2oc4c(c2CC3)cccc4)CCN1C([3H])([3H])[3H] 7996470
91827340 7990 0 None 15 3 Human 10.1 pKd = 10.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 1 0 3 3.3 O=C1N(C)[C@]2(CCN3[C@H](C2)c2oc4c(c2CC3)cccc4)CCN1C([3H])([3H])[3H] 7996470
3952 3861 3 None None None Human 6.4 pKd = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5353646 3861 3 None None None Human 6.4 pKd = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
5443 3861 3 None None None Human 6.4 pKd = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
CHEMBL1331786 3861 3 None None None Human 6.4 pKd = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
DB00629 3861 3 None None None Human 6.4 pKd = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 230 2 2 2 1.6 NC(=N/N=C\c1c(Cl)cccc1Cl)N 36101495
108094 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
108094 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
108094 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
528 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
528 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
528 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
CHEMBL10332 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
CHEMBL10332 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7908642
CHEMBL10332 8046 24 None -1 3 Human 8.7 pKd = 8.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 8819505
13179 7740 0 None 1 3 Human 8.9 pKd = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 3 2.7 ClC1=CC([125IH])=CC(Cl)=C1NC2=NCCN2 8930173
171037444 7740 0 None 1 3 Human 8.9 pKd = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 3 2.7 ClC1=CC([125IH])=CC(Cl)=C1NC2=NCCN2 8930173
223 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
223 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
223 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
643606 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
643606 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
643606 8038 0 None 2 4 Human 9.5 pKd = 9.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 8819505
1395 99516 64 None -2 9 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
3652 99516 64 None -2 9 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
CHEMBL1535 99516 64 None -2 9 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
DB01611 99516 64 None -2 9 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 335 9 2 4 3.8 CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 None
2719 1891 63 None -1 8 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
5535 1891 63 None -1 8 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
607 1891 63 None -1 8 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
CHEMBL76 1891 63 None -1 8 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
DB00608 1891 63 None -1 8 Human 8.3 pKi = 8.3 Binding
Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscineActivity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine
Drug Central 319 8 1 3 4.8 CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC None
3535 176350 66 None -29 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
5280805 176350 66 None -29 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
CHEMBL226335 176350 66 None -29 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
DB01698 176350 66 None -29 3 Human 8.3 pKi = 8.3 Binding
Binding affinity to adrenergic alpha2c receptorBinding affinity to adrenergic alpha2c receptor
Drug Central 610 6 10 16 -1.7 C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O None
2695 8361 59 None -25 5 Human 8.3 pKi = 8.3 Binding
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
5504 8361 59 None -25 5 Human 8.3 pKi = 8.3 Binding
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
7310 8361 59 None -25 5 Human 8.3 pKi = 8.3 Binding
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
CHEMBL770 8361 59 None -25 5 Human 8.3 pKi = 8.3 Binding
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
DB00797 8361 59 None -25 5 Human 8.3 pKi = 8.3 Binding
NoneNone
Drug Central 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 None
1058 199583 51 None 1 3 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
222757 199583 51 None 1 3 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
CHEMBL282575 199583 51 None 1 3 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
DB13953 199583 51 None 1 3 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 376 2 1 3 5.1 C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O None
28417 83476 34 None -1 12 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
779 83476 34 None -1 12 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
CHEMBL1479 83476 34 None -1 12 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
DB01406 83476 34 None -1 12 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 0 1 3 4.2 C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C None
3054 315981 60 None -21 25 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
448537 315981 60 None -21 25 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
875 315981 60 None -21 25 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
CHEMBL411 315981 60 None -21 25 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
DB00255 315981 60 None -21 25 Human 8.3 pKi = 8.3 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 268 4 2 2 4.8 CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1 None
12574 5302 68 None -87 6 Human 8.2 pKi = 8.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
1856 5302 68 None -87 6 Human 8.2 pKi = 8.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
4810 5302 68 None -87 6 Human 8.2 pKi = 8.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
CHEMBL19236 5302 68 None -87 6 Human 8.2 pKi = 8.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
DB09242 5302 68 None -87 6 Human 8.2 pKi = 8.2 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC None
11634155 366004 33 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 317 4 0 4 3.2 COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2 None
2609 366004 33 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 317 4 0 4 3.2 COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2 None
CHEMBL519344 366004 33 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 317 4 0 4 3.2 COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2 None
2402 6855 40 None -1 14 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
5095 6855 40 None -1 14 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
7295 6855 40 None -1 14 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
CHEMBL589 6855 40 None -1 14 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
DB00268 6855 40 None -1 14 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 260 7 1 2 3.5 CCCN(CCC)CCc1cccc2c1CC(=N2)O None
104903 119144 14 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
4063 119144 14 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
CHEMBL1630578 119144 14 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
DB13050 119144 14 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 624 6 0 8 5.5 C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1 None
1364 371049 49 None -1 7 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
3598 371049 49 None -1 7 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
CHEMBL496 371049 49 None -1 7 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
DB00756 371049 49 None -1 7 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 2 2 2 6.6 Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl None
1767 470192 12 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
4158 470192 12 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
CHEMBL796 470192 12 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
DB00422 470192 12 None -1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 233 3 1 3 2.1 COC(=O)C(c1ccccc1)C1CCCCN1 None
10836 38380 5 None -1 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
1732 38380 5 None -1 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
CHEMBL1201201 38380 5 None -1 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
DB01577 38380 5 None -1 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 149 3 1 1 1.8 CN[C@@H](C)Cc1ccccc1 None
1836 5276 50 None -31 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
3340 5276 50 None -31 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
5281040 5276 50 None -31 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
CHEMBL787 5276 50 None -31 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
DB00471 5276 50 None -31 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 585 12 2 4 8.9 OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1 None
2495 509455 0 None -1 13 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 396 6 0 3 6.5 ClC1=CC=C(CS[C@@H](CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1 None
1960 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
505 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
6921840 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL1437 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
DB00368 5823 49 None -12 26 Mouse 8.2 pKi = 8.2 Binding
Binding affinity to mouse alpha-2C receptor expressed in COS7 cellsBinding affinity to mouse alpha-2C receptor expressed in COS7 cells
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
2436 470362 35 None -10 14 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
68617 470362 35 None -10 14 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
CHEMBL809 470362 35 None -10 14 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
DB01104 470362 35 None -10 14 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 305 2 1 1 5.2 CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 None
2406 200565 63 None -11 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
3032 200565 63 None -11 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
CHEMBL290106 200565 63 None -11 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
DB04813 200565 63 None -11 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 354 2 2 3 5.9 Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O None
3408 41852 27 None -11 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
5353853 41852 27 None -11 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
CHEMBL1262 41852 27 None -11 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
DB00239 41852 27 None -11 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 427 6 0 4 6.1 Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 None
1355 42931 34 None -2 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
3561 42931 34 None -2 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
CHEMBL1289 42931 34 None -2 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
DB00793 42931 34 None -2 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 360 2 0 1 4.4 Clc1cc(Cl)c(OCC#CI)cc1Cl None
2338 461820 42 None -1 13 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
237 461820 42 None -1 13 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
CHEMBL7568 461820 42 None -1 13 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
DB01103 461820 42 None -1 13 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 399 9 1 4 6.0 CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 None
2600 8239 59 None -3 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
2608 8239 59 None -3 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
5405 8239 59 None -3 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
CHEMBL17157 8239 59 None -3 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
DB00342 8239 59 None -3 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 471 8 2 3 6.4 OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O None
2342 1238 31 None -1 6 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
331 1238 31 None -1 6 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
7124 1238 31 None -1 6 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
CHEMBL1201250 1238 31 None -1 6 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
DB00767 1238 31 None -1 6 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 404 6 0 6 2.4 CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC None
1353 3909 69 None -54 49 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
3559 3909 69 None -54 49 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
86 3909 69 None -54 49 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
CHEMBL54 3909 69 None -54 49 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
DB00502 3909 69 None -54 49 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 6 1 3 4.4 Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl None
2536 308773 12 None -8 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 None
5354 308773 12 None -8 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 None
CHEMBL404849 308773 12 None -8 15 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 337 12 2 3 5.6 CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1 None
1443 4143 26 None -11 9 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
33625 4143 26 None -11 9 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
501 4143 26 None -11 9 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
CHEMBL279516 4143 26 None -11 9 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
DB08950 4143 26 None -11 9 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 347 5 2 2 3.6 O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2 None
191 833 62 None -28 26 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
201 833 62 None -28 26 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
2170 833 62 None -28 26 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
CHEMBL1113 833 62 None -28 26 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
DB00543 833 62 None -28 26 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 313 0 1 4 3.4 Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1 None
1482 367203 61 None -1 2 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
60838 367203 61 None -1 2 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
CHEMBL481 367203 61 None -1 2 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
DB00762 367203 61 None -1 2 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 586 4 1 9 4.1 CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC None
463 2890 18 None -48 13 Human 8.2 pKi = 8.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
6918097 2890 18 None -48 13 Human 8.2 pKi = 8.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
837 2890 18 None -48 13 Human 8.2 pKi = 8.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
CHEMBL2051956 2890 18 None -48 13 Human 8.2 pKi = 8.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
DB14068 2890 18 None -48 13 Human 8.2 pKi = 8.2 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 609 10 1 8 6.0 COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C None
2080 352858 63 None -1 22 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
33630 352858 63 None -1 22 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
CHEMBL47050 352858 63 None -1 22 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
DB13791 352858 63 None -1 22 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assayDisplacement of [3H]Rauwolscine from human alpha 2C adrenergic receptor expressed in MDCK cells by radioligand binding assay
Drug Central 523 7 1 2 7.5 OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 None
2435 7298 64 None -5 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
60149 7298 64 None -5 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
98 7298 64 None -5 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
CHEMBL12713 7298 64 None -5 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
DB06144 7298 64 None -5 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 440 5 1 3 4.6 Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O None
1634 163834 36 None -21 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
4011 163834 36 None -21 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
CHEMBL21731 163834 36 None -21 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
DB00934 163834 36 None -21 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 4 1 1 4.2 CNCCCC12CCC(c3ccccc31)c1ccccc12 None
11079 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
3369 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
4436 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
5509 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
CHEMBL761 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
DB06711 5576 48 None -2 4 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 None
214 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
2740 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
5566 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
66064 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL422 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00831 8400 48 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 407 4 0 4 4.9 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
16362 6358 55 None -4 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
2172 6358 55 None -4 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
90 6358 55 None -4 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
CHEMBL1423 6358 55 None -4 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
DB01100 6358 55 None -4 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 461 7 1 3 5.9 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2 None
1028 599 43 None -61 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
479 599 43 None -61 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
5816 599 43 None -61 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL679 599 43 None -61 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
DB00668 599 43 None -61 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O None
2286 6468 43 None -52 24 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
4927 6468 43 None -52 24 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
7282 6468 43 None -52 24 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
CHEMBL643 6468 43 None -52 24 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
DB01069 6468 43 None -52 24 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 3 0 3 4.2 CN(C(CN1c2ccccc2Sc2c1cccc2)C)C None
2247 1042 63 None -18 37 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
249 1042 63 None -18 37 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
2603 1042 63 None -18 37 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
CHEMBL296419 1042 63 None -18 37 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
DB00637 1042 63 None -18 37 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 458 8 1 5 5.4 COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2 None
2335 26122 15 None -2 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
3018 26122 15 None -2 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
CHEMBL1182210 26122 15 None -2 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
DB11125 26122 15 None -2 12 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 412 11 0 2 6.1 CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1 None
2181 6363 43 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
4830 6363 43 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
92 6363 43 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
CHEMBL440294 6363 43 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
DB09286 6363 43 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 375 7 1 4 2.6 O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N None
3157 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
6604102 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
6604576 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
7170 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
954 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
CHEMBL1363589 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
CHEMBL707 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
DB00590 3031 53 None -67 11 Human 8.2 pKi = 8.2 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 451 4 2 8 1.5 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2 None
3468 350117 13 None -1 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
4138 350117 13 None -1 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
CHEMBL459265 350117 13 None -1 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
DB00406 350117 13 None -1 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 372 4 0 2 4.5 CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1 None
33741 503500 0 None 1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 215 1 2 3 1.9 C1CN=C(NC2=CC=CC3=C2CCCC3)N1 None
3620 503500 0 None 1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 215 1 2 3 1.9 C1CN=C(NC2=CC=CC3=C2CCCC3)N1 None
5524 503500 0 None 1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 215 1 2 3 1.9 C1CN=C(NC2=CC=CC3=C2CCCC3)N1 None
DB13064 503500 0 None 1 3 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 215 1 2 3 1.9 C1CN=C(NC2=CC=CC3=C2CCCC3)N1 None
183 84935 67 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
2162 84935 67 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
CHEMBL1491 84935 67 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
DB00381 84935 67 None -1 6 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 408 8 2 7 2.3 CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl None
3168 23567 68 None -63 19 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
966 23567 68 None -63 19 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
CHEMBL1108 23567 68 None -63 19 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
DB00450 23567 68 None -63 19 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 379 6 1 4 3.7 O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1 None
2800 179440 13 None -1 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
700 179440 13 None -1 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
CHEMBL2355051 179440 13 None -1 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
DB00882 179440 13 None -1 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 405 9 0 2 6.6 CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1 None
2398 1965 48 None -4 22 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
2801 1965 48 None -4 22 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
701 1965 48 None -4 22 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
CHEMBL415 1965 48 None -4 22 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
DB01242 1965 48 None -4 22 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 314 4 0 2 4.5 CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C None
104870 199119 37 None -1 11 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
2558 199119 37 None -1 11 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
5374 199119 37 None -1 11 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
CHEMBL279085 199119 37 None -1 11 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 209 2 1 4 1.3 C=CCN1CCc2nc(N)sc2CC1 None
66265 194428 9 None -1 19 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
832 194428 9 None -1 19 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL248702 194428 9 None -1 19 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
DB01191 194428 9 None -1 19 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1 None
277 2680 45 None -66 34 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
2913 2680 45 None -66 34 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
765 2680 45 None -66 34 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
CHEMBL516 2680 45 None -66 34 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
DB00434 2680 45 None -66 34 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 287 0 0 1 4.7 CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1 None
1830 5270 37 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
207 5270 37 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
23897 5270 37 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
CHEMBL460 5270 37 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
DB01618 5270 37 None -1 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 276 3 1 3 2.0 CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1 None
2657 470626 56 None -1 3 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
5472 470626 56 None -1 3 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
CHEMBL833 470626 56 None -1 3 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
DB00208 470626 56 None -1 3 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 2 0 2 4.0 Clc1ccccc1CN1CCc2sccc2C1 None
3952 327526 35 None -5 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl None
5702063 327526 35 None -5 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl None
CHEMBL420 327526 35 None -5 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl None
DB00629 327526 35 None -5 11 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 230 2 3 2 1.8 N=C(N)N/N=C/c1c(Cl)cccc1Cl None
213 8386 39 None -8 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
2717 8386 39 None -8 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
5533 8386 39 None -8 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
CHEMBL621 8386 39 None -8 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
DB00656 8386 39 None -8 22 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 371 5 0 6 2.4 Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2 None
3151 3013 70 None -18 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
945 3013 70 None -18 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
965 3013 70 None -18 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
CHEMBL219916 3013 70 None -18 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
DB01184 3013 70 None -18 18 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 425 5 2 5 3.4 Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2 None
1398859 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
3584 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
5401 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
7302 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
CHEMBL1481149 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
CHEMBL611 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
DB01162 8235 54 None -50 13 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 387 4 2 7 0.9 COc1cc2nc([nH]c(=N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1 None
3658 8894 44 None -10 7 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
517 8894 44 None -10 7 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
5709 8894 44 None -10 7 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
CHEMBL312448 8894 44 None -10 7 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
DB06694 8894 44 None -10 7 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C None
240 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
2769 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
44279790 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
660 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
6917698 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
CHEMBL1729 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
DB00604 1945 27 None -7 23 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 465 9 2 6 3.4 COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N None
2351 6685 46 None -4 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
2820 6685 46 None -4 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
5035 6685 46 None -4 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
CHEMBL81 6685 46 None -4 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
DB00481 6685 46 None -4 21 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 473 7 2 6 6.1 Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O None
11141 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
120 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
135413504 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
43008 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
CHEMBL290194 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
DB01425 712 34 None 1 2 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 315 6 2 5 1.3 C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC None
1547484 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
2761 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
654 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
9072 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
CHEMBL43064 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
DB00568 1937 56 None -4 20 Human 8.2 pKi = 8.2 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 368 6 0 2 5.1 c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1 None
103 8980 49 None -3 31 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
2875 8980 49 None -3 31 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
5736 8980 49 None -3 31 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL285802 8980 49 None -3 31 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
DB09225 8980 49 None -3 31 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 331 4 0 3 4.9 CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C None
209 6223 60 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
2113 6223 60 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4748 6223 60 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
CHEMBL567 6223 60 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
DB00850 6223 60 None -2 16 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 403 6 1 5 3.9 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
2726 1895 54 None -21 48 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
621 1895 54 None -21 48 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
83 1895 54 None -21 48 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
CHEMBL71 1895 54 None -21 48 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
DB00477 1895 54 None -21 48 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C None
1613 4786 46 None -1 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
205 4786 46 None -1 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
3964 4786 46 None -1 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
CHEMBL831 4786 46 None -1 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
DB00408 4786 46 None -1 28 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 327 0 0 4 3.8 CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2 None
2865 8961 54 None -13 33 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
59 8961 54 None -13 33 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
60854 8961 54 None -13 33 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
CHEMBL708 8961 54 None -13 33 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
DB00246 8961 54 None -13 33 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 412 4 1 5 3.8 O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2 None
100 8289 46 None -6 34 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
2637 8289 46 None -6 34 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
5452 8289 46 None -6 34 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
CHEMBL479 8289 46 None -6 34 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
DB00679 8289 46 None -6 34 Human 8.2 pKi = 8.2 Binding
NoneNone
Drug Central 370 4 0 4 5.9 CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1 None
1593 4768 42 None -6 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
30668 4768 42 None -6 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
9868 4768 42 None -6 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
CHEMBL17860 4768 42 None -6 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
DB04948 4768 42 None -6 4 Human 8.2 pKi = 8.2 Binding
Displacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cellsDisplacement of [3H]RS-79948-197 from human adrenoceptor aplha 2C expressed in CHO cells
Drug Central 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl None
1960 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
439260 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
505 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
6921840 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
CHEMBL1437 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
DB00368 5823 49 None -28 26 Human 8.1 pKi = 8.1 Binding
Binding affinity for human Alpha-2C adrenergic receptorBinding affinity for human Alpha-2C adrenergic receptor
Drug Central 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O None
2105 6217 26 None -45 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
47811 6217 26 None -45 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
48 6217 26 None -45 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
CHEMBL531 6217 26 None -45 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
DB01186 6217 26 None -45 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 None
2202 6371 70 None -4 11 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
4850 6371 70 None -4 11 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
49 6371 70 None -4 11 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
CHEMBL1371770 6371 70 None -4 11 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
DB12478 6371 70 None -4 11 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 None
2599 116531 16 None 2 17 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 None
5404 116531 16 None 2 17 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 None
CHEMBL1714574 116531 16 None 2 17 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 531 8 0 8 4.5 CC(C)N1CCN(c2ccc(OCC3COC(Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1 None
1222 3419 44 None -1 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
3396 3419 44 None -1 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
85 3419 44 None -1 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
CHEMBL46516 3419 44 None -1 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
DB04842 3419 44 None -1 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 475 7 1 3 5.3 Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1 None
1201549 1234 18 None -18 20 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
333 1234 18 None -18 20 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
7601 1234 18 None -18 20 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
CHEMBL1201203 1234 18 None -18 20 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
DB00245 1234 18 None -18 20 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 307 4 0 2 4.4 CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1 None
212 8291 39 None -1 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
2639 8291 39 None -1 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
941651 8291 39 None -1 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
CHEMBL1201 8291 39 None -1 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
DB01623 8291 39 None -1 25 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 443 5 0 5 3.5 CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C None
3191 202914 68 None -3 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
977 202914 68 None -3 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
CHEMBL305660 202914 68 None -3 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
DB11742 202914 68 None -3 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 469 9 0 3 7.2 CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1 None
228 919 20 None -3 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
33 919 20 None -3 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
6005 919 20 None -3 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
CHEMBL53 919 20 None -3 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
DB00714 919 20 None -3 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O None
242 971 74 None -16 38 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
34 971 74 None -16 38 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
60795 971 74 None -16 38 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
CHEMBL1112 971 74 None -16 38 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
DB01238 971 74 None -16 38 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 447 7 1 4 4.9 O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl None
2284 6466 25 None -8 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
4926 6466 25 None -8 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
7281 6466 25 None -8 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
CHEMBL564 6466 25 None -8 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
DB00420 6466 25 None -8 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 284 4 0 3 4.2 CN(CCCN1c2ccccc2Sc2c1cccc2)C None
1200 3405 44 None -2 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
12488 3405 44 None -2 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
941361 3405 44 None -2 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
CHEMBL30008 3405 44 None -2 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
DB04841 3405 44 None -2 23 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 404 6 0 2 5.4 C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F None
2216 921 27 None -4 4 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
229 921 27 None -4 4 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
7117 921 27 None -4 4 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
CHEMBL647 921 27 None -4 4 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
DB00964 921 27 None -4 4 Human 8.1 pKi = 8.1 Binding
Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cellsCompound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells
Drug Central 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 None
1971 5840 38 None -2 24 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
2404 5840 38 None -2 24 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
4543 5840 38 None -2 24 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
CHEMBL445 5840 38 None -2 24 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
DB00540 5840 38 None -2 24 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 263 3 1 1 3.8 CNCCC=C1c2ccccc2CCc2c1cccc2 None
1212 3415 38 None -9 41 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
204 3415 38 None -9 41 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
3372 3415 38 None -9 41 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
CHEMBL726 3415 38 None -9 41 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
DB00623 3415 38 None -9 41 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 437 6 1 5 4.3 OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F None
135398745 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
1982 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
4585 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
47 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
CHEMBL715 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
DB00334 5933 69 None -20 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 312 1 1 5 1.7 CN1CCN(CC1)C1=c2cc(sc2=Nc2c(N1)cccc2)C None
1214 506896 0 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 549 12 0 6 6.8 CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F None
3372 506896 0 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 549 12 0 6 6.8 CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F None
133 5073 43 None -11 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
1723 5073 43 None -11 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
28693 5073 43 None -11 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
CHEMBL19215 5073 43 None -11 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
DB13520 5073 43 None -11 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 403 4 1 4 4.1 O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C None
1001 365921 35 None -2 5 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
10219 365921 35 None -2 5 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
CHEMBL50588 365921 35 None -2 5 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
DB13393 365921 35 None -2 5 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 480 7 1 6 4.9 CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21 None
31101 1504 27 None -8 28 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
35 1504 27 None -8 28 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
403 1504 27 None -8 28 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
CHEMBL493 1504 27 None -8 28 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
DB01200 1504 27 None -8 28 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C None
4209 6430 0 None -14 21 Human 8.1 pKi = 8.1 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
4893 6430 0 None -14 21 Human 8.1 pKi = 8.1 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
503 6430 0 None -14 21 Human 8.1 pKi = 8.1 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
CHEMBL2 6430 0 None -14 21 Human 8.1 pKi = 8.1 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
DB00457 6430 0 None -14 21 Human 8.1 pKi = 8.1 Binding
Ability to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptorAbility to displace [3H]rauwolscine from cloned human Alpha-2C adrenergic receptor
Drug Central 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 None
37 1606 47 None -9 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
460 1606 47 None -9 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
54746 1606 47 None -9 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
CHEMBL1201087 1606 47 None -9 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
DB00248 1606 47 None -9 17 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C None
1816 5164 69 None -4 15 Human 8.1 pKi = 8.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
4205 5164 69 None -4 15 Human 8.1 pKi = 8.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
7241 5164 69 None -4 15 Human 8.1 pKi = 8.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
CHEMBL654 5164 69 None -4 15 Human 8.1 pKi = 8.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
DB00370 5164 69 None -4 15 Human 8.1 pKi = 8.1 Binding
Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptorInhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor
Drug Central 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 None
3294 4099 60 None -1 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
71360 4099 60 None -1 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
87 4099 60 None -1 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
CHEMBL14376 4099 60 None -1 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
DB04946 4099 60 None -1 24 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 8 0 6 4.8 COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C None
26987 1955 32 None -107 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
6063 1955 32 None -107 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
671 1955 32 None -107 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
CHEMBL1626 1955 32 None -107 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
DB00283 1955 32 None -107 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 343 6 0 2 5.1 Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C None
2585 1662 62 None -24 22 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
522 1662 62 None -24 22 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
551 1662 62 None -24 22 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
CHEMBL723 1662 62 None -24 22 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
DB01136 1662 62 None -24 22 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 406 10 3 5 3.7 COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O None
2381 200503 44 None -1 4 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
68712 200503 44 None -1 4 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
CHEMBL289480 200503 44 None -1 4 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
DB11738 200503 44 None -1 4 Human 8.1 pKi = 8.1 Binding
Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counterDisplacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter
Drug Central 180 3 1 3 1.2 C1COC(NC(C2CC2)C2CC2)=N1 None
2274 6448 36 None -2 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
4917 6448 36 None -2 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
7279 6448 36 None -2 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
CHEMBL728 6448 36 None -2 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
DB00433 6448 36 None -2 25 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 373 4 0 4 4.6 CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2 None
213046 4852 48 None -10 9 Human 8.1 pKi = 8.1 Binding
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
4168 4852 48 None -10 9 Human 8.1 pKi = 8.1 Binding
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
7461 4852 48 None -10 9 Human 8.1 pKi = 8.1 Binding
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
CHEMBL1237021 4852 48 None -10 9 Human 8.1 pKi = 8.1 Binding
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
DB08815 4852 48 None -10 9 Human 8.1 pKi = 8.1 Binding
antagonist with moderate affinityantagonist with moderate affinity
Drug Central 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 None
180 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
200 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
2160 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
CHEMBL629 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
DB00321 829 44 None -6 32 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 277 3 0 1 4.2 CN(CCC=C1c2ccccc2CCc2c1cccc2)C None
2142 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
502 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
5775 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
CHEMBL597 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
DB00692 6301 41 None -6 18 Human 8.1 pKi = 8.1 Binding
Binding affinity against Alpha-2C adrenergic receptor from human clones.Binding affinity against Alpha-2C adrenergic receptor from human clones.
Drug Central 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 None
129211 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
2562 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
488 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
CHEMBL836 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
DB00706 8177 49 None -31 14 Human 8.1 pKi = 8.1 Binding
Binding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligandBinding affinity against human Alpha-2C adrenergic receptor using [3H]rauwolscine as radioligand
Drug Central 408 11 2 6 2.3 CCOc1ccccc1OCCN[C@@H](Cc1ccc(c(c1)S(=O)(=O)N)OC)C None
2180 140074 14 None -3 18 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 None
6761 140074 14 None -3 18 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 None
CHEMBL1909072 140074 14 None -3 18 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 401 5 1 4 4.5 NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 None
115237 118408 70 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
4137 118408 70 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
CHEMBL1621 118408 70 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
DB01267 118408 70 None -1 26 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 426 4 1 7 3.1 Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O None
134551 741 18 None -4 19 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
271 741 18 None -4 19 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
885 741 18 None -4 19 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
CHEMBL1403281 741 18 None -4 19 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 575 5 3 6 2.4 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C None
135 5144 38 None -6 42 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
1796 5144 38 None -6 42 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
4184 5144 38 None -6 42 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
CHEMBL6437 5144 38 None -6 42 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
DB06148 5144 38 None -6 42 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 264 0 0 2 3.1 CN1CCN2C(C1)c1ccccc1Cc1c2cccc1 None
2389 6775 83 None -12 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
5073 6775 83 None -12 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
96 6775 83 None -12 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
CHEMBL85 6775 83 None -12 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
DB00734 6775 83 None -12 45 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 410 4 0 6 3.6 Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2 None
135398737 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
2818 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
38 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
722 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL253391 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
CHEMBL42 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
DB00363 1973 61 None -3 61 Human 8.1 pKi = 8.1 Binding
NoneNone
Drug Central 326 0 1 4 3.7 CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2 None
1043 3255 6 None -8 33 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
149 3255 6 None -8 33 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
8223 3255 6 None -8 33 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
CHEMBL442 3255 6 None -8 33 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
DB00696 3255 6 None -8 33 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 581 4 3 6 2.0 O=C([C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
10531 2923 15 None -16 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
121 2923 15 None -16 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
888 2923 15 None -16 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
CHEMBL1732 2923 15 None -16 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
DB00320 2923 15 None -16 30 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 583 4 3 6 2.1 CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O None
107715 443066 16 None -7 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
887 443066 16 None -7 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
CHEMBL601773 443066 16 None -7 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
DB13345 443066 16 None -7 21 Human 8.1 pKi = 8.1 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 611 5 3 6 2.7 CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O None
124 6070 37 None -26 25 Human 8.1 pKi = 8.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2032 6070 37 None -26 25 Human 8.1 pKi = 8.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
4636 6070 37 None -26 25 Human 8.1 pKi = 8.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
CHEMBL762 6070 37 None -26 25 Human 8.1 pKi = 8.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
DB00935 6070 37 None -26 25 Human 8.1 pKi = 8.1 Binding
Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin)
Drug Central 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C None
2601 8241 23 None -1 19 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
443951 8241 23 None -1 19 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
56 8241 23 None -1 19 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
CHEMBL73151 8241 23 None -1 19 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
DB13399 8241 23 None -1 19 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC None
1588 4738 26 None -4 28 Human 8.0 pKi = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
28864 4738 26 None -4 28 Human 8.0 pKi = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
43 4738 26 None -4 28 Human 8.0 pKi = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
CHEMBL157138 4738 26 None -4 28 Human 8.0 pKi = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
DB00589 4738 26 None -4 28 Human 8.0 pKi = 8.0 Binding
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
Drug Central 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC None
11978813 1488 62 None -25 28 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
5014 1488 62 None -25 28 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
7672 1488 62 None -25 28 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
CHEMBL2105760 1488 62 None -25 28 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
DB09128 1488 62 None -25 28 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 433 7 1 5 4.7 O=c1ccc2c([nH]1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2 None
102 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
3659 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
8969 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
92766 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL15245 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
CHEMBL31410 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
DB01392 8930 44 None -60 31 Human 8.0 pKi = 8.0 Binding
Displacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cellsDisplacement of [3H]RX821002 from human recombinant alpha2C adrenoceptor expressed in CHO cells
Drug Central 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 None
521 2888 53 None -17 8 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
5311068 2888 53 None -17 8 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
835 2888 53 None -17 8 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
CHEMBL778 2888 53 None -17 8 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
DB00633 2888 53 None -17 8 Human 8.0 pKi = 8.0 Binding
NoneNone
Drug Central 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C None
1593 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
30668 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
9868 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
CHEMBL17860 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
DB04948 4768 42 None -6 4 Human 7.2 pKi = 7.2 Binding
Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human &alpha;<sub>2C</sub>-AR.
Guide to Pharmacology 258 3 1 3 2.8 CC(C1=NCCN1)Oc1c(Cl)cccc1Cl 22341244
1816 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
1816 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
4205 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
4205 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
7241 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
7241 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
CHEMBL654 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
CHEMBL654 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
DB00370 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 15771415
DB00370 5164 69 None -4 15 Human 7.4 pKi = 7.4 Binding
Inhibition of [<sup>3</sup>H]rauwolscine binding.Inhibition of [<sup>3</sup>H]rauwolscine binding.
Guide to Pharmacology 265 0 0 3 2.5 CN1CCN2C(C1)c1ccccc1Cc1c2nccc1 35224877
2695 8361 59 None -25 5 Human 5.4 pKi = 5.4 Binding
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
5504 8361 59 None -25 5 Human 5.4 pKi = 5.4 Binding
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
7310 8361 59 None -25 5 Human 5.4 pKi = 5.4 Binding
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
CHEMBL770 8361 59 None -25 5 Human 5.4 pKi = 5.4 Binding
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
DB00797 8361 59 None -25 5 Human 5.4 pKi = 5.4 Binding
Inhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S bindingInhibition of agonist-stimulated [<sup>35</sup>S]GTP&gamma;S binding
Guide to Pharmacology 160 2 1 2 1.2 c1ccc(cc1)CC1=NCCN1 9605427
13129 6038 0 None None None Human 10.6 pKi = 10.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
71301276 6038 0 None None None Human 10.6 pKi = 10.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
CHEMBL4297312 6038 0 None None None Human 10.6 pKi = 10.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
DB12057 6038 0 None None None Human 10.6 pKi = 10.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.8 C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC 33296042
12574 5302 68 None -87 6 Human 4.8 pKi = 4.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
1856 5302 68 None -87 6 Human 4.8 pKi = 4.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
4810 5302 68 None -87 6 Human 4.8 pKi = 4.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
CHEMBL19236 5302 68 None -87 6 Human 4.8 pKi = 4.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
DB09242 5302 68 None -87 6 Human 4.8 pKi = 4.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 241 2 2 6 0.8 CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC 36101495
523 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
523 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
5707 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
5707 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
CHEMBL297362 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
CHEMBL297362 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
DB11477 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 36101495
DB11477 8892 50 None -1 3 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 220 1 1 3 3.2 Cc1cccc(c1NC1=NCCCS1)C 9605427
1028 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
1028 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
479 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
479 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
5816 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
5816 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
CHEMBL679 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL679 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
DB00668 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00668 599 43 None -61 18 Human 5.4 pKi = 5.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNC[C@@H](c1ccc(c(c1)O)O)O 9605427
1960 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
1960 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
1960 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
1960 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
439260 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
439260 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
439260 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
439260 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
505 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
505 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
505 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
505 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
6921840 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
6921840 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
6921840 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
6921840 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
CHEMBL1437 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
CHEMBL1437 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
CHEMBL1437 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
CHEMBL1437 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
DB00368 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 25080296
DB00368 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 36101495
DB00368 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9605427
DB00368 5823 49 None -28 26 Human 5.7 pKi = 5.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 169 2 4 4 0.1 NC[C@@H](c1ccc(c(c1)O)O)O 9824686
1343 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
1343 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
3519 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
3519 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
522 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
522 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
CHEMBL862 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
CHEMBL862 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
DB01018 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 36101495
DB01018 3863 47 None -17 9 Human 5.8 pKi = 5.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 245 2 2 1 1.3 O=C(Cc1c(Cl)cccc1Cl)N=C(N)N 9605427
4508 6384 62 None -199 9 Human 6.0 pKi = 6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
509 6384 62 None -199 9 Human 6.0 pKi = 6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
838 6384 62 None -199 9 Human 6.0 pKi = 6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
CHEMBL1740 6384 62 None -199 9 Human 6.0 pKi = 6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
DB11124 6384 62 None -199 9 Human 6.0 pKi = 6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 183 3 4 4 0.4 CNCC(c1ccc(c(c1)O)O)O 9605427
11079 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
3369 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
4436 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
5509 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
CHEMBL761 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
DB06711 5576 48 None -2 4 Human 6.4 pKi = 6.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 210 2 1 2 2.4 C1CN=C(N1)Cc1cccc2c1cccc2 36101495
121850 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
121850 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
525 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
525 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
CHEMBL216097 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 35224877
CHEMBL216097 1498 0 None -15 3 Human 6.5 pKi = 6.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 215 2 1 3 1.6 CC1N(CC2=NCCN2)Cc2c1cccc2 7996470
124 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
124 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
124 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
124 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
2032 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
2032 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
2032 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
2032 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
4636 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
4636 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
4636 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
4636 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
CHEMBL762 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
CHEMBL762 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
CHEMBL762 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
CHEMBL762 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
DB00935 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 25080296
DB00935 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 36101495
DB00935 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 7996470
DB00935 6070 37 None -26 25 Human 6.6 pKi = 6.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 260 2 2 3 2.9 Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C 9605427
2435 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
2435 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
2435 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
2435 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
2435 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
395 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
395 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
395 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
395 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
395 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
520 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
520 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
520 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
520 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
520 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
CHEMBL844 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
CHEMBL844 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
CHEMBL844 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
CHEMBL844 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
CHEMBL844 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
DB00484 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 36101495
DB00484 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9227000
DB00484 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9605427
DB00484 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9760042
DB00484 1490 0 None -42 8 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 291 1 2 5 1.8 Brc1c(ccc2c1nccn2)NC1=NCCN1 9824686
2726 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
2726 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
2726 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
621 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
621 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
621 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
83 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
83 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
83 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
CHEMBL71 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
CHEMBL71 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
CHEMBL71 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
DB00477 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 1353247
DB00477 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 35224877
DB00477 1895 54 None -21 48 Human 6.7 pKi = 6.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 318 4 0 3 4.9 CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C 7908642
2803 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
2803 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
2803 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
2803 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
516 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
516 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
516 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
516 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
704 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
704 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
704 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
704 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
CHEMBL134 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
CHEMBL134 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
CHEMBL134 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
CHEMBL134 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
DB00575 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 36101495
DB00575 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9605427
DB00575 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9760042
DB00575 1967 0 None -22 11 Human 6.9 pKi = 6.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 229 1 2 3 2.4 Clc1cccc(c1NC1=NCCN1)Cl 9824686
3658 8894 44 None -10 7 Human 7.0 pKi = 7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
517 8894 44 None -10 7 Human 7.0 pKi = 7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
5709 8894 44 None -10 7 Human 7.0 pKi = 7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
CHEMBL312448 8894 44 None -10 7 Human 7.0 pKi = 7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
DB06694 8894 44 None -10 7 Human 7.0 pKi = 7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 2 1 2 3.1 Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C 36101495
12575 4064 28 None -19 5 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
54459 4064 28 None -19 5 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
CHEMBL10316 4064 28 None -19 5 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
DB12551 4064 28 None -19 5 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 204 1 1 4 0.8 C1CN=C(N1)C2COC3=CC=CC=C3O2 35224877
122211 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 10531390
122211 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 12770928
122211 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 15655528
122211 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 2849109
524 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 10531390
524 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 12770928
524 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 15655528
524 955 0 None -1 3 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 406 5 0 5 3.6 COc1ccccc1N1CCN(CC1)CCC1C(=O)c2ccccc2C(C1=O)(C)C 2849109
2105 6217 26 None -45 25 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
47811 6217 26 None -45 25 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
48 6217 26 None -45 25 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
CHEMBL531 6217 26 None -45 25 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
DB01186 6217 26 None -45 25 Human 7.2 pKi = 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 4 1 2 4.3 CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3 12388666
4209 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
4209 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
4209 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
4209 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
4893 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
4893 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
4893 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
4893 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
503 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
503 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
503 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
503 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
CHEMBL2 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
CHEMBL2 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
CHEMBL2 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
CHEMBL2 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
DB00457 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 1353247
DB00457 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 35224877
DB00457 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7908642
DB00457 6430 0 None -14 21 Human 7.3 pKi = 7.3 Binding
UnclassifiedUnclassified
Guide to Pharmacology 383 4 1 8 1.8 COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1 7996470
228 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
33 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
6005 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
CHEMBL53 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
DB00714 919 20 None -3 24 Human 7.4 pKi = 7.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 267 0 2 3 2.9 CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O 12388666
2216 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
2216 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
229 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
229 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
7117 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
7117 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
CHEMBL647 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
CHEMBL647 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
DB00964 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 36101495
DB00964 921 27 None -4 4 Human 7.5 pKi = 7.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 244 1 3 4 1.9 Nc1cc(Cl)c(c(c1)Cl)NC1=NCCN1 8784451
31101 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
31101 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
35 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
35 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
403 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
403 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
CHEMBL493 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
CHEMBL493 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
DB01200 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 12388666
DB01200 1504 27 None -8 28 Human 7.6 pKi = 7.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 653 5 3 6 3.2 CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C 36101495
213046 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
213046 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
4168 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
4168 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
7461 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
7461 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
CHEMBL1237021 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
CHEMBL1237021 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
DB08815 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 20404009
DB08815 4852 48 None -10 9 Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 492 5 0 6 4.3 O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1 35224877
2741 723 0 None None None Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
6437063 723 0 None None None Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
CHEMBL104049 723 0 None None None Human 7.7 pKi = 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 314 5 1 2 4.8 C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)C(=O)CCC1(C)C 15771415
2142 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 12770928
2142 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 15655528
2142 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 2849109
502 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 12770928
502 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 15655528
502 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 2849109
5775 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 12770928
5775 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 15655528
5775 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 2849109
CHEMBL597 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 12770928
CHEMBL597 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 15655528
CHEMBL597 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 2849109
DB00692 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 12770928
DB00692 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 15655528
DB00692 6301 41 None -6 18 Human 7.8 pKi = 7.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 281 4 2 4 2.8 Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1 2849109
11959 3161 0 None -4 4 Human 7.9 pKi = 7.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 405 5 1 7 3.0 Cn1c(=O)c(c(cn1)NCCN1CCC(CC1)c1noc2c1ccc(c2)F)Cl 22824189
9909267 3161 0 None -4 4 Human 7.9 pKi = 7.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 405 5 1 7 3.0 Cn1c(=O)c(c(cn1)NCCN1CCC(CC1)c1noc2c1ccc(c2)F)Cl 22824189
521 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
521 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
521 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
521 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
5311068 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
5311068 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
5311068 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
5311068 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
835 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
835 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
835 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
835 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
CHEMBL778 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
CHEMBL778 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
CHEMBL778 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
CHEMBL778 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
DB00633 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 36101495
DB00633 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9605427
DB00633 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9760042
DB00633 2888 53 None -17 8 Human 8.2 pKi = 8.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 200 2 1 1 3.2 Cc1cccc(c1C)[C@@H](c1c[nH]cn1)C 9824686
102 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
102 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
102 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
102 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
3659 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
3659 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
3659 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
3659 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
8969 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
8969 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
8969 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
8969 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
92766 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
92766 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
92766 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
92766 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
CHEMBL15245 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
CHEMBL15245 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
CHEMBL15245 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
CHEMBL15245 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
CHEMBL31410 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
CHEMBL31410 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
CHEMBL31410 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
CHEMBL31410 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
DB01392 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 1353247
DB01392 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 35224877
DB01392 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7908642
DB01392 8930 44 None -60 31 Human 8.4 pKi = 8.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
108094 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
108094 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
526 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
526 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
CHEMBL10332 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 35224877
CHEMBL10332 6965 0 None -1 3 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 234 2 1 5 0.8 COC1(COc2c(O1)cccc2)C1=NCCN1 7996470
12576 1064 66 None -1 4 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
71310 1064 66 None -1 4 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
CHEMBL353972 1064 66 None -1 4 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
DB11481 1064 66 None -1 4 Human 8.5 pKi = 8.5 Binding
UnclassifiedUnclassified
Guide to Pharmacology 212 2 1 1 2.9 CCC1(CC2=CC=CC=C2C1)C3=CN=CN3 35224877
499 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
499 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
499 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
499 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
5685 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
5685 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
5685 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
5685 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
CHEMBL25554 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 1353247
CHEMBL25554 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 35224877
CHEMBL25554 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7908642
CHEMBL25554 8838 14 None -4 15 Human 8.8 pKi = 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 345 8 1 6 2.5 COc1cccc(c1OCCNCC1COc2c(O1)cccc2)OC 7996470
5268 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
5268 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
53 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
53 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
CHEMBL300555 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 35224877
CHEMBL300555 7428 34 None -6 18 Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 379 3 1 5 2.3 O=C1NCN(C21CCN(CC2)CC1COc2c(O1)cccc2)c1ccccc1 7996470
13130 6036 0 None None None Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
171037438 6036 0 None None None Human 8.9 pKi = 8.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 285 2 0 3 3.9 [H][C@@]12N(CCC[C@@]1(C)OCC)CCC3=C2OC4=C3C=CC=C4 23718812
136 6696 31 None 3 17 Human 9.1 pKi = 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
643606 6696 31 None 3 17 Human 9.1 pKi = 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
CHEMBL10347 6696 31 None 3 17 Human 9.1 pKi = 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 354 1 2 4 2.6 COC(=O)[C@@H]1[C@@H](O)CC[C@H]2[C@@H]1C[C@@H]1N(C2)CCc2c1[nH]c1c2cccc1 7996470
13128 6915 0 None 3 3 Human 9.4 pKi = 9.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
9908992 6915 0 None 3 3 Human 9.4 pKi = 9.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
CHEMBL4303564 6915 0 None 3 3 Human 9.4 pKi = 9.4 Binding
UnclassifiedUnclassified
Guide to Pharmacology 364 3 0 4 2.4 CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC 35224877
1588 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
1588 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
1588 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
28864 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
28864 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
28864 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
43 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
43 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
43 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
CHEMBL157138 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
CHEMBL157138 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
CHEMBL157138 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
DB00589 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
DB00589 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 35224877
DB00589 4738 26 None -4 28 Human 9.6 pKi = 9.6 Binding
UnclassifiedUnclassified
Guide to Pharmacology 338 3 2 2 2.8 CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC 9227000
12577 5214 0 None 15 3 Human 9.9 pKi = 9.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
189711 5214 0 None 15 3 Human 9.9 pKi = 9.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
CHEMBL1257057 5214 0 None 15 3 Human 9.9 pKi = 9.9 Binding
UnclassifiedUnclassified
Guide to Pharmacology 339 0 0 3 3.3 CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C 35224877
179 827 77 None -1 12 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2159 827 77 None -1 12 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
963 827 77 None -1 12 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
CHEMBL243712 827 77 None -1 12 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
DB06288 827 77 None -1 12 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 369 7 2 6 1.3 CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC None
2149 461549 10 None -1 9 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
26934 461549 10 None -1 9 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
4786 461549 10 None -1 9 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
CHEMBL61006 461549 10 None -1 9 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
DB00397 461549 10 None -1 9 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 151 2 2 2 1.1 CC(N)C(O)c1ccccc1 None
1150 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
3337 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
65801 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
66264 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
91452 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
CHEMBL87493 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
DB00574 473039 11 None -1 19 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 231 4 1 1 3.2 CCNC(C)Cc1cccc(C(F)(F)F)c1 None
134 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
1775 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
6604697 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
9681 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
CHEMBL1065 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
CHEMBL1397576 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
DB00247 5109 16 None -7 31 Human 8.2 pKi None 8.2 Binding
NoneNone
Drug Central 353 4 2 4 1.9 CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO None
119570 6422 62 None -13 14 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
2233 6422 62 None -13 14 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
953 6422 62 None -13 14 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
CHEMBL301265 6422 62 None -13 14 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
DB00413 6422 62 None -13 14 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 211 3 2 4 1.6 CCCN[C@H]1CCc2c(C1)sc(n2)N None
11954293 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
3036780 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
4115 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
9903970 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL3187365 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
CHEMBL504548 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
DB06216 212936 14 None -5 28 Human 8.1 pKi None 8.1 Binding
NoneNone
Drug Central 285 0 0 2 4.3 CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1 None
2202 6371 70 None -4 11 Human 7.2 pKi None 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
4850 6371 70 None -4 11 Human 7.2 pKi None 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
49 6371 70 None -4 11 Human 7.2 pKi None 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
CHEMBL1371770 6371 70 None -4 11 Human 7.2 pKi None 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
DB12478 6371 70 None -4 11 Human 7.2 pKi None 7.2 Binding
UnclassifiedUnclassified
Guide to Pharmacology 298 3 0 6 1.5 c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2 12388666
37 1606 47 None -9 17 Human 7.7 pKi None 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
460 1606 47 None -9 17 Human 7.7 pKi None 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
54746 1606 47 None -9 17 Human 7.7 pKi None 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
CHEMBL1201087 1606 47 None -9 17 Human 7.7 pKi None 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
DB00248 1606 47 None -9 17 Human 7.7 pKi None 7.7 Binding
UnclassifiedUnclassified
Guide to Pharmacology 451 8 2 4 3.2 C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C 12388666
219050 6861 20 None -7 13 Human 8.8 pKi None 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
52 6861 20 None -7 13 Human 8.8 pKi None 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
CHEMBL431367 6861 20 None -7 13 Human 8.8 pKi None 8.8 Binding
UnclassifiedUnclassified
Guide to Pharmacology 346 6 2 2 5.0 Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2 12388666
2601 8241 23 None -1 19 Human 9.1 pKi None 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
443951 8241 23 None -1 19 Human 9.1 pKi None 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
56 8241 23 None -1 19 Human 9.1 pKi None 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
CHEMBL73151 8241 23 None -1 19 Human 9.1 pKi None 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666
DB13399 8241 23 None -1 19 Human 9.1 pKi None 9.1 Binding
UnclassifiedUnclassified
Guide to Pharmacology 340 3 2 2 2.9 CCN(C(=O)N[C@@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3)CC 12388666